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iiiMIREX AND CHLORDECONE
FOREWORD 
This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary. 
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein.  Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is 
also presented, but is described in less detail than the key studies.  The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced.
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile 
begins with a relevance to public health discussion which would allow a public health professional to 
make a real-time determination of whether the presence of a particular substance in the environment 
poses a potential threat to human health.  The adequacy of information to determine a substance's health 
effects is described in a health effects summary.  Data needs that are of significance to the protection of 
public health are identified by ATSDR and EPA. 
Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, intermediate, and chronic health effects;
(B) A determination of whether adequate information on the health effects of each substance is 
available or in the process of development to determine the levels of exposure that present a 
significant risk to human health due to acute, intermediate, and chronic duration exposures; 
and 
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels 
of exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and 
local levels; interested private sector organizations and groups; and members of the public.  ATSDR plans 
to revise these documents in response to public comments and as additional data become available.  
Therefore, we encourage comments that will make the toxicological profile series of the greatest use.
Electronic comments may be submitted via: www.regulations.gov.  Follow the on-line instructions for 
submitting comments. 
Written comments may also be sent to:  Agency for Toxic Substances and Disease Registry 
     Division  of  Toxicology  and  Human  Health  Sciences
     Environmental  Toxicology  Branch  
1600 Clifton Road, N.E. 
Mail Stop S102-1
Atlanta, Georgia 30329-4027
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The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section 
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related 
authorities” of the statute.  This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that 
pose the most significant potential threat to human health, as determined by ATSDR and the EPA.  
Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a 
toxicological profile for each substance on the list.  In addition, ATSDR has the authority to prepare 
toxicological profiles for substances not found at sites on the NPL, in an effort to “…establish and 
maintain inventory of literature, research, and studies on the health effects of toxic substances” under 
CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as 
otherwise necessary to support the site-specific response actions conducted by ATSDR.  
 
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been 
peer-reviewed.  Staffs of the Centers for Disease Control and Prevention and other Federal scientists have 
also reviewed the profile.  In addition, this profile has been peer-reviewed by a nongovernmental panel 
and is being made available for public review.  Final responsibility for the contents and views expressed 
in this toxicological profile resides with ATSDR. 
 
 
Patrick N. Breysse, Ph.D., CIH 
Director, National Center for Environmental Health and 
Agency for Toxic Substances and Disease Registry 
Centers for Disease Control and Prevention 
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CHAPTER 1.  RELEVANCE TO PUBLIC HEALTH 
 
1.1   OVERVIEW AND U.S. EXPOSURES 
 
ATSDR’s Toxicological Profile for Mirex and Chlordecone was released in 1995.  In order to update the 
literature in this profile, ATSDR conducted a literature search focused on health effects information as 
described in Appendix B.  Chapters 2, 3, and 7 were revised to reflect the most current health effects and 
regulations/guidelines data.  In some cases, other sections of the profile were updated as needed or for 
consistency with the updated health effects data.  However, the focus of the update to this profile is on 
health effects information. 
 
Mirex and chlordecone are structurally similar highly-chlorinated derivatives of cyclopentadiene.  The 
only structural difference between mirex and chlordecone is that mirex has two bridgehead chlorine atoms 
where chlordecone has a carbonyl oxygen atom.  Mirex was commercially introduced in the United States 
in 1959 for use in pesticide formulations and as an industrial fire retardant.  In the 1960s, mirex was 
commonly used to control fire ants in southern States.  Mirex was banned for use in the United States in 
1978, except for use on pineapples until stocks on hand were exhausted.  Chlordecone was mainly 
registered for use in the United States to control banana root borer, although it was also used to control 
other pests.  All registered products containing chlordecone were effectively canceled in 1978. 
 
People living in areas surrounding hazardous waste sites may be exposed to mirex or chlordecone 
primarily via dermal contact with, or ingestion of, contaminated soil since these compounds bind to soil 
particles.  The other major means of exposure for people living near hazardous waste sites is ingestion of 
indigenous wildlife since mirex and chlordecone are bioconcentrated in fish and animals.  Ingestion of 
mirex or chlordecone from drinking water is unlikely because of their limited solubility in water (Kenaga 
1980).  Similarly, inhalation exposure to mirex or chlordecone following volatilization from contaminated 
media is not likely to be a major route of exposure since these chemicals are essentially nonvolatile.  For 
the general population, the most likely route of exposure to mirex or chlordecone is via ingestion of 
contaminated food because these chemicals have been observed to persist in soil for decades following 
cessation of application as pesticides.  Both of these chemicals are excreted very slowly and 
bioaccumulate in the body after exposure.  
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1.2   SUMMARY OF HEALTH EFFECTS  
 
Mirex.  Animal studies indicate that mirex exposure may result in a variety of adverse health effects in 
exposed populations.  The primary organs affected by mirex in experimental animals are the liver, 
kidneys, selected developmental endpoints, and thyroid (see Figure 1-1).  In the liver, mirex causes 
adaptive changes similar to those seen with other chlorinated hydrocarbon insecticides as well as 
decreased hepatobiliary function and decreased glycogen storage.  In the kidneys, increases in 
glomerulosclerosis and proteinuria have been observed.  Ocular lesions include the development of 
cataracts in the eyes of the young if exposure occurs during a critical period immediately after birth.  In 
the thyroid, an increase in cystic follicles or a collapse of follicles has been observed.  Decreased fertility 
and marked developmental toxicity have been observed following exposure to mirex.  Mirex exposure 
results in testicular atrophy and reproductive failure.  Adverse developmental effects seen in fetuses 
and/or young animals following maternal and/or early postnatal exposure to mirex include cataracts, 
cardiovascular disturbances, visceral anomalies, increased resorptions, and increased stillbirths.  Also, 
mirex is a liver carcinogen in animals. 
 
Chlordecone.  The primary targets of chlordecone toxicity in experimental animals are the liver, kidneys, 
nervous system, reproductive system, endocrine system, and selected developmental endpoints (see 
Figure 1-2).  Studies in humans exposed occupationally to chlordecone demonstrate toxic effects on the 
nervous system, liver, and reproductive system.  Tremors, unfounded anxiety or irritability, blurring of 
vision, headache, and increases in cerebrospinal fluid pressure were found in workers exposed to high 
levels of chlordecone during its manufacture.  In addition, several workers exhibited liver effects such as 
hepatomegaly, evidence of increased microsomal enzyme activity, mild inflammatory changes, and fatty 
degeneration.  Reproductive toxicity consisted of decreased sperm and sperm motility.  Studies in animals 
have supported these findings and, in addition, have demonstrated adverse effects of chlordecone on the 
kidney and thermoregulation.  Animal studies also show effects on the female estrous cycle, uterus, and 
ovaries and decreased viability and development of fetuses.  Liver cancer has also been observed in 
animal studies.  Animal studies have also demonstrated the potential for greatly potentiated hepatotoxicity 
of haloalkanes such as carbon tetrachloride after exposure to chlordecone.  The effects observed in 
occupationally-exposed workers and treated animals were related to chlordecone levels much higher than 
environmentally-relevant levels. 
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Figure 1-1.  Graph of Health Effects Found in Animals Following Oral Exposure to 
Mirex 
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Figure 1-2.  Graph of Health Effects Found in Animals Following Oral Exposure to 
Chlordecone 
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Neurological Effects 
 
Mirex.  Animal studies have demonstrated lethargy, weakness, diarrhea, hyperexcitability, tremors, and 
convulsions as a result of mirex exposure (Chu et al. 1981a; Curtis and Hoyt 1984; Fujimori et al. 1983; 
Gaines and Kimbrough 1970; Kendall 1974a; Larson et al. 1979a; Mehendale 1981b). 
 
Chlordecone.  Strong evidence for neurotoxicity of chlordecone has been obtained in human studies.  
Interviews of workers exposed to high levels of chlordecone during its manufacture revealed a high 
percentage of workers with histories of tremors, unfounded nervousness or anxiety, and visual difficulties 
(Cannon et al. 1978).  The tremors were characterized as resembling intention tremors and occurred 
mainly in the upper extremities (Taylor 1982, 1985).  In more severe cases, the lower extremities were 
involved and gait disturbances were apparent.  Peripheral nerve biopsies of the more severely affected 
workers showed decreased numbers of small myelinated and unmyelinated axons in the absence of 
significant myelin abnormalities (Martinez et al. 1978).  Although mood and memory disturbances were 
reported by many workers, testing revealed active encephalopathy in only one subject (Taylor 1982, 
1985).  Reports of blurring of vision were found to be associated with an opsoclonus-like phenomenon, in 
which rapid random eye movements followed horizontal saccades (Taylor 1982, 1985).  This was 
attributed to a loss of inhibitory control of saccadic activity.  Headaches were also reported by a number 
of workers (Taylor 1982, 1985).  Cerebrospinal fluid pressure was elevated in three of these individuals, 
and relief of cerebrospinal fluid pressure resulted in amelioration of the headaches (Sanborn et al. 1979). 
 
Studies in animals have shown similar effects (tremor, exaggerated startle response, gait disturbances) 
(e.g., Aldous et al. 1984; Cannon and Kimbrough 1979; EPA 1986c; Klingensmith and Mehendale 1982a; 
Larson et al. 1979b; NCI 1976; Squibb and Tilson 1982b).  
 
Hepatic Effects 
 
Mirex.  Although human data on the hepatic effects of mirex are minimal, animal studies have shown that 
the liver undergoes both adaptive and toxic changes following oral exposure.  The primary toxic effects of 
mirex are inhibition of hepatobiliary excretion (Berman et al. 1986; Davison et al. 1976; Mehendale 1976, 
1977c; Teo and Vore 1991) and depletion of hepatic glycogen stores (Elgin et al. 1990; Ervin and 
Yarbrough 1983; Fujimori et al. 1983; Jovanovich et al. 1987; Kendall 1979).  A 28-day study in 
Sprague-Dawley rats reported a decrease in hepatic microsomal aniline hydroxylase.  Histopathological 
findings in this study included fatty vacuolation, panlobular ballooning of hepatocytes, moderate lobular 
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pattern with perinuclear clear zone, and perivenous cytoplasmic ballooning with anisokaryosis in liver 
(Chu et al. 1980b, 1981b).  A 21-month study in Sprague-Dawley rats reported a decrease in hepatic 
microsomal aniline hydroxylase.  Histopathological findings in this study included panlobular 
cytoplasmic vacuolation with loss of basophilia, fatty infiltration, and anisokaryosis in liver (Chu et al. 
1981c).  F344/N male and female rats fed mirex doses (males: 0.007, 0.07, 0.7, 1.8, 3.8 mg/kg/day; 
females: 0.007, 0.08, 0.7, 2.0, 3.9 mg/kg/day) for 2 years developed histopathological changes, which 
included hepatocytomegaly with eosinophilic cytoplasm observed in males and females at 
>0.7 mg/kg/day.  Fatty metamorphosis (cytoplasmic vacuoles consistent with intracellular fat 
accumulation) and necrosis of hepatocytes (focal and centrilobular) were increased in males and females 
at >0.7 mg/kg/day.  Dilation of the sinusoids (by blood or proteinaceous material) was observed in males 
at >0.7 mg/kg/day and in females only at the highest dose tested (NTP 1990). 
 
Chlordecone.  Guzelian et al. (1980) evaluated liver function in a group of 32 male workers involved in 
the manufacture of chlordecone who exhibited signs or symptoms of chlordecone toxicity and blood 
chlordecone levels ≥600 ng/mL.  Twenty of the 32 patients exhibited liver enlargement; common 
histopathological findings on liver biopsy included proliferation of the smooth endoplasmic reticulum, 
increased microsomal enzyme activity, increased serum alkaline phosphatase, lipofuscin accumulation, 
mild inflammatory changes, mild portal fibrosis, fatty infiltration, and/or paracrystalline mitochondrial 
inclusions.  Normal results were obtained for serum bilirubin, albumin, globulin, prothrombin time, 
cholesterol, γ-glutamyl transpeptidase, alanine transaminase (ALT), and aspartate transaminase (AST).  
Sulfobromophthalein clearance was normal (sulfobromophthalein clearance is an indicator of liver 
function).  Within 2–3 years following cessation of exposure, livers appeared normal in size and 
ultrastructural changes had resolved.  The study authors considered the hepatic changes to largely 
represent adaptive responses to chlordecone.  The results of animal studies support these findings and 
indicate that oral exposure to chlordecone at doses as low as 0.5–5 mg/kg/day may also result in 
decreased hepatobiliary function (Curtis and Hoyt 1984; Curtis and Mehendale 1979; Curtis et al. 1979b, 
1981; Mehendale 1977b, 1981b; Teo and Vore 1991); decreased hepatic glycogen (Fujimori et al.  1983); 
and increased serum nonprotein nitrogen compounds and enzymes, and decreased serum triglycerides and 
low-density lipoprotein (LDL) cholesterol (Chetty et al. 1993a, 1993b). 
 
Reproductive Effects 
 
Mirex.  No studies are available to assess the reproductive effects of mirex in humans.  Oral studies in 
animals suggest that both male and female reproductive systems are adversely affected by mirex.  
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Reported effects in males include decreased fertility (Khera et al. 1976), decreased seminal vesicle weight 
(Dai et al. 2001), and decreased sperm count and testicular degeneration (Yarbrough et al. 1981).  
Reported effects in females include increased resorptions and failure of pregnancy (Grabowski and Payne 
1980; Khera et al. 1976); decreased ovarian and uterine weights and reduced blood flow to the ovaries, 
uterus, and fetuses (Buelke-Sam et al. 1983); decreased numbers of litters (Gaines and Kimbrough 1970); 
and decreases in mating and litter size (Chu et al. 1981b).  Male and female mice treated for 30 days prior 
to mating, and then for an additional 90 days, experienced decreased number of litters per producing pair 
and decreased litter size (Ware and Good 1967). 
 
Chlordecone.  Available studies involving human exposure to chlordecone suggest that adverse 
reproductive effects can occur in males as a result of occupational exposure to chlordecone (Guzelian 
1982a; Taylor 1982, 1985; Taylor et al. 1978).  Abnormal spermatogenesis has been observed among 
workers exposed at a chemical plant (Guzelian 1982a, 1982b).  Chlordecone has demonstrated an 
estrogen-like action in animals (Huber 1965; Uphouse et al. 1984). 
 
Mammalian studies indicate that testicular atrophy can occur at low doses of chlordecone in the diet for 
3 months; doses were well below the level that causes overt maternal toxicity (Larson et al. 1979b).  
Dietary exposure at twice the higher levels for 3 months resulted in complete reproductive failure of 
female mice (Huber 1965).  Chlordecone is well known for its estrogenic effects on mammalian 
reproductive organs when administered by oral (Hammond et al. 1978) or parenteral (Johnson et al. 1990; 
Pinkston and Uphouse 1988; Sierra and Uphouse 1986) routes.  The effects of neonatal exposure to 
chlordecone on reproductive function in rats and mice are similar to those seen after prenatal exposure.  
Multiple injections of chlordecone to neonatal female rats increased uterotropic response (Gellert 1978); 
uterine weights increased in a dose-related manner (Gellert 1978; Hammond et al. 1979).  Parenteral 
administration of a daily dose of chlordecone to 1-day-old female mouse pups produced cellular 
proliferation and hypertrophy in the entire reproductive tract and keratinization of the vagina within 
4 days of treatment in a dose-dependent manner (Eroschenko and Mousa 1979). 
 
Renal Effects.  Studies in animals indicated an increase in the severity of renal lesions in rats following 
chronic-duration oral exposures to both mirex (NTP 1990) and chlordecone (Larson et al. 1979b). 
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Endocrine Effects. 
 
Mirex.  Result of studies in rats indicate that mirex is toxic to the thyroid.  Reversible reduction in colloid 
density, a thickening of follicular epithelium, and angular collapse of the follicles, but no effect on serum 
levels of triiodothyronine (T3) or thyroxine (T4), were reported in rats following repeated oral exposure 
to mirex for ≥28 days (Chu et al. 1980a, 1981a, 1981b).  In other studies, ultrastructural analyses of 
thyroids from rats treated for 28 days showed dilation of the rough endoplasmic reticulum and increased 
numbers of columnar cells with irregularly-shaped lysosomal bodies, dilation of cisternae, and increased 
vacuolization (Singh et al. 1982, 1985).  Similar effects were observed following dietary exposure for 
148 days (Chu et al. 1981a).  Dietary exposure for 2 years also resulted in an increase in cystic follicles in 
male rats (NTP 1990).  Studies in animals also indicate that the adrenal gland hypertrophies and releases 
increased levels of corticosterone in response to mirex exposure (Ervin and Yarbrough 1985; Jovanovich 
et al. 1987; Williams and Yarbrough 1983).  Other studies in animals have demonstrated increased 
adrenal weight; increased cholesterol, lipid, and protein content (Williams and Yarbrough 1983); 
increased adrenal weight and increased serum adrenocorticotropic hormone (Ervin and Yarbrough 1985; 
Jovanovich et al. 1987); and decreased body fats (Jovanovich et al. 1987). 
 
Chlordecone.  Increased relative adrenal weight was observed following a single oral dose of chlordecone 
in rats (Swanson and Wooley 1982).  Enlargement of the adrenal gland, with hyperplasia and hypertrophy 
of the cortical cells, was observed in a 30-day dietary study in rats (Cannon and Kimbrough 1979); 
decreased adrenal lipid was observed in a 90-day dietary study in rats (Larson et al. 1979b).  Consistent 
with a corticosterone-induced increase in lipid utilization, decreased body fat was observed following 
dietary exposure of rats for 15–20 days (Klingensmith and Mehendale 1982a; Mehendale et al. 1977, 
1978b) or exposure of mice for 33 days (Fujimori et al. 1983).  In contrast to the absence of mirex-
induced effects on the adrenal medulla, oral exposure to chlordecone for 8 days resulted in a decrease in 
the medullary content of epinephrine in rats (Baggett et al. 1980). 
 
Developmental Effects 
 
Mirex.  One human study provides suggestive evidence that gestational exposure to mirex may disrupt 
reproductive hormones in boys (Araki et al. 2018).  Animal studies demonstrated that prenatal exposure 
to mirex can induce a high incidence of dysrhythmias that can persist into the postnatal period 
(Grabowski 1983a).  These effects were sufficiently severe to cause some fetal deaths (Grabowski and 
Payne 1983a).  Cataracts and other lesions of the lens were induced in young animals exposed to mirex 
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during a critical period (between postpartum days 1 and 8) (Chernoff et al. 1979b; Gaines and Kimbrough 
1970; Rogers and Grabowski 1984; Scotti et al. 1981). 
 
Chlordecone.  Gestational exposure of rats and mice to chlordecone resulted in increased stillbirths and 
decreased postnatal viability (Chernoff and Kavlock 1982; Chernoff and Rogers 1976; EPA 1986c; Gray 
and Kavlock 1984; Gray et al. 1983; Kavlock et al. 1985; Seidenberg and Becker 1987; Seidenberg et al. 
1986), decreased fetal or neonatal weight and/or skeletal ossification (Chernoff and Kavlock 1982; 
Chernoff and Rogers 1976; EPA 1986c; Gray and Kavlock 1984; Kavlock et al. 1985, 1987b; Seidenberg 
et al. 1986), and anomalies and malformations such as enlarged renal pelvis, undescended testes, enlarged 
cerebral ventricles, clubfoot, fused vertebrae or ribs, and encephalocele (Chernoff and Rogers 1976; 
Kavlock et al. 1985).  Anovulation and persistent vaginal estrus were observed in female offspring of 
maternal rats given chlordecone during gestation (Gellert and Wilson 1979).  Gestational exposure also 
resulted in subtle neurological changes in the offspring later in life (Rosecrans et al. 1982; Seth et al. 
1981; Squibb and Tilson 1982a). 
 
Body Weight Effects 
 
Mirex.  Animal studies show decreases in serum glucose (Chu et al. 1981b; Ervin and Yarbrough 1983; 
Fujimori et al. 1983; Jovanovich et al. 1987; Robinson and Yarbrough 1978a; Williams and Yarbrough 
1983; Yarbrough et al. 1981) and decreases in body weight or body weight gain (Buelke-Sam et al. 1983; 
Byrd et al. 1981; Chadwick et al. 1977; Chernoff et al. 1979a, 1979b; Chu et al. 1981a; Curtis and Hoyt 
1984; Davison et al. 1976; Elgin et al. 1990; Fujimori et al. 1983; Jovanovich et al. 1987; Khera et al. 
1976; Larson et al. 1979a; Mehendale et al. 1973; NTP 1990; Ritchie and Ho 1982; Rogers and 
Grabowski 1984; Villeneuve et al. 1977). 
 
Chlordecone.  Workers exposed to high levels of chlordecone at a facility where it was manufactured 
experienced an unexplained weight loss (Cannon et al. 1978), with losses of up to 60 pounds in 4 months 
in at least one individual (Taylor et al. 1978).  Animal studies have also demonstrated weight loss that in 
some cases was quite large (Albertson et al. 1985; Cannon and Kimbrough 1979; Chernoff and Kavlock 
1982; Chernoff and Rogers 1976; Curtis and Hoyt 1984; Curtis and Mehendale 1979; EPA 1986c; 
Fabacher and Hodgson 1976; Huang et al. 1980; Kavlock et al. 1987b; Klingensmith and Mehendale 
1982a; Larson et al. 1979b; Mehendale et al. 1977, 1978b; Pryor et al. 1983; Seidenberg et al. 1986; 
Simmons et al. 1987; Smialowicz et al. 1985; Swanson and Wooley 1982; Uzodinma et al. 1984a).  
Consistent with the results for mirex, loss of body fat (Fujimori et al. 1983; Klingensmith and Mehendale 
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1982a; Mehendale et al. 1977, 1978b) and decreased serum glucose levels (Fujimori et al. 1983) were 
seen. 
 
Cancer.  Studies in mice and rats have demonstrated the ability of mirex to cause liver tumors (Innes et 
al. 1969; NTP 1990; Ulland et al. 1977), adrenal gland pheochromocytomas (NTP 1990), and rare renal 
tumors (NTP 1990).  A study in mice and rats also showed the ability of chlordecone to increase liver 
tumors (NCI 1976).  The U.S. Department of Health and Human Services categorized both mirex and 
chlordecone (Kepone) as reasonably anticipated to be human carcinogens (NTP 2016a, 2016b).  EPA has 
classified chlordecone as likely to be carcinogenic to humans (IRIS 2009).  Mirex has not been assessed 
for carcinogenicity by EPA (IRIS 1992).  The International Agency for Research on Cancer (IARC 
1987a, 1987b) has classified mirex and chlordecone as Group 2B substances (possibly carcinogenic to 
humans). 
 
1.3   MINIMAL RISK LEVELS (MRLs) 
 
No data were available from which to derive inhalation MRLs for mirex.  As presented in Figure 1-3, 
available data have identified the kidney and liver as sensitive targets of mirex toxicity following oral 
exposure.  No acute- or intermediate-duration oral MRLs were derived for mirex due to inadequacy of 
available data (see Appendix A).  The oral database was considered adequate for derivation of a chronic-
duration oral MRL for mirex.  The MRL value is summarized in Table 1-1 and discussed in detail in 
Appendix A. 
 
No data were available from which to derive inhalation MRLs for chlordecone.  As presented in 
Figure 1-4, available data have identified the kidney and liver as sensitive targets of chlordecone toxicity 
following oral exposure.  The oral database was considered adequate for derivation of acute-, 
intermediate-, and chronic-duration oral MRLs for chlordecone.  The MRL values are summarized in 
Table 1-2 and discussed in detail in Appendix A. 
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Figure 1-3.  Summary of Sensitive Targets of Mirex – Oral 
  
The liver, developmental endpoints, reproductive endpoints, and endocrine system are the most 
sensitive targets of mirex.   
Numbers in circles are the lowest LOAELs (mg/kg/day) for all health effects in animals; no reliable dose-
response data were available for humans. 
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Figure 1-4.  Summary of Sensitive Targets of Chlordecone – Oral 
  
The liver and endocrine system are the most sensitive targets of chlordecone.  
Numbers in circles are the lowest LOAELs (mg/kg/day) for all health effects in animals; no reliable dose-
response data were available for humans. 
 
 
 
MIREX AND CHLORDECONE  13 
 
1.  RELEVANCE TO PUBLIC HEALTH 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
Table 1-1.  Minimal Risk Levels (MRLs) for Mirexa 
 
Exposure duration MRL Critical effect Point of departure 
Uncertainty and 
modifying factors Reference 
Inhalation exposure (ppm) 
 Acute Insufficient data for MRL derivation 
 Intermediate Insufficient data for MRL derivation 
 Chronic Insufficient data for MRL derivation 
Oral exposure (mg/kg/day) 
 Acute Insufficient data for MRL derivation 
 Intermediate Insufficient data for MRL derivation 
 Chronic 
(provisional) 
0.0003 Liver lesions 0.075 (NOAEL) UF 100 
MF 3b 
NTP 1990 
 
aSee Appendix A for additional information. 
bModifying factor of 3 to protect for developmental toxicity. 
 
LOAEL = lowest-observed-adverse-effect level; MF = modifying factor; NOAEL = no-observed-adverse-effect level; 
UF = uncertainty factor 
 
Table 1-2.  Minimal Risk Levels (MRLs) for Chlordeconea 
 
Exposure 
duration MRL Critical effect 
Point of 
departure 
Uncertainty 
factor Reference 
Inhalation exposure (ppm) 
 Acute Insufficient data for MRL derivation 
 Intermediate Insufficient data for MRL derivation 
 Chronic Insufficient data for MRL derivation 
Oral exposure (mg/kg/day) 
 Acute 0.01 Neurological effects 1.25 (NOAEL) 100 EPA 1986a 
 Intermediate 
(provisional) 
0.003 Neurological and male 
reproductive effects 
0.26 (NOAEL) 100 Linder et al. 
1983 
 Chronic 0.0005 Renal effects 0.05 (NOAEL) 100 NTP 1990 
 
aSee Appendix A for additional information.  
 
LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level 
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CHAPTER 2.  HEALTH EFFECTS 
 
2.1   INTRODUCTION  
 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of mirex and 
chlordecone.  It contains descriptions and evaluations of toxicological studies and epidemiological 
investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic 
data to public health. 
 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
 
Mirex and chlordecone are structurally similar insecticides that are derivatives of cyclopentadiene.  The 
only structural difference is that mirex has two bridgehead chlorine atoms where chlordecone has a 
carbonyl oxygen atom.  As suggested by this similarity in structure, these two chemicals share some 
similarities in their toxicity profiles.  However, the toxicity profiles of these two chemicals differ in a 
number of aspects.  Therefore, each chemical will be discussed separately below. 
 
To help public health professionals and others address the needs of persons living or working near hazardous 
waste sites, the information in this section is organized by health effect.  These data are discussed in terms of 
route of exposure (inhalation, oral, and dermal) and three exposure periods:  acute (≤14 days), intermediate 
(15–364 days), and chronic (≥365 days). 
 
As discussed in Appendix B, a literature search was conducted to identify relevant studies examining health 
effect endpoints.  Figure 2-1 for mirex and Figure 2-2 for chlordecone provide overviews of the database of 
studies in humans or experimental animals included in this chapter of the profile.  These studies evaluate the 
potential health effects associated with inhalation, oral, or dermal exposure to mirex or chlordecone, but may 
not be inclusive of the entire body of literature. 
 
Summaries of the human observational studies for mirex and chlordecone are presented in Tables 2-1 and 
2-2, respectively.  Animal inhalation studies are not available for mirex or chlordecone.  Animal oral 
studies are presented in Table 2-3 and Figure 2-3 for mirex and Table 2-4 and Figure 2-4 for chlordecone.  
Animal dermal studies are presented in Table 2-5 for mirex and Table 2-6 for chlordecone. 
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Levels of significant exposure (LSEs) for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.  
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an endpoint should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these endpoints.  ATSDR believes 
that there is sufficient merit in this approach to warrant an attempt at distinguishing between "less 
serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.  Levels of exposure associated with cancer (Cancer Effect Levels, CELs) are 
indicated in Table 2-3 and Figure 2-3 for mirex and Table 2-4 and Figure 2-4 for chlordecone. 
 
A User's Guide has been provided at the end of this profile (see Appendix C).  This guide should aid in 
the interpretation of the tables and figures for LSEs and MRLs. 
 
Mirex.  Human data regarding potential health effects of mirex exposure are limited to assessment of 
possible associations between mirex blood levels and selected health outcomes.  No data were located 
regarding occupational exposure to mirex. 
 
As illustrated in Figure 2-1, human studies related to mirex predominantly evaluated reproductive, 
developmental, and cancer endpoints, as well as diabetes.  The human data do not provide exposure-
response data for mirex.  Available animal data suggest the following sensitive targets of mirex toxicity: 
 
• Developmental endpoint:  Particularly sensitive developmental effects following prenatal and/or 
early postnatal exposure to mirex in animals were cardiac dysrhythmias, cataracts, and other 
lesions of the lens. 
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• Reproductive endpoint:  Studies in animals suggest that both male and female reproductive 
systems are adversely affected by mirex, indicated by histopathologic effects on reproductive 
organs and decreased fertility resulting from mirex treatment of either males or females. 
 
• Hepatic endpoint:  In the liver, mirex causes adaptive changes similar to those seen with other 
chlorinated hydrocarbon insecticides as well as decreased hepatobiliary function, decreased 
glycogen storage, and histopathologic lesions. 
 
• Renal endpoint:  Increases in glomerulosclerosis and proteinuria have been observed in the 
kidneys of mirex-treated animals. 
 
• Endocrine endpoint:  Adverse effects were observed in the thyroid and adrenal glands of mirex-
treated animals. 
 
• Cancer:  The carcinogenicity of mirex has been demonstrated, particularly in the liver of both 
male and female rats and mice. 
 
Chlordecone.  Within a single cohort of 133 men exposed to chlordecone during its production in the 
mid-1970s, as many as 76 experienced neurological symptoms.  Other effects in some workers included 
oligospermia and liver enlargement.  There were no measurements of chlordecone levels in the working 
environment.  Industrial hygiene was poor at the facility; therefore, chlordecone exposure may have 
included inhalation, oral, and/or dermal routes.  Other human data regarding potential health effects is 
limited to assessments of possible associations between chlordecone blood levels, placental levels, and/or 
levels in maternal milk in studies of a population in Guadeloupe, French West Indies, where chlordecone 
had been used on banana plantations. 
 
As illustrated in Figure 2-2, human studies related to chlordecone predominantly evaluated reproductive, 
developmental, and neurological endpoints.  The human data do not provide exposure-response data for 
chlordecone.  Available human and animal data suggest the following sensitive targets of chlordecone 
toxicity: 
 
• Hepatic endpoint:  Some people involved in the production of chlordecone exhibited liver effects 
such as hepatomegaly, evidence of increased microsomal enzyme activity, mild inflammatory 
changes, and fatty degeneration. 
 
• Renal endpoint:  Increased severity of selected kidney lesions have been observed in rats 
chronically exposed to chlordecone. 
 
• Endocrine endpoint:  Chlordecone treatment of animals resulted in effects on the adrenal gland 
that included increased weight, depletion of epinephrine, hyperplasia, loss of adrenal lipid, and 
histopathologic lesions. 
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• Neurological endpoint:  Tremors, unfounded anxiety or irritability, blurring of vision, headache, 
and increases in cerebrospinal fluid pressure were found in workers exposed to high levels of 
chlordecone during its manufacture. 
 
• Reproductive endpoint:  Some men involved in the production of chlordecone exhibited decreases 
in sperm count and motility.  Adverse effects on the reproductive system have been demonstrated 
in male and female animals exposed to chlordecone. 
 
• Developmental endpoint:  Effects such as increased stillbirths, decreased postnatal viability, 
delayed skeletal ossification, selected anomalies and malformations, and subtle neurological 
changes have been associated with gestational exposure to chlordecone in animals. 
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Figure 2-1.  Overview of the Number of Studies Examining Mirex Health Effects 
  
Most studies examined the potential body weight, hepatic, and developmental effects of mirex 
More studies evaluated health effects in animals than humans (counts represent studies examining endpoint) 
 
 
*Includes studies discussed in Chapter 2.  A total of 161 studies include those finding no effect.  Most studies examined multiple endpoints.  
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Figure 2-2.  Overview of the Number of Studies Examining Chlordecone Health Effects 
  
Most studies examined the potential body weight, hepatic, and neurological effects of chlordecone 
More studies evaluated health effects in animals than humans (counts represent studies examining endpoint) 
 
 
*Includes studies discussed in Chapter 2.  A total of 198 studies include those finding no effect.  Most studies examined multiple endpoints. 
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Table 2-1.  Studies Designed to Evaluate Associations Between Mirex in Blood and Health Outcomes in Humans 
 
Reference and study population Exposure  Outcomes 
Diabetes 
Aminov et al. 2016 
 
Cross-sectional study of an adult 
Native-American (Mohawk) 
population (224 men and 377 women, 
18–84 years of age; 41 men and 
70 women diabetics) 
Exposure:  Serum mirex level (MDL 0.02 ppb) 
Serum mirex <MDL in 16.1% of subjects (mean 
0.12±0.15 ppb; range <MDL–1.67 ppb); 
categorization by quartile 
 
Logistic regression adjustments:  sex, age 
category, lifetime smoking status, other 
analytes (selected polychlorinated biphenyls 
and chlorinated pesticides) 
No association between serum mirex level and risk of 
diabetes 
 
OR 1.36; 95% CI 0.50, 3.68; p=0.54 
Codru et al. 2007 
 
Cross-sectional study of an adult 
Native-American (Mohawk) 
population (352 subjects; 134 males 
and 218 females ≥30 years of age; 
71 diabetics) 
Exposure:  Serum mirex level (MDL 0.02 ppb) 
86.4% of subjects had measurable serum mirex 
levels (mean 0.13±0.16 ppb) 
Categorization by tertile according to mirex wet-
weight and lipid-adjusted concentration 
(concentrations not specified) 
 
Logistic regression adjustments:  sex, age 
category, lifetime smoking status, other 
analytes (selected polychlorinated biphenyls 
and chlorinated pesticides) 
 
No association between serum mirex level and risk of 
diabetes 
 
OR (95% CI): 
 
Wet-weight: 
0.7 (0.3, 1.7); T2 vs T1 
0.3 (0.1, 0.8); T3 vs T1 
 
Lipid-adjusted: 
0.6 (0.3, 1.4); T2 vs T1 
0.3 (0.1, 0.9); T3 vs T1 
 
Everett and Matheson 2010 
 
Cross-sectional study of 
3,364 participants in 1999–2004 
NHANES survey 
Exposure:  Serum mirex level (maximum LOD 
14.6 ng/g lipid adjusted); mirex blood level was 
above the maximum limit of detection in 7.7% of 
participants 
 
Comparisons made between subjects with 
serum mirex <14.6 ng/g lipid adjusted (referent 
group) and subjects with serum mirex 
≥14.6 ng/g lipid 
 
Logistic regression adjustments:  age, 
gender, race/ethnicity, education, poverty 
income ratio, body mass index, waist 
circumference, physical activity, family history 
of diabetes 
No association between serum mirex levels above the 
maximum LOD and risk of total diabetes or pre-diabetes 
 
OR (59% CI): 
 
1.65(0.93, 2.92) for total diabetes 
1.15(0.65, 2.03) for pre-diabetes 
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Table 2-1.  Studies Designed to Evaluate Associations Between Mirex in Blood and Health Outcomes in Humans 
 
Reference and study population Exposure  Outcomes 
Son et al. 2010 
 
Selected participants in a community-
based health survey in South Korea; 
included 40 subjects with fasting 
blood glucose level ≥126 mg/dL or 
who were taking antidiabetic 
medication (considered type 2 
diabetes cases) and 40 age- and sex-
matched subjects with mean fasting 
plasma glucose of 87.7±9.3 mg/dL; 
average age of 55.6 years; 52.5% 
males 
Exposure:  Median serum concentration of 
mirex by wet weight categorized by tertile: 
T1: 6.6 pg/g 
T2: 11.7 pg/g 
T3: 27.8 pg/g 
 
Logistic regression adjustments:  age, sex, 
body mass index, alcohol, smoking, total 
cholesterol, triglyceride 
 
Exposure:  Lipid-standardized median serum 
concentration of mirex by tertile: 
T1: 1.0 ng/g lipid 
T2: 2.0 ng/g lipid 
T3: 4.5 ng/g lipid 
 
Logistic regression adjustments:  age, sex, 
body mass index, alcohol, smoking 
Serum mirex level was associated with risk of diabetes 
by wet-weight evaluation, but not by lipid-standardized 
evaluation 
 
OR (95% CI): 
 
Wet weight (ptrend 0.04): 
1.4 (0.2, 8.6); T2 vs T1 
6.5 (CI 1.1, 40.1); T3 vs T1 
 
Lipid-standardized (ptrend 0.08): 
1.6 (0.4, 6.6); T2 vs T1 
3.7 (0.9, 15.8); T3 vs T1 
Metabolic syndrome 
Rosenbaum et al. 2017 
 
Cross-sectional study of 
548 residents of Anniston, Alabama 
included in the Anniston Community 
Health Survey (68% female; mean 
age 53.6±16.2 years; 56% white, 44% 
African American, 59% met criteria for 
metabolic syndrome) 
Exposure:  Serum mirex level (LOD not 
specified) 
 
Categorized by quintile (parts per trillion): 
Q1: 1.30–24.24 
Q2: 24.25–48.44 
Q3: 48.45–74.16 
Q4: 74.17–128.96 
Q5: 128.97–2,574.40 
 
Logistic regression adjustments:  age; 
educational status, sex; marital status, race; 
body mass index, family history of heart 
disease, diabetes; liver disease; alcohol 
consumption; current smoking status; total 
lipids 
No association between serum mirex level and risk of 
metabolic syndrome 
 
OR (95% CI): 
 
0.59 (0.27, 1.29); Q2 vs Q1 
0.77 (0.34, 1.74); Q3 vs Q1 
0.64 (0.26, 1.57); Q4 vs Q1 
0.58 (0.23–1.45); Q5 vs Q1 
 
Reproductive effects 
Grindler et al. 2015 Exposure:  Serum mirex level Among women 45–55 years of age, serum mirex was 
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Table 2-1.  Studies Designed to Evaluate Associations Between Mirex in Blood and Health Outcomes in Humans 
 
Reference and study population Exposure  Outcomes 
 
Cross-sectional survey using 
NHANES data from 1999–2008 
 
Primary analysis: menopausal women 
(>30 years of age) with a laboratory 
assessment of endocrine-disrupting 
chemicals 
 
Secondary analysis: 225 women 45–
55 years of age 
 
Minimum: 0.50 ng/g 
Median: 3.89 ng/g 
90th percentile: 9.46 ng/g 
Maximum: 2,960 ng/g 
 
Logistic regression adjustments:  age, 
reference date year, serum lipids, education, 
race/ethnicity, smoking, alcohol intake 
positively associated with being menopausal 
 
OR 3.00; 95% CI 1.57, 5.73 
Lebel et al. 1998 
 
Case-control study of 86 women with 
endometriosis and 70 controls 
Exposure:  Serum mirex level (LOD 0.02–
0.03 µg/L); mirex was measurable in 56% of 
subjects 
No significant difference in crude geometric mean mirex 
level (lipid-standardized) between endometriosis cases 
and controls 
 
Cases: 3.4 µg/kg lipids (95% CI 2.9, 3.9) 
Controls: 3.1 µg/kg lipids (95% CI 2.6, 3.6) 
Upson et al. 2013 
 
Population-based case-control study 
of endometriosis among 18–49-year-
old enrollees of a health care system 
in Washington State (248 surgically-
confirmed endometriosis cases and 
538 population-based controls) 
Exposure:  Serum mirex level (LOD 10 pg/g; 
median mirex level 15.47 pg/g); categorized 
into three groups: 
 
All endometriosis: 
Low: ≤10 pg/g 
Middle: >10.0–15.47 pg/g 
High: >15.47 pg/g 
 
Ovarian endometriosis: 
Low: ≤10 pg/g 
Middle: >10.0–15.47 pg/g 
High: >15.47 pg/g 
 
Logistic regression adjustments:  age, 
reference date year, serum lipids, education, 
race/ethnicity, smoking, alcohol intake 
Borderline positive association between mirex serum 
level and risk of endometriosis, but no association 
between mirex serum level and risk of ovarian 
endometriosis 
 
OR (95% CI): 
 
All endometriosis: 
1.1 (0.7, 1.8); middle vs low 
1.5 (1.0, 2.2); high vs low 
 
Ovarian endometriosis: 
1.3 (0.8, 2.2); middle vs low 
1.2 (0.7, 2.1); high vs low 
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Developmental effects 
Araki et al. 2018 
 
Prospective birth cohort (Hokkaido 
Study Sapporo Cohort) of 
232 pregnant women (23–35 weeks 
of gestation) who presented at an 
obstetrics and gynecology hospital 
between July 2002 and October 2005, 
lived in the Sapporo City area, 
planned to deliver at the facility, and 
provided maternal serum and cord 
blood samples for analysis of 
maternal organochlorine pesticide 
levels and cord blood levels of 
selected steroid and reproductive 
hormones 
Exposure:  Maternal serum mirex level (LOD 
0.5 pg/g wet weight). 
 
Minimum: 0.88 pg/g 
25th percentile: 4.11 pg/g 
50th percentile: 6.04 pg/g 
75th percentile: 8.53 pg/g 
Maximum: 30.11 pg/g 
 
Categorized by quartile: 
Q1: ≤4.12 pg/g 
Q2: 4.13–6.04 pg/g 
Q3: 6.05–8.52 pg/g 
Q4: ≥8.53 pg/g 
 
Linear regression adjustments:  maternal 
age, parity, gestational age 
Among boys: maternal serum mirex inversely associated 
with cord blood testosterone, cortisol, cortisone, 
prolactin; testosterone-androstenedione (T-A) ratio, 
androstenedione-dehydroepiandosterone (A-DHEA) 
ratio; positively associated with cord blood DHEA, FSH, 
adrenal androgen-glucocorticoid (AA-G) ratio, FSH-
inhibin B ratio 
 
Testosterone: β -0.262; 95% CI -0.492, -0.032 
Cortisol: β -0.588; 95% CI -0.959, -0.218 
Cortisone: β -0.572; 95% CI -1.002, -0.142 
Prolactin: β -0.262; 95% CI -0.492, -0.032 
T-A ratio: β -0.202; 95% CI -0.350, -0.053 
A-DHEA ratio: β -0.274; 95% CI -0.494, -0.054 
DHEA: β 0.213; 95% CI 0.007, 0.420 
FSH: β 0.229; 95% CI -0.004, 0.453 
AA-G ratio: β 0.744; 95% CI 0.249, 1.239 
FSH-inhibin B ratio: β 0.299; 95% CI 0.009, 0.589 
 
Adjusted regression coefficients (β values) based on 
10-fold increase of maternal serum mirex and 
log10-transformed hormone level) 
 
Among boys: least square means of cord blood hormone 
levels by quartile of maternal serum mirex revealed 
inverse associations for cord blood testosterone 
(ptrend 0.039) and for T-A ratio (ptrend 0.016) 
Denham et al. 2005 
 
Population-based cohort of 
138 Akwesasne Mohawk Indian girls 
10–16.9 years of age 
 
Exposure:  Serum mirex level (LOD 0.02 ppb) 
 
Referent: <0.02 ppb 
Low: 0.02–0.03 ppb 
High: 0.04–1.17 ppb 
 
Menarcheal status (pre- or postmenarcheal) 
predicted using binary logistic regression 
analysis; age, socioeconomic status, and body 
No association between serum mirex and menarcheal 
status 
 
β 0.73; SE 0.955; p=0.45 (low vs referent) 
β 0.13; SE1.052; p=0.91 (high vs referent) 
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Reference and study population Exposure  Outcomes 
mass index were tested as potential 
confounders 
Fenster et al. 2006 
 
Longitudinal birth cohort study of the 
health of pregnant women (n=385) 
and their children living in Salinas 
Valley, California, and enrolled in 
CHAMACOS; the study evaluated 
possible associations between in 
utero organochlorine pesticide 
exposure (including mirex) and fetal 
growth and length of gestation 
Exposure:  Presence of detectable mirex 
maternal blood (LOD range 0.01–0.69 ng/g 
lipid) 
 
Detected in 85.9% of blood samples from 
384 women (mean level of 0.3 ng/g lipid; range 
0.04–15.9 ng/g lipid) 
No association between maternal blood mirex level and 
length of gestation, birth weight, or crown-heel length 
 
Length of gestation: β -0.12; 95% CI -0.49, 0.26 
Birth weight: β -87; 95% CI -207, 33 
Crown-heel length: β -0.39; 95% CI -1.01, 0.22 
 
Fernandez et al. 2007 
 
Nested case-control study of 
48 newborns diagnosed with 
cryptorchidism and/or hypospadias 
and 114 boys without malformations 
matched by gestational age, date of 
birth, and parity; subjects were 
identified at Granada University 
Hospital in Granada, Spain  
Exposure:  Presence of detectable mirex in 
placental sample (LOD in the range of 0.1–
3 ng/mL, not otherwise specified in study 
report) 
 
Detected in 12/48 cases (mean level of 
1.4 ng/mL [SD 1.0]; range 1.0–3.0 ng/mL) and 
18/114 controls (mean level of 3.7 ng/mL [SD 
3.7]; range 1.0–15.0 ng/mL) 
 
Logistic regression adjustments:  mother’s 
age at delivery, infant weight at birth 
Detectable mirex in placenta was positively associated 
with urogenital malformations 
 
OR 3.42; 95% CI 1.19, 9.77; (mirex ≥LOD vs <LOD) 
Guo et al. 2014 
 
A total of 81 pairs of mothers and 
newborns enrolled at four hospitals in 
four different cities in China; the study 
evaluated possible associations 
between mirex in maternal serum and 
birth weight and between mirex in 
newborn cord serum and birth weight 
Exposure:  Maternal serum mirex detected in 
47/71 samples: 
Mean 0.36 ng/g lipid 
Median 0.23 ng/g lipid 
Minimum <0.4 pg/Ml (LOD) 
Maximum 66.36 ng/g lipid) 
 
Cord serum mirex detected in 13/60 samples: 
Mean 0.27 ng/g lipid 
Median <LOD 
Minimum <LOD 
Maximum 23.94 ng/g lipid) 
 
Maternal serum mirex not associated with birth weight: 
β -32.9; 95% CI -138.4, 72.6)a 
 
Cord serum mirex not associated with birth weight: 
β -111.6; 95% CI -339.3, 116.2b 
 
 
MIREX AND CHLORDECONE  25 
 
2.  HEALTH EFFECTS 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
Table 2-1.  Studies Designed to Evaluate Associations Between Mirex in Blood and Health Outcomes in Humans 
 
Reference and study population Exposure  Outcomes 
Multivariate linear regression adjustments:  
maternal age, maternal body mass index at 
delivery, infant gender, gestational week 
Puertas et al. 2010 
 
Population-based randomly-sampled 
birth cohort (n=104) recruited 
between 2000 and 2002 in Granada, 
Spain, and evaluated for cognitive 
development at 4 years of age 
Exposure:  Placental mirex (presence or 
absence, based on LOQ of 1 ng/mL) 
 
Referent: <1 ng/mL in 77/104 placentas 
High: ≥1 ng/mL in 27/104 placentas 
Median: 1.4 ng/mL; range 0.5–19.1 ng/mL 
 
Multivariate regression adjustments:  age at 
evaluation, gestational age, maternal education 
level, maternal mental health, maternal 
emotional bond of affection toward children, 
testing psychologist, sum of DDTs and 
hexachlorobenzene 
Mirex presence in placenta was negatively associated 
with: 
 
Working memory (β -6.23 p=0.01) 
Quantitative functions (β -7.61 p=0.04) 
Breast cancer 
Itoh et al. 2009 
 
Case-control study of 403 breast 
cancer patients and 403 matched 
pairs at four hospitals in Japan 
Exposure:  Lipid-adjusted serum mirex 
concentration; categorized by quartile median: 
Q1: 1.4 ng/g lipid 
Q2: 1.9 ng/g lipid 
Q3: 2.4 ng/g lipid 
Q4: 3.5 ng/g lipid 
 
Logistic regression adjustments:  serum total 
lipid concentration, body mass index, 
menopausal status and age at menopause, 
smoking status, fish consumption, vegetable 
consumption, family history of breast cancer in 
a first-degree relative, age at first childbirth, 
parity, age at menarche, history of breast 
cancer screening, history of breast feeding, 
age, area of residence 
Negative association between lipid-adjusted median 
serum mirex concentration and risk of breast cancer 
 
OR 0.56; 95% CI 0.28, 1.13; Q2 vs Q1 
OR 0.60; 95% CI 0.30, 1.19; Q3 vs Q1 
OR 0.40; 95%CI 0.19, 0.84; Q4 vs Q1 
 
ptrend 0.02 
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Moysich et al. 1998 
 
Subset of 154 cases and 
192 community controls (ages 41–
85 years) from a case-control study of 
postmenopausal breast cancer in 
western New York 
Exposure:  Serum mirex based on LOD (0.06–
0.99 ng/g): 
 
<LOD 
>LOD 
 
Logistic regression adjustments:  age, 
education, family history of breast cancer, 
parity, quetelet index (body mass index), 
duration of lactation (except for never lactated 
subjects), age at first birth, years since last 
pregnancy, fruit and vegetable intake, serum 
lipids 
 
Total study group (154 cases, 192 controls): No 
association between detectable mirex in serum and risk 
of postmenopausal breast cancer 
 
OR 1.37; 95% CI 0.78, 2.39 (>LOD vs <LOD) 
 
Never lactated group (46 cases, 61 controls): Borderline 
positive association between detectable mirex in serum 
and risk of postmenopausal breast cancer 
 
OR 2.42; 95% CI 0.98, 4.32 (>LOD vs <LOD) 
 
Ever lactated group (85 cases, 106 controls): No 
association between detectable mirex in serum and risk 
of postmenopausal breast cancer 
 
OR 1.08; 95% CI 0.52–2.25 (>LOD vs <LOD) 
Prostate cancer 
Koutros et al. 2015a, 2015b 
 
Nested case-control study using data 
from the population-based Janus 
Serum Bank cohort of Norway.  
Subjects were 149 cases of 
metastatic prostate cancer with no 
history of cancer (except 
nonmelanoma skin cancer) and were 
diagnosed at least 2 years after 
serum collection and 314 controls 
matched by region, date of blood 
draw, and age at blood draw 
Exposure:  Plasma level of mirex (LOD not 
specified); median levels were 1.8 ng/g lipid 
(range 0.1–37.1) for cases and 1.7 ng/g lipid 
(range 0.1–18.3) for controls; categorized by 
quartile to approximate equal numbers of cases 
per quartile 
 
Statistical analysis adjustments:  county, age 
at blood draw, date at blood draw 
Negative association between lipid-adjusted serum 
mirex concentration and risk of prostate cancer 
 
OR per unit increase ln-transformed ng/g lipid: 
 
OR 1.01; 95% CI 0.55, 1.86; Q2 vs Q1 
OR 0.94; 95% CI 0.50, 1.77; Q3 vs Q1 
OR 1.73; 95% CI 0.90, 3.31; Q4 vs Q1 
 
ptrend 0.07 
Sawada et al. 2010 
 
Nested case-control study using data 
from the Japan Public Health Center-
based Prospective Study.  Nested 
case-control subjects were 
201 newly-diagnosed prostate cancer 
Exposure:  Plasma level of lipid-adjusted mirex 
(LOD 3.0 pg/g wet) categorized by quartile: 
 
Q1: <3.1 pg/g lipid-adjusted 
Q2: 3.1–4.0 pg/g lipid-adjusted 
Q3: 4.1–5.9 pg/g lipid-adjusted 
Q4: ≥6.0 pg/g lipid-adjusted 
Negative association between lipid-adjusted serum 
mirex concentration and risk of prostate cancer 
 
OR 0.54; 95% CI 0.30, 0.97; Q2 vs Q1 
OR 0.85; 95% CI 0.49, 1.46; Q3 vs Q1 
OR 1.14 (0.61, 2.13); Q4 vs Q1 
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cases and 2 controls for each case  
Statistical analysis adjustments:  smoking 
status, alcohol intake (≥1–2 times/week), 
marital status, body mass index, daily intake of 
green tea and miso soup (measured or reported 
at baseline) 
ptrend 0.22 
Non-Hodgkin’s lymphoma 
Spinelli et al. 2007 
 
Population-based case-control study 
in British Columbia, Canada, including 
422 pretreatment non-Hodgkin’s 
lymphoma cases and 460 controls 
Exposure:  Mirex in serum (lipid-adjusted) 
categorized by low or high concentration: 
 
Low: ≤1.43 ng/g 
High: >1.43–60.46 ng/g 
 
 
Logistic regression adjustments: age, sex 
Positive association between lipid-adjusted serum mirex 
and risk of non-Hodgkin’s lymphoma 
 
OR 1.44; 95% CI 1.08, 1.92 (high versus low) 
 
ptrend 0.013 
 
aSamples with detection rate >50%, but <80% stratified into three groups using LOD and median concentration of detected samples as cut 
points. 
bSamples with detection rate >20%, but <50% stratified by the LOD value into two groups. 
 
CHAMACOS = Center for the Health Assessment of Mothers and Children of Salinas; CI = confidence interval; DDT = dichlorodiphenyltrichloroethane; 
FSH = follicle-stimulating hormone; ln = natural log; LOD = limit of detection or level of detection; LOQ = limit of quantitation; MDL = method detection limit; 
NHANES = National Health and Nutrition Examination Survey; OR = odds ratio; Q = quartile; SD = standard deviation; SE = standard error; T = tertile; 
vs = versus 
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Cardiovascular effects 
Saunders et al. 2014 
 
Subpopulation of 779 pregnant 
women in the TIMOUN prospective 
mother-child cohort study 
(Guadeloupe, French West Indies) 
between November 2004 and 
December 2007 
Exposure:  Serum chlordecone level (LOD 
0.06 µg/L) 
 
Q1: <0.17 µg/L; referent 
Q2: 0.17–0.38 µg/L 
Q3: 0.39–0.80 µg/L 
Q4: >0.80 µg/L 
 
Multiple logistic regression adjustments:  
maternal place of birth, place of enrollment, 
maternal age, pre-pregnancy body mass index, 
maternal weight gain during pregnancy, total 
lipids in maternal plasma 
Serum chlordecone negatively associated with 
hypertensive disorders during pregnancy 
 
Quartile n 
Q1 28 OR 1.0 (referent) 
Q2 19 OR 0.6; 95% CI 0.3, 1.1; Q2 vs Q1 
Q3 7 OR 0.2; 95% CI 0.1, 0.5; Q3 vs Q1 
Q4 11 OR 0.3; 95% CI 0.1, 0.6; Q4 vs Q1 
 
Serum chlordecone not associated with preeclampsia 
 
Quartile n 
Q1 7 OR 1.0 (referent) 
Q2 8 OR 1.1; 95% CI 0.3, 2.8; Q2 vs Q1 
Q3 9 OR 1.2; 95% CI 0.4, 3.4; Q3 vs Q1 
Q4 7 OR 1.0; 95% CI 0.4, 1.7; Q4 vs Q1 
Diabetes 
Saunders et al. 2014 
 
Subpopulation of 779 pregnant 
women in the TIMOUN prospective 
mother-child cohort study 
(Guadeloupe, French West Indies) 
between November 2004 and 
December 2007 
Exposure:  Serum chlordecone level (LOD 
0.06 µg/L) 
 
Q1: <0.17 µg/L; referent 
Q2: 0.17–0.38 µg/L 
Q3: 0.39–0.80 µg/L 
Q4: >0.80 µg/L 
 
Multiple logistic regression adjustments:  
maternal place of birth, place of enrollment, 
maternal age, pre-pregnancy body mass index, 
maternal weight gain during pregnancy, total 
lipids in maternal plasma 
Serum chlordecone not associated with diabetes 
mellitus during pregnancy 
 
Quartile n 
Q1 20 OR 1.0 (referent) 
Q2 25 OR 1.1; 95% CI 0.6, 2.2; Q2 vs Q1 
Q3 10 OR 0.5; 95% CI 0.2, 1.1; Q3 vs Q1 
Q4 16 OR 0.7; 95% CI 0.3, 1.5; Q4 vs Q1 
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Endocrine effects 
Emeville et al. 2013 
 
Population-based cross-sectional 
study using a random sample of 
277 healthy, non-obese, middle-aged 
men from the French West Indies 
Exposure:  Serum chlordecone level (LOD 
0.06 µg/L) 
 
Geometric mean: 0.40 µg/L 
90th percentile: 1.74 µg/L 
Maximum: 44.1 µg/L 
 
Linear regression adjustments:  variable 
according to particular steroid hormone 
analyzed, but included age, alcohol, season of 
blood sampling, body mass index, education, 
PCB-153, smoking, waist-to-hip ratio, and/or 
blood total lipids 
No association between serum chlordecone and blood 
levels of steroid hormones 
Developmental effects 
Boucher et al. 2013 
 
Subpopulation of 141 pregnant 
women in the TIMOUN prospective 
mother-child cohort study 
(Guadeloupe, French West Indies) 
between November 2004 and 
December 2007 
Exposure:  Chlordecone cord blood level (LOD 
0.06 µg/L): 
 
Referent: <0.06 µg/L (LOD) 
Low: 0.07–0.24 µg/L 
High: 0.24–3.91 µg/L 
 
Linear regression adjustments: included child 
gender, maternal education, as well as the 
following by test category: 
Personal-social: HOME, breastfeeding duration 
Communication: HOME, family income, 
maternal occupation, marital status, 
breastfeeding duration 
Problem solving: parity, breastfeeding duration, 
maternal age 
Fine motor: child age 
Gross motor: marital status, breastfeeding 
duration 
Cord blood chlordecone level was negatively associated 
with ASQ score for fine motor function among boys 
evaluated at 18 months of age 
 
β -32; p=0.028 for fine motor function (high vs referent) 
 
Result indicates that prenatal exposure to chlordecone 
may impair fine motor development in boys 
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Cordier et al. 2015 
 
Subpopulation of 111 pregnant 
women in TIMOUN prospective 
mother-child cohort study 
(Guadeloupe, French West Indies) 
between November 2004 and 
December 2007 
Exposure:  Chlordecone cord blood level (LOD 
0.06 µg/L): 
 
Referent: <0.06 µg/L (LOD) 
Low: 0.06–0.31 µg/L 
High: ≥0.31 µg/L 
 
Chlordecone in maternal milk samples at 
3 months postdelivery (LOD 0.34 µg/L): 
 
Referent: <0.5 µg/L 
Low: 0.5–0.9 µg/L 
High: ≥0.9 µg/L 
 
Linear regression adjustments: hemolysis, 
storage duration, sex, level of education, ln 
PCB-153, ln p,p′-DDE, total lipids 
Chlordecone level in cord blood positively associated 
with increased TSH level in male infants at 3 months: 
 
61.3% increased TSH; 95% CI 2.0, 155.0; p=0.04 
(high vs referent) 
 
No apparent effect on the pathway between prenatal 
chlordecone exposure and fine motor child development 
assessed at 18 months of age 
Costet et al. 2015 
 
Subpopulation of 222 pregnant 
women in the TIMOUN prospective 
mother-child cohort study 
(Guadeloupe, French West Indies) 
between November 2004 and 
December 2007  
Exposure:  Chlordecone cord blood level (LOD 
0.06 µg/L): 
 
Referent: <0.06 µg/L (LOD) 
Low: 0.06–0.306 µg/L 
High: ≥0.306 µg/L 
 
Chlordecone in maternal milk samples at 
3 months postdelivery (LOD 0.34 µg/L): 
 
Referent: <0.34 µg/L (LOD) 
Low: 0.34–1.10 µg/L 
High: ≥1.10 µg/L 
Chlordecone in cord blood was associated with a higher 
body mass index at 3 months in boys: 
 
β 0.9; 95% CI 0.0, 1.8 (high vs referent) 
 
Chlordecone in cord blood was associated with a higher 
body mass index at 8 months in girls: 
 
β 0.7; 95% CI 0.0, 1.5 (high vs referent) 
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Dallaire et al. 2012 
 
Subpopulation of up to 153 infants of 
women in the TIMOUN prospective 
mother-child cohort study 
(Guadeloupe, French West Indies) 
who were pregnant between 
November 2004 and December 2007 
Exposure:  Chlordecone cord blood level (LOD 
0.06 µg/L): 
 
Referent: <0.06 µg/L (LOD) 
Low: >0.06–0.31 µg/L 
High: >0.31 µg/L 
 
Model adjustments for Fagan tests of infant 
intelligence: pre-pregnancy maternal 
employment status, cord plasma lipid 
concentration, infant vitamin supplementation, 
postnatal exposure to maternal tobacco smoke, 
number of adults living with the infant 
 
Model adjustments for motor function tests: 
plasma lipid concentration, age of infant at 
testing, birthplace of mother, domestic violence 
Chlordecone cord blood level was positively associated 
with reduced novelty preference on the Fagan Tests of 
Infant Intelligence: 
 
β -0.19; 95% CI -0.35, -0.04; p=0.022 (high vs referent) 
 
ptrend 0.019 
Detectable levels of chlordecone in cord blood were 
associated with higher risk of obtaining low scores on 
the fine motor development scale: 
 
OR 1.25; 95% CI 1.07, 1.45 (p=0.002) 
Hervé et al. 2016 
 
Subpopulation of 593 pregnant 
women in the TIMOUN prospective 
mother-child cohort study 
(Guadeloupe, French West Indies) 
between November 2004 and 
December 2007   
Exposure:  Chlordecone cord blood level (LOD 
0.02 µg/L): 
 
Referent: <0.08 µg/L 
Low: 0.08–0.20 µg/L 
Medium: 0.20–0.41 µg/L 
High: ≥0.41 µg/L 
 
Linear regression adjustments: gestational 
age, sex of the newborn, maternal height, 
maternal body mass index, enrollment site, 
place of birth, family situation, education level, 
parity, gestational hypertension, gestational 
diabetes 
No association between cord blood chlordecone and 
gestational weight 
 
β -11; 95% CI -154, 13; p=0.80 (high vs referent) 
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Kadhel et al. 2014 
 
Subpopulation of 818 pregnant 
women in the TIMOUN prospective 
mother-child cohort study 
(Guadeloupe, French West Indies) 
between November 2004 and 
December 2007  
Exposure:  Chlordecone maternal blood level 
(LOD 0.06 µg/L): 
 
Q1: <0.14 µg/L; referent 
Q2: 0.14–0.28 µg/L 
Q3: 0.29–0.51 µg/L 
Q4: 0.52–0.97 µg/L 
Q5: >0.98 µg/L 
 
Linear regression adjustments: maternal 
age, place of birth, enrollment site, marital 
status, educational level, body mass index, high 
blood pressure during pregnancy, total plasma 
lipid level 
A 1-log10 increase in chlordecone concentration was 
associated with a decreased length of gestation: 
 
β -27 weeks; 95% CI -0.50, -0.03 
 
A 1-log10 increase in chlordecone concentration was 
associated with an increased risk of preterm birth: 
 
HR 1.6; 95% CI 1.1, 2.3 
Prostate cancer 
Multigner et al. 2010 
 
Population-based case-control study 
of 623 prostate cancer cases and 671 
controls in Guadeloupe, French West 
Indies 
Exposure:  Plasma chlordecone level (LOD 
0.25 µg/L): 
 
Q1: ≤0.25 µg/L (LOD); referent 
Q2: >0.25–0.47 µg/L 
Q3: >0.47–0.96 µg/L 
Q4: >0.96 µg/L 
 
Multivariate logistic model adjustments:  
age, total plasma lipid concentration, waist-to-
hip ratio, history of prostate cancer screening 
Chlordecone plasma concentration was positively 
associated with: 
 
Risk of prostate cancer overall: 
 
OR 1.73; 95% CI 1.04, 2.88 (Q4 vs Q1) 
 
Risk of prostate cancer among subjects with family 
history of prostate cancer: 
 
OR 3.00; 95% CI 1.12, 8.07 (Q4 vs Q1) 
 
Risk of prostate cancer among subjects with past 
residence in western countries: 
 
OR 2.71; 95% CI 1.26, 5.83 (Q4 vs Q1) 
 
CI = confidence interval; HOME = Home Observation for Measurement of the Environment; HR = hazard ratio; PCB-153 = 2,2',4,4',5,5'-hexachloro-1,1'-biphenyl; 
p,p′-DDE = dichlorodiphenyldichloroethylene; ln = natural log; LOD = limit of detection or level of detection; OR = odds ratio; Q = quartile or quintile; 
TSH = thyroid stimulating hormone; vs = versus 
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Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
ACUTE EXPOSURE 
1 Rat 
(Sprague-
Dawley) 
36 M 
8 d 
ad lib 
(F) 
0, 17 BI, HP Endocr 17    
Baggett et al. 1980 
2 Rat 
(Sprague-
Dawley) 
5–11 M 
3 days 
1 time/day 
(GO) 
0, 50 OF Hepatic  50  Impaired biliary excretion 
of glucuronide conjugates; 
increased bile flow 
Berman et al. 1986 
3 Rat 
(CD)  
6–7 F 
GD 5, 5–9, 
5–14  
1, 5, or 
10 days 
1 time/day 
(GO) 
0, 10 BW, DX, OF, 
OW 
Bd wt   10 35–52% decrease in 
maternal weight gain 
Cardio   10 Significant decrease of 
maternal cardiac output 
and heart weight 
Hepatic  10  Significant increase in 
maternal liver weight 
Immuno  10  32% decrease in maternal 
spleen weight 
Repro  10  Decreased blood flow to 
ovaries, uterus, and 
fetuses; decreased 
ovarian and uterine weight 
 Develop  10  Decreased pup viability 
and pup weight; increased 
resorptions; fetal edema 
Buelke-Sam et al. 1983 
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4 Rat 
[CRL-
COBS;CD 
(SD)] 
20–30 F 
GD 5–14 or 
6–15 
1 time/day 
(GO) 
0, 10 BW, DX, LE, 
OW 
Death   10 24–25% maternal 
mortality 
Bd wt   10 >30% depressed maternal 
body weight 
Repro   10 Decreased gravid uterine 
weight 
Develop   10 >59% fetuses with edema; 
increased prenatal 
mortality; >20% decrease 
in pup body weight 
Byrd et al. 1981 
5 Rat 
(CD) 
10–38 F 
GD 7–16 
1 time/day 
(GO) 
0, 5, 7, 9.5, 
19, 38 
BW, DX, LE Death   9.5 16% maternal mortality 
Bd wt 7  9.5 36% decrease in maternal 
weight gain 
Develop 5 7 9.5 Delayed ossification; 
edematous live fetuses 
(7 mg/kg); enlarged 
cerebral ventricles and 
undescended testes 
(9.5 mg/kg) 
Chernoff et al. 1979a 
6 Rat 
(Long-
Evans) 
10–45 F 
PPD 1–4 
1 time/day 
(GO) 
1, 2.5, 5, 10 BW, DX, LE, 
OP 
Develop   10 F 35–36% mortality and 
cataracts in pups 
Chernoff et al. 1979a 
7 Rat 
(Long-
Evans) 
3–20 F 
Once 
GD 1, 2, 3, 4, 
5, 6, 7, 8, 10, 
or 14 
(GO) 
0, 10, 15 OP Develop   10  Cataracts in pups at 
postnatal days 12–14 
Chernoff et al. 1979a 
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8 Rat 
(Sprague-
Dawley) 
4 or 8 NS 
14 days 
ad lib 
(F) 
0, 0.5, 5 BW, OF, OW Bd wt 5    
Hepatic   5 Disruption of liver cord 
cells; focal stasis; central 
or midzonal hepatocellular 
necrosis 
Davison et al. 1976 
9 Rat 
(Wistar) 
7–29 M 
7–29 F 
3–7 days 
ad lib 
(F) 
0, 2, 750, 
1,000 
BI, BW, OW Bd wt 2 750  16–17% decrease in body 
weight gain 
Hepatic 2 750  Decreased hepatic 
glycogen; increased lipid 
accumulation 
Elgin et al. 1990 
10 Rat 
(Sprague-
Dawley) 
5–20 M 
Once 
(GO) 
0, 100 BC, BI, BW, 
HE, OF, OW 
Hemato  100  12% decreased 
hematocrit 
Hepatic  100  Significantly decreased 
hepatic glycogen 
Other 
noncancer 
 100  Decreased blood glucose 
Ervin and Yarbrough 1983 
11 Rat 
(Sprague-
Dawley) 
3–11 M 
Once 
(GO) 
0, 100 BC, BW, OW Endocr   100 88% increase in serum 
adrenocorticotropic 
hormone 
Ervin and Yarbrough 1985 
12 Rat 
(Sherman) 
NS M,F 
Once 
(GO; corn oil) 
NS LE Death   740 M 
600 F 
LD50 
LD50 >3,000 mg/kg with 
peanut oil as vehicle 
Gaines 1969 
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13 Rat 
(Sherman) 
10 F 
Once 
(GO) 
8 dose 
levels; lowest 
dose tested: 
50 mg/kg 
LE Death   365 LD50 
Gaines and Kimbrough 1970 
14 Rat 
(Long-
Evans) 
3–11 F 
GD 8.5–15.5 
or 6.5–15.5 
1 time/day 
(GO) 
0, 5, 6, 7, 10 DX, OF Develop   5 First-degree heart block in 
fetuses; decreased 
number of litters at 
10 mg/kg/day 
Grabowski and Payne 1980 
15 Rat 
(Long-
Evans) 
NS F 
GD 8.5–15.5 
1 time/day 
(GO) 
0, 6 DX Develop   6 36% edematous fetuses 
Grabowski 1981 
16 Rat 
(Long-
Evans) 
NS F 
GD 8.5–15.5 
or 15.5–21.5 
1 time/day 
(GO) 
0, 0.1, 0.25, 
0.5, 1, 1.5, 3, 
6 
DX, FX Develop   0.1 Cardiac arrhythmia 
Grabowski 1983a 
17 Rat 
(Long-
Evans) 
8–17 F 
 
GD 8.5–15.5 
1 time/day 
(GO) 
0, 6 BW, DX Develop   6 23% stillborn pups; 
dyspnea; cardiac rhythm 
blockade 
Grabowski and Payne 1983a 
18 Rat 
(Long-
Evans) 
9–13 F 
GD 8.5–15.5 
1 time/day 
(GO) 
0, 6 DX Develop   6 First degree heart block in 
fetuses; 14% increased 
fetal mortality 
Grabowski and Payne 1983b 
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19 Rat 
(Sprague-
Dawley) 
6 M 
Once 
(GO) 
0, 50 BC, BI, OF Hepatic  50  Increased bile flow rate 
Hewitt et al. 1986a 
20 Rat 
(Wistar) 
10–29 M 
10–29 F 
7 days 
ad lib 
(F) 
0, 2 BC, BI, OF, 
OW 
Hepatic  2  Two-fold increase in liver 
weight; increased 
cholesterol and 
triglycerides 
Jovanovich et al. 1987 
21 Rat 
(Wistar) 
7 F 
4 days 
(F) 
0, 1,000 BC, BI, BW, 
OW 
Bd wt   1,000 30% lower mean body 
weight; 77% reduction in 
body fat 
Hepatic  1,000  Two-fold increase in liver 
weight and serum 
triglycerides; 25% 
decreased in liver 
glycogen and glucose 
Endocr   1,000 Two-fold increase in 
adrenal weight 
Other 
noncancer 
 1,000  Reduced food intake; 88% 
reduction in serum 
glucose 
Jovanovich et al. 1987 
22 Rat 
(Mai-Wistar) 
50 M 
Once 
(GO) 
0, 200 BI, OF Hepatic  200  Hepatic glycogen 
depletion; periportal 
liposis; degeneration of 
endoplasmic reticulum 
Kendall 1979 
23 Rat 
(Wistar) 
18–20 F 
GD 6–15 
1 time/day 
(GO) 
0, 1.5, 3, 6, 
12.5 
LE, OF Death   6 4/20 maternal rats died 
Repro   12.5 Pregnancy failure in 45% 
of dams 
Khera et al. 1976 
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24 Rat 
(Wistar) 
20 M 
10 days 
1 time/day 
(GO) 
0, 1.5, 3, 6 OF Repro 3  6 Significantly decreased 
fertility 
Khera et al. 1976 
25 Rat 
(Sprague-
Dawley) 
3 M 
Once 
(GO) 
0, 10 BI Hepatic 10    
Klingensmith and Mehendale 1983b 
26 Rat 
(Sprague-
Dawley) 
3 M 
Once 
(GO) 
0, 20 BI, OF Hepatic  20  Induction of P450b and 
P450e mRNAs in liver 
Kocarek et al. 1991 
27 Rat 
(CD-1) 
8 M, 8 F 
5 days 
1 time/day 
(GO) 
0, 5, 10, 25, 
50 
LE, CS, GN Death   50 2/8 females died 
Mehendale et al. 1973 
28 Rat 
(Sprague-
Dawley 
3–4 M 
3 days 
1 time/day 
(GO) 
0, 50 OF Hepatic  50  Suppressed biliary 
excretion; increased bile 
flow 
Mehendale 1977c 
29 Rat 
(Sprague-
Dawley) 
6 F 
1 days 
1 or 2 times 
(GO) 
0, 1.2, 3.6, 
12, 36, 60, 
90, 120, 180, 
240 
BI, OF Hepatic  240  Increased serum ALT 
Mitra et al. 1990 
30 Rat 
(Sprague-
Dawley) 
6 M 
3 days 
1 time/day 
(GO) 
0, 0.5, 2, 10 BC, BI, HP, 
OW 
Hepatic  10  Swollen hepatocytes 
Renal 10    
Plaa et al. 1987 
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31 Rat 
(Sprague-
Dawley) 
5–12 M 
Once 
(GO) 
0, 5 BC, BI, OF, 
OW 
Hepatic 5    
Other 
noncancer 
 5  Decreased blood glucose 
Robinson and Yarbrough 1978a 
32 Rat 
(Long-
Evans) 
NS F 
GD 8–15 
1 time/day 
(GO) 
0, 6 BI, DX, HP Develop   6 F Cataracts in 49.6% of 
fetuses; 14% fetal 
mortality on GD 21 
Rogers and Grabowski 1983 
33 Rat 
(Long-
Evans) 
3–12 F 
PPD 1–4 
1 time/day 
(GO) 
0, 10 BW HP BI Develop   10 F 10–20% decrease in pup 
weight; cataracts 
Rogers and Grabowski 1984 
34 Rat 
(Long-
Evans) 
5–7 F 
GD 8–15 
1 time/day 
(GO) 
0, 6 BC, DX, HE Develop  6  Decrease in fetal 
hematocrit and plasma 
glucose 
Rogers et al. 1984 
35 Rat 
(Sherman) 
NS 
PPD 1–4 
1 time/day 
(GO) 
0, 5 DX, HP, OP Develop   5 Neonatal cortical 
degeneration and necrosis 
in lens of eye 
Scotti et al. 1981 
36 Rat 
(Sprague-
Dawley) 
7–10 F 
Once 
(GO) 
0, 100 BC, BI, OF Hepatic  100  Decreased hepatic 
glutathione 
Sunahara and Chiesa 1992 
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37 Rat 
(Sprague-
Dawley) 
4–8 F 
3 days 
1 time/day 
(GO) 
0, 12.5, 25, 
50 
BI, OF Hepatic  12.5  Decreased hepatic ion 
transport 
Teo and Vore 1990 
38 Rat 
(Sprague-
Dawley) 
5–8 M 
3 days 
1 time/day 
(GO) 
0, 50 BI, BW, OF, 
OW 
Hepatic  50  Decreased biliary function; 
decreased bile flow; 
decreased concentration 
and secretion of bile acid 
Teo and Vore 1991 
39 Rat 
(Sprague-
Dawley) 
6 M 
14 days 
1 time/day 
(GO) 
0, 0.1, 1.0, 
10 
BC, BI, BW, 
FI, HE, HP, 
OW 
Bd wt   10 55% decrease in body 
weight gain 
Hemato 10    
Hepatic  1  Significantly increased 
relative liver weight; 
significantly increased 
serum lactic 
dehydrogenase  
Villeneuve et al. 1977 
40 Rat 
(Sprague-
Dawley) 
5–7 M 
Once 
(GO) 
0, 20, 50, 
100, 150 
BI, OW Hepatic  50  Two-fold increase in liver 
weight 
Other 
noncancer 
 20  Increased serum 
corticosterone 
Williams and Yarbrough 1983 
41 Mouse 
(CD-1) 
10–25 F 
PPD 1–4 
1 time/day 
(GO) 
0, 1.5, 3.0, 
6.0, 9.0 
DX Develop   6 32% pup mortality 
Chernoff et al. 1979a 
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42 Mouse 
(CD-1) 
NS 
PPD 1–4 
1 time/day 
(GO) 
0, 1.5, 3.0, 
6.0, 9.0 
DX Develop  1.5 3 11–14% lower pup weight 
at 1.5 mg/kg/day; 
cataracts in pups at 
3 mg/kg/day; decreased 
pup viability at 
6 mg/kg/day 
Chernoff et al. 1979a 
43 Mouse 
(CD-1) 
24–25 F 
GD 8–12 
1 time/day 
(GO) 
0, 7.5 BW, DX, MX Develop   7.5 Increased mortality.  
Decreased pup weight on 
LDs 1 and 3 
Chernoff and Kavlock 1982 
44 Mouse 
(C57BL/6) 
23–32 M 
2 days 
1 time/day 
(GO) 
0, 30 BC, BI Hepatic  30  Elevated serum ALT and 
AST 
Fouse and Hodgson 1987 
45 Mouse 
(ICR) 
15 M 
14 days 
1 time/day 
(GO) 
0, 10, 25, 50 BW, FI, LE, 
WI 
Death   10 12/15 rats died 
Bd wt  10  >10% decrease in body 
weight 
Other 
noncancer 
 10  20% decrease in plasma 
glucose; decreased food 
and water consumption 
Fujimori et al. 1983 
46 Mouse 
(ICR) 
3–8 M 
PPD 54 and 
58 
(GO) 
0, 10, 25 BC, BI Hepatic 10 25  Decreased hepatic 
glycogen 
Other 
noncancer 
10 25  Decreased serum glucose 
and lactate; decreased 
free fatty acids 
Fujimori et al. 1983 
47 Mouse 
(CD-1) 
NS F 
GD 8–12 
1 time/day 
(G) 
0, 7.5 BH, BW, DX, 
FX, MX, OF, 
OW, TG 
Develop   7.5 56% increased mortality in 
pups 
Gray et al. 1983 
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48 Mouse 
(Swiss 
Webster) 
6–16 M 
Once 
(GO) 
0, 10, 50, 
250 
HP, OW Hepatic  50  Slight hepatocyte 
vacuolization and loss of 
basophilic staining 
Renal 50    
Hewitt et al. 1979 
49 Dog 
(Mongrel) 
1–5 M 
Once 
(GO) 
125, 250, 
500, 750, 
1,000, 1,250, 
1,500 
LE Death   1,250 3/5 dogs died 
Larson et al. 1979a 
INTERMEDIATE EXPOSURE 
50 Rat 
(Sprague-
Dawley) 
4–5 M 
15 days 
ad lib 
(F) 
0, 0.5 BC, BI, HP, 
OW 
Hepatic  0.5  Decreased hepatobiliary 
function 
Bell and Mehendale 1985 
51 Rat 
(CD) 
17–21 F 
PPD 1–46 
ad lib 
(F) 
0, 1.25 DX, OP Develop   1.25 Cataracts, outlined lenses, 
increased still births, 10–
19% decreased postnatal 
growth 
Chernoff et al. 1979b 
52 Rat 
(CD) 
21–24 F 
GD 4–
PPD 46 
ad lib 
(F) 
0, 1.25 DX Develop   1.25 Decreased postnatal 
viability; increased 
stillbirths, cataracts, and 
outlined lenses 
Chernoff et al. 1979b 
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53 Rat 
(Sprague-
Dawley) 
10 M 
28 days 
ad lib 
(F) 
0, 0.05 BC, BI, BW, 
CS, FI, HE, 
HP 
Bd wt 0.05    
Hemato 0.05    
Hepatic 0.05    
Renal 0.05    
Endocr 0.05    
Other 
noncancer 
(not 
specified) 
0.05    
Chu et al. 1980a 
54 Rat 
(Sprague-
Dawley) 
5M, 5F 
28 days 
ad lib 
(F) 
0, 6.2 BC, BW, CS, 
FI, HE, HP, 
OF, OW 
Bd wt 6.2    
Hepatic  6.2  >34% increased liver 
weight; histopathologic 
liver lesions (e.g., 
hepatocellular 
hypertrophy, 
anisokaryosis, fatty 
vacuolation) 
Endocr  6.2  Thyroid lesions (e.g., 
reduced colloid density 
with collapse of follicles, 
increased epithelial 
height) 
Chu et al. 1980c 
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55 Rat 
(Sprague-
Dawley) 
15 M, 20 F 
M: 91 days 
premating, 
15 days 
mating 
(106 days) 
F: 91 days 
premating, 
15 days 
mating, 
gestation, 
lactation 
(148 days) 
ad lib (F) 
Premating 
and mating: 
0, 0.25, 0.5, 
1, 2 
BC, BW, DX, 
FI, GN, HE, 
HP, MX, OF, 
OW 
Hemato 2    
Hepatic  0.25  Dose-related increased 
incidence and severity of 
histopathologic liver 
lesions 
Endocr  0.25  Dose-related increased 
incidence and severity of 
histopathologic thyroid 
lesions 
Neuro 1  2 Hypoactivity, irritability, 
tremors 
Repro   0.25 Dose-related decreased 
numbers of females 
exhibiting sperm in vaginal 
smears; dose-related 
decreased litter size 
Develop   0.25 Cataracts in 4/10 female 
pups (0/14 controls) at 
0.25 mg/kg/day; 
significantly decreased 
21-day pup survival at 
1 mg/kg/day 
Chu et al. 1981b 
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56 Rat 
(Sprague-
Dawley) 
10M 
28 d  
ad lib 
(F) 
0, 0.25, 2.5 BC, BW, CS, 
EA, GN, HE, 
HP, LE, OW 
Hemato 2.5    
Hepatic  0.25  Liver lesions (fatty 
infiltration, cytoplasmic 
vacuolation, anisokaryosis 
and necrosis of 
hepatocytes) 
Endocr  0.25  Thyroid lesions (thickening 
of follicular epithelium; 
loss of colloid and 
collapse of follicles) 
Other 
noncancer 
 0.25  Decreased serum glucose 
Chu et al. 1981a 
57 Rat 
(Sprague-
Dawley) 
3–11 M 
15 days 
(F) 
0, 1, 5 BW, CS, OF Bd wt 1  5 39% decreased mean 
body weight gain 
Hepatic  1  Impaired biliary excretion 
Neuro 1  5 Lethargy 
Curtis and Hoyt 1984 
58 Rat 
(Sprague-
Dawley) 
5–6 M 
15 days 
ad lib 
(F) 
0, 0.5 BC, BW, CS, 
HP, OW 
Hepatic 0.5    
Curtis et al. 1981 
59 Rat 
(Sprague-
Dawley) 
5 M 
15 days 
ad lib 
(F) 
0, 0.5 BW, CS, EA, 
FI, HP, OF, 
OW 
Bd wt 0.5    
Hepatic 0.5    
Curtis and Mehendale 1980 
MIREX AND CHLORDECONE  46 
 
2.  HEALTH EFFECTS 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
Table 2-3.  Levels of Significant Exposure to Mirex – Oral 
 
Figure 
keya 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
60 Rat 
(Sprague-
Dawley) 
8 NS 
28 days 
ad lib 
(F) 
0, 0.5, 5 BW, HP, OF Bd wt  5  15% lower mean final 
body weight than controls 
Hepatic   0.5 Disruption of liver cord 
cells; focal bile stasis; 
central or midzonal 
hepatocellular necrosis 
Davison et al. 1976 
61 Rat 
(Zivac-
Miller) 
15–30 NS 
NS 
5–
6 days/week 
1 time/day  
(GO) 
5, 12.5, 25 BH, CS Neuro   5  Decrease in operant 
behavior 
Dietz and McMillan 1979 
62 Rat 
(Sherman) 
10 F 
90 days 
ad lib 
(F) 
2.5, 5, 7.5, 
10, 12.5 
LE Death   6.2 LDLO 
Gaines and Kimbrough 1970 
63 Rat 
(Sherman) 
10 M, 10 F 
166 days 
ad lib 
(F) 
M: 0, 0.04–
0.09, 0.21–
0.48, 1.3–3.1 
F: 0.06–0.1, 
0.31–0.49, 
1.8–2.8 
BI, HP, OF, 
OW 
Hepatic 0.48 1.3  Bile stasis; decreased 
hepatic glycogen, 
multinucleation 
Gaines and Kimbrough 1970 
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64 Rat 
(Sherman) 
10 M, 10 F 
2-generation 
repro 
ad lib 
(F) 
M: 0, 1.3–3.1 
F: 0, 1.8–2.8, 
0.31–0.49 
DX, OF Repro 0.31  1.8 Decreased number of 
litters and number of live 
births from mirex-treated 
maternal rats only 
Develop 0.31  1.8 Cataracts, decreased live 
births, increased mortality 
through weaning among 
pups from mirex-treated 
maternal rats only 
Gaines and Kimbrough 1970 
65 Rat 
(Charles 
River) 
10 M, 10 F 
13 weeks 
ad lib 
(F) 
0, 0.25, 1, 4, 
16, 64 
LE Death   64 M: 50% mortality 
F: 100% mortality 
Bd wt 16  64 M: 33–34% lower mean 
final body weight than 
controls 
Hemato 4 16  Decreased hemoglobin 
Hepatic 1 4  Hepatocellular vacuolation 
Renal 64    
Neuro 16  64 Hyperexcitability, tremors, 
convulsions 
Larson et al. 1979a 
66 Rat 
(Sprague-
Dawley) 
5M 
<30 days 
ad lib 
(F) 
0, 5 CS, OF, OW Gastro  5  Diarrhea 
Hepatic  5  Impaired biliary excretion 
Neuro   5 Lethargy 
Mehendale 1981b 
67 Rat 
(Sprague-
Dawley) 
10 M 
28 days 
ad lib 
(F) 
0, 0.25, 2.5 HP Endocr 0.25 2.5  Increase in large 
irregularly shaped 
lysosomes in the thyroid 
Singh et al. 1982 
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68 Rat 
(Sprague-
Dawley) 
10 M 
28 days 
ad lib 
(F) 
0, 0.25, 2.5 OF Endocr  0.25  Dilation of rough 
endoplasmic reticulum 
cisternae of thyroid in 
weanling rats 
Singh et al. 1985 
69 Rat 
(Long-
Evans) 
3–5 M 
61–113 days 
ad lib 
(F) 
0, 0.9 BH Neuro 0.9    
Thorne et al. 1978 
70 Rat 
(Sprague-
Dawley) 
10 M 
28 days 
ad lib 
(F) 
0, 0.025, 
0.25, 2.5, 
3.75 
BC Hemato 3.75    
Hepatic 3.75    
Endocr 0.25 2.5  Significantly decreased 
serum thyroid T3 
Repro 2.5  3.75 Hypocellularity of the 
seminiferous tubules; 
testicular degeneration 
Yarbrough et al. 1981 
71 Mouse 
(CD-1) 
3 M 
21 days 
(G) 
0, 5 BW, OW Bd wt 5    
Hepatic  5  >2-fold increase in mean 
absolute liver weight 
Repro  5  27% decrease in mean 
absolute seminal vesicle 
weight 
Dai et al. 2001 
72 Mouse 
(ICR) 
15 M 
15 days 
1 time/day 
(GO) 
0, 10 LE Death   10 100% mortality 
Fujimori et al. 1983 
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73 Mouse 
(Swiss-
Webster) 
6 M 
15 days 
ad lib 
(F) 
0, 1.3 BW, OW, FI, 
HP, BC, BI 
Bd wt 1.3    
Hepatic 1.3    
Other 
noncancer 
(not 
specified) 
1.3    
Mehendale et al. 1989 
74 Mouse 
(BALB/c) 
(CFW) 
43–50 M 
43–50 F 
120 days 
ad lib 
(F) 
0, 0.65 OR Repro 0.65    
Ware and Good 1967 
75 Mouse 
(BALB/c) 
102–108 M, 
102–108 F 
120 days 
ad lib 
(F) 
0, 0.65 OR Repro 0.65    
Ware and Good 1967 
76 Dog 
(Beagle) 
2 M, 2 F 
13 weeks 
ad lib 
(F) 
0, 0.1, 0.5, 
2.5 
HE, UR, HP, 
BW 
Bd wt 0.5  2.5 58–74% decrease in body 
weight gain 
Hemato 0.5 2.5  Increased hematocrit and 
leukocyte count 
Hepatic 0.5 2.5  Increased serum alkaline 
phosphatase, impaired 
biliary excretion 
Renal 2.5    
Larson et al. 1979a 
77 Gerbil 
(Mongolian) 
4–5 M 
15 days 
ad lib 
(F) 
0, 5.4 BC, BI Hepatic 5.4    
Cai and Mehendale 1990 
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CHRONIC EXPOSURE 
78 Rat 
(Sprague-
Dawley) 
10 M, 10 F 
21 months 
ad lib 
(F) 
0, 0.07, 0.32 BC, BW, CS, 
FI, GN, HE, 
HP, LE, OW 
Bd wt 0.32    
Hemato 0.32    
Hepatic 0.32    
Chu et al. 1981c 
79 Rat 
(F344/N) 
First study: 
52 M, 52 F 
Second 
study: 52 F 
2 years 
ad lib 
(F) 
First study: 
Combined 
sexes: 0, 
0.007, 0.075, 
0.75, 1.95, 
3.85 
Second 
study: 
F: 0, 3.9, 7.7 
BW, CS, FI, 
GN, HP, LE 
Death   1.95 63% mortality in males 
Bd wt 1.95 3.85  Up to 17–18% lower mean 
body weight 
Hepatic 0.075b 0.75  Focal and centrilobular 
necrosis; fatty 
metamorphosis; dilation of 
sinusoids 
Renal 0.075 0.75  Increased incidence of 
epithelial hyperplasia of 
the renal pelvis at 
0.75 mg/kg/day; increased 
severity of nephrotoxicity 
at 1.95 mg/kg/day 
Cancer   0.75 CEL: neoplastic liver 
nodules in males, 
mononuclear cell leukemia 
in females  
NTP 1990 
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80 Rat 
(CD) 
20 or 26 M 
20 or 26 F 
18 months 
followed by 
6 months of 
recovery 
ad lib 
(F) 
0, 2.4, 4.9 BW, GN, HP, 
LE 
Death   2.4 Decreased survival of 
males and females after 
treatment week 52 
Bd wt 2.4    
Hepatic  2.4  Megalocytosis in the liver 
of 14/26 males and 
8/26 females; no 
incidences among controls 
Cancer   4.9 CEL: neoplastic nodules in 
the liver of 7/26 males 
(0/20 controls); 
hepatocellular carcinoma 
in 4/26 males 
Ulland et al. 1977 
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81 Mouse 
(C57BL/6 x 
C3H/ANF)  
(C57BL/6 x 
AKR) 
18 M, 18 F 
21 days by 
gavage, in 
food until 
terminal 
sacrifice at 
weeks 59–70 
0, 3.8 (TWA) LE Death   3.8 100% mortality; 11% in 
controls 
Cancer   3.8 CEL: hepatomas in males 
and females of both 
mouse strains 
Innes et al. 1969 
 
aThe number corresponds to entries in Figure 2-3; differences in levels of health effects and cancer effects between male and females are not indicated in 
Figure 2-3.  Where such differences exist, only the levels of effect for the most sensitive gender are presented. 
bUsed to derive a provisional chronic-duration oral minimal risk level (MRL) of 0.0003 mg/kg/day for mirex; dose divided by an uncertainty factor of 100 (10 for 
extrapolation from animals to humans, and 10 for human variability) and modifying factor of 3 (to protect for developmental toxicity); see Appendix A for more 
detailed information regarding the provisional MRL. 
 
ad lib = ad libitum; ALT = alanine transaminase; AST = aspartate transaminase; Bd wt or BW = body weight; BC = serum (blood) chemistry); BH = behavioral; 
BI = biochemical changes; Cardio = cardiovascular; CEL = cancer effect level; CS = clinical signs; Develop = developmental; DX = developmental toxicity; 
EA = enzyme activity; Endocr = endocrine; (F) = feed; F = female(s); FI = food intake; FX = fetal toxicity; (G) = gavage-not specified GD = gestation day(s); 
(GF) = gavage or diet; GN = gross necropsy; (GO) = gavage-oil; HE = hematology; Hemato = hematological; HP = histopathology; Immuno = immunological; 
LD = lactation day; LD50 = lethal dose, 50% kill; LDL0 = lowest lethal dose; LE = lethality; LOAEL = lowest-observed-adverse-effect level; M = male(s); 
MX = maternal toxicity; Neuro = neurological; NOAEL = no-observed-adverse-effect level; NS = not specified; OF = organ function; OP = ophthalmology;; OW = 
organ weight; PPD = postpartum day; Repro = reproductive; RNA = ribonucleic acid; T3 = triiodothyronine; TG = teratogenicity; TWA = time-weighted average; 
UR= urinalysis; WI = water intake  
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MIREX AND CHLORDECONE  57 
 
2.  HEALTH EFFECTS 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
Figure 2-3.  Levels of Significant Exposure to Mirex – Oral 
Chronic (≥365 days) 
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ACUTE EXPOSURE 
1 Rat 
(Sprague-
Dawley) 
14 M 
Once 
(GO) 
0, 50 BH, BW, CS Bd wt  50  11% weight loss 
Neuro   50 Tremors; splaying of legs 
Albertson et al. 1985 
2 Rat 
(Sprague-
Dawley) 
4–5 M 
Once 
(GO) 
0, 25, 50, 
100 
CS, BI Neuro 50  100 Mild tremors 
Aldous et al. 1984 
3 Rat 
(Sprague-
Dawley) 
3–15 M 
10 days 
1 time/day 
(GO) 
0, 2.5, 5, 10 BI, CS Neuro 5  10 Mild tremors 
Aldous et al. 1984 
4 Rat 
(Sprague-
Dawley) 
15–68 M 
8 days 
(F) 
0, 17 HP, BI Bd wt  17  Depletion of body fat 
Endocr  17  Depletion of epinephrine 
in adrenal medulla 
Neuro   17 Tremor, hyperexcitability 
Baggett et al. 1980 
5 Rat 
(CD) 
26–42 F 
GDs 7–16  
1 time/day 
(GO) 
0, 2, 6, 10 BW, DX, LE, 
OW 
Death   10 19% maternal mortality 
Bd wt  2  15% decrease in maternal 
body weight gain 
Develop 6  10 Increased number of 
fetuses with enlarged 
renal pelvis, edema, 
undescended testes, or 
enlarged cerebral 
ventricles; reduced fetal 
weight, reduced 
ossification 
Chernoff and Rogers 1976 
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6 Rat 
(Long-
Evans) 
5 F 
4 days 
1 time/day 
(GO) 
0, 15 DX, LE Death   15 40% mortality 
Develop 15    
Chernoff et al. 1979a 
7 Rat 
(Sprague-
Dawley) 
3–7 M 
Once 
(GO) 
0, 5 BC, BI, BW, 
OF, OW 
Hepatic 5    
Davis and Mehendale 1980 
8 Rat 
(Sprague-
Dawley) 
6 M 
10 days 
1 time/day 
(GO) 
0, 2.5, 5, 10 BI Neuro 10 25  Decreased dopamine 
binding and uptake; 
decreased norepinephrine 
uptake 
Desaiah 1985 
9 Rat 
(Sprague-
Dawley) 
4 NS 
10 days 
(F) 
0, 2.5, 5, 10 BI Neuro  2.5  >20% decreased total 
brain calmodulin 
Desaiah et al. 1985 
10 Rat 
(Sprague-
Dawley) 
50 M 
Once 
(GO) 
0, 72–98 CS, OF Musc/skel  72–98  Muscle weakness 
Neuro   72–98 Tremors; hyperexcitability; 
abnormal gait 
Egle et al. 1979 
11 Rat 
(NS) 
6 NS 
Once 
(G) 
0, 40 BH, BI, HP Neuro   40 Tremors 
End et al. 1981 
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12 Rat 
(Fischer- 
344) 
10–14 M 
10 days 
1 time/day 
(GO) 
0, 0.625, 
1.25, 2.5, 5, 
10 
BC, BW, OF, 
OW 
Bd wt 5  10 10% lower mean terminal 
body weight  
Hepatic 5 10  Increased serum alkaline 
phosphatase, ALT, AST 
Renal 5 10  Increased blood urea 
nitrogen 
Endocr 5 10  38% increased relative 
adrenal weight 
Immuno 5 10  Decreased spleen and 
thymus weights, leukocyte 
counts, natural killer cell 
activity, and Concanavalin 
A responsiveness 
Neuro 1.25b 2.5  Increased startle response 
Other 
noncancer 
5 10  Decreased serum 
cholesterol and glucose 
EPA 1986c 
13 Rat 
(Fischer 
344) 
24 F 
GDs 7–16 
1 time/day 
(GO) 
0, 10 DX, LE  Develop   10 84% decreased PPD 3 
pup survival 
EPA 1986c 
14 Rat 
(Sherman) 
NS M 
NS F 
Once 
(GO) 
NS CS, LE  Death   125 LD50 
Gaines 1969 
15 Rat 
(Sprague-
Dawley) 
NS F 
GDs 14–20 
1 time/day 
(GO) 
0, 15 BI, DX, OF, 
OW  
Develop   15 Anovulation and persistent 
vaginal estrus in offspring 
Gellert and Wilson 1979 
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16 Rat 
(Sprague-
Dawley) 
4–6 M 
Once 
(GO) 
0, 15.2 BI Hepatic 15.2    
Glende and Lee 1985 
17 Rat 
(Sprague-
Dawley) 
3 M 
3 days 
1 time/day 
(GO) 
0, 10, 25, 50 BH, BI Neuro  25 50 Decreased Na+-
K+ATPase; decreased 
oligomycin sensitive 
Mg2+ATPase (25 mg/kg); 
increased activity; tremor; 
exaggerated startle 
response; abnormal gait 
(50 mg/kg) 
Jordan et al. 1981 
18 Rat 
(Sprague-
Dawley) 
5 M 
5 days 
(F) 
0, 5 BC, BW, CS, 
FI, OF, OW 
Bd wt 5    
Hepatic 5    
Neuro   5 Tremors; exaggerated 
startle response 
Klingensmith and Mehendale 1982a 
19 Rat 
(Sprague-
Dawley) 
6 M 
3 days 
1x/d 
(GO) 
0, 8.3, 16.7, 
25 
BI Cardio  8.3  Decreased 45Ca-uptake 
and Ca2+ ATPase activity 
Kodavanti et al. 1990a 
20 Rat 
(Wistar) 
10 M, 10 F 
Once 
(GO) 
 LE Death   132 M 
126 F 
LD50 
Larson et al. 1979b 
21 Rat 
(Sprague-
Dawley) 
4–6 M 
2–3 days 
1 time/day 
(GO) 
0, 10, 25, 50 CS, HP Musc/skel 10 25  Increased Mg2+ ATPase 
activity in muscle 
sarcoplasmic reticulum 
Neuro   25 Tremors 
Mishra et al. 1980 
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22 Rat 
(Sprague-
Dawley) 
6 M 
3 days 
1 time/day 
(GO) 
0, 0.5, 2, 10 BC, BI, HP, 
OW 
Hepatic 10    
Renal 10    
Plaa et al. 1987 
23 Rat 
(Fischer 
344) 
8–10 M 
Once 
(GO) 
 LE Death   91.3 M LD50 
Pryor et al. 1983 
24 Rat 
(Fischer 
344) 
10 M 
10 days 
1 time/day 
 
0, 0.625, 
1.25, 2.5, 5, 
10 
BC, CS, OW Bd wt 5 10  19% decrease in body 
weight 
Hemato 5 10  Decreased neutrophils 
Neuro 5  10 Tremors  
Smialowicz et al. 1985 
25 Rat 
(Sprague- 
Dawley) 
8–10 F 
Once 
(GO) 
0, 35, 55, 75 BW, CS, OF, 
OW 
Bd wt  75  12% decrease in body 
weight 
Endocr  35  Increased relative adrenal 
weight 
Immuno  75  Decreased thymus weight 
Neuro   35 Tremors; exaggerated 
startle response 
Repro   35 Persistent estrus 
Other 
noncancer 
35 55  Decrease in colonic 
temperature 
Swanson and Woolley 1982 
26 Rat 
(Sprague- 
Dawley) 
5–8 M 
3 days 
1 time/day 
(GO) 
0, 18.75 BI, BW, OF, 
OW 
Bd wt 18.75    
Hepatic  18.75  Increased bile flow; 
decreased bile acid 
concentration and 
secretory rate 
Teo and Vore 1991 
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27 Mouse 
(ICR) 
7 M 
2–4 days 
1 time/day 
(GO) 
0, 25, 50 CS Neuro   25 Severe tremors; motor 
incoordination 
Chang-Tsui and Ho 1979 
28 Mouse 
(ICR) 
NS M 
2–3 days 
1 time/day 
(GO) 
0, 50 BI Neuro  50  Decreased dopamine and 
norepinephrine uptake; 
decreased dopamine 
binding 
Chang-Tsui and Ho 1980 
29 Mouse  
(CD-1) 
25 F 
GDs 8–12 
1 time/day 
(GO) 
0, 20 LE, CS Death   20 16% mortality 
Bd wt   20 61% decrease in maternal 
body weight gain 
Develop   20 Decreased survival and 
body weight of pups on 
PPDs 1 and 3 
Chernoff and Kavlock 1982 
30 Mouse 
(CD-1) 
12–26 F 
GDs 7–16 
10 days 
1 time/day 
(GO) 
0, 2, 4, 8, 12 BW, DX, MX, 
OW 
Develop 8  12 Increase fetal deaths; 
increased club foot 
Chernoff and Rogers 1976 
31 Mouse 
(CD-1) 
NS F 
PPDs 1–4 
1 time/day 
(GO) 
0, 6, 18, 24 DX, LE Death   24 4 of 9 maternal mice died 
Develop   18 64% pup mortality; 100% 
pup mortality at 
24 mg/kg/day 
Chernoff et al. 1979a 
32 Mouse 
(ICR) 
10 M 
12 days 
1 time/day 
(GO) 
0, 25, 50 CS, LE Death   25 100% mortality 
Neuro   25 Mild tremors 
Desaiah et al. 1980b 
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(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
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(mg/kg/day) Effect 
33 Mouse 
(C57BL/6) 
13–32 M 
2 days 
1 time/day 
(GO) 
0, 30 BC, BI, CS Hepatic 30    
Fouse and Hodgson 1987 
34 Mouse 
(ICR) 
5–9 M 
1–11 days 
1 time/day 
(GO) 
0, 10, 25, 50 BH, BI Neuro   10 Motor incoordination 
Fujimori et al. 1982b 
35 Mouse 
(ICR) 
3–8 M 
4 days 
1 time/day 
(GO) 
0, 10, 25 BC, BI Hepatic  25  Decreased hepatic 
glycogen 
Other 
noncancer 
 25  Decreased serum glucose 
and lactate 
Fujimori et al. 1983 
36 Mouse 
(ICR) 
6–12 M 
5 or 8 days  
1 time/day 
(GO) 
0, 25 BH, BI Neuro  25  Decreased striatal 
dopamine synthesis 
uptake and release 
Fujimori et al. 1986 
37 Mouse 
(CD-1) 
NS F 
GDs 8–12 
1 time/day 
(G) 
0, 20 BH, BW, DX, 
FX, MX, OF, 
OW, TG 
Develop   20 Decreased postnatal 
viability 
Gray et al. 1983 
38 Mouse 
(ICR) 
4–5 M 
Once 
(GO) 
0, 25 BH, BI Neuro  25  Increased brain calcium in 
mice 6–8 weeks old; 
decreased brain calcium 
in adults 
Hoskins and Ho 1982 
39 Mouse 
(ICR) 
3–4 M 
8 days 
1 time/day 
(GO) 
0, 25 BH, BI Neuro  25  Tremors 
Hoskins and Ho 1982 
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Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
40 Mouse 
(ICR) 
15 M 
2–14 days 
1 time/day 
(GO) 
0, 10, 25, 50 BH, BI, CS Bd wt  10  10–15% decrease in 
maternal weight gain 
Neuro   10 Decreased motor 
coordination; tremors 
Huang et al. 1980 
41 Mouse 
(CD-1) 
15–40 F 
Once 
GD 8 
(GO) 
0, 110, 125 DX, LE Death   110 25% mortality 
Develop   125 Increased resorptions and 
malformations; decreased 
viable litters 
Kavlock et al. 1985 
42 Mouse 
(ICR/SIM) 
27–28 F 
GDs 8–12 
1 time/day 
(GO) 
0, 24 BW, DX, LE  Death   24 18% mortality 
Bd wt   24 85% decrease in maternal 
weight gain 
Develop   24 Decreased fetal survival 
and neonatal weight gain; 
increased still births 
Seidenberg et al. 1986 
43 Mouse 
(CD-1) 
6–15 F 
2 weeks 
5 days/week 
1 time/day 
(GO) 
0, 2, 4, 8 OF Repro   2 Induction of persistent 
vaginal estrus 
Swartz et al. 1988 
44 Rabbit 
(NS) 
NS 
Once 
(GO) 
 LE Death   71 LD50 
Larson et al. 1979b 
45 Dog 
(NS) 
NS 
Once 
(GO) 
 LE Death   250 LD50 
Larson et al. 1979b 
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Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
INTERMEDIATE EXPOSURE 
46 Rat 
(Sprague- 
Dawley) 
4–5 M 
15 days 
(F) 
0, 0.86, 2.15, 
4.31, 8.61 
BI, CS Neuro 2.15  4.31 Tremors 
Agarwal and Mehendale 1984c 
47 Rat 
(Fischer-
344) 
25 F 
105 days 
(F) 
0, 0.11, 0.68 BI, BW Bd wt 0.68    
Endocr 0.68    
Ali et al. 1982 
48 Rat 
(Sherman) 
24–25 M, 
22–25 F 
3 months 
(F) 
M: 0, 1.17- 
1.58 
F: 0, 1.62- 
1.71 
BW, CS, DX, 
HP, OF, OW 
Bd wt  
1.62 F 
1.17 M 
 
 13% lower mean body 
weight gain 
Hepatic  1.17 M 
1.62 F 
 Focal necrosis 
Endocr  1.17 M 
1.62 F 
 Reversible hyperplasia of 
adrenal cortex 
Neuro   1.17 M 
1.62 F 
Tremor, hyperactivity, 
exaggerated startle 
response 
Repro 1.17 M 1.62 F  Decreased number of 
litters born to control 
males mated to 
chlordecone-treated 
females 
Develop 1.17 M 
1.62 F 
   
Cannon and Kimbrough 1979 
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Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
49 Rat 
(Sprague-
Dawley) 
6 M 
15 days 
(F) 
0, 0.086, 
0.86, 4.3, 8.6 
BC, BI, BW, 
OF, OW 
Hepatic 0.86 4.3  Significantly increased 
serum nonprotein nitrogen 
compounds and enzymes 
Other 
noncancer 
 8.6  Decreased serum 
triglycerides, LDL, and 
cholesterol 
Chetty et al. 1993a 
50 Rat 
(Sprague- 
Dawley) 
10 M 
28 days 
(F) 
0, 0.086 BC, BI, BW, 
CS, FI, HP 
Bd wt 0.086    
Hemato 0.086    
Hepatic 0.086    
Renal 0.086    
Chu et al. 1980a 
51 Rat 
(Sprague- 
Dawley) 
3–11 M 
15 days 
(F) 
0, 1.7, 8.6 BH, BI, BW, 
CS, OF, OW 
Bd wt 1.7  8.6 99% decrease in body 
weight gain 
Hepatic  1.7  Impaired biliary excretion 
Increases in liver weight, 
serum ALT, and AST at 
5 mg/kg/day 
Neuro 1.7  8.6 Tremors and 
hypersensitivity to sound 
and touch 
Curtis and Hoyt 1984 
52 Rat 
(Sprague- 
Dawley) 
20 M 
15 days 
(F) 
0, 0.86, 4.31, 
12.92 
BI, BW, CS, 
FI, GN, OF, 
OW 
Bd wt 0.86  4.31 63% lower body weight 
gain 
Neuro 4.31  12.92 Tremors; hyperexcitability 
Curtis and Mehendale 1979 
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No./group 
Exposure 
parameters 
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(mg/kg/day) 
Parameters 
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(mg/kg/day) 
Less 
serious 
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(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
53 Rat 
(Zivac- 
Miller) 
1–5 M, 3 F 
90 days 
5–
6 days/week 
1 time/day 
(GO) 
1, 5, 10 BH, CS, LE Neuro   1 Decrease in operant 
behavior; tremors 
Dietz and McMillan 1979 
54 Rat 
(Sprague- 
Dawley) 
4–5 M 
15 days 
(F) 
0, 0.82 BI, BW, FI, 
HP, OW, WI 
Bd wt 0.82    
Faroon and Mehendale 1990 
55 Rat 
(Sprague- 
Dawley) 
5 M 
15 or 
20 days 
(F) 
0, 8.6 BH, BW, CS, 
FI, OW 
Bd wt   8.6 48–49% decrease in body 
weight gain 
Hepatic 8.6    
Neuro   8.6 Progressively increased 
constant tremors 
Other 
noncancer 
 8.6  36% decrease in 
epididymal fat 
Klingensmith and Mehendale 1982a 
56 Rat 
(Wistar) 
5 M, 5 F 
3–9 months 
during a 
2-year study 
(F) 
M: 0, 0.092, 
0.46, 0.92, 
2.30, 4.61, 
7.37 
F: 0, 0.10, 
0.51, 1.03, 
2.56, 5.13, 
8.21 
BC, BW, CS, 
FI, HP, OW, 
UR 
Bd wt 0.92 M 
1.03 F 
2.30 M  
2.56 F 
Up to 20% lower mean 
body weight 
Up to 24% lower mean 
body weight  
Hemato 7.37 M 
8.21 F 
   
Hepatic 0.92 M 
1.03 F 
2.30 M 
2.56 F 
 Congestion in liver of 
3/5 males and 2/5 females 
at 3 months 
     
Endocr 7.37 M 
1.03 F 
 
2.56 F 
 Loss of adrenal lipid in 
2/5 females at 3 months 
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(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
Neuro 0.92 M 
1.03 F 
 2.30 M 
2.56 F 
Tremors (earlier onset and 
increased severity with 
increasing dose) up to 
6 months, regressing 
thereafter; incidences by 
sex not reported 
Repro 0.92 M  2.30 M Testicular atrophy in 
4/5 males at 3 months 
Other 
noncancer 
0.92 M 
2.56 F 
2.30 M  Increased metabolic rate 
in males at 9 months 
Larson et al. 1979b 
57 Rat 
(Sprague- 
Dawley) 
10 M 
90 days 
(F) 
0, 0.26, 0.83, 
1.67 
CS, DX, OF Neuro 0.26c 0.83  Hyperexcitability; mild 
tremors at 0.83 and 
1.67 mg/kg/day 
Repro 0.26c 0.83  46–48% decreased sperm 
motility and viability; 19% 
decreased epididymal 
sperm concentration 
Develop 1.67    
Linder et al. 1983 
58 Rat 
(Sprague- 
Dawley) 
4 F 
16 days 
(F) 
0, 3.95, 8.54, 
11.63 
BI, BW, CS, 
FI, OW 
Bd wt   3.95 Dose-related depressed 
body weight gain (28– 
78% less than controls) 
Neuro   3.95 Tremors; hypersensitivity 
to noise and stress 
Mehendale et al. 1978b 
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Serious 
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(mg/kg/day) Effect 
59 Rat 
(Sprague-
Dawley) 
5 M 
30–35 days 
(F) 
0, 8.6 BH, CS, LE, 
OF, OW 
Death   8.6 2/5 died 
Bd wt  8.6  Significantly decreased 
body weight gain 
Hepatic  8.6  Impaired biliary function 
Neuro   8.6 Tremors, hyperactivity, 
exaggerated startle 
response 
Mehendale 1981b 
60 Rat 
(Sprague- 
Dawley) 
4–5 M 
15 days 
(F) 
0, 4.3 OF Hepatic  4.3  Decreased hepatobiliary 
function 
Mehendale 1990a 
61 Rat 
(Sprague- 
Dawley) 
4 M 
15 days 
(F) 
0, 0.86 BC Hepatic 0.86    
Mehendale et al. 1991 
62 Rat 
(Fischer 
344) 
9–10 M 
15 weeks 
5 days/week 
1 time/day 
(GO) 
0, 2.8, 4.1, 
7.1, 11.2 
BH, CS, LE Death   4.1 6/10 died 
Bd wt  2.8  >10% decrease in body 
weight gain 
Neuro 2.8  4.1 Increased startle response 
Other 
noncancer 
 7.1  Increased body 
temperature 
Pryor et al. 1983 
63 Rat 
(Fischer- 
344) 
8–12 M 
90 days 
(F) 
0, 0.86, 3.0 BH, CS Neuro   0.86 Exaggerated startle 
response 
Squibb and Tilson 1982b 
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64 Mouse 
(ICR) 
15 M 
33 days 
1 time/day 
(GO) 
0, 10, 25, 50 BI, CS, GN, 
LE 
Death   10 100% mortality 
Gastro  NS  Mild diarrhea 
Neuro   10 Tremors; decreased motor 
coordination 
Other 
noncancer 
 10  Decreased adipose tissue; 
decreased plasma 
glucose 
Fujimori et al. 1983 
65 Mouse 
(BALB/c) 
24–36 M, 
24–36 F 
5 months 
(1 month 
premating 
and through 
production of 
two litters 
(F) 
0, 0.93, 1.86 OF Repro   0.93 36% decrease in second 
litters 
Good et al. 1965 
66 Mouse 
(BALB/c) 
4–70 M,F 
2–12 months 
(F) 
1.87, 5.60, 
7.47, 11.21, 
13.08, 14.95, 
18.68 
BW, HP, LE, 
OW 
Death   11.21 12% mortality in adults; 
100% morality in juveniles 
Bd wt 7.47 11.21  Decreased body weight in 
juveniles and adults 
Hepatic  7.47  Focal necrosis, cellular 
hypertrophy, hyperplasia, 
congestion; liposphere 
formation and decreased 
numbers of mitochondria 
Neuro 1.87  5.60 Tremor 
Repro   7.47 Increased estrus 
Huber 1965 
67 Mouse 
(BALB/c) 
14 M,14 F 
160 days 
(F) 
0, 7.47 OF Repro   7.47 Persistent vaginal estrus; 
reversible reproductive 
failure 
Huber 1965 
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68 Mouse 
(BALB/c) 
8 M, 8 F 
130 days 
(F) 
0, 1.87, 5.60, 
7.01 
OF Repro   1.87 8% decrease in litter size 
and 19% increase in pair-
days to litter; constant 
estrus at 3.9 mg/kg/day 
Develop 1.87  7.01 Decreased postnatal 
survival 
Huber 1965 
69 Mouse 
(Swiss- 
Webster) 
6 M 
15 days 
(F) 
0, 1.8 BC, BI, BW, 
FI, HP, OW 
Bd wt 1.8    
Hepatic 1.8    
Mehendale et al. 1989 
70 Mouse 
(CD-1) 
6 F 
4 weeks 
5 days/week 
1 time/day 
(GO) 
0, 8 BH, CS Neuro   8 Slight tremors; increased 
reactivity to noise 
Swartz and Schutzmann 1986 
71 Mouse 
(CD-1) 
6–22 F 
4 or 6 weeks 
5 days/week 
1 time/day 
(GO) 
0, 2, 4, 8 OF Repro   2 Increased ovulation; 
persistent vaginal estrus 
Swartz et al. 1988 
72 Gerbil 
(Mongolian) 
4–5 M 
15 days 
(F) 
0, 5.4 BC, BI Hepatic 5.4    
Cai and Mehendale 1990 
73 Gerbil 
(Mongolian) 
4–5 M 
15 days 
(F) 
0, 5.4 BI, HP Hepatic 5.4    
Cai and Mehendale 1991b 
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LOAEL 
(mg/kg/day) Effect 
CHRONIC EXPOSURE 
74 Rat 
(Sprague- 
Dawley) 
4–10 M 
21 months 
(GO) 
0, 0.07 BI, BW, HE, 
HP 
Hemato 0.07    
Chu et al. 1981c 
75 Rat 
(Wistar) 
40 M, 40 F 
Up to 2 years 
(F) 
0, 0.05, 0.25, 
0.5, 1.25, 
2.5, 4.0 
BC, BW, CS, 
FI, HE, HP, 
OW, UR 
Death   1.25 Decreased survival in 
females; 100% mortality in 
both sexes at 2.5 and 
4.0 mg/kg/day for treated 
for 25 and 17 weeks, 
respectively 
Bd wt 0.5 1.25  >10% decreased body 
weight gain at 1 and 
2 years 
Cardio 1.25   No effect among survivors 
at 1 and 2 years 
Hemato 0.5 1.25  Depressed hematocrit 
levels at 1 and 2 years 
Hepatic 0.25 0.5  Fatty changes in liver at 
1 and 2 years 
Renal 0.05d 0.25  Proteinuria and increased 
severity of 
glomerulosclerosis at 
1 and 2 years 
Neuro 0.5  1.25 Tremor; observed as early 
as weeks 2–3 at the two 
highest dose levels 
Larson et al. 1979b 
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76 Rat 
(Osborne- 
Mendel) 
44–50 M 
45–49 F 
80 weeks 
(F) 
M: 0, 0.4, 1.2 
F: 0, 0.9, 1.3 
CS, HE, HP, 
LE 
Death   1.2 M 
1.3 F 
Decreased survival among 
males and females 
Hemato  0.4 M 
0.9 F 
 Anemia 
Hepatic  0.4 M 
0.9 F 
 Fatty infiltration and liver 
degeneration 
Dermal  0.4 M 
0.9 F 
 Dermatitis 
Neuro   0.4 M 
0.9 F 
Tremors 
Cancer   1.2 M 
1.3 F 
CEL: hepatocellular 
carcinoma 
NCI 1976 
77 Mouse 
(B6C3F1) 
48–49 M 
49–50 F 
80 weeks 
(F) 
M: 0, 2.6, 3.0 
F: 0, 2.6, 5.2 
CS, LE Death   2.6 Decreased survival in 
males 
Hepatic  2.6  Hepatocellular hyperplasia 
Neuro  2.6  Tremors 
Cancer   2.6 CEL: hepatocellular 
carcinoma 
NCI 1976 
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(mg/kg/day) Effect 
78 Dog 
(beagle) 
2 M, 2 F 
124–
128 weeks 
(F) 
0, 0.025, 
0.125, 0.625 
BC, BW, HP, 
OW 
Neuro 0.625    
Larson et al. 1979b 
 
aThe number corresponds to entries in Figure 2-4; differences in levels of health effects and cancer effects between male and females are not indicated in 
Figure 2-4.  Where such differences exist, only the levels of effect for the most sensitive gender are presented. 
bUsed to derive an acute-duration Minimal Risk Level (MRL) of 0.01 mg/kg/day for chlordecone; dose divided by an uncertainty factor of 100 (10 for extrapolation 
from animals to humans and 10 for human variability; see Appendix A for more detailed information regarding the MRL. 
cUsed to derive a provisional intermediate-duration MRL of 0.003 mg/kg/day; dose divided by an uncertainty factor of 100 (10 for extrapolation from animals to 
humans and 10 for human variability; see Appendix A for more detailed information regarding the provisional MRL. 
dUsed to derive a chronic-duration MRL of 0.0005 mg/kg/day for chlordecone; dose divided by an uncertainty factor of 100 (10 for extrapolation from animals to 
humans and 10 for human variability; see Appendix A for more detailed information regarding the MRL. 
 
ALT = alanine aminotransferase; AST = aspartate transaminase; ATPase = adenosinetriphosphatase; BC = serum (blood) chemistry; Bd wt or BW = body weight; 
BH = behavioral; BI = biochemical changes; Cardio = cardiovascular; CEL = cancer effect level; CS = clinical signs; Develop = developmental; 
DX = developmental toxicity; Endocr = endocrine; (F) = feed; F = female(s); FI = food intake; FX = fetal toxicity; (G) = gavage, not specified; 
Gastro = gastrointestinal; GD = gestation day; (GO) = gavage, oil; GN = gross necropsy; HE = hematology; Hemato = hematological; HP = histopathology; 
Immuno = immunological; LD50 = lethal dose, 50% kill; LDL = low-density lipoprotein; LE = lethality; LOAEL = lowest-observed-effect level; M = male(s); 
Musc/skel = musculoskeletal; MX = maternal toxicity; Neuro = neurological; NOAEL = no-observed-adverse-effect level; NS = not specified; OF = organ function; 
OW = organ weight; PPD = post-partum day; Repro = reproductive; TG = teratogenicity; UR = urinalysis; WI = water intake 
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Figure 2-4.  Levels of Significant Exposure to Chlordecone – Oral 
Acute (≤14 days) 
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Figure 2-4.  Levels of Significant Exposure to Chlordecone – Oral 
Acute (≤14 days) 
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Figure 2-4.  Levels of Significant Exposure to Chlordecone – Oral 
Intermediate (15–364 days) 
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Figure 2-4.  Levels of Significant Exposure to Chlordecone – Oral 
Intermediate (15–364 days) 
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Figure 2-4.  Levels of Significant Exposure to Chlordecone – Oral 
Chronic (≥365 days) 
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Table 2-5.  Levels of Significant Exposure to Mirex – Dermal 
 
Species 
(strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
ACUTE EXPOSURE 
Rat 
(Sherman) 
10 M,10 F 
NS NS LE Death   >2,000 LD50 
Gaines 1969 
INTERMEDIATE EXPOSURE 
Mouse 
(CD-1) 
30 F 
4 weeks 
3 times/week 
(paint) 
0, 3.6 BI, HP Cancer   3.6 F Skin tumor promotion  
Meyer et al. 1993 
Mouse 
(CD-1) 
30 F 
20 weeks 
2 times/week 
(paint) 
0, 3.6 BI, HP Cancer   3.6 F Skin tumor promotion 
Meyer et al. 1994 
Mouse 
(CD-1) 
30 F 
4 weeks 
3 times/week 
(paint) 
0, 3.6 HP Cancer  3.6 F  Mild epidermal hyperplasia 
Moser et al. 1992 
Mouse 
(CD-1) 
30 F 
20 or 
34 weeks 
3 times/week 
(paint) 
0, 0.45, 0.9, 
1.8, 3.6 
BI, HP Cancer   0.45 F Skin tumor promotion 
Moser et al. 1992 
Mouse 
(CD-1) 
30 M, 30 F 
20 weeks 
3 times/week 
(paint) 
0, 3.6 CS, GN, HP Cancer   0.45 F Skin tumor promotion 
Moser et al. 1993 
 
BI = biochemical changes; CS = clinical signs; F = female(s); GN = gross necropsy; HP = histopathology; LD50 = lethal dose, 50% kill; LE = lethality; 
LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level; NS = not specified; M = male(s) 
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Species (strain) 
No./group 
Exposure 
parameters 
Doses 
(mg/kg/day) 
Parameters 
monitored Endpoint 
NOAEL 
(mg/kg/day) 
Less 
serious 
LOAEL 
(mg/kg/day) 
Serious 
LOAEL 
(mg/kg/day) Effect 
ACUTE EXPOSURE 
Rat 
(Sherman) 
10M,10F 
NS NS LE Death   >2,000 LD50 
Gaines 1969 
Rabbit 
(NS) 
10M 
NS 20 LE Death   410 M LD50 
Larson et al. 1979b 
 
F = female(s); LD50 = lethal dose, 50% kill; LE = lethality; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level; NS = not 
specified; M = male(s) 
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2.2   DEATH 
 
Mirex.  Oral LD50 values for mirex obtained in rats have been somewhat variable.  In one study, 
administration of mirex in corn oil resulted in an LD50 value in females of 365 mg/kg (Gaines and 
Kimbrough 1970), whereas in another study, the LD50 values in male and female rats were 740 and 
600 mg/kg, respectively, after administration of mirex in corn oil, but in excess of 3,000 mg/kg after 
administration in peanut oil (Gaines 1969).  Mehendale et al. (1973) reported death of 2/5 female rats 
during a 5-day period of mirex gavage dosing at 50 mg/kg/day.  Pregnant rats appear to be somewhat 
more sensitive to the lethal effect of mirex.  Although a single oral dose of mirex at 25 mg/kg resulted in 
no mortality in nonpregnant females (Mehendale et al. 1973), 16–25% mortality in pregnant rats occurred 
at doses ranging from 6 to 10 mg/kg/day over a 10–11-day period during gestation (Byrd et al. 1981; 
Chernoff et al. 1979b; Khera et al. 1976) and mortality rates of 32–36% were observed in rat and mouse 
pups exposed through the milk during the first 4 days of lactation at these doses (Chernoff et al. 1979b).  
Four of 20 maternal rats died during oral exposure to mirex at 6 mg/kg/day on gestation days 6–15 (Khera 
et al. 1976).  Twelve of 15 mice died during a 14-day study that employed oral dosing with mirex at 
10 mg/kg/day (Fujimori et al. 1983).  In male dogs, a single oral dose of mirex at 1,250 mg/kg was lethal 
to three of five treated animals; there were no deaths among five dogs similarly treated at 1,000 mg/kg 
(Larson et al. 1979a). 
 
Several studies evaluated mortality in laboratory animals orally exposed to mirex for intermediate 
durations.  Mortality was increased in adult male rats at doses as low as 5 mg/kg/day for 30 days 
(Mehendale 1981b), in adult female rats at doses as low as 6.2 mg/kg/day for 90 days (Gaines and 
Kimbrough 1970; Larson et al. 1979a), and in rat pups at 1.8–2.8 mg/kg/day for the duration of lactation 
(Gaines and Kimbrough 1970).  In mice, 100% mortality occurred following 1.3 mg/kg/day for 60 days 
and 0–25% mortality occurred at 0.65 mg/kg/day for 120 days (Ware and Good 1967).  Death occurred in 
one of two dogs treated orally with mirex at 2.5 mg/kg/day for 13 weeks (Larson et al. 1979a).  In a 
2-year study in rats, males exhibited mirex treatment-related increased mortality at 1.8 mg/kg/day 
(63 versus 15% in controls), but females exhibited no mirex-related decrease in survival at as much as 
7.7 mg/kg/day (NTP 1990).  In an 18-month oral study of mice, unscheduled death was observed among 
all mice at 3.6 mg mirex/kg/day (Innes et al. 1969).  In a 15-month study, Wolfe et al. (1979) reported 
20 and 92% mortality among mice ingesting mirex at 0.24 and 2.4 mg/kg/day, respectively. 
 
The dermal LD50 value for mirex in rats was reported to be in excess of 2,000 mg/kg (Gaines 1969). 
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Chlordecone.  Single-dose oral LD50 values in rats for chlordecone were reported to be 126 mg/kg in 
females (Larson et al. 1979b) and 91.3 mg/kg (Pryor et al. 1983) and 132 mg/kg (Larson et al. 1979b) in 
males.  An oral LD50 for male and female rats was 125 mg/kg (Gaines 1969).  LD50 values for male 
rabbits and dogs (sex not specified) were 71 and 250 mg/kg, respectively (Larson et al. 1979b).  A single 
oral dose of 110 mg/kg resulted in the death of 5/20 pregnant mice; at 125 mg/kg, death occurred in 
17/40 pregnant mice (Kavlock et al. 1985).  No mortality was observed in male rats dosed with 
chlordecone at approximately 10 mg/kg/day for 10 days (Simmons et al. 1987), but 8/42 pregnant mice 
died during oral treatment with chlordecone at 10 mg/kg/day on gestation days 7–16 (Chernoff and 
Rogers 1976).  Gavage dosing of 24 mg chlordecone/kg/day during gestation days 8–12 resulted in the 
death of 5/27 pregnant mice (Seidenberg et al. 1986).  Ingestion of milk from dams given 18 mg 
chlordecone/kg/day during the first 4 days of lactation resulted in 64% mortality in mouse pups (Chernoff 
et al. 1979b).  Daily oral administration of chlordecone to male mice at 25 or 50 mg/kg/day resulted in 
100% mortality by treatment days 12 and 6, respectively (Desaiah et al. 1980a). 
 
In intermediate-duration studies of male rats, 2/5 rats died during 5 weeks of oral exposure to chlordecone 
at 8.6 mg/kg/day (Mehendale 1981b) and 6/10 rats died during 15 weeks of treatment at 4.1 mg/kg/day 
(Pryor et al. 1983).  In mice of both sexes, at a dose of 11.21 mg/kg/day for up to 12 months, only 12% 
mortality was observed among adult mice, whereas all four treated juvenile mice died, indicating a greater 
sensitivity in immature mice (Huber 1965).  All 15 male mice exposed orally with chlordecone at 
10 mg/kg/day died during a scheduled 33-day dosing period (Fujimori et al. 1983).  Survival was 
decreased in female rats receiving chlordecone from the diet at 1.25 mg/kg/day for up to 2 years (Larson 
et al. 1979b), both male and female rats receiving chlordecone from the diet at 1.2–1.3 mg/kg/day for up 
to 80 weeks (NCI 1976), and male mice receiving chlordecone from the diet at 2.6 or 3.0 mg/kg/day for 
up to 80 weeks (NCI 1976). 
 
The dermal LD50 value for chlordecone in rats was reported to be in excess of 2,000 mg/kg (Gaines 
1969).  In male rabbits exposed dermally to chlordecone in corn oil, an LD50 value of 410 mg/kg was 
reported (Larson et al. 1979b). 
 
2.3   BODY WEIGHT 
 
Mirex.  No studies were located regarding body weight effects in humans exposed to mirex.  Decreases 
>10% in body weight or body weight gain have been observed in studies of laboratory animals following 
acute-, intermediate-, and chronic-duration oral exposure to mirex (Buelke-Sam et al. 1983; Byrd et al. 
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1981; Chadwick et al. 1977; Chernoff et al. 1979a, 1979b; Chu et al. 1981b; Curtis and Hoyt 1984; 
Davison et al. 1976; Elgin et al. 1990; Fujimori et al. 1983; Jovanovich et al. 1987; Khera et al. 1976; 
Larson et al. 1979a; Mehendale et al. 1973; NTP 1990; Ritchie and Ho 1982; Rogers and Grabowski 
1984; Villeneuve et al. 1977). 
 
Chlordecone.  Weight loss was reported among 27 of 133 workers examined as a result of intermediate- 
or chronic-duration occupational exposures to chlordecone (Cannon et al. 1978).  Weight loss (up to 
60 pounds in 4 months) was reported in 10 of 23 workers with blood chlordecone levels in excess of 
2 μg/L (Taylor et al. 1978).  Decreases >10% in body weight or body weight gain have also been 
observed in studies of laboratory animals following acute-, intermediate-, and chronic-duration oral 
exposure to chlordecone (Albertson et al. 1985; Cannon and Kimbrough 1979; Chernoff and Kavlock 
1982; Chernoff and Rogers 1976; Curtis and Hoyt 1984; Curtis and Mehendale 1979; EPA 1986c; 
Fabacher and Hodgson 1976; Huang et al. 1980; Kavlock et al. 1987b; Klingensmith and Mehendale 
1982a; Larson et al. 1979b; Mehendale et al. 1977, 1978b; Pryor et al. 1983; Seidenberg et al. 1986; 
Simmons et al. 1987; Smialowicz et al. 1985; Swanson and Wooley 1982).  In the report by Larson et al. 
(1979b), the decreases in body weight were observed in the presence of increases in food consumption, 
indicating a decrease in food utilization efficiency and/or increased stress to the animals. 
 
2.4   RESPIRATORY 
 
Mirex.  No studies were located regarding respiratory effects in humans or animals exposed to mirex. 
 
Chlordecone.  Pleuritic chest pains were reported by 32 of 133 workers examined for toxicity following 
intermediate- or chronic-duration occupational exposure at a chlordecone-manufacturing facility (Cannon 
et al. 1978); pleuritic chest pains were reported by 18 of 23 workers with blood levels in excess of 2 μg/L.  
Further examination of these workers did not reveal any dyspnea, and chest x-rays revealed no lung 
pathology (Taylor 1982, 1985).  Extremely limited information was located regarding respiratory effects 
in animals following oral exposure to chlordecone.  Routine histopathological examination of the lungs of 
rats in both 90-day and 2-year feeding studies with doses as high as 4 mg/kg/day showed no adverse 
effects.  Also, routine histopathological examination of the lungs of dogs exposed to doses as high as 
0.625 mg/kg/day in a 2-year feeding study showed no effects (Larson et al. 1979b).  It is unclear how 
many lung tissue samples were actually examined; the dog study used only two animals/sex/dose. 
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2.5   CARDIOVASCULAR 
 
Mirex.  No studies were located regarding cardiovascular effects in humans exposed to mirex.  Limited 
information was located regarding cardiovascular effects of mirex in animals.  Changes in blood flow 
patterns were seen in pregnant rats given gavage doses of mirex at 10 mg/kg/day for varying periods 
during pregnancy (Buelke-Sam et al. 1983).  In this study, a single oral dose resulted in a decrease in 
blood flow to the stomach, while 5 and 10 daily doses resulted in decreased blood flow to other essential 
internal organs (lungs, liver, spleen, or kidneys).  Five days of exposure also resulted in decreased cardiac 
output, but this effect had disappeared by day 10 of exposure.  There was also a significant decrease in the 
heart weight of the maternal rats.  Another study showed that rats given mirex at 100 mg/kg/day by 
gavage for 3 days experienced a slight inhibition of Na+K+ATPase in myocardial membranes (Desaiah 
1980).  The biological significance of this effect is unknown.  There was no gross or histopathological 
evidence of mirex-related adverse cardiac effects among rats ingesting mirex for 13 weeks at doses as 
high as 64 mg/kg/day (Larson et al. 1979a). 
 
Chlordecone.  Symptoms associated with the cardiovascular system were not commonly reported by 
133 workers exposed for intermediate or chronic durations to unspecified levels of chlordecone at a 
chlordecone-manufacturing facility (Cannon et al. 1978; Taylor 1982, 1985; Taylor et al. 1978).  
Furthermore, results from electrocardiography of 23 workers with active symptoms of chlordecone 
intoxication were normal (Taylor 1982, 1985).  Maternal serum chlordecone was not associated with 
hypertensive disorders or preeclampsia in a subpopulation of pregnant women in the TIMOUN 
prospective mother-child cohort study in Guadeloupe, French West Indies where pesticides (including 
chlordecone) were extensively used on banana plantations (Saunders et al. 2014).  See Table 2-2 for 
additional study details. 
 
Available information regarding the cardiovascular effects of chlordecone in animals is also limited.  
Acute-duration studies have primarily examined biochemical parameters.  For example, gavage dosing of 
rats with chlordecone (≥10 mg/kg/day for 3 days) resulted in inhibition of myocardial Na+K+ATPase 
(Desaiah 1980).  At ≥25 mg/kg/day, inhibition of mitochondrial Mg2+ATPase occurred; decreased 
norepinephrine and dopamine binding to myocardial membranes was observed at 50 mg/kg/day.  
Similarly, inhibition of calcium uptake, Ca2+ATPase activity, and protein phosphorylation was observed 
in rat cardiac sarcoplasmic reticulum following gavage doses of chlordecone at 8.3 mg/kg/day for 3 days 
(Kodavanti et al. 1990a).  Because of the importance of calcium regulation in all phases of the cardiac 
cycle, this might indicate a decrease in cardiac effectiveness. 
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Vasodilation of tail vessels has been observed in rats following oral administration of chlordecone for 
90 days at 4 mg/kg/day (Larson et al. 1979b).  The cause of the vasodilation was not investigated, but was 
suggested to have been associated with altered thermoregulatory mechanism. 
 
Routine histopathological analyses of heart samples have not shown significant changes following oral 
exposure of rats to chlordecone for 2 years at 1.25 mg/kg/day or dogs for 124–128 weeks at 
0.625 mg/kg/day (Larson et al. 1979b).  However, these studies are limited in that it is unclear how many 
heart samples were actually examined, and the dog study employed only two animals/sex/dose. 
 
2.6   GASTROINTESTINAL 
 
Mirex.  No studies were located regarding gastrointestinal effects in humans exposed to mirex.  Limited 
information was located regarding gastrointestinal effects in animals following oral exposure to mirex; 
however, the available data indicate that diarrhea is a relatively common result of high-dose mirex 
exposure.  Several acute- and intermediate-duration studies have identified diarrhea in treated animals, 
but few of these studies presented sufficient information to assign a LOAEL for this effect.  Diarrhea was 
identified as a predominant sign in female rats that died during a l0-day gavage study, but the mirex doses 
at which this was observed were not specified (6 or 12.5 mg/kg/day) (Khera et al. 1976).  Similarly, 
diarrhea was noted as one of the clinical signs seen in rats after a single gavage dose, but it was unclear 
whether this effect occurred at the lowest dose (100 mg/kg) at which clinical signs were observed (Gaines 
and Kimbrough 1970).  Diarrhea was observed in rats fed a total of 365 mg/kg over 12 days, but the daily 
dose was not specified (Kendall 1974a).  Mild diarrhea was observed in treated rats (5 mg/kg/day) 
starting on the 8th day of exposure and continuing over the duration of a 30-day dietary study (Mehendale 
1981b).  Diarrhea was also observed in a 90-day gavage study of rats, but the dose (5, 12.5, or 
25 mg/kg/day) at which it was observed was not reported (Dietz and McMillan 1979).  Severe diarrhea 
was reported in mice following gastric intubation with mirex for up to 15 days, but the report did not state 
which of the doses (10, 25, or 50 mg/kg/day) caused this effect (Fujimori et al. 1983).  Necropsy showed 
hemorrhagic intestines, indicating a gastrointestinal origin for the diarrhea rather than a neurally mediated 
response. 
 
Chlordecone.  No studies were located regarding gastrointestinal effects in humans exposed to 
chlordecone.  Mild diarrhea has also been observed in a 33-day gavage study of mice receiving 
chlordecone at 10 mg/kg/day; however, necropsy revealed no evidence of treatment-related effects on 
MIREX AND CHLORDECONE  88 
 
2.  HEALTH EFFECTS 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
stomach or intestines (Fujimori et al. 1983).  Likewise, routine histopathological analyses of 
gastrointestinal tissues showed no compound-related effects in rats after 2 years of oral exposure to 
chlordecone at 1.25 mg/kg/day or in dogs after 124–128 weeks of exposure at 0.625 mg/kg/day (Larson et 
al. 1979b).  Both of these studies are limited in that it is unclear whether tissues from all exposed animals 
were examined and only two animals/sex/group were included in the dog study. 
 
2.7   HEMATOLOGICAL 
 
Mirex.  No studies were located regarding hematological effects in humans exposed to mirex.  Adverse 
hematological effects have not been reported to be a prominent feature of mirex toxicity in animals.  No 
effects on standard hematological parameters were observed after 14 days of exposure of male rats to 
mirex at 10 mg/kg/day (Villeneuve et al. 1977).  However, a single oral dose of 100 mg/kg mirex to rats 
resulted in a 12% increase in hematocrit (Ervin and Yarbrough 1983).  The hematocrit was increased 26–
27% in adrenalectomized rats.  The significance of this effect is unclear.  Most intermediate-duration 
studies have shown no effect of mirex on hematological parameters.  No effect on routine hematological 
parameters occurred in rats treated for 28 days at oral doses as high as 3.75 mg/kg/day (Chu et al. 1980a; 
Yarbrough et al. 1981).  In addition, no effects were observed among rats receiving mirex from the food 
for 148 days at 2 mg/kg/day (Chu et al. 1981a).  In contrast, oral exposure of rats to mirex for 13 weeks 
resulted in decreased hemoglobin at 16 mg/kg/day and increased leukocytes at 64 mg/kg/day (Larson et 
al. 1979a).  Increased hematocrit was reported for a male dog that died during a 13-week study in which 
the dog received mirex from the food at 2.5 mg/kg/day (Larson et al. 1979a).  There was no evidence of 
mirex treatment-related hematological effects among rabbits following repeated dermal application 
(unspecified amount) of mirex for 9 weeks (Larson et al. 1979a). 
 
Chlordecone.  No studies were located regarding hematological effects in humans exposed to 
chlordecone.  Studies examining the hematological effects of chlordecone in experimental animals have 
also given predominantly negative results.  In intermediate-duration studies in rats, no effect on any 
hematological parameters occurred following 28 days of dietary exposure to chlordecone at 
0.086 mg/kg/day (Chu et al. 1980a) or 90 days of dietary exposure at doses up to 7.37 or 8.21 mg/kg/day 
for males and females, respectively (Larson et al. 1979b).  Similarly, in chronic-duration studies, no 
effects were seen during routine hematology in rats receiving chlordecone from the food for 2 years at up 
to 1.25 mg/kg/day or in dogs receiving chlordecone from the food for 124–128 weeks at doses up to 
0.625 mg/kg/day (Larson et al. 1979b). 
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2.8   MUSCULOSKELETAL 
 
Mirex.  No studies were located regarding musculoskeletal effects in humans or animals exposed to 
mirex. 
 
Chlordecone.  Skeletal muscle biopsies obtained from six workers who had experienced tremors, muscle 
weakness, gait ataxia, and incoordination as a result of intermediate- or chronic-duration occupational 
exposure to high concentrations of chlordecone revealed a predominance of fiber grouping characteristic 
of myopathic conditions, and a slight increase in lipochrome content (Martinez et al. 1978); the biological 
significance of this effect is unknown.  It is unclear whether the myopathy was a direct toxic effect of 
chlordecone on the muscle or whether the myopathy was a consequence of neuronal dysfunction.  
Arthralgia in the proximal joints was reported by 4 of 23 workers with active symptoms of chlordecone 
intoxication (Taylor 1982, 1985); no cause for the joint pain could be determined. 
 
Studies examining the effects of acute-duration oral exposure to large amounts of chlordecone suggest 
that direct toxic effects of chlordecone on muscle occur.  A single gavage dose of chlordecone to rats at 
between 72 and 98 mg/kg resulted in increasing muscle weakness (Egle et al. 1979).  Weakness was 
observed on the first day of treatment and continued to increase throughout a 49-day observation period.  
Following 2–3 days of oral exposure to chlordecone (25 and 50 mg/kg/day), inhibition of Mg2+ATPase 
was observed in sarcoplasmic reticulum of treated rats (Mishra et al. 1980).  There was no histopathologic 
evidence of chlordecone-related effects on skeletal muscle among laboratory animals treated for longer 
durations at lower dose levels.  For example, no compound-related effects were reported among rats 
receiving chlordecone from the diet for 90 days at up to 7.37 and 8.21 mg/kg/day (males and females, 
respectively), other rats treated for or 2 years at up to 1.25 mg/kg/day, or dogs treated for 124–128 weeks 
at up to 0.625 mg/kg/day (Larson et al. 1979b). 
 
2.9   HEPATIC 
 
Mirex.  The hepatotoxicity of mirex in humans has not been demonstrated.  One study of human subjects 
(sex and number not specified) from a chronically-exposed cohort in southeast Ohio assessed the potential 
for mirex to induce cytochrome P4501A2 (CYP1A2) using a breath test that measures caffeine 
metabolism.  The mirex-exposed subjects had elevated caffeine metabolism as compared to negative 
control individuals (subjects with no known exposure to mirex or polyhalogenated biphenyls or other 
related chemicals) in which the metabolism did not increase (Lambert et al. 1992).  However, the study 
did not assess liver function. 
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Mirex-related hepatic effects have been well characterized in experimental animals.  The changes 
observed in livers include both adaptive and toxic effects.  The adaptive effects observed are those 
generally produced by halogenated hydrocarbons and include the following:  
 
• Increased liver weight or size (Abston and Yarbrough 1976; Byard et al. 1975; Chadwick et al. 
1977; Chambers and Trevethan 1983; Chu et al. 1980b, 1981a, 1981b; Curtis and Hoyt 1984; Dai 
et al. 2001; Davison et al. 1976; Elgin et al. 1990; Ervin and Yarbrough 1983; Fujimori et al. 
1983; Fulfs et al. 1977; Gaines and Kimbrough 1970; Hewitt et al. 1979; Jovanovich et al. 1987; 
Karl and Yarbrough 1984; Larson et al. 1979a; Mehendale 1981b; Mehendale et al. 1973; Pittz et 
al. 1979; Plaa et al. 1987; Purushotham et al. 1988; Ritchie and Ho 1982; Robacker et al. 1981; 
Robinson and Yarbrough 1978a, 1978c; Teo and Vore 1991; Thottassery and Yarbrough 1991; 
Villeneuve et al. 1977; Warren et al. 1978; Williams and Yarbrough 1983; Wilson and Yarbrough 
1988; Yarbrough et al. 1981, 1984, 1986a, 1986b, 1992) 
 
• Hepatocellular hypertrophy (Davison et al. 1976; Fulfs et al. 1977; Gaines and Kimbrough 1970; 
Ulland et al. 1977; Yarbrough et al. 1981) 
 
• Cytoplasmic eosinophilia with migration of basophilic granules (Chu et al. 1981a; NTP 1990; 
Yarbrough et al. 1981) 
 
•  Increased smooth endoplasmic reticulum content (Baker et al. 1972; Curtis et al. 1981; Davison 
et al. 1976; Fulfs et al. 1977; Gaines and Kimbrough 1970; Mehendale et al. 1989) 
 
• Increased microsomal protein content (Chambers and Trevethan 1983; Davison et al. 1976; Elgin 
et al. 1990; Karl and Yarbrough 1984; Klingensmith and Mehendale 1983b; Pittz et al. 1979; 
Villeneuve et al. 1977; Yarbrough et al. 1981, 1986a) 
 
• Increased CYP450 content (Baker et al. 1972; Chambers and Trevethan 1983; Cianflone et al. 
1980; Curtis et al. 1981; Davison et al. 1976; Fujimori et al. 1983; Iverson 1976; Klingensmith 
and Mehendale 1983b; Kocarek et al. 1991; Peppriell 1981; Robacker et al. 1981; Robinson and 
Yarbrough 1978a; Yarbrough et al. 1981, 1986a) 
 
• Increased NADPH2-cytochrome c reductase (Chambers and Trevethan 1983; Fujimori et al. 
1983; Robacker et al. 1981; Yarbrough et al. 1986a), accompanied or unaccompanied by an 
increase in microsomal enzyme activity (Byard et al. 1975; Chadwick et al. 1977; Chambers and 
Trevethan 1983; Chu et al. 1981a, 1981b; Cianflone et al. 1980; Curtis et al. 1981; Fabacher and 
Hodgson 1976; Iverson 1976; Mehendale et al. 1973; Robacker et al. 1981; Stevens et al. 1979; 
Villeneuve et al. 1977; Warren et al. 1978; Yarbrough et al. 1981, 1986a) 
 
Marked hepatic toxicity has been observed in laboratory animals orally exposed to mirex.  The primary 
form of hepatotoxicity observed in rats is hepatobiliary toxicity, typically expressed as decreased 
hepatobiliary excretion of selected substances often in the presence of increased bile flow (e.g., Bell and 
Mehendale 1985; Berman et al. 1986; Curtis and Mehendale 1979; Dahlstrom-King et al. 1992; Hewitt et 
al. 1986a; Larson et al. 1979a; Mehendale 1976, 1977c, 1979; Teo and Vore 1991).  Decreased uptake of 
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substances into rat hepatocytes was observed after gavage dosing, suggesting that transport of substances 
into hepatocytes may contribute to the decrease in their biliary excretion (Teo and Vore 1990). 
 
Other evidence of generalized mirex-related hepatic toxicity in orally-exposed laboratory animals 
includes: 
 
• Increases in serum ALT and/or AST (Fouse and Hodgson 1987; Mitra et al. 1990) 
 
• Periportal liposis and degeneration of the endoplasmic reticulum (Kendall 1979) 
 
• Increased hepatic lipids or decreased hepatic glutathione or glucocorticoid receptors (Ervin and 
Yarbrough 1983; Sunahara and Chiesa 1992; Thottassery and Yarbrough 1991) 
 
• Swollen hepatocytes or megalocytosis (NTP 1990; Plaa et al. 1987; Ulland et al. 1977) 
 
• Increased hepatic lipid (Fulfs et al. 1977) 
 
• Increased serum triglycerides (Jovanovich et al. 1987) 
 
• Hepatic glycogen depletion in rats (Elgin et al. 1990; Ervin and Yarbrough 1983; Jovanovich et 
al. 1987; Kendall 1974a, 1979) and mice (Fujimori et al. 1983) 
 
• Vacuolation, necrosis, and/or degeneration (Chu et al. 1981b; Davison et al. 1976; Gaines and 
Kimbrough 1970; Hewitt et al. 1979; Larson et al. 1979a; NTP 1990) 
 
Chlordecone.  Mild hepatomegaly (occasionally with splenomegaly) was noted in 9 of 23 workers with 
chlordecone blood levels in excess of 2 μg/L, but there were no observed changes in organ function and 
only slight increases in serum alkaline phosphatase in several of the men (Taylor 1982, 1985; Taylor et al. 
1978).  When liver function and structure were evaluated in 32 men exposed to high concentrations of 
chlordecone while employed for 1–22 months (5.6 months average) in the production of chlordecone, 
hepatomegaly was reported in 20 of the workers, 10 of whom exhibited minimal splenomegaly as well 
(Guzelian et al. 1980).  In the exposed workers, urinary excretion of glucaric acid was significantly 
increased and the half-life of antipyrine in the blood was significantly decreased, indicating increased 
microsomal enzyme activity.  Needle biopsies of hepatic tissue from 12 of the 32 workers showed marked 
proliferation of smooth endoplasmic reticulum in several samples.  All of these are considered to be 
adaptive changes.  Limited evidence of hepatic toxicity in these workers included small increases in 
serum alkaline phosphatase in 7 of the 32 workers.  In addition, liver biopsies showed lipofuscin 
accumulation in 11 of 12, mild inflammatory changes in 5 of 12, vacuolization of nuclei in 3 of 12, mild 
portal fibrosis in 3 of 12, fatty infiltration in 3 of 12, and paracrystalline mitochondrial inclusions in 4 of 
12 individuals tested.  Retention of sulfobromophthalein was normal; serum levels of bilirubin, albumin, 
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globulin, ALT and AST activity, and γ-glutamyl transferase activity were also normal (Guzelian et al. 
1980). 
 
Chlordecone causes both adaptive and toxic changes in the livers of experimental animals.  Adaptive 
responses of the liver seen after oral exposure of rats, mice, or gerbils to chlordecone include the 
following: 
 
• Increased liver size or weight (Cannon and Kimbrough 1979; Chernoff and Rogers 1976; Curtis 
and Mehendale 1979; EPA 1986c; Fabacher and Hodgson 1976; Fujimori et al. 1983; Huber 
1965; Larson et al. 1979b; Mehendale 1981b; Mehendale et al. 1977, 1978b; Purushotham et al. 
1988; Simmons et al. 1987; Swartz and Schutzmann 1986, 1987) 
 
• Hepatocellular hypertrophy (Cannon and Kimbrough 1979) 
 
• Increased smooth endoplasmic reticulum content (Curtis et al. 1981; Lockard et al. 1983a, 
1983b; Mehendale et al. 1989) 
 
• Increased microsomal protein content (Chambers and Trevethan 1983; Klingensmith and 
Mehendale 1982b, 1983b; Mehendale et al. 1977, 1978b) 
 
• Increased CYP450 content (Agarwal and Mehendale 1984a; Britton et al. 1987; Cai and 
Mehendale 1990; Chambers and Trevethan 1983; Chaudhury and Mehendale 1991; Fabacher and 
Hodgson 1976; Fujimori et al. 1983; Kitchin and Brown 1989; Klingensmith and Mehendale 
1982b, 1983b; Kocarek et al. 1991; Mehendale et al. 1977, 1978b) 
 
• Increased NADPH2-cytochrome c reductase (Chambers and Trevethan 1983; Fujimori et al. 
1983; Mehendale et al. 1977, 1978b); and/or microsomal enzyme activity (Chaudhury and 
Mehendale 1991; Cianflone et al. 1980; Curtis et al. 1981; Fabacher and Hodgson 1976; 
Klingensmith and Mehendale 1982b; Mehendale et al. 1977, 1978b) 
 
Indicators of chlordecone-induced liver toxicity in orally-exposed laboratory animals include: 
 
• Decreased bile acid concentration, decreased bile acid secretion, and increased bile flow (Teo and 
Vore 1991) 
 
• Decreased serum triglycerides and LDL cholesterol (Chetty et al. 1993a, 1993b) 
 
• Increased serum alkaline phosphatase and ALT (EPA 1986c) 
 
• Increased mannitol recovery (indicates decreased permeability of the canalicular membrane) or 
increased lysosomal fragility (Hewitt et al. 1986a, 1990) 
 
• Decreased hepatic glycogen (Fujimori et al. 1983) 
 
MIREX AND CHLORDECONE  93 
 
2.  HEALTH EFFECTS 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
• Vacuolation, necrosis, and/or degeneration (Cannon and Kimbrough 1979; Hewitt et al. 1979; 
Huber 1965; NCI 1976) 
 
• Hepatocellular hyperplasia (NCI 1976) 
 
Several studies reported decreased biliary excretion of selected xenobiotics following repeated oral 
exposure to chlordecone (e.g., Curtis and Hoyt 1984; Curtis and Mehendale 1979; Curtis et al. 1979b, 
1981; Faroon and Mehendale 1990; Faroon et al. 1991; Mehendale 1977b).  These effects were observed 
in the absence of biochemical or histopathological evidence of chlordecone treatment-related adverse 
liver effects.  The altered biliary excretion of selected xenobiotics is not considered of itself representative 
of an adverse liver effect; therefore, the results are not summarized in Table 2-4 or plotted in Figure 2-4. 
 
Ultrastructural changes in livers from rats receiving chlordecone from the diet for 15 days at 
0.86 mg/kg/day included fragmentation of, and/or a decrease in rough endoplasmic reticulum, minute 
vacuolation of the cytoplasm, and/or tortuous bile canaliculi and deformed and swollen microvilli (Curtis 
et al. 1981; Faroon and Mehendale 1990; Faroon et al. 1991).  These ultrastructural changes were 
observed in the absence of light microscopic evidence of histopathological liver effects.  Furthermore, 
similar ultrastructural effects were not observed in another study that employed similar exposure of the 
same strain of rats (Lockard et al. 1983a, 1983b).  Therefore, these ultrastructural changes are not 
considered evidence of chlordecone treatment-related adverse liver effects and are not summarized in 
Table 2-4 or plotted in Figure 2-4. 
 
2.10   RENAL 
 
Mirex.  No data were located regarding renal effects in humans exposed to mirex.  No effect on rat kidney 
weight or blood urea nitrogen and no adverse histopathological findings were reported following a single 
oral dose at 50 mg/kg or three daily doses at 10 mg/kg/day (Plaa et al. 1987).  No effect on kidney weight, 
blood urea nitrogen, or ion exchange in the kidneys and no adverse histopathological findings were 
reported in mice following a single oral dose at 50 mg/kg (Hewitt et al. 1979).  No treatment-related 
histopathological renal effects or changes in urinalysis parameters were observed in 13-week oral studies 
of rats receiving mirex from the diet at doses as high as 64 mg/kg/day or dogs receiving mirex from the 
diet at doses as high as 2.5 mg/kg/day (Larson et al. 1979a).  Chu et al. (1980a) reported moderate focal 
lymphoid aggregates and multiple focal interstitial mononuclear infiltrates in the kidneys of 2/10 rats 
following dietary exposure to mirex for 28 days at 0.05 mg/kg/day.  However, the significance of these 
findings is limited by the low number of animals with these findings and the use of only a single dose, 
precluding determination of the presence or absence of a dose-response relationship.  Nephropathy 
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increased in severity in rats following 2 years of dietary exposure to mirex at 20.7 mg/kg/day among 
males and ≥2 mg/kg/day among females (NTP 1990).   
 
Chlordecone.  No data were located regarding renal effects in humans exposed to chlordecone.  Increases 
in blood urea nitrogen and kidney weight were observed following a 10-day oral exposure of rats to 
chlordecone at 10 mg/kg/day (EPA 1986c).  An increase in eosinophilic inclusions in the proximal 
tubules was observed in 2 of 10 rats examined following oral exposure to chlordecone for 28 days at 
0.05 mg/kg/day (Chu et al. 1980a).  However, the biological significance of this finding is unknown 
based on the small number of animals with this lesion and the use of only one dose, precluding the 
determination of a dose-response relationship.  Renal pathology was observed in rats following 
intermediate- and chronic-duration exposures to relatively small oral doses of chlordecone.  At 9 months 
of a 2-year oral study of rats receiving chlordecone from the diet at doses in the range of 0.05–
4 mg/kg/day, higher concentrations of urinary protein were reported in all groups of chlordecone-treated 
males and in females treated ≥0.51 mg/kg/day compared to controls (Larson et al. 1979b).  At most time 
points ≥1 year, higher concentrations of urinary protein were observed in males and females at all 
treatment levels.  However, statistical comparisons were not performed and only 5 males and 5 females 
per group were evaluated, thus precluding meaningful conclusions regarding adverse effect levels.  At 
12- and 24-month sacrifices, relative kidney weights among chlordecone-treated groups were not 
significantly different from those of controls.  At 12-month sacrifice, there was no evidence of treatment-
related kidney lesions.  At 2-year terminal sacrifice, the severity of observed glomerulosclerosis was 
increased in both males and females at doses ≥0.25 mg/kg/day.  No increases in urinary protein or adverse 
histopathological changes were seen in the kidneys of dogs receiving chlordecone from the diet for 124–
128 weeks at 0.625 mg/kg/day (Larson et al. 1979b). 
 
2.11   DERMAL 
 
Mirex.  No data were located regarding dermal effects in humans exposed to mirex.  Hair loss in the very 
young is the primary dermal effect observed in animals as a result of oral exposure to mirex.  Hair loss 
was reported in an acute-duration exposure study in which rats were given a total of 365 mg/kg over a 
12-day period (Kendall 1974a), but a LOAEL could not be determined because the daily dose was not 
reported.  Hair loss was also reported in a 90-day gavage study in rats (5, 12.5, and 25 mg/kg/day) (Dietz 
and McMillan 1979), but the specific dose associated with this effect was not specified, precluding 
determination of LOAEL for this effect.  Mild epidermal proliferation was reported among mice 
administered dermal application of mirex at 3.6 mg/kg, 3 times/week for 4 weeks (Moser et al. 1992).  
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Application of an unspecified amount of mirex to the skin of rabbits for 6–7 hours/day, 5 days/week for 
9 weeks, resulted in slight erythema and scaling after day 5 (Larson et al. 1979a).  This effect was 
reversible after 2 days without treatment. 
 
Chlordecone.  Eighty-nine of 133 workers interviewed as a result of intermediate- or chronic-duration 
occupational exposure to high concentrations of chlordecone during its manufacture reported skin rashes 
of an erythematous, macropapular nature at some time during occupational exposure to high 
concentrations of chlordecone during its manufacture (Cannon et al. 1978).  Among 23 of these workers 
with blood chlordecone levels in excess of 2 μg/L, 6 men reported rashes following exposure (Taylor et 
al. 1978).  It is likely that these rashes were the direct result of dermal exposure.  However, insufficient 
information was given to eliminate a systemic effect resulting from inhalation and/or oral exposure. 
 
No signs of dermal irritation were observed in rabbits following dermal application of a 20% solution of 
chlordecone in corn oil of chlordecone (Larson et al. 1979b).  No effects on the skin were observed during 
routine histopathological analyses of the skin of rats receiving chlordecone from the diet for 90 days at 
doses as high as 7.37–8.21 mg/kg/day or for 2 years at doses as high as 4 mg/kg/day, or in dogs exposed 
for 124–128 weeks at doses as high as 0.625 mg/kg/day (Larson et al. 1979b).  Increased dermatitis was 
reported in an 80-week dietary cancer bioassay of rats receiving chlordecone from the diet at doses as low 
as 0.4 mg/kg/day (NCI 1976). 
 
2.12   OCULAR 
 
Mirex.  No data were located regarding ocular effects in humans exposed to mirex. 
 
Production of cataracts in the very young was observed in rats receiving mirex orally during 12 days at a 
total dose of 365 mg/kg (Kendall 1974a); a LOAEL could not be determined because the daily dose was 
not reported.  Cataracts were produced in other newborn rats and mice following early postnatal oral 
exposure (Chernoff et al. 1979b; Rogers and Grabowski 1984; Scotti et al. 1981).  Cataracts were 
characterized as diffuse anterior corneal opacities, and lenses were found to have increased water and 
sodium content relative to potassium content (Rogers and Grabowski 1984).  Histopathological analyses 
showed increased vacuoles, pyknotic nuclei, swollen fibers, and/or degeneration.  Cataracts were 
produced in newborn rodents that received mirex indirectly through the mother’s milk (Chernoff et al. 
1979b; Rogers and Grabowski 1984).  Administration of mirex directly to the newborn by gavage at 
5 mg/kg/day starting on postpartum day 1 resulted in swelling of the lens fibers as early as postpartum 
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day 7, with degeneration and necrosis of the lenses apparent with increasing duration of exposure (Scotti 
et al. 1981).  Dietary exposure of maternal animals to mirex at doses as low as 1.25 mg/kg/day during 
postpartum days 1–4 or to doses as low as 1.8–2.8 mg/kg/day throughout the period of lactation (Gaines 
and Kimbrough 1970) also resulted in cataracts in rat pups.  Exposure during the first few days of life 
appears to be critical to the development of cataracts.  A single oral dose resulted in cataracts only if 
administered on or before postpartum day 6 and resulted in outlined lenses if administered on or before 
postpartum day 8 (Chernoff et al. 1979b).  Eye irritation was also reported in a 90-day gavage study of 
rats (5, 12.5, and 25 mg/kg/day), but the specific dose associated with this effect was not specified, thus 
precluding determination of a LOAEL (Dietz and McMillan 1979). 
 
Chlordecone.  Vision was blurred in 15 of 23 workers with chlordecone blood levels in excess of 2 μg/L; 
the workers were occupationally exposed during the manufacture of chlordecone (Taylor 1982, 1985).  
Other effects on vision are discussed in Section 2.15 (Neurological).   
 
There was no indication of treatment-related ocular effects on the offspring of maternal rats or mice orally 
exposed to chlordecone during the first 4 days of lactation at doses as high as 10 and 24 mg/kg/day, 
respectively (Chernoff et al. 1979a). 
 
2.13   ENDOCRINE 
 
Thyroid 
   
Mirex.  No data were located regarding endocrine effects in humans exposed to mirex.  Studies in rats 
indicate that mirex is toxic to the thyroid (Chu et al. 1981a, 1981b; NTP 1990; Singh et al. 1982, 1985).  
Doses of 0.25 mg/kg/day for 28 days resulted in a reversible reduction in colloid, a thickening of 
follicular epithelium, and angular collapse of the follicles, but no effect on serum levels of T3 or T4 (Chu 
et al. 1980b, 1981a, 1981b).  Ultrastructural analyses of thyroids from rats treated for 28 days showed 
dilation of the rough endoplasmic reticulum at 0.25 mg/kg/day and increased columnar cells with 
irregularly shaped lysosomal bodies, dilation of cisternae, and increased vacuolization at 2.5 mg/kg/day 
(Singh et al. 1982, 1985).  Similar effects were observed following dietary exposure to 0.25 mg/kg/day 
for 148 days (Chu et al. 1981a) and for 28 days (Chu et al. 1981b).  Dietary exposure to 0.7 mg/kg/day 
and above for 2 years also resulted in an increase in cystic follicles in male rats (NTP 1990).   
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Chlordecone.  No studies were located regarding thyroid effects in humans or animals exposed to 
chlordecone. 
 
Adrenal 
 
Mirex.  No studies were located regarding adrenal gland effects in humans exposed to mirex.  Studies in 
animals indicate that the adrenal gland hypertrophies and releases increased levels of corticosterone in 
response to mirex exposure (Ervin and Yarbrough 1985; Jovanovich et al. 1987; Williams and Yarbrough 
1983).  Single gavage doses of 20 mg/kg resulted in an increased level of serum corticosterone in rats 
(Williams and Yarbrough 1983); 100 mg/kg resulted in increases of adrenal weight, cholesterol, lipid, and 
protein content (Williams and Yarbrough 1983) and increased serum adrenocorticotropic hormone (Ervin 
and Yarbrough 1985).  Seven days of exposure at 1,000 mg/kg/day also increased adrenal weight in rats 
(Jovanovich et al. 1987).  Consistent with the ability of corticosterone to mobilize fatty acids for energy, a 
decrease in body fats was observed in this study.  No effects on the adrenal medulla were observed 
following 8-day dietary exposure of rats to mirex at 17 mg/kg/day (Baggett et al. 1980). 
 
Chlordecone.  Emeville et al. (2013) found no association between serum chlordecone and blood levels 
of steroid hormones in a population-based cross-sectional study of 277 healthy, non-obese, middle-aged 
men from the French West Indies.  See Table 2-2 for additional study details. 
 
Limited information is available regarding the effects of chlordecone on the adrenal glands of animals.  
Increased relative adrenal weight was observed in rats following a single oral dose of 35 mg/kg (Swanson 
and Wooley 1982) and following 10 days of gavage dosing at 10 mg/kg/day (EPA 1986c).  An enlarged 
adrenal with hyperplasia and hypertrophy of the cortical cells was observed in rats receiving chlordecone 
from the diet for 3 months at 1.17 mg/kg/day (Cannon and Kimbrough 1979).  Decreased adrenal lipid 
was reported for rats receiving chlordecone from the diet for 90 days at 2.56 mg/kg/day (Larson et al. 
1979b).  Consistent with a corticosterone-induced increase in lipid utilization, decreased body fat was 
observed in rats receiving chlordecone from the diet for 16 days at 2.5 or 5 mg/kg/day (Mehendale et al. 
1977, 1978b), 15 or 20 days at 5 mg/kg/day (Klingensmith and Mehendale 1982a), or in mice treated for 
33 days at 10 mg/kg/day (Fujimori et al. 1983).  In contrast to the absence of mirex-related noncancer 
effects on the adrenal medulla, chlordecone induced a decrease in the medullary content of epinephrine of 
rats orally treated for 8 days at 17 mg/kg/day (Baggett et al. 1980). 
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2.14   IMMUNOLOGICAL 
 
Mirex.  No studies were located regarding immunological effects in humans exposed to mirex.  Available 
information regarding potential for mirex-induced immunological effects in animals is limited to a single 
account of 32% decreased spleen weight among maternal rats gavaged with mirex at 10 mg/kg/day for up 
to 10 days during gestation (Buelke-Sam et al. 1983).  Oral administration of chlordecone in corn oil to 
male Fischer 344 rats did not cause dose-related changes in lymphoproliferative responses of splenic 
lymphocytes to the T-cell mitogens, phytohemagglutinin or pokeweed mitogen; it did cause decreases in 
the proliferative response to the T-cell mitogen, concanavalin A, and the B-cell mitogen, Salmonella 
typhimurium mitogen, but only at a dose (10 mg/kg/day for 10 days) that also resulted in impaired overall 
health of the rats (EPA 1986c; Smialowicz et al. 1985).  Statistically significant reductions in spleen and 
thymus weights, and in natural killer cell activity of splenocytes against allogeneic (W/Fu-Gl rat 
lymphoma) and xenogeneic (YAK-1 mouse lymphoma) tumor cell lines (EPA 1986c; Smialowicz et al. 
1985), were observed in rats only at a dose (10 mg/kg/day) producing generalized toxicity.  Also, a slight 
decrease in total leukocyte count (EPA 1986c) and a 49% decrease in neutrophils (Smialowicz et al. 
1985) were observed at toxic doses.  The authors suggested that these effects were associated with the 
compromised health status of the animals and were not due to selective toxicity toward the immune 
system.  The limitations of these studies include lack of information on cell-mediated functions, such as 
alloantigen reactivity and cytotoxicity, and on humoral immunity in the treated animals.  However, as part 
of a study evaluating the effects of calcium deficiency on the toxicity of chlordecone in male rats, an 
increase in plaque-forming cells was observed at the lowest chlordecone dose tested (0.86 mg/kg/day) 
(Chetty et al. 1993c). 
 
Chlordecone.  No studies were located regarding immunological effects in humans exposed to 
chlordecone.  A significant reduction of thymus weight was also observed in rats 3 weeks after a single 
oral dose of chlordecone at 75 mg/kg (Swanson and Wooley 1982).  It is likely that this effect may have 
been associated with generalized toxicity in the experimental animals. 
 
2.15   NEUROLOGICAL 
 
Mirex.  No studies were located regarding neurological effects in humans exposed to mirex.  Clinical 
signs indicative of neurotoxicity have not been widely reported in animals treated with mirex.  However, 
a number of studies did note some abnormal behavior following oral administration of mirex.  Following 
acute-duration exposures of rats to large doses (12.5–>365 mg/kg) of mirex, lethargy, weakness, 
hyperexcitability, and/or tremors have been observed (Gaines and Kimbrough 1970; Kendall 1974a).  
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Although the precise doses associated with specific neurotoxic effects were not specified in these studies, 
single oral doses at ≥100 mg/kg were necessary.  Juvenile rats showed a high sensitivity to acute exposure 
to mirex immediately after birth.  Lactational exposure via dams treated with mirex at 2.5 mg/kg/day on 
lactation days 1–4 caused no behavioral abnormalities at the time of exposure, but resulted in increased 
activity when the offspring reached adulthood (Reiter 1977). 
 
Intermediate-duration exposures to mirex generally resulted in lethargy as the predominant clinical sign at 
lower exposures and hyperexcitability at higher doses.  Lethargy was observed at a mirex dose level of 
5 mg/kg/day during both 15- and 30-day dietary studies in rats (Curtis and Hoyt 1984; Mehendale 1981b).  
Decreased operant responding was also observed in rats gavaged for 90 days at 5 mg/kg/day (Dietz and 
McMillan 1979).  Mirex had no effect on motor coordination of mice gavaged for 15 days at 
10 mg/kg/day, but some mice were observed to become too weak to balance on a glass rod during the 
15-day treatment period (Fujimori et al. 1983).  In a 13-week dietary study of rats, mirex treatment at 
16 mg/kg/day did not affect behavior, but at 64 mg/kg/day, rats became hyperexcitable and developed 
tremors and convulsions (Larson et al. 1979a).  Longer-duration exposures also resulted in increased 
excitability.  Hypoactivity, irritability, and tremors were observed in rats receiving mirex from the diet for 
up to 148 days at 2 mg/kg/day (Chu et al. 1981a). 
 
Chlordecone.  Examinations of 133 workers occupationally exposed to chlordecone during its production 
revealed 61 cases of tremors, 58 cases of nervousness or unfounded anxiety, and 42 cases of visual 
difficulties (Cannon et al. 1978).  Tremors were observed in all 23 workers with blood chlordecone levels 
in excess of 2 μg/L (Taylor et al. 1978).  The tremors were characterized as intention tremors or as 
occurring with a fixed posture against gravity (Taylor 1982, 1985).  The tremors were most apparent in 
the upper extremities, but were also detectable in the lower extremities.  In the more severe cases, gait 
was affected.  Mental disturbances consisting of irritability and poor recent memory were reported by 
13 of the 23 workers.  Standard tests of memory and intelligence showed clear evidence of an 
encephalopathy in 1 of the 13 workers (Taylor 1982, 1985).  The worker with encephalopathy reported 
auditory and visual hallucinations and demonstrated whole-body myoclonic jerks in response to loud 
noises.  In 15 of the 23 workers, vision was blurred (Taylor 1982, 1985).  Other effects on vision were 
characterized by a disruption of ocular motility by a brief series of rapid multidirectional eye movements 
at the end of a saccade (a quick, simultaneous movement of both eyes between two or more phases of 
fixation in the same direction).  Visual acuity and smooth pursuit eye movements were unaffected.  The 
rapid eye movements were considered to conform to the usual description of opsoclonus (a saccadic 
oscillation without intersaccadic intervals, consisting of conjugate multidirectional saccades occurring in 
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random directions with varying amplitudes).  Headaches of mild-to-moderate severity were reported by 
9 of the 23 workers.  Three of these nine workers had increased cerebrospinal fluid pressure and 
papilledema (Sanborn et al. 1979; Taylor 1982, 1985).  Nerve conduction velocity tests, 
electroencephalography, radioisotope brain scans, computerized tomography, and analyses of cerebral 
spinal fluid content were normal.  Sural nerve biopsies obtained from five workers with detectable tremor, 
mental disturbances consisting of irritability and poor recent memory, rapid random eye movements, 
muscle weakness, gait ataxia, incoordination, or slurred speech revealed a greatly decreased number of 
small myelinated and unmyelinated axons (Martinez et al. 1978).  Ultrastructural analyses of the nerves 
showed increased interstitial collagen, redundant folds in the Schwann cell cytoplasm, and the presence of 
occasional crystalloid inclusions suggesting that chlordecone exerted a direct toxic effect on the Schwann 
cell.  Examination of 16 of the 23 affected individuals from 5 to 7 years after cessation of exposure and 
after body levels of chlordecone had been substantially reduced showed that 9 were asymptomatic, 5 had 
persistent tremor or nervousness, and 3 had emotional problems (Taylor 1982, 1985). 
 
The neurotoxicity of chlordecone, which includes tremoring and/or a time-dependent exaggerated startle 
response, has been widely studied in experimental animals.  Single oral doses of chlordecone resulted in 
increased tremoring and/or an exaggerated response to audio or tactile stimuli (Albertson et al. 1985; 
Aldous et al. 1984; Egle et al. 1979; End et al. 1981; Huang et al. 1980; Hwang and Van Woert 1979; 
Maier and Costa 1990; Swanson and Wooley 1982).  Following single oral doses as low as 3.5 mg/kg in 
rats, increased tremoring during handling was observed for up to 1 week (Swanson and Wooley 1982).  In 
mice, tremors, decreased motor coordination, and hyperexcitability were observed following a single oral 
dose of chlordecone at 10 mg/kg (Huang et al. 1980).  In these studies, the tremors were apparent at 
earlier times when higher doses were used than when lower doses were used.  Abnormal gait was also 
apparent after single oral doses of 72–98 mg/kg (Egle et al. 1979).  Slightly lower multiple oral doses 
given over several days produced increased tremors, exaggerated startle responses, and/or abnormal gait 
(Aldous et al. 1984; Baggett et al. 1980; Chang-Tsui and Ho 1979; Desaiah et al. 1980a; Fujimori et al. 
1982b; Hoskins and Ho 1982; Huang et al. 1980; Jordan et al. 1981; Klingensmith and Mehendale 1982b; 
Mishra et al. 1980; Smialowicz et al. 1985).  In rats, tremors and an exaggerated startle response were 
observed at oral doses as low as 5 mg/kg/day over 5 days (Klingensmith and Mehendale 1982b).  An 
increased startle response without visible tremoring was observed at doses as low as 2.5 mg/kg/day over 
10 days (EPA 1986c).  This study was part of a toxicity screen performed at EPA in which male Fischer-
344 rats received gavage doses of chlordecone at 0.625–10 mg/kg/day for 10 consecutive days.  At a dose 
of 2.5 mg/kg/day, the amplitude of the acoustic startle response was significantly increased with the 
highest decibel stimulus (80 decibels).  At 5 and 10 mg/kg/day, the amplitude of the acoustic startle 
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response was significantly increased with all intensities of stimulus (50, 65, and 80 decibels).  Motor 
activity in a figure-8 maze was decreased at 10 mg/kg/day.  An acute-duration oral MRL was developed 
for chlordecone based neurological effects reported by EPA (1986c). 
 
Tremoring, accompanied or unaccompanied by increased responsiveness to touch and noise, have also 
been observed in a number of intermediate-duration studies of chlordecone (Agarwal and Mehendale 
1984c; Cannon and Kimbrough 1979; Curtis and Hoyt 1984; Curtis and Mehendale 1979; Dietz and 
McMillan 1979; Fujimori et al. 1983; Huber 1965; Klingensmith and Mehendale 1982a; Larson et al. 
1979b; Linder et al. 1983; Mehendale 1981b; Mehendale et al. 1978; Pryor et al. 1983; Squibb and Tilson 
1982b; Swartz and Schutzmann 1986, 1987).  Mild tremors were observed in rats receiving chlordecone 
from the diet for up to 90 days at doses as low as 0.83 mg/kg/day (Linder et al. 1983).  This study 
identified a NOAEL of 0.26 mg/kg/day; a provisional intermediate-duration oral MRL was derived for 
chlordecone based on the results of Linder et al. (1983).  Squibb and Tilson (1982b) reported increased 
startle response among rats receiving chlordecone from the diet at an estimated dose of 0.86 mg/kg/day, 
but no tremoring or effects on reflexes such as the tail flick response or the negative geotaxis test were 
observed, indicating that the startle response may be a sensitive indicator of chlordecone-induced 
neuronal function (Squibb and Tilson 1982b).  Chronic-duration studies in rats have also demonstrated 
increased tremoring.  Tremoring was observed at 1.25 mg/kg/day but not at 0.5 mg/kg/day in a 2-year rat 
dietary study (Larson et al. 1979b).  Tremoring was also observed in rats and mice receiving chlordecone 
from the diet for up to 80 weeks at doses as low as 0.4 and 3.0 mg/kg/day, respectively (NCI 1976).  No 
tremors or other behavioral abnormalities were observed in dogs receiving chlordecone from the diet for 
up to 2 years at 0.625 mg/kg/day (Larson et al. 1979b). 
 
Several acute-duration studies have attempted to correlate the tremoring with underlying neurochemical 
changes.  However, in many cases, it has been difficult to determine whether the effects observed were 
causative or the result of other underlying effects.  Inhibition of brain Na+K+ATPase and Mg2+ATPases 
has been correlated with the onset and diminution of tremoring in both rats and mice (Bansal and Desaiah 
1985; Desaiah et al. 1980a; Jordan et al. 1981).  However, other studies have not produced similar results 
(Maier and Costa 1990; Mishra et al. 1980).  In rats, mixed results have been obtained regarding changes 
in norepinephrine and dopamine levels in brains from treated animals.  Although norepinephrine uptake 
and dopamine uptake and binding were decreased (Chang-Tsui and Ho 1980; Desaiah 1985) and striatal 
dopamine synthesis, uptake, and release were inhibited (Fujimori et al. 1986) at tremorgenic doses, no 
effect was observed on norepinephrine or on dopamine content (Aldous et al. 1984; End et al. 1981) or 
synthesis (End et al. 1981) at equally tremorgenic doses.  Effects on calcium have also been observed in 
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treated rats and mice.  Decreased calcium uptake occurred in rats following a single oral dose of 40 mg/kg 
(End et al. 1981), and decreased brain calcium content was observed in adult mice following a single oral 
dose of 25 mg/kg (Hoskins and Ho 1982).  Decreased brain calmodulin was observed in rats at 
2.5 mg/kg/day for 10 days (Desaiah et al. 1985). 
 
2.16   REPRODUCTIVE 
 
Mirex.  Possible associations between serum mirex and selected reproductive health outcomes were 
evaluated in three studies.  Among 225 women 45–55 years of age and participants in the National Health 
and Nutrition Examination Survey (NHANES), serum mirex was positively associated with being 
menopausal (Grindler et al. 2015).  There was no significant difference in geometric mean mirex level 
(lipid-standardized) between 86 endometriosis cases and 70 controls in a case-control study (Lebel et al. 
1998).  A borderline positive association was reported for mirex serum level and risk of endometriosis in 
a population-based case-control study among 18–49-year-old enrollees of a health care system in 
Washington State; however, no association was found when cases were limited to ovarian endometriosis 
(Upson et al. 2013).  See Table 2-1 for additional study details. 
 
Studies in animals suggest that both male and female reproductive systems are adversely affected by 
mirex.  Gavage treatment of male rats to 6 mg/kg/day mirex daily for 10 days decreased their fertility 
significantly.  Although residues of mirex were found in the testes, this did not affect reproduction 
parameters in subsequent mating trials.  The authors attributed the observed decrease in the incidence of 
pregnancy in females mated with males in this dose group in the first trial to a subclinical toxic effect as 
suggested by reduction in body weight gain in the dosed males (Khera et al. 1976).  Gestational exposure 
of female rats with higher dosages (12.5 mg/kg/day; gestation days 6–15) of mirex resulted in increased 
resorptions and failure of pregnancy in 45% of dams (Grabowski and Payne 1980; Khera et al. 1976).  
Gestational gavage treatment of female rats at 10 mg/kg/day for 5 days resulted in decreased ovarian and 
uterine weights and reduced blood flow to the ovaries, uterus, and fetuses (Buelke-Sam et al. 1983).  This 
effect was not observed if the duration of exposure during gestation was shortened to 1 day or lengthened 
to 10 days; thus, the significance of this effect is unknown. 
 
Gavage administration of mirex to adult male CD-1 mice at 5 mg/kg/day for 21 days resulted in 
approximately 27% decreased mean absolute seminal vesicle weight; the mean body weight of mirex-
treated mice was not significantly different from controls (Dai et al. 2001).  In a 28-day dietary study, 
decreased sperm count was noted in male rats at dosages as low as 0.025 mg/kg/day; testicular 
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degeneration was observed at dosage levels of 2.5 and 3.7 mg/kg/day (Yarbrough et al. 1981).  However, 
there was no evidence of treatment-related effects on fertility when mirex was fed to male rats at 1.3–
3.1 mg/kg/day for 2 generations (Gaines and Kimbrough 1970).  In contrast, females given 1.8–
2.8 mg/kg/day for 2 generations produced decreased numbers of litters (Gaines and Kimbrough 1970).  
Administration of 0.25 mg/kg/day to male and female rats for 91 days prior to mating and then through 
lactation resulted in decreases in mating and litter size (Chu et al. 1981b).  Male and female mice treated 
at 0.65 mg/kg/day for 30 days prior to mating, and then for an additional 90 days, experienced reduced 
fecundity and reduced litter size and number of offspring (Ware and Good 1967); however, only one 
dosage level was tested.  Dietary exposure of wild mice to 2.4 mg/kg/day mirex for 15 months inhibited 
reproduction (Wolfe et al. 1979).  However, this study was limited in that few reproductive parameters 
were measured and mice of unknown genetic background were used. 
 
Chlordecone.  The available human data on chlordecone provide qualitative evidence to support the 
conclusion that intermediate- or chronic-duration exposures to high concentrations of chlordecone in the 
workplace causes oligospermia and decreases sperm motility among male workers (Guzelian 1982a, 
1982b; Taylor 1982, 1985; Taylor et al. 1978).  The threshold for abnormally low sperm counts was 
considered to be approximately 1 µg chlordecone per liter of serum, and the number of motile sperm cells 
increased as the serum chlordecone concentration decreased (Guzelian 1982a).  Despite loss of sperm 
motility in some of the workers, there were no reported difficulties with fertility (Taylor 1982, 1985).  
These studies, however, can only be used as suggestive evidence of chlordecone-induced male 
reproductive toxicity because the airborne concentrations of chlordecone and the frequency of exposure 
were not quantified and effects on sperm morphology were not examined. 
 
Chlordecone produced reproductive toxicity in both male and female animals.  Gavage dosing of male 
rats at 0.625, 1.25, or 5 mg/kg/day for 10 days resulted in decreased sperm count; however, increased 
sperm count was observed at 2.5 and 10 mg/kg/day and increased relative testes weight was noted at 
10 mg/kg/day (EPA 1986c).  In a dominant lethality study, male rats were administered chlordecone by 
gavage for 5 days at 11.4 mg/kg/day, followed 2 days later by a 14-week mating period whereby the 
males were mated with naive, nulliparous females each week for 14 consecutive weeks (Simon et al. 
1986).  There was no effect on male fertility under the conditions of the study.  Persistent vaginal estrus 
was reported in female mice administered chlordecone by gavage for 2 weeks at 2 mg/kg/day (Swartz et 
al. 1988). 
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Effects observed after intermediate-duration exposure of male and female mice to chlordecone include 
decreases in numbers of litters, litter size, and frequency of litter production (Good et al. 1965; Huber 
1965).  These effects were observed at dietary doses as low as 1.87 mg/kg/day for 130 days (Huber 1965) 
and 0.93 mg/kg/day for 6 months (Good et al. 1965). 
 
Dietary exposure of male rats to ≥0.83 mg/kg/day of chlordecone for 90 days resulted in decreased sperm 
motility and viability; at ≥1.67 mg/kg/day, decreases in seminal vesicle and prostate weights were 
observed (Linder et al. 1983).  Despite these effects, the fertility, litter size, sperm morphology, sperm 
count, and histopathology of male gonads were unaffected.  In a reproductive toxicity study, Cannon and 
Kimbrough (1979) evaluated the effects of chlordecone on fertility of male and female rats receiving 
chlordecone from the diet for 3 months at 0 or 1.17–1.58 mg/kg/day (males) and 0 or 1.62–
1.71 mg/kg/day (females).  During a 4.5-month recovery period, mating of untreated females to 
chlordecone-treated males, chlordecone-treated females to untreated males, chlordecone-treated males to 
chlordecone-treated females, and untreated males to untreated females were performed twice.  There were 
no apparent effects on fertility in pairings of control females with chlordecone-treated males; however, no 
litters were produced from matings of chlordecone-treated females to untreated males.  In mice treated at 
higher doses (5.2 mg/kg/day chlordecone for 160 days), no effect on spermatogenesis occurred, but a 
decrease in litter size was observed when treated males were mated with control females (Huber 1965).  
Testicular atrophy was reported for adolescent rats receiving chlordecone from the diet for 90 days at 
2.3 mg/kg/day as part of a 2-year study (Larson et al. 1979b). 
 
Intermediate-duration oral exposure of female animals indicates that chlordecone may cause effects such 
as persistent vaginal estrus, decreased ovulation, and reproductive failure.  Persistent vaginal estrus was 
observed in female mice receiving chlordecone for 3–6 weeks at doses as low as 1.87–2 mg/kg/day 
(Huber 1965; Swartz and Mall 1989; Swartz et al. 1988).  Increased atresia of follicles (Swartz and Mall 
1989), decreased ovulation (Swartz et al. 1988), and small- and medium-sized follicles (Swartz and Mall 
1989) were observed in mice after 4 weeks of exposure to 8 mg/kg/day of chlordecone.  Similarly, 
decreased numbers of corpora lutea were observed in mice receiving chlordecone from the diet for 
130 days at 1.87 mg/kg/day (Huber 1965).  Decreased numbers of litters or complete reproductive failure 
were observed among female rats receiving chlordecone from the diet for 3 months at 1.62–
1.71 mg/kg/day and female mice receiving chlordecone from the diet for 160 days at 5.2 mg/kg/day for 
160 days (Huber 1965). 
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The only animal study that referred to reproductive effects following dermal exposure to chlordecone was 
conducted in rabbits by Allied Chemical.  This study was not available for review.  A published review of 
the study (Epstein 1978) indicated that chlordecone applied to shaved skin for 8 hours/day, 5 days/week, 
for 3 weeks induced testicular atrophy in two of six rabbits following application at 5 mg/kg and in one of 
six rabbits following application at 10 mg/kg.  No other toxic effects were noted.  This study is limited by 
the lack of dose response and lack of a NOAEL for the effect observed. 
 
2.17   DEVELOPMENTAL 
 
Mirex.  A cohort of 104 mother-son pairs was studied for effects of endocrine disrupting chemicals on the 
developing brain functions (Puertas et al. 2010).  The mirex median level in the placenta samples 
(27 placenta) was 1.4 ng/g placenta (range: 0.5–19.1 ng/g placenta).  This exposure level was statistically 
significant (p=0.01) and inversely associated with cognitive development at 4 years of age and caused a 
reduction of 5.15 points in working memory and 7.33 points in the quantitative area compared to 
unexposed children of the same age and gender.   
 
Araki et al. (2018) reported significant (p<0.05) inverse associations between maternal serum mirex and 
male cord blood testosterone, prolactin, cortisol, cortisone, androstenedione/dehydroepiandrosterone, and 
testosterone/androstenedione.  Significant (p<0.05) significant positive associations were noted for 
maternal serum mirex and male cord blood dehydroepidandrosterone, follicle stimulating hormone (FSH), 
adrenal androgen/glucocorticoid, and FSH/inhibin B.  In categorical quartiles of maternal serum mirex, 
significant inverse associations for cord blood testosterone (ptrend 0.039) and for testosterone/
androstenedione (ptrend 0.016).  These results provide suggestive evidence for mirex-induced effects on 
reproductive hormones in male fetuses.  The study was part of the Hokkaido Study Sapporo Cohort, a 
prospective birth cohort in Japan. 
 
No association was found between serum mirex and menarcheal status in a population-based cohort of 
138 Akwesasne Mohawk Indian girls 10–16.9 years of age (Denham et al. 2005).  Mirex presence in 
placenta was positively associated with risk of urogenital malformations in male offspring in a case-
control study that included 48 newborns with cryptorchidism and/or hypospadias and 114 boys without 
malformations at a Hospital in Granada, Spain (Fernandez et al. 2007).  However, the mean concentration 
of mirex in placentas from the control group was 3.7±3.37 ng/g of lipid, compared to only 1.4±1.1 ng/g of 
lipid in placentas from the group with urogenital malformations, a finding that underscores the fact that 
this association could not be attributed to mirex per se, but only to a combination of mirex and other 
MIREX AND CHLORDECONE  106 
 
2.  HEALTH EFFECTS 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
mirex-like compounds.  Mirex presence in placenta was negatively associated with working memory and 
quantitative functions in a population-based, randomly-sampled birth cohort of 104 children evaluated for 
cognitive development at 4 years of age (Puertas et al. 2010).  No association was found between 
maternal blood mirex level and length of gestation, birth weight, or crown-heel length in a longitudinal 
birth cohort study of the health of pregnant women and their children living in Salinas Valley, California, 
and enrolled in the Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS) 
(Fenster et al. 2006).  No association was found between maternal serum mirex level and birth weight or 
newborn cord serum mirex and birth weight in a small study of mother/newborn pairs enrolled at 
hospitals in China (Guo et al. 2014).  See Table 2-1 for additional details from these studies. 
 
Exposure of maternal rats and mice to mirex during gestation resulted in increases in resorptions and 
stillbirths and decreases in postnatal viability at doses as low as 6–10 mg/kg/day when administered 
during periods of gestation (Buelke-Sam et al. 1983; Byrd et al. 1981; Grabowski 1983a; Grabowski and 
Payne 1980, 1983a, 1983b; Gray et al. 1983; Rogers and Grabowski 1983).  Examination of fetuses at the 
end of gestation showed increases in the incidence of edematous fetuses and fetuses with cardiac 
arrhythmias (primarily first-degree heart block) (Buelke-Sam et al. 1983; Byrd et al. 1981; Chernoff et al. 
1979a; Grabowski 1981, 1983a; Grabowski and Payne 1980, 1983a, 1983b; Kavlock et al. 1982; Khera et 
al. 1976).  The final trimester appeared to be the most sensitive period for induction of cardiac 
dysrhythmias; the incidence was slightly increased at doses as low as 0.1 mg/kg/day during gestation 
days 15.5–21.5 (Grabowski 1983a).  These effects were generally seen at lower doses than the increases 
in mortality.  Other visceral anomalies were not widely reported, but instances of anomalies such as 
enlarged cerebral ventricles, undescended testes, ectopic gonads, hydrocephaly, scoliosis, cleft palate, 
fleshy heart, enlarged atrium, or short tail were reported in a few studies (Chernoff et al. 1979a; Kavlock 
et al. 1982; Khera et al. 1976).  Additional effects observed in fetuses included decreases in skeletal 
ossification (Chernoff et al. 1979a), fetal weight (Buelke-Sam et al. 1983; Byrd et al. 1981; Chernoff and 
Kavlock 1982; Gray and Kavlock 1984; Gray et al. 1983; Kavlock et al. 1982; Khera et al. 1976), serum 
glucose and hematocrit (Rogers et al. 1984), serum plasma proteins (Grabowski 1981), fetal liver weight 
and glycogen content (Kavlock et al. 1982), renal protein and alkaline phosphatase (Kavlock et al. 1982), 
kidney weights at postpartum day 250 (Gray and Kavlock 1984; Gray et al. 1983), and increased dyspnea 
(Grabowski and Payne 1983a) and liver and thyroid lesions (Chu et al. 1981a).  Cataracts were also 
observed in offspring in several studies (Chernoff et al. 1979a; Chu et al. 1981a; Gaines and Kimbrough 
1970; Rogers and Grabowski 1983; Rogers et al. 1984); however, cataracts also resulted from early 
postnatal exposure (Chernoff et al. 1979b; Rogers and Grabowski 1984; Scotti et al. 1981). 
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Chlordecone.  Several human studies were designed to evaluate possible associations between cord blood 
chlordecone levels and risk of developmental effects in subpopulations of mothers participating in the 
TIMOUN prospective mother-child cohort study in Guadeloupe, French West Indies, where pesticides 
(including chlordecone) were extensively used on banana plantations.  Cord blood chlordecone level was 
negatively associated with fine motor function among 18-month-old boys in a subpopulation of 
141 mothers, indicating that prenatal exposure to chlordecone may impair fine motor development 
(Boucher et al. 2013).  Cord blood chlordecone level was positively associated with increased thyroid-
stimulating hormone (TSH) level in male infants evaluated at 3 months following birth; a total of 
111 mothers were included in the study (Cordier et al. 2015).  No effect on the pathway between prenatal 
chlordecone exposure and fine motor child development was apparent at 18-month assessment.  Cord 
blood chlordecone level was positively associated with increased body mass index in boys evaluated at 
3 months of age and in girls at 8 months of age in a study that included 222 mothers (Costet et al. 2015).  
Cord blood chlordecone level was associated with signs of neurodevelopmental delay in 7-month-old 
infants; up to 153 infants were included in the study (Dallaire et al. 2012).  Hervé et al. (2016) found no 
association between cord blood chlordecone level and gestational weight in a study that included 
593 mothers.  A 1-log10 increase in chlordecone concentration was associated with decreased length of 
gestation in a study that included 818 mothers (Kadhel et al. 2014).  A major limitation of these studies is 
the lack of data regarding chlordecone exposure levels.  See Table 2-2 for additional study details. 
 
Although impaired spermatogenesis among male workers occupationally exposed to chlordecone did not 
appear to affect their fertility (Guzelian 1982a, 1982b; Taylor 1982, 1985; Taylor et al. 1978), it is unclear 
whether abnormalities in their sperm may have resulted in developmental effects in offspring. 
 
Gestational exposure of rats and mice to chlordecone resulted in increased stillbirths and decreased 
postnatal viability (Chernoff and Kavlock 1982; Chernoff and Rogers 1976; EPA 1986c; Gray and 
Kavlock 1984; Gray et al. 1983; Kavlock et al. 1985; Seidenberg and Becker 1987; Seidenberg et al. 
1986).  The increase in fetal/pup mortality was observed at doses as low as 10 mg/kg/day when 
administered to rats during gestation days 7–16 (EPA 1986c) and at doses as low as 12 mg/kg/day when 
administered to mice during gestation days 7–16 (Chernoff and Rogers 1976).  Edema was reported in rat 
fetuses at doses of 10 mg/kg/day during gestation days 7–16 (Chernoff and Rogers 1976), but this effect 
was not noted in other developmental toxicity studies with chlordecone.  Other indicators of 
developmental toxicity included decreased fetal or neonatal weight and/or skeletal ossification (Chernoff 
and Kavlock 1982; Chernoff and Rogers 1976; EPA 1986c; Gray and Kavlock 1984; Kavlock et al. 1985, 
1987b; Seidenberg et al. 1986) and a few instances of anomalies and malformations such as enlarged 
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renal pelvis, undescended testes, enlarged cerebral ventricles, clubfoot, fused vertebrae or ribs, and 
encephalocele (Chernoff and Rogers 1976; Kavlock et al. 1985).  Anovulation and persistent vaginal 
estrus were observed in female offspring of maternal rats given 15 mg/kg/day of chlordecone on gestation 
days 14–20 (Gellert and Wilson 1979).  However, no effects on vaginal patency or fertility were observed 
in female offspring of maternal mice gavaged at 20 mg/kg/day during gestation days 8–12 or 14–18 (Gray 
and Kavlock 1984). 
 
Exposure of female rats to chlordecone for 60 days prior to mating through lactation day 12 showed 
subtle neurological changes in the offspring later in life (Rosecrans et al. 1982; Seth et al. 1981; Squibb 
and Tilson 1982a).  Although major reflexes were unaltered, the offspring of dams exposed to 
0.3 mg/kg/day showed increased serotonin turnover and decreased dopamine in response to stress 
(Rosecrans et al. 1982).  Offspring of mice exposed to 0.075 mg/kg/day in this exposure paradigm 
showed an increased reactivity to apomorphine (a dopamine agonist) (Squibb and Tilson 1982a).  These 
studies suggest that perinatal exposure to low doses of chlordecone may affect dopaminergic function in 
adult offspring; however, none of these studies demonstrated a treatment-related effect on neurological 
function.  Therefore, the results are not summarized in Table 2-4 or plotted in Figure 2-4.  Squibb and 
Tilson (1982a) also noted significantly depressed mean body weight in the male and female offspring at 
postpartum day 100 from mothers receiving chlordecone from the diet at 0.45 and ≥0.075 mg/kg/day, 
respectively.  However, the toxicological significance of this finding is uncertain because there was no 
effect on offspring body weight at postpartum day 30.  Therefore this result is not summarized in 
Table 2-4 or plotted in Figure 2-4. 
 
Laessig et al. (2007) administered chlordecone (5 mg/kg) in a single intraperitoneal dose to pregnant 
Sprague-Dawley rats on gestation day 16 and assessed its effect on sexually-differentiated behavior of the 
adult offspring.  The offspring were gonadectomized on postnatal day (PND) 50 to eliminate effects of 
circulating hormones and were sequentially tested for sex-typic spontaneous behaviors in open field 
(PND 60) and elevated plus maze (PND 61–63) tests to chlordecone assessed the effects of prenatal 
exposure of Sprague-Dawley rats to chlordecone on sexually differentiated behavior.  Gonadectomized 
male and female offspring were also assessed for reproductive behavior following sex-specific steroid 
treatment.  On PND 68 or 69, male and female offspring were treated with a chemical paradigm that 
induces lordosis (a female sexual behavior).  On PND 70, male offspring received a testosterone implant; 
these males were assessed 6 weeks later for mounting behavior with a sexually-responsive female.  On 
PND 120, blood was collected from male and female offspring for assessment of serum testosterone 
levels.  There were no apparent chlordecone treatment-related effects on time to parturition, litter size, sex 
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ratio, or growth indices of offspring compared to controls.  Chlordecone-exposed (in utero) 
gonadectomized female offspring exhibited significantly increased ratio of inner to total crossings in the 
open field; significant increases in lordosis response with steroid priming and mounting with prolonged 
testosterone administration were observed in both male and female offspring.  These results suggest that 
chlordecone may interfere with estrogen-dependent events during sexual differentiation of the brain that 
impact later activation of hormone-dependent behavior. 
 
2.18   OTHER NONCANCER 
 
Diabetes 
 
Mirex.  Possible associations between mirex serum levels and risk of diabetes were evaluated in several 
population-based human studies (Aminov et al. 2016; Codru et al. 2007; Everett and Matheson 2010; Son 
et al. 2010).  There was no convincing evidence of mirex-related increased risk of diabetes.  Refer to 
Table 2-1 for individual study details.  Serum glucose levels were decreased uniformly in all studies that 
examined this parameter following oral exposure of animals to high doses of mirex (Chu et al. 1981b; 
Ervin and Yarbrough 1983; Fujimori et al. 1983; Jovanovich et al. 1987; Robinson and Yarbrough 1978a; 
Williams and Yarbrough 1983; Yarbrough et al. 1981).  Decreases were observed following single oral 
doses as low as 5 mg/kg in rats (Robinson and Yarbrough 1978a) and dietary doses as low as 
0.25 mg/kg/day for 28 days in rats (Chu et al. 1981b). 
 
Chlordecone.  No association was found between maternal serum chlordecone and risk of diabetes 
mellitus in a subpopulation of pregnant women participating in the TIMOUN prospective mother-child 
cohort study in Guadeloupe, French West Indies where pesticides (including chlordecone) were 
extensively used on banana plantations (Saunders et al. 2014).  Reports of chlordecone-induced effects on 
serum glucose in animals were limited to a single report of decreased serum glucose in mice exposed for 
4 days at doses as low as 25 mg/kg/day or for 33 days at doses as low as 10 mg/kg/day (Fujimori et al. 
1983). 
 
Thermoregulation 
 
Mirex.  No studies were located regarding thermoregulatory effects in humans or animals exposed to 
mirex. 
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Chlordecone.  No data were located regarding thermoregulatory effects in humans exposed to 
chlordecone.  Chlordecone was shown to cause a decrease in core temperature following ingestion of a 
single dose of 55 or 75 mg/kg in rats (Swanson and Wooley 1982).  The core temperatures were 
depressed for up to 12 days after administration of 75 mg/kg of chlordecone.  Slight hyperthermia 
occurred after the body temperature recovered.  Slight hyperthermia was also observed in rats after 
12 weeks of exposure at 7.1 mg/kg/day (Pryor et al. 1983). 
 
Metabolic Syndrome 
 
Mirex.  Rosenbaum et al. (2017) found no association between serum mirex level and occurrence of 
metabolic syndrome in a cross-sectional study of 548 residents of Anniston, Alabama.  See Table 2-1 for 
additional study details. 
 
2.19   CANCER 
 
Mirex.  A positive association between mirex blood level and risk of non-Hodgkin lymphoma (NHL) was 
reported within a population-based, case-control study of 422 pretreatment NHL cases and 460 matched 
controls in British Columbia, Canada (Spinelli et al. 2007).  A negative association was found between 
lipid-adjusted median serum mirex concentration and risk of breast cancer in a case-control study of 
403 breast cancer patients and 403 matched controls at four hospitals in Japan (Itoh et al. 2009).  No 
association was found between blood mirex level and risk of postmenopausal breast cancer in a case-
control study of 154 postmenopausal breast cancer cases and 192 community controls in two counties of 
northwestern New York state (Moysich et al. 1998).  In a nested case-control study using data from the 
Japan Public Health Center-Based Prospective Study, Sawada et al. (2010) found no evidence of a 
positive association between lipid-adjusted serum mirex concentration and risk of prostate cancer.  The 
study included 201 newly-diagnosed prostate cancer cases and 2 controls for each case.  In another nested 
case-control study using data from the Norwegian Janus Serum Bank Cohort, Koutros et al. (2015a, 
2015b) found no evidence of a positive association between lipid-adjusted serum mirex concentration and 
risk of metastatic prostate cancer.  This study included 149 cases of metastatic prostate cancer with no 
history of cancer (except nonmelanoma skin cancer) and were diagnosed at least 2 years after serum 
collection and 314 controls matched by region, date of blood draw, and age at blood draw.  See Table 2-1 
for additional details from these studies. 
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The carcinogenicity of mirex has been demonstrated in animal studies.  An increase in the incidence of 
neoplastic liver nodules (described as nonencapsulated, circumscribed areas of parenchyma usually 
occupying the space of several lobules) was observed in male CD rats receiving mirex from the diet for 
18 months at 4.9 mg/kg/day (Ulland et al. 1977).  NTP (1990) fed mirex in the diet to F344/N rats 
(52/sex) for 2 years at 0, 0.1, 1.0, 10, 25, or 50 ppm.  Based on absence of observable toxic effects in 
female rats, other groups of females were similarly treated at 0, 50, or 100 ppm mirex in the diet.  
Estimated average mirex doses to the males and females (combined) in the initial portion of the study 
were 0, 0.007, 0.075, 0.75, 1.95, and 3.85 mg/kg/day, respectively.  In the second portion of the study, 
estimated doses to the 0, 50, and 100 ppm females were 0, 3.9, and 7.7 mg/kg/day, respectively.  
Significantly increased incidences of neoplastic liver nodules (usually consisting of enlarged hepatocytes 
with eosinophilic or clear cytoplasm arranged in irregular distorted cords one or two cell layers thick, but 
some consisting of cells with basophilic cytoplasm) were observed among male rats at doses 
≥0.75 mg/kg/day (incidences of 14/52, 15/52, and 26/52 for 0.75, 1.95, and 3.85 mg/kg/day dose groups, 
respectively, versus 3/52 among controls) and among female rats in the second portion of the study at 
3.9 and 7.7 mg/kg/day (incidences of 23/52 and 30/52, respectively, versus 2/52 among controls).  
Incidences of hepatocellular carcinoma among mirex-treated male and female rats were not significantly 
different from that of controls.  Incidences of benign or malignant pheochromocytoma (combined) in the 
adrenal gland of male rats occurred with a significant positive dose-related trend; incidences at 
1.95 mg/kg/day (18/51) and 3.85 mg/kg/day (20/51) were significantly higher than that of controls 
(10/51).  Most adrenal gland pheochromocytomas were benign.  Transitional cell papillomas of the renal 
pelvis of male rats occurred with a significant positive dose-related trend, although the tumor was only 
observed in 1/51 and 3/52 males at the dose levels of 1.95 and 3.85 mg/kg/day, respectively.  Female rats 
exhibited significantly increased incidence of mononuclear cell leukemia at doses ≥0.075 mg/kg/day 
(14/52, 18/52, 27/104, and 14/52 at 0.075, 0.75, 1.95, 3.85–3.9, and 7.7 mg/kg/day, respectively, versus 
14/104 among controls; incidences from the two portions of the study combined).  NTP concluded that 
under the conditions of the study, there was clear evidence of carcinogenic activity among the high-dose 
male and female F344/N rats.  An audit summary of this report states that because of an apparent 
disproportionate number of liver tissue samples taken from the high-dose groups, additional and 
comparative liver sections were made for control groups of both sexes and the high-dose male group after 
the initial Pathology Working Group (PWG) review of this study.  A second PWG, convened to review 
the liver sections, concluded that any discrepancies noted during the review of the pathology materials 
were minor in nature and not clustered in any one group of study animals.  Consequently, the NTP 
considered the data produced from this study supportive of the conclusion of clear evidence of 
carcinogenic activity for mirex in F344/N rats. 
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Both male and female mice (18/sex/dose) of the (C57BL/6 x C3H/Anf)F1 or (C57BL/6 x AKR)F1 strains 
showed a significant increase in the incidence of hepatomas in a screening study in which mirex was 
administered first by gavage from 7 until 28 days of age at 10 mg/kg/day and then in the diet at 28 ppm 
(estimated dose of 3.38 mg/kg/day) until terminal sacrifice at weeks 59–70 (estimated time-weighted 
average dose of 3.8 mg/kg/day) (Innes et al. 1969). 
 
Chlordecone.  Plasma chlordecone level was positively associated with risk of prostate cancer in a 
population-based, case-control study of 623 prostate cancer cases and 671 controls in Guadeloupe, French 
West Indies, where pesticides (including chlordecone) were extensively used on banana plantations 
(Multigner et al. 2010).  The positive association appeared to be strongest among subjects with family 
history of prostate cancer and among subjects with past residence in western countries.  See Table 2-2 for 
additional study details. 
 
Liver biopsy samples taken from 12 workers with hepatomegaly resulting from intermediate or chronic-
duration exposures to unspecified high levels of chlordecone showed no evidence of cancer (Guzelian et 
al. 1980).  However, conclusions from this study are limited by the very small number of workers 
sampled, the relatively brief duration of exposures, and the absence of a sufficient latent period for tumor 
development.  The average exposure of the subjects was 5–6 months and were examined immediately 
after exposure. 
 
Chlordecone was shown to be carcinogenic in rats and mice.  The results of NCI (1976) bioassays in mice 
and rats clearly suggest that chlordecone induces hepatocellular carcinomas in both sexes of rats and 
mice.  Administration of chlordecone to Osborne-Mendel rats via the diet for 80 weeks resulted in a 
significant increase in the incidence of hepatocellular carcinomas over pooled controls in both males and 
females at time-weighted average doses of 1.2 mg/kg/day in males and 1.3 mg/kg/day in females (NCI 
1976).  In the NCI (1976) bioassay of rats, the incidence of hepatocellular carcinomas was significantly 
increased (p<0.05) in both sexes with a dose-related trend.  The incidence of hepatocellular carcinomas in 
high-dose males and females were 7 and 22% for males and females, respectively.  Nevertheless, this 
study had several limitations.  Initial doses were not well tolerated because the Maximum Tolerated Dose 
(MTD) was exceeded, as indicated by excessive deaths.  Doses were reduced 17–33% from initial doses 
once or twice during the experiment.  During the final 75 days of treatment, high-dose males received 
chlordecone on alternative weeks only.  Doses above the MTD were used for 42–386 days.  An unusually 
high mortality rate occurred in control animals, and only pooled controls were used in this bioassay. 
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Administration of chlordecone to B6C3F1 mice for 80 weeks also resulted in significantly increased 
incidences of hepatocellular carcinomas in both males and females at doses as low as 2.6 mg/kg/day (NCI 
1976).  In the NCI (1976) bioassay in mice, the incidence of hepatocellular carcinomas was significantly 
increased (p<0.05) in both males and females with a dose-related trend.  The incidences of hepatocellular 
carcinomas were 81 and 88% in low- and high-dose males, respectively, and 52 and 47% in low-and 
high-dose females, respectively.  In addition, a decrease of latency time of tumor appearance was 
observed in treated mice, as compared to controls.  Nevertheless, this study had several limitations.  An 
abnormally high incidence (32%) of hepatocellular carcinomas was found in the matched control group of 
male mice.  In addition, initial doses were not well tolerated because of exceedance of the MTD, as 
indicated by excessive deaths.  Doses were reduced 25–50% from initial doses once or twice during the 
experiment.  Doses above the MTD were used for 90–134 days.  An unusually high mortality rate 
occurred in controls animals as well. 
 
In its evaluations, the Department of Health and Human Services (DHHS) has determined that both mirex 
and chlordecone may reasonably be anticipated to be carcinogenic on the basis of sufficient evidence of 
carcinogenicity in animals (NTP 1994).  The Integrated Risk Information System (IRIS) of EPA does not 
include a carcinogenicity evaluation for mirex (see IRIS 1992).  EPA (IRIS 2009) evaluated available 
human and animal data for chlordecone and determined that chlordecone is likely to be carcinogenic to 
humans, based on increased incidence of hepatocellular carcinomas in both sexes of rats and mice (NCI 
1976). 
 
Mirex has been shown to be a nonmutagenic hepatocarcinogen in animals.  Mirex was tested at a dermal 
dose of 3.6 mg/kg for 4 weeks in female CD-1 mice to evaluate tumor promoter activity and evidence of 
epidermal hyperplasia after initiation with 7,12-dimethyl-benz[a]anthracene (DMBA) at 200 nmol/day for 
1 week (Meyer et al. 1993; Moser et al. 1992, 1993).  Positive control mice were treated with 2 nmol/day 
of the phorbol ester tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA), following initiation 
with DMBA.  A third group of mice was treated with both 3.6 mg/kg mirex and 2 nmol/day TPA for 
4 weeks following initiation with DMBA.  Multiple applications of mirex for 4 weeks to the DMBA-
initiated mice resulted only in minimal increase in the number of nucleated epidermal cell layers.  In 
contrast, a definitive hyperplastic response of 6–7 cell layers was observed after repeated application with 
TPA to the DMBA-initiated mice.  Mice that were promoted with mirex or TPA without DMBA initiation 
did not develop tumors.  At 20 weeks, DMBA-initiated mice promoted with 3.6 mg/kg mirex developed 
an average of 14.2 tumors.  Mice promoted with 2 nmol/day TPA bore 4.7 tumors per mouse.  Mice co-
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promoted with 3.6 mg/kg mirex and 2 nmol TPA gave a greater-than-additive response (35.4 tumors per 
mouse).  The tumor incidence was also greater than additive in mice co-promoted with 3.6 mg/kg mirex 
and 2 nmol/day TPA.  The tumors consisted mainly of papillomas with some squamous cell carcinomas.  
The study also found a 90% incidence (activation) of the c-Ha-ras tumor gene in these co-promoted 
tumors.  Under conditions where both 3.6 mg/kg/day mirex and 2 nmol/day gave a similar tumor yield, 
only the TPA response was associated with biochemical markers of enhanced cell proliferation, induction 
of epidermal ornithine decarboxylase activity and increased DNA synthesis, and hyperplasia.  On the 
basis of the data, the authors concluded that there is evidence for a dual effect of mirex during co-
promotion: first, as an independent tumor promoter with a mechanism different than that of phorbol esters 
and, second, as a compound that also potentiates skin tumor promotion by TPA. 
 
A second study examined the effects of DMBA initiated mirex-promoted tumors in female mice on 
ovarian hormones.  This study found that the loss of ovary (OVX) protected the female mice (40%) from 
mirex tumor promotion.  Tumor promotion was unaffected in DMBA-initiated OVX mice promoted with 
TPA.  Based on the data, the authors concluded that there is a structural specificity in the tumor-
promoting ability of mirex in mouse skin and that mirex is a much more effective skin tumor promoter in 
female CD-1 mice than in male CD-1 mice or OVX mice (Meyer et al. 1994). 
 
2.20   GENOTOXICITY 
 
Available data suggest that neither mirex nor chlordecone are genotoxic. 
 
Limited information is available regarding the potential for mirex- or chlordecone-induced genotoxicity in 
vivo (Table 2-7).  Mirex did not induce dominant lethal mutations following gavage treatment of male rats 
at 1.5–6.0 mg/kg/day for 10 consecutive days (Khera et al. 1976).  Single gavage dosing of female 
Sprague-Dawley rats with mirex at 90 or 120 mg/kg resulted in no evidence of significant damage to 
DNA as measured by alkaline elution (Mitra et al. 1990).  Oral administration of mirex to male mice at 
86.8 mg/kg/day for 5 days did not induce DNA strand breaks in hepatocytes (Umegaki et al. 1993).  
Miyagawa et al. (1995) reported 4–9.5-fold increases in replicative DNA synthesis within hepatocytes of 
8-week-old male B6C3F1 mice at 24–39 hours following gavage administration of mirex at 60 mg/kg.  
Marked disturbances in the distribution of ploidy (diploid and tetraploid nuclei) were observed in livers 
from male Sprague-Dawley rats fed 100 ppm mirex (equivalent to ≈5 mg/kg/day) for 13 months 
(Abraham et al. 1983).  Mirex selectively reduced the number of tetraploids with the most significant 
reduction noted in hepatocellular carcinomas; however, nuclei in the areas adjacent to these tumors were 
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also primarily composed of diploids.  These data should be interpreted with caution since isolation of 
nuclei from tumors is difficult and because “of the fantastic variety of forms that tumor nuclei assume” 
(Smuckler et al. 1976).  Additionally, the relevance to humans is not clear since human liver is mainly 
composed of diploid cells (99%) and contains few tetraploids (Adler et al. 1981). 
 
Table 2-7.  In Vivo Genotoxicity of Mirex and Chlordecone in Orally-Exposed 
Animals 
 
Species Endpoint Results Reference 
Mirex 
Male rat germinal cells Dominant lethal mutations – Khera et al. 1976 
Rat hepatocytes DNA damage (alkaline elution) – Mitra et al. 1990 
Mouse hepatocytes DNA strand breaks – Umegaki et al. 1993 
Mouse hepatocytes DNA synthesis + Miyagawa et al. 1995 
Rat hepatocytes Selective reduction of polyploid cells + Abraham et al. 1983 
Chlordecone 
Male rat germinal cells Dominant lethal mutations – Simon et al. 1986 
Rat hepatocytes DNA damage (alkaline elution) – Kitchin and Brown 1989 
Rat hepatocytes Unscheduled DNA synthesis/DNA 
strand breaks 
+/– Ikegwuonu and Mehendale 
1991 
 
DNA = deoxyribonucleic acid; – = negative result; + = positive result; +/– = inconclusive results 
 
Chlordecone did not induce dominant lethal mutations following gavage treatment of male rats for 5 days 
at 3.6 or 11.4 mg /kg/day (Simon et al. 1986).  There was no evidence of chlordecone-induced DNA 
damage following gavage treatment of female Sprague-Dawley rats at 19 or 57 mg/kg both 21 and 
4 hours prior to sacrifice (Kitchin and Brown 1989).  Chlordecone induced a low level of unscheduled 
DNA synthesis in hepatocytes from male Sprague-Dawley rats gavaged at 10 mg/kg (Ikegwuonu and 
Mehendale 1991).  However, the response (≈1.2-fold over control) was too marginal to conclude a 
positive effect.  The comparative evaluation of chlordecone effects on adenosine diphosphate-
ribosyltransferase (ADPRT) activity and DNA strand breaks provided inconsistent results.  Although the 
data suggest that chlordecone treatment increased DNA strand breaks, ADPRT activity was suppressed 
rather than stimulated, as would be expected when DNA strand breaks occur. 
 
Results from genotoxicity testing of mirex and chlordecone in vitro are summarized in Table 2-8.  Mirex 
was not mutagenic to Salmonella typhimurium strains TA98, TA100, TA1535, or TA1537 either with or 
without exogenous metabolic activation (Mortelmans et al. 1986; Probst et al. 1981; Schoeny et al. 1979).  
Probst et al. (1981) found no evidence of a mutagenic response in S. typhimurium strains TA1538, C3076, 
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D3052, or G46 or Escherichia coli strains WP2 or WP2 uvrA either with or without exogenous metabolic 
activation.  Mirex was also negative for the induction of prophage in E. coli either with or without 
exogenous metabolic activation (Houk and DeMarini 1987).  Mirex was not mutagenic to human foreskin 
fibroblasts (Detroit-550) either with or without exogenous metabolic activation (Tong et al. 1981).   
 
Table 2-8.  Genotoxicity of Mirex and Chlordecone In Vitro 
 
Species (test system) Endpoint 
Results 
Reference 
Activation 
With Without 
Mirex 
Salmonella typhimurium TA98, 
TA100, TA1535, TA1537 
Gene mutation – – Mortelmans et al. 1986 
S. typhimurium TA98, TA100, 
TA1535, TA1537 
Gene mutation – – Schoeny et al. 1979 
S. typhimurium TA98, TA100, 
TA1535, TA1537, TA1538, 
C3076, D3052, G46 
Gene mutation – – Probst et al. 1981 
Escherichia coli WP2, 
WP2uvrA 
Gene mutation – – Probst et al. 1981 
E. coli WP2s (λ), SR714 λ Prophage induction – – Houk and DeMarini 1987 
Human foreskin fibroblasts 
(Detroit-550 cells) 
Gene mutation – – Tong et al. 1981 
Mouse hepatocytes Preferential binding to 
polyploid cells 
NA + Rosenbaum and Charles 
1986 
Rat, mouse, and/or hamster 
hepatocytes 
Unscheduled DNA 
synthesis 
NA – Maslansky and Williams 
1981; Probst et al. 1981; 
Williams 1980 
Chinese hamster lung 
fibroblasts (V79) 
Inhibition of metabolic 
cooperation 
NA + Tsushimoto et al. 1982 
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Table 2-8.  Genotoxicity of Mirex and Chlordecone In Vitro 
 
Species (test system) Endpoint 
Results 
Reference 
Activation 
With Without 
Chlordecone 
S. typhimurium TA98, TA100, 
TA1535, TA1537 
Gene mutation – – Mortelmans et al. 1986 
S. typhimurium TA98, TA100, 
TA1535, TA1537 
Gene mutation – – Schoeny et al. 1979 
S. typhimurium TA98, TA100, 
TA1535, TA1537, TA1538, 
C3076, D3052, G46 
Gene mutation – – Probst et al. 1981 
E. coli WP2, WP2uvrA Gene mutation – – Probst et al. 1981 
Rat liver epithelial cells Gene mutation – – Williams 1980 
Testicular cells from human 
organ transplant donors 
Single-stranded DNA 
breaks 
NA + Bjorge et al. 1996 
Rat testicular cells Single-stranded DNA 
breaks 
NA + Bjorge et al. 1996 
Chinese hamster ovary cells Structural chromosome 
aberrations 
– – Galloway et al. 1987 
Chinese hamster ovary cells Sister chromatid 
exchange 
– + Galloway et al. 1987 
Chinese hamster M3-1 cells Structural chromosome 
aberrations 
NR +/– Bale 1983 
Rat, mouse, and/or hamster 
hepatocytes 
Unscheduled DNA 
synthesis 
NA – Maslansky and Williams 
1981; Probst et al. 1981 
Chinese hamster lung 
fibroblasts (V79) 
Inhibition of metabolic 
cooperation 
NA + Tsushimoto et al. 1982 
 
DNA = deoxyribonucleic acid; NA = not applicable; NR= not reported; – = negative result; + = positive result; +/–
 = inconclusive results 
 
Rosenbaum and Charles (1986) provided evidence that mirex preferentially binds to freshly prepared 
polyploid mouse hepatocytes; the response was partially Na+ dependent and completely Ca2+ dependent.  
Subcytotoxic doses of mirex did not induce unscheduled DNA synthesis in primary hepatocytes 
recovered from rats, mice, or hamsters (Maslansky and Williams 1981; Williams 1980).  Similar results 
were obtained by Probst et al. (1981) using primary rat hepatocytes exposed to 1,000 μmol/L mirex.  
Metabolic cooperation between 6-thioguanine-resistant (6-TGr) mutants (HGPRT-) and 
6-thioguanineinsensitive (6-TGs) wild-type (HGPRT+) Chinese hamster lung fibroblasts (V79) was 
inhibited by mirex (Tsushimoto et al. 1982). 
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In agreement with the findings from microbial gene mutation studies with mirex, there is no evidence that 
chlordecone is a mutagen for S. typhimurium or E. coli (Mortelmans et al. 1986; Probst et al. 1981; 
Schoeny et al. 1979).  Williams (1980) found no evidence of mutagenicity in chlordecone-treated rat liver 
epithelial cells either with or without exogenous metabolic activation.  Chlordecone (≥300 µM) induced 
significantly increased frequencies of single-stranded DNA (ssDNA) breaks in testicular cells from 
human organ transplant donors and from Wistar rats (Bjorge et al. 1996).  Chlordecone did not increase 
the frequency of Chinese hamster ovary cells with abnormal chromosome morphology over a 
nonactivated concentration range of 10–20 mg/L or an activated concentration range of 5–15 mg/L 
(Galloway et al. 1987).  Chlordecone (1.67–10.00 mg/L) did increase the frequency of sister chromatid 
exchange in Chinese hamster ovary cells, but only without exogenous metabolic activation and only in the 
presence of cell-cycle delay (Galloway et al. 1987).  Evidence of a clastogenic effect reported by Bale 
(1983) for Chinese hamster M3-1 cells exposed to 2, 4, or 6 mg/L chlordecone was inconclusive.  The 
significant (p<0.05) increase in the aberration yield at 6 mg/L could not be fully assessed because 
chromatid and chromosome gaps (the predominant type of aberration) were included in the statistical 
analysis and there was a high background frequency of cells treated with solvent (dimethyl sulfoxide) that 
had abnormal values.  Subcytotoxic doses of chlordecone did not induce unscheduled DNA synthesis in 
primary hepatocytes recovered from rats, mice, or hamsters (Maslansky and Williams 1981; Williams 
1980).  Similar results were obtained by Probst et al. (1981) using primary rat hepatocytes exposed to 
1,000 μmol/L chlordecone.  Metabolic cooperation between 6-thioguanine-resistant (6-TGr) mutants 
(HGPRT-) and 6-thioguanineinsensitive (6-TGs) wild-type (HGPRT+) Chinese hamster lung fibroblasts 
(V79) was inhibited by chlordecone (Tsushimoto et al. 1982). 
 
2.21   MECHANISMS OF ACTION 
 
Pharmacokinetic Mechanisms.  The specific mechanism by which mirex is transferred from the gut, 
lungs, or skin to the blood is not known.  However, mirex is a highly stable, lipophilic compound that is 
resistant to metabolism.  It has a high lipid:water partition coefficient, so it partitions readily to fat and 
demonstrates a very high potential for accumulation in tissues (Chambers et al. 1982; Ivie et al. 1974b). 
 
The specific mechanism by which chlordecone is transferred from the gut, lungs, or skin to the blood is 
not known.  However, the preferential distribution of chlordecone to the liver rather than the fat tissues 
suggests that it may be transported in the plasma differently from other organochlorine compounds (Soine 
et al. 1982).  In vitro and in vivo studies of human, rat, and pig plasma showed that chlordecone is 
preferentially bound by albumin and high-density lipoproteins (HDL), which may explain its tissue 
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distribution.  Other organochlorine pesticides such as aldrin and dieldrin bind to very-low-density 
lipoproteins (VLDL) and LDL and distribute preferentially to fat (Soine et al. 1982). 
 
Hepatotoxicity.  Several studies have attempted to define the mechanism by which mirex and chlordecone 
inhibit hepatobiliary excretion.  At very high levels, both mirex (Chetty et al. 1983a; Desaiah 1980) and 
chlordecone (Bansal and Desaiah 1985; Chetty et al. 1983a; Curtis and Mehendale 1979; Desaiah et al. 
1980a, 1991; Jinna et al. 1989; Jordan et al. 1981; Kodavanti et al. 1990a; Mehendale 1979) depress 
ATPase activity or cellular energy utilization at moderate to relatively high doses (2.5–100 and 50–
100 mg/kg/day, respectively), thereby inhibiting the biliary excretion of substances.  The inhibition does 
not appear to be due to inhibition of metabolism of the substance to be excreted in the bile or to decreased 
bile flow (Mehendale 1977c).  Possible explanations for the decreased excretion of metabolites in the bile 
include decreased uptake of substances by the hepatocyte (Teo and Vore 1990), a decreased transfer of 
chemicals from the hepatocyte to the bile (Berman et al. 1986), and leaking of metabolites from the bile 
duct via a paracellular pathway (Curtis and Hoyt 1984).  The decrease in transfer may be due to decreased 
permeability of the canalicular membrane (Hewitt et al. 1986a) resulting from inhibition of the 
Mg2+ATPase activity of the bile canaliculi (Bansal and Desaiah 1985; Curtis 1988; Curtis and Mehendale 
1981) or perturbations of plasma membrane (Rochelle et al. 1990).  Although the precise mechanism for 
the hypothermia induced by chlordecone is unknown, data suggest a role of central nervous system 
dopaminergic or α-noradrenergic activity in expression of hypothermia.  The decrease in body 
temperature produced by chlordecone was mimicked by intracisternal norepinephrine (Cook et al. 1988a, 
1988b) and was blocked by administration of α-noradrenergic antagonists and by 6-hydroxydopamine, a 
treatment that depletes noradrenergic neurons in the brain (Cook et al. 1988b).  Pretreatment with the 
dopamine antagonist, haloperidol, was also capable of blocking the hypothermia (Hsu et al. 1986).  It has 
been suggested that the decrease in body temperature is the result of centrally mediated vasodilation 
(Cook et al. 1988a, 1988b), but direct evidence for this has not yet been obtained. 
 
Mitochondrial oligomycin-sensitive Mg2+ATPase is thought to play a major role in oxidative 
phosphorylation (Boyer et al. 1977).  It has been suggested that impairment of mitochondrial energy 
metabolism by chlordecone may contribute to the decreases in body weight observed following exposure 
to this chemical (Desaiah 1981). 
 
Carpenter et al. (1996) examined ultrastructural, protein, and lipid profiles in the livers of chlordecone-
treated mice.  Male C57BL/6N mice were administered chlordecone intraperitoneally, followed 3 days 
later by intraperitoneal injection of radiolabeled chlordecone.  Livers and kidneys were subsequently 
MIREX AND CHLORDECONE  120 
 
2.  HEALTH EFFECTS 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
removed for assessment of radioactivity.  Livers were examined for histological and ultrastructural 
changes and total lipid content and fatty acid profiles in livers and kidneys were determined.  
Pretreatment with unlabeled chlordecone resulted in dose-dependent decreased accumulation of 
chlordecone in the liver; renal accumulation was not affected.  Chlordecone induced marked hepatic 
mitochondrial swelling, decreased the number of cytoplasmic lipid droplets in hepatocytes, induced 
proliferation and vesiculation of smooth endoplasmic reticulum, and increased the number of intracellular 
peroxisome-like structures.  Chlordecone did not alter the total lipid content of the liver or kidney.  The 
changes in the liver suggest that chlordecone caused alterations in hepatocellular transport, storage, and 
metabolism pathways via increased hepatocyte secretory activity. 
 
Neurotoxicity.  Several studies have been undertaken in an attempt to define the mechanism of the 
neurotoxic effects of chlordecone.  No single mechanism has been identified that readily explains the 
neurotoxic effects of chlordecone.  However, studies have revealed substantial information regarding the 
effects of chlordecone on the nervous system.  Chlordecone does not appear to act through a mechanism 
similar to other chlorinated hydrocarbon insecticides such as dieldrin or lindane.  Chlordecone has a 
different profile of neurotoxicity in that it primarily causes hyperexcitability and tremors, but no 
convulsions, and appears to lack activity at the γ-aminobutyric acid (GABA) receptor in mammals 
(Bloomquist et al. 1986; Chang-Tsui and Ho 1979; Lawrence and Casida 1984; Seth et al. 1981).  
Chlordecone has been shown to be a potent antagonist of the picrotoxinin binding site on the GABA 
receptor in cockroaches (Matsumura 1985).  However, this finding is difficult to interpret based on the 
poor binding at a comparable site in mammalian tissues. 
 
The hyperexcitability and tremor induced by chlordecone are similar to that produced by dichloro-
diphenyldichloroethane (DDT).  However, it has been suggested that the mechanism of these tremors is 
different; diphenylhydantoin exacerbates chlordecone-induced tremor but suppresses tremor induced by 
DDT (Hong et al. 1986; Tilson et al. 1985, 1986b).  The tremors induced by chlordecone appear to be 
initiated in the central nervous system above the level of the spinal cord, since transection of the spinal 
cord resulted in elimination of the tremors below the level of transection (Hwang and Van Woert 1979). 
 
Several pharmacological studies indicate that α-noradrenergic and serotonergic transmitter systems in the 
central nervous system are the primary neurotransmitter systems involved in the expression of the tremor 
and enhanced startle response produced by chlordecone (Gerhart et al. 1982, 1983, 1985; Herr et al. 1987; 
Hong et al. 1984; Hwang and Van Woert 1979).  These conclusions are supported by a number of studies 
examining brain neurochemistry following administration of tremorgenic doses of chlordecone (Brown et 
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al. 1991; Chen et al. 1985; Hong et al. 1984; Tilson et al. 1986b; Uphouse and Eckols 1986).  However, 
dopamine (Desaiah 1985; Fujimori et al. 1982b) and acetylcholine (Aronstam and Hong 1986; Gerhart et 
al. 1983, 1985) have also been implicated. 
 
At the cellular level, chlordecone causes spontaneous neurotransmitter release (End et al. 1981) and 
increases in free intracellular calcium in synaptosomes (Bondy and Halsall 1988; Bondy and McKee 
1990; Bondy et al. 1989; Komulainen and Bondy 1987).  This appears to be due, at least in part, to 
increased permeability of the plasma membrane (Bondy and Halsall 1988; Bondy and McKee 1990; 
Bondy et al. 1989; Komulainen and Bondy 1987), activation of voltage-dependent calcium channels 
(Komulainen and Bondy 1987), and inhibition of brain mitochondrial calcium uptake (End et al. 1979, 
1981). 
 
Chlordecone also decreased the activity of calmodulin-stimulated enzymes (Kodavanti et al. 1988, 1989c; 
Vig et al. 1990b, 1991) and of enzymes integral to maintenance of neuronal energy and ionic gradients; 
Na+K+ATPase (Bansal and Desaiah 1982; Chetty et al. 1983b; Desaiah 1981; Desaiah et al. 1980a, 1980b; 
Folmar 1978; Jinna et al. 1989; Singh et al. 1984), oligomycin-sensitive Mg2+ATPase (Chetty et al. 
1983b; Desaiah et al. 1980a, 1980b; Jinna et al. 1989; Mishra et al. 1980), and Ca2+ATPase (Desaiah et al. 
1991; Jinna et al. 1989; Mishra et al. 1980) activities in brain tissues have been shown to be decreased by 
exposure to chlordecone both in vivo and in vitro.  It is unclear whether inhibition of these enzymes is 
directly responsible for the effects of chlordecone on intracellular calcium or whether these changes are 
coincidental with the changes in intracellular calcium. 
 
Reproductive Toxicity.  Mechanisms underlying many of the adverse effects of chlordecone on 
reproductive function may be related to the estrogenic properties of chlordecone.  Following both in vitro 
(Bulger et al. 1979; Hammond et al. 1979) and parenteral administration (Williams et al. 1989a), 
chlordecone was shown to bind to estrogen receptors and to cause translocation of the receptor from the 
cytoplasm to the nuclear fraction.  When the activity of chlordecone was compared in uterine and brain 
tissues, the effect was greater in the uterine tissue (Williams et al. 1989a).  Chlordecone caused the 
translocation of estrogen receptors from the cytosolic to the nuclear fraction in both isolated rat uteri and 
ovariectomized immature rats (Bulger et al. 1979; Williams et al. 1989a).  These results indicate that 
chlordecone may act directly on the uterus.  Johnson (1996) found that chlordecone-induced uterine 
effects (hypertrophy, hyperplasia) observed in ovariectomized immature rats were enhanced by 
coadministration of estradiol.  These results suggest that both the estrogen and xenoestrogen are 
influencing uterine hypertrophy and hyperplasia by a single mechanism.  Chlordecone demonstrated 
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fairly high affinity for recombinant human estrogen receptors (Bolger et al. 1998; Scippo et al. 2004).  
Chlordecone exhibited approximately equal affinity for both subtypes of human estrogen receptors (ERα 
and ERβ) (Kuiper et al. 1998); the binding affinity was on the order of 1,000-fold less than that of 
estradiol.  In a study by Johnson et al. (1995), uterine levels of adenosine 3'5'-cyclic monophosphate 
(cAMP) decreased with increasing uterine weight following repeated exposure to chlordecone in 
ovariectomized immature rats.  Levels of cAMP were not decreased in similarly treated rats that were also 
given the antiestrogen (ICI-182,780), indicating that the chlordecone-induced effect on cAMP is estrogen 
receptor-dependent. 
 
The affinity of chlordecone for estrogen appears to be tissue-dependent.  Although competition between 
[3H]estradiol and chlordecone was comparable in magnitude within estrogen receptor preparations from 
brain or uterine tissues of rats, in vivo binding of chlordecone in the brain of ovariectomized rats was 
much less than that observed in the uterus (Williams et al. 1989b).  The basis for this may result, at least 
in part, from a greater time requirement for chlordecone to reach a concentration in the brain that could 
result in a significant estrogenic effect.  Although chlordecone may mimic the effect of estrogen in uterine 
tissue, chlordecone appears to function as an estrogen antagonist in central nervous tissue (Huang and 
Nelson 1986; Uphouse et al. 1986). 
 
Chlordecone has been evaluated for its potential to bind to receptors other than the estrogen receptor and 
was found to have relatively high affinity for recombinant human progesterone receptors (Scippo et al. 
2004).  In ovariectomized (NBZ x NZW) F1 mice, both estradiol (an estrogen) and chlordecone were 
shown to accelerate development of the autoimmune disorder, systemic lupus erythematosus (Wang et al. 
2007a).  However, it was found that chlordecone was not simply mimicking estrogen, based on 
contrasting effects on splenic B-cells populations.  In a follow-up a study, also in ovariectomized (NBZ x 
NZW) F1 mice, Wang et al. (2007b) compared the effects of chlordecone and estradiol treatment on 
serum levels of the autoimmune-accelerating hormone, prolactin.  In chlordecone-treated mice, they 
found a dose-dependent decrease in prolactin levels (compared to controls).  However, in estradiol-treated 
mice, prolactin levels were 10–20 folds higher than controls.  In a related study, chlordecone exhibited 
characteristics of a partial androgen antagonist, based on reduced inhibition of 5α-dihydroxytestosterone-
mediated activation of luciferase activity by 6.9 μM chlordecone in the human PC-3 prostate carcinoma 
cell line (Schrader and Cooke 2000). 
 
Results from a study by Das et al. (1997) indicate that chlordecone-induced uterine effects may also be 
induced via a pathway other than that which includes the estrogen receptor.  Chlordecone upregulated 
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uterine expression of an estrogen-responsive gene, lactoferrin, in ERα knockout mice, whereas these 
effects were not elicited by 17β-estradiol.  Neither the estrogen receptor antagonist ICI-182,780 nor 
17β-estradiol inhibited the chlordecone-induced uterine expression of lactoferrin in these mice.   
 
Substantially less is known about the mechanism by which mirex causes reproductive toxicity.  Mirex 
does not, however, appear to produce its reproductive toxicity by mimicking estrogen (Gellert 1978; 
Hammond et al. 1979).  Dai et al. (2001) hypothesized that modulation of testosterone metabolism via 
induction of specific CYP isoforms may be a contributing factor in mirex-induced antiandrogenic effects.  
Evidence includes significantly increased (3.1-fold greater than controls) total CYP contents in 
homogenated livers of adult male CD-1 mice administered mirex by gavage at 5 mg/kg/day for 21 days 
(Dai et al. 2001).  Western blot analysis indicated that CYP2E1 and CYP3A were the isoforms induced to 
the greatest extent.  Incubation of testosterone with microsomes from the treated mice resulted in an 
approximately 2.5-fold increase in testosterone hydrolase activity. 
 
Developmental Toxicity.  No information was located regarding possible mechanisms of mirex 
developmental toxicity.  Laessig et al. (2007) administered chlordecone (5 mg/kg) in a single 
intraperitoneal dose to pregnant Sprague-Dawley rats on gestation day 16 and assessed its effect on 
sexually-differentiated behavior of the adult offspring.  The offspring were gonadectomized on PND 50 to 
eliminate effects of circulating hormones and were sequentially evaluated for sex-typic spontaneous 
behaviors in open field (PND 60) and elevated plus maze (PND 61–63) performance.  Gonadectomized 
male and female offspring were also assessed for reproductive behavior following sex-specific steroid 
treatment.  On PND 68 or 69, male and female offspring were treated with a chemical paradigm that 
induces lordosis (a female sexual behavior).  On PND 70, male offspring received a testosterone implant; 
these males were assessed 6 weeks later for mounting behavior with a sexually-responsive female.  On 
PND 120, blood was collected from male and female offspring for assessment of serum testosterone 
levels.  There were no apparent chlordecone treatment-related effects on time to parturition, litter size, sex 
ratio, or growth indices of offspring compared to controls.  Chlordecone-exposed (in utero) 
gonadectomized female offspring exhibited significantly increased ratio of inner to total crossings in the 
open field; significant increases in lordosis response with steroid priming and mounting with prolonged 
testosterone administration were observed in both male and female offspring.  These results suggest that 
chlordecone may interfere with estrogen-dependent events during sexual differentiation of the brain that 
impact later activation of hormone-dependent behavior. 
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Tumor Promotion.  There is convincing evidence that mirex and chlordecone interfere with cell-to-cell 
communication.  Tsushimoto et al. (1982) demonstrated that metabolic cooperation between 
6-thioguanine-resistant (6-TGr) mutants (HGPRT-) and 6-TGr wild-type (HGPRT+) Chinese hamster lung 
fibroblasts (V79) was inhibited by both mirex and chlordecone.  In this assay system, the ability of 
HGPRT+ cells to transport a lethal substrate (formed from the metabolism of 6-thioguanine) to HGPRT 
cells (6-TGr) is evaluated.  Transport of the mononucleotide of thioguanine from the HGPRT+ to the 
HGPRT- cells occurs presumably through gap junctions and results in the killing of heretofore 6-TGr 
cells.  Therefore, increased survival of the HGPRT- cells in the presence of a test material indicates an 
interference with metabolic cooperation.  Mirex doses ranging from 3 to 12 mg/L induced a dose-related 
increase in the recovery of 6-TGr colonies.  The maximum percentage recovery of 6-TGr cells (≈70%) 
was noted at 12 mg/L.  Chlordecone also inhibited metabolic cooperation at concentrations well below the 
cytotoxic level.  However, in contrast to the mirex data, chlordecone produced a much steeper dose-
response between 1 and 4 mg/L with the maximum percentage of 6-TGr cell recovery (70%) occurring at 
4 mg/L.  While it is tempting to speculate that chlordecone is a more potent inhibitor of metabolic 
cooperation, the differences observed may be explained by differences in solubility.  Chlordecone also 
reversibly disrupted gap junctional communication in human embryonic palatal mesenchyme cells when 
tested by assessing Lucifer yellow dye transfer (Caldwell and Loch-Caruso 1992). 
 
Starcevic et al. (2001) designed an experiment to test whether chlordecone disrupts adherens junctions in 
human breast epithelial cells cultured on Matrigel.  When exposed to chlordecone, MCF-10ATG3B 
human breast epithelial cells exhibited significantly decreased E-cadherin and beta-catenin protein levels; 
desmoglein and α- and γ-catenin levels did not vary significantly from control levels.  Chlordecone also 
caused disruption in E-cadherin-γ-catenin association.  These results indicate that chlordecone disrupts 
cellular architecture, which may ultimately play a role in development of neoplastic lesions.  Chlordecone 
in combination with other xenobiotic chemicals such as carbon tetrachloride and ether reduced the 
threshold values of toxicity by several folds for those chemicals and decreased the aromatase activity by 
50% in some cases.  Prolonged exposures to low doses of xenobiotics amplified aromatase inhibition by 
50 times.  Because chlordecone is known to bioaccumulate, chronic, low-level exposures may result in 
body burden levels that could also affect cell signaling mechanisms (Benachour et al. 2007). 
 
Collectively, results from several studies provide evidence that mirex acts as a tumor promoter with a 
mechanism different from that of phorbol esters and that mirex potentiates skin tumor promotion by TPA 
in DMBA-initiated mice (Meyer et al. 1993, 1994; Moser et al. 1992, 1993).  Twenty weeks of thrice 
weekly dermal application of mirex (200 nmole) to DMBA-initiated mice resulted in 96% skin tumor 
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incidence with an average of 4 tumors/mouse; similar treatment of other mice with TPA (2 nmole) 
resulted in 78% tumor incidence with 14 tumors/mouse.  TPA-treated (but not mirex-treated) mice 
exhibited a hyperplastic response; this result indicates that mechanisms of mirex tumor promotion differ 
from those of TPA.  Co-application of 200 nmole mirex and 2 nmole TPA on DMBA-initiated mouse 
skin yielded 28 tumors/mouse (compared to 14 tumors/mouse after mirex treatment separately and 
4 tumors/mouse after TPA treatment separately).  In addition, co-treatment with mirex and TPA resulted 
in earlier tumor development; after 8 weeks of promotion, 90% of cotreated mice bore tumors compared 
to 47% of mice treated with mirex separately and 17% of mice treated with TPA separately.  Mirex-
promoted skin tumors in DMBA-initiated mice were 3 times more prevalent in female than male mice and 
3 times less prevalent in ovariectomized mice, suggesting that ovarian hormones may influence mirex-
tumor promotion sensitivity. 
 
Kim and coworkers (Kim and Smart 1995; Kim et al. 1997) reported that mirex promoted the 
development of papillomas involving a Ha-ras mutation in DMBA-initiated mice.  The ovarian hormone 
17β-estradiol may be involved in mirex skin tumor promotion in mice.  Porter et al. (2002) assessed the 
role of 17β-estradiol in mirex skin tumor promotion by applying topical mirex to ovariectomized mice 
that had subcutaneous implants either with or without the hormone.  Ovariectomized mice with implanted 
17β-estradiol exhibited normal physiological levels of serum 17β-estradiol throughout the treatment 
period.  The 17β-estradiol implants restored approximately 80% of the mirex tumor promoting response 
of intact mice.  17β-Estradiol implants in male mice increased sensitivity to mirex tumor promotion as 
well, but not to the level of response seen in intact female mice. 
 
There are convincing data from a metabolic cooperation assay (Tsushimoto et al. 1982) and a dye transfer 
assay (Caldwell and Loch-Caruso 1992) indicating that mirex and chlordecone interfere with intracellular 
communication.  Inhibition of cell-to-cell communication is a property exhibited by numerous promoters 
(Williams 1980).  Similarly, the data indicating that both agents probably induce liver tumors in rodents 
through epigenetic/promoter mechanisms are supported by the striking similarities that these test 
materials share with many established promoters: (1) tumors induced by mirex or chlordecone are found 
predominantly in rat or mouse livers; (2) neither agent is genotoxic; (3) both agents induce ornithine 
decarboxylase activity; (4) there is no evidence of covalent binding to DNA; and (5) both agents lack 
reactive functional groups.  Mirex has not been evaluated for promoter activity in vivo; however, 
chlordecone was shown to be a tumor promotor in a two-stage assay in which the initiator, 
diethylnitrosamine, was given orally to partially hepatectomized Sprague-Dawley rats followed by 
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subcutaneous doses of chlordecone.  The treatment resulted in hyperplastic liver nodules in seven of eight 
initiated males and hepatocellular carcinomas in five of six initiated females. 
 
The weight of evidence from in vivo and in vitro genetic toxicology tests, in vivo liver function studies, 
and the two-stage tumor promotion assay is adequate to conclude that chlordecone is a promotor rather 
than an initiator of carcinogenesis.  While the evaluation of mirex in an in vivo tumor promoter assay is 
desirable, it is, nevertheless, concluded that there is sufficient evidence to consider mirex a probable 
promoter. 
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CHAPTER 3.  TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, 
BIOMARKERS, CHEMICAL INTERACTIONS 
 
3.1   TOXICOKINETICS  
 
Mirex.  Mirex is absorbed from the digestive tract of animals.  Following exposure to mirex, an initial 
rapid excretion of the majority of the ingested mirex occurs via the feces within the first 48 hours 
postdosing.  This fecal mirex represents unabsorbed compound.  Once absorbed, mirex is widely 
distributed throughout the body, but is sequestered in the fat.  It has a long retention time in the body.  
Mirex is not metabolized in humans, rodents, cows, or minipigs.  The parent compound is the only 
radiolabeled compound that has been found in the plasma, fat, and feces.  In animals, mirex is excreted 
unchanged mainly in the feces; urinary excretion is negligible.  Mirex is also excreted in human milk.  
Only a very limited number of studies were located regarding the toxicokinetics of mirex via inhalation or 
dermal routes.  Limited data indicate that mirex is absorbed by rats following exposure to the compound 
in cigarette smoke. 
 
Chlordecone.  Occupational studies indicate that chlordecone is absorbed via the inhalation and oral 
routes.  Chlordecone is readily absorbed from the gastrointestinal tract of humans and animals.  
Chlordecone is widely distributed throughout the body and concentrates in the liver of humans and 
animals.  It has a long retention time in the body.  Chlordecone is metabolized to chlordecone alcohol in 
humans, gerbils, and pigs.  Rats, guinea pigs, and hamsters cannot convert chlordecone to chlordecone 
alcohol.  Chlordecone, chlordecone alcohol, and their glucuronide conjugates are slowly excreted in the 
bile and eliminated in the feces.  However, a substantial enterohepatic recirculation of chlordecone exists 
that curtails its excretion in the feces.  Chlordecone is also excreted in saliva and mother’s milk.  Only a 
very limited number of studies were located regarding the toxicokinetics of chlordecone via inhalation or 
dermal routes.  Occupational studies indicate that chlordecone can be absorbed via inhalation and oral 
routes.  Limited animal data indicate that dermal absorption of chlordecone is low. 
 
3.1.1   Absorption  
 
Mirex.  Very limited data show that inhaled mirex can be rapidly absorbed into the blood of rats (Atallah 
and Dorough 1975; Dorough and Atallah 1975).  The fate of [14C] mirex in cigarette smoke was assessed 
in rats with the aid of a smoking device (Atallah and Dorough 1975; Dorough and Atallah 1975).  Eight 
5-mL puffs were administered to the trachea of rats at 15-second intervals.  At 2–4 minutes after 
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inhalation, 47% of the radiolabel was exhaled, 36% was found in the lung, 11% was found in the blood, 
and 1% was found in the heart. 
 
Several studies in rats indicate that mirex is absorbed from the digestive tract (Byrd et al. 1982; Gibson et 
al. 1972; Mehendale et al. 1972).  Experiments with rats given single oral doses of mirex ranging from 
0.2 to 10 mg/kg showed that an initial rapid excretion of mirex occurs in the feces within the first 
48 hours post-dosing (Byrd et al. 1982; Gibson et al. 1972; Mehendale et al. 1972).  The excretion of 
mirex in the feces within this time period is attributed to unabsorbed mirex.  A majority (85–94%) of the 
total quantity excreted after 7 days is eliminated in this first rapid excretion phase (Gibson et al. 1972; 
Mehendale et al. 1972).  Other data provided an absorption estimate of 69%, which occurred with female 
rats given a single oral dose of 10 mg/kg (Byrd et al. 1982).  Similarly, most of the fecal mirex was 
recovered within the first 48 hours.  This was attributed to the elimination of unabsorbed mirex (Byrd et 
al. 1982).  Intestinal absorption of mirex was slightly decreased by the presence of an existing body 
burden (Gibson et al. 1972).  For example, rats fed 12.5 mg/kg of unlabeled mirex before administration 
of a single dose (0.2 mg/kg) of mirex excreted 25% of the administered dose in the feces, as compared 
with 18% excretion for the animals given only a single dose (Gibson et al. 1972). 
 
Mirex is rapidly absorbed by rats and monkeys.  Peak plasma concentrations of 14C-mirex occurred within 
4–7 hours after female rats were given a single oral dose of 10 mg/kg (Byrd et al. 1982) and within 
2 hours after male rats were administered a single oral dose of 100 mg/kg (Brown and Yarbrough 1988).  
14C-Mirex levels in plasma peaked 5 hours after oral administration of 1 mg/kg to a female rhesus 
monkey (Wiener et al. 1976).  Thereafter, the decline in plasma 14C concentration continued at a much 
slower rate and paralleled that in the intravenously-dosed monkeys (Wiener et al. 1976). 
 
Mirex rapidly entered the maternal bloodstream of pregnant rats dosed orally with 5 mg/kg on gestation 
days 15, 18, or 20 (Kavlock et al. 1980).  Four hours after oral dosing on gestation day 15, the plasma 
concentration of mirex was 13 ppm.  Mirex plasma concentrations were significantly affected by both the 
time of administration and the hour of observation.  Higher plasma concentrations were found at older 
gestation ages (13 ppm on gestation day 15, compared to 23 ppm on gestation day 20; measured 4 hours 
after administration).  Plasma concentrations declined with time after dosing (Kavlock et al. 1980). 
 
Mirex concentrations in plasma of pregnant goats fed daily doses of 1 mg/kg for 61 weeks stabilized after 
15 weeks (Smrek et al. 1977).  An increase in the dose from 1 to 10 mg/kg at the end of the study resulted 
in an increase in the plasma level of mirex.  Females dosed for 18 weeks starting at the first day 
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postpartum had plasma levels that were similar to females that were started on mirex in early pregnancy 
(Smrek et al. 1977). 
 
Chlordecone.  Chlordecone is absorbed after occupational exposure; however, due to extremely poor 
workplace hygiene in available sources of human data, relative contributions from inhalation, oral, and 
dermal exposure routes are not available (Cannon et al. 1978; Cohn et al. 1978; Taylor 1982, 1985).  
Mean blood levels of workers exposed to chlordecone at a manufacturing plant in Hopewell, Virginia 
were 2.53 ppm for workers manifesting illness (nervousness or unfounded anxiety; pleuritic chest pain; 
weight loss of up to 60 pounds in 4 months; visual difficulties; skin rashes of an erythematous, 
macropapular nature) and 0.6 ppm for workers with no illness (Cannon et al. 1978).  Two months 
following cessation of exposure, blood levels in workers were in excess of 2 ppm (Taylor 1982, 1985).  
Following exposure in humans, mean half-lives of 96 days (range of 63–148 days) (Adir et al. 1978) and 
165 days (Cohn et al. 1978) in blood have been reported for chlordecone.  This relatively long half-life 
may be due to the high degree of lipid solubility and limited metabolism of chlordecone. 
 
Chlordecone is readily absorbed (90%) from the gastrointestinal tract of rodents and has a long half-life 
(Egle et al. 1978).  In rats exposed to a single oral dose of 40 mg/kg chlordecone, the blood half-lives at 4, 
8, and 14 weeks posttreatment were 8.5, 24, and 45 days, respectively (Egle et al. 1978).  Chlordecone is 
also rapidly absorbed by pregnant rats (Kavlock et al. 1980).  Four hours after dosing (5 mg/kg) on 
gestation day 15, the plasma concentration of chlordecone was 6 ppm. 
 
Chlordecone is absorbed to a limited extent following dermal exposure in rats (Hall et al. 1988; Shah et 
al. 1987).  The percent of dose absorbed was determined by dividing the radioactivity in the body 
(carcass) and in the excreta by the total radioactivity recovered (in carcass, excreta, treated skin, and 
washes of the application materials).  The results showed that fractional absorption decreased as the dose 
of chlordecone increased.  At 72 hours after exposure to 0.29, 0.54, or 2.68 μmol 14C-chlordecone/cm2, 
skin penetration of chlordecone in young rats was 10.17, 7.23, and 1.93%, respectively, of the applied 
dose.  Skin penetration of chlordecone in adult rats at 72 hours was 9.2, 5.96, and 1.03% for the low-, 
middle-, and high-dose groups, respectively.  The area of application when expressed as the percentage of 
the total surface area (≈2.3%) was the same in both young and adult rats.  The actual amount of 
chlordecone absorbed (0.03 pmol/cm2) was similar for all dose groups, suggesting that saturation 
occurred at the low dose.  No significant age-dependent differences in dermal absorption were seen. 
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3.1.2   Distribution  
 
Mirex.  Mirex has been detected in a variety of human samples.  Mirex levels of 0.16–5.94 and 0.3–
1.13 ppm (males and females, respectively) were found in adipose tissue samples taken either from 
postmortem examinations or during surgery (Kutz et al. 1974).  The adipose tissue samples came from 
individuals who lived in areas in which mirex was used extensively in a program to control fire ants.  
Adipose tissue levels of mirex ranging from 0.03 to 3.72 ppm have been found in residents living near a 
dump site in Tennessee (Burse et al. 1989).  Mirex has also been detected in human serum samples (e.g., 
Butler Walker et al. 2003; Fenster et al. 2006; Greizerstein et al. 1999; Schell et al. 2003; van Oostdam et 
al. 2004), milk samples from lactating women (Fitzgerald et al. 2001; Greizerstein et al. 1999; Mes et al. 
1978; Newsome and Ryan 1999; Newsome et al. 1995), and placental tissue and umbilical cord blood 
(Butler Walker et al. 2003; Lopez-Espinosa et al. 2007).   
 
Only very limited animal data were located regarding the distribution of absorbed mirex following 
inhalation exposure.  Mirex was found in the lungs (36%), blood (11%), and hearts (1%) of rats exposed 
to mirex in cigarette smoke (Atallah and Dorough 1975; Dorough and Atallah 1975). 
 
Following oral dosing in animals, mirex is distributed to various tissues and sequestered in fat.  Females 
generally accumulated greater amounts than males.  Mirex demonstrated an affinity for lipids in male and 
female rats given a single oral dose of mirex (0.2 mg/kg); highest concentrations were found in fat 
(Chambers et al. 1982; Gibson et al. 1972).  The levels in fat of females were approximately 2 times 
higher than levels in fat of males (Chambers et al. 1982).  For females, mirex levels in the fat ranged from 
338 to 944 ng/g at 7 days and increased to 483–1,043 ng/g at 14 days.  For males, mirex levels in fat 
ranged from 161 to 479 ng/g at 7 days and from 419 to 530 ng/g at 14 days.  Mirex also accumulated in 
nervous tissue, with females accumulating higher amounts than males (Chambers et al. 1982).  Mirex 
concentrations in the nervous tissue in males and females at 7 days posttreatment were 13.228 ng/g and 
40–59 ng/g, respectively; concentrations declined during posttreatment days 7–14.  Mirex accumulated in 
various other tissues of both males and females, including gastrointestinal tract, liver, lung, heart, kidney, 
adrenals, brain, skeletal muscle, spleen, and thymus (Chambers et al. 1982; Gibson et al. 1972). 
 
Seven days after a single administration of mirex (6 mg/kg) to rats, 34% of the total dose was retained in 
the tissues and organs; 27.8% was stored in the fat, 3.2% was stored in the muscle, and 1.75% was stored 
in the liver (Mehendale et al. 1972).  The remaining tissues each retained <1% of the total dose.  No 
metabolite of mirex was detected in the tissues.  The repetitive administration of 10 mg/kg mirex to rats 
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resulted in an accumulation of mirex in several tissues (plasma, liver, kidney, fat), with more 
accumulating in fat tissue (Plaa et al. 1987).  Following oral administration of 1 mg/kg 14C-mirex to a 
female rhesus monkey, the highest tissue levels of radioactivity were found in fat, followed by large 
intestine, adrenal glands, liver, ovaries, and peripheral nerves (Wiener et al. 1976).  The administered 
dose of radioactivity was distributed as follows: 55.3% was recovered in fat and ≤2% was recovered in 
the remaining tissues.  Mirex was the only labeled compound identified in fat.  Mirex fed to minipigs for 
7 consecutive days (3–4.5 mg/kg/day) was distributed to backfat (41.5 ppm), liver (1.24 ppm), kidney 
(0.44 ppm), plasma (0.04 ppm), and red blood cells (0.01 ppm) at 9 days after dosing (Morgan et al. 
1979). 
 
Mirex was detected in brains from male rats within 0.5–2 hours after a single oral dose of 100 mg/kg 
mirex (Brown and Yarbrough 1988).  By 96 hours, the following concentrations (in μmol 14C-mirex/g) 
were measured in the brain regions: cerebral cortex (0.47), cerebellum (0.50), brain stem (0.73), and 
spinal cord (0.75).  Mirex was also distributed to the liver, kidneys, testes, and omental fat.  Peak tissue 
concentrations of mirex in the kidneys, testes, liver, and omental fat occurred 12, 48, 48, and 96 hours 
postdosing, respectively.  Following a single oral dose of 50 mg/kg mirex to mice, mirex was distributed 
to the brain; mirex levels in the striatum and medulla/pons were significantly higher than in the cortex, 
midbrain, or cerebellum at 48 hours postdosing (Fujimori et al. 1982a).  However, at 6, 12, and 96 hours 
postdosing, discrete brain area levels of mirex did not differ significantly.  Mirex levels in whole brain 
and plasma were 3–40 times lower than levels found in chlordecone-treated mice, and mirex showed less-
specific distribution in discrete areas of the brain than did chlordecone (Fujimori et al. 1982a).  Samples 
of brain tissue from rats fed 0, 0.089, or 0.89 mg mirex/kg/day for 34–49 days showed that mirex 
accumulates in rat brain tissue in a dose-dependent manner; mirex levels in brain tissue were 7–8 times 
higher in the high-dose group than in the low-dose group (Thorne et al. 1978). 
 
Mirex accumulates in maternal tissues, readily crosses the placenta of animals, and accumulates in fetal 
tissues.  Maximum concentrations of mirex found in the placenta of rats ranged from 3.5 to 4 ppm at 
4 hours postdosing (Kavlock et al. 1980).  Mirex levels in the placenta at 48 hours postdosing were <50% 
of the 4-hour level.  The uptake of mirex by fetal organs was in the order of liver > brain = heart > kidney 
in a ratio of 3:2:2:1.  Fetal mirex concentrations remained low at 4 hours postdosing, increased slightly at 
24 hours, and decreased thereafter.  The decline noted in the second 24-hour period was due to both organ 
growth and mirex elimination.  Mirex accumulated in maternal and fetal tissues at all dose levels (1.5, 3, 
6, 12.5 mg/kg given on gestation days 6–15) (Khera et al. 1976).  At the 12.5 mg/kg/day dose level, fetal 
brain levels were >3 times higher (31.5 ppm) than mean maternal brain levels (8.87 ppm).  All other mean 
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fetal tissue values were lower than mean maternal values.  The highest maternal levels of mirex were 
found in the fat, indicating the potential for long-term sequestering of the compound. 
 
In a study in which dams were dosed with 1 or 10 mg/kg of mirex on days 2–5 postpartum, mirex was 
found in the stomach milk of pups (Kavlock et al. 1980).  Mirex appeared in the milk in direct proportion 
to the dose.  Mirex was also distributed to the liver, brain, and eyes of the pups in the approximate ratio of 
40:4:1.  Mirex tissue levels paralleled milk levels. 
 
Mirex concentrations in adipose tissues of goats fed daily doses of 1 mg/kg did not reach a steady state, 
but continued to increase throughout a 61-week exposure period and did not seem to be affected by 
pregnancy or lactation (Smrek et al. 1977).  When the dose was increased from 1 to 10 mg/kg, the adipose 
tissue levels did not increase dramatically.  Twenty-eight days postdosing, the following residue levels 
were found in tissues of lactating cows given daily doses of 0.005 mg/kg/day for 28 days: 0.21 ppm in fat, 
0.03 ppm in liver, and 0.02 ppm in kidney (Dorough and Ivie 1974).  Muscle and brain contained no 
detectable residues.  Mirex was the only compound identified in the fat.  Analyses of the composition of 
residues in liver and kidney were not performed. 
 
There was a dose-related increase in the levels of mirex in fat of rats fed 0.02, 0.2, or 1.5 mg/kg/day for 
16 months (Ivie et al. 1974b).  Mirex levels in fat were 120-fold higher than corresponding dietary 
intakes.  Mirex levels increased in tissues throughout the exposure period, with fat accumulating the 
highest amounts of mirex.  No plateau of residue accumulation occurred in any tissue during the feeding 
period.  Removal of animals from treatment after 6 months resulted in a decline of residue levels in all 
tissues. 
 
Mirex is rapidly absorbed and distributes to plasma and liver after intraperitoneal injection.  Peak 
concentrations were seen at 3 hours postdosing in plasma and 6 hours postdosing in the liver following 
single or multiple doses of mirex (4 mg/kg) injected into mice (Charles et al. 1985).  Significant amounts 
were rapidly taken up by the liver (21–29%) within the first 3–6 hours postdosing.  Plasma-to-liver ratios 
were low (<1), indicating an increased influx of the chemical into tissue.  Mirex decay curves for plasma 
and liver during 72 hours postdosing showed a biphasic pattern that consisted of a rapid phase (up to 
24 hours) and a slow phase (24–72 hours).  For plasma, the half-lives were 9.2 and 62.8 hours for the 
rapid and slow phases, respectively.  For liver, the half-lives for the rapid and slow phases were 12.1 and 
62.4 hours, respectively (Charles et al. 1985). 
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Mirex was rapidly cleared from the blood of rats following intravenous injection of 10 mg/kg (Byrd et al. 
1982).  Mirex blood levels at 8 hours postinjection were <4% of the levels seen 2 minutes postinjection.  
Pharmacokinetic modeling predicted that intravenously administered mirex was quickly cleared from the 
blood into a rapidly equilibrating compartment.  Over the next several weeks, mirex was redistributed to a 
slowly equilibrating compartment, which acted as a depot for mirex storage (Byrd et al. 1982).  The 
biological half-life of mirex was estimated to be 435 days (Byrd et al. 1982). 
 
Following a single intravenous dose of 1 mg/kg to female rhesus monkeys, 86–87% of the administered 
dose was recovered in fat, 3.7–10% in skin, 0.6–1.7% in skeletal muscle, and <0.5% in other tissues 
(Wiener et al. 1976).  Mirex was the only compound identified in fat. 
 
Chlordecone.  In humans, chlordecone is absorbed and distributed to various tissues and has a long 
retention time in the body (Cannon et al. 1978; Cohn et al. 1978; Taylor 1982, 1985).  Chlordecone was 
eliminated slowly from the blood (half-life of 165 days) and fat (half-life of 125 days) of industrial 
workers (Cohn et al. 1978).  Tissue-to-blood ratios for liver, fat, muscle, and gallbladder bile were 15, 
6.7, 2.9, and 2.5, respectively (Guzelian et al. 1981).  The relatively higher partition of chlordecone to 
blood (fat-to-blood concentration ratio of 1:7) compared to that of other organochlorine pesticides (e.g., 
DDT with a fat-to-blood concentration ratio of 300:1) may be explained by the fact that chlordecone is 
bound specifically by the proteins in plasma, particularly high-density lipoproteins (HDLs), unlike most 
organochlorine pesticides, which distribute among tissues in direct proportion to the concentration of 
tissue fat (Guzelian et al. 1981). 
 
In rats, chlordecone was absorbed and distributed to various tissues, with the highest concentrations in 
liver (Egle et al. 1978; Hewitt et al. 1986b; Plaa et al. 1987).  Chlordecone was detected in liver 
(125.8 mg/kg), adipose tissue (27.3 mg/kg), kidney (25.2 mg/kg), and plasma (4.9 mg/L) of rats 8 days 
following a single oral dose of 50 mg/kg (Hewitt et al. 1986b).  Chlordecone was detected in liver, 
kidney, and fat of rats following single or repetitive dosing (0.5, 1, 2, 2.5, 5, 10, or 25 mg/kg) (Plaa et al. 
1987).  For all dose groups, the liver contained the highest concentration, followed by kidney, then fat.  
The ratios of tissue levels in animals that received multiple doses to levels in animals that received single 
doses were as follows: 4.27 (plasma), 3.27 (liver), 3.74 (kidney), and 3.42 (fat).  These ratios show an 
even accumulation of chlordecone in the tissues.  Rats given four daily doses of 10 mg/kg chlordecone 
had tissue-to-blood distribution ratios for fat, liver, muscle, and skin of 15, 55, 5, and 6, respectively 
(Bungay et al. 1981). 
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Studies show that pretreatment with an inducer (phenobarbital) or inhibitor (SKF-525A) of CYP450 
causes an alteration in the distribution of chlordecone in rats (Aldous et al. 1983).  Following a single oral 
dose of chlordecone alone, the liver had the highest chlordecone level, followed by adrenal gland, lung, 
kidney, and spinal cord (Aldous et al. 1983).  Pretreatment with phenobarbital (particularly with multiple 
phenobarbital doses) caused an increase in the accumulation of chlordecone in the liver compared to 
animals given no pretreatment.  This hepatic increase resulted in a significant decrease of chlordecone 
levels in other tissue (e.g., brain, kidney, muscle) as well as significantly reduced excretion.  Pretreatment 
with SKF-525A caused a nonsignificant reduction in chlordecone levels in the liver and significant 
increases in digestive system tissues.  The results of the chlordecone distribution following SKF-525A 
pre-dosing must be interpreted with caution, since the effects may have resulted partly from SKF-525A-
mediated decreases in absorption of chlordecone (Aldous et al. 1983). 
 
Following a single oral dose of 50 mg/kg chlordecone to male mice, chlordecone was distributed to the 
brain (Fujimori et al. 1982a; Wang et al. 1981).  The results showed that the striatum and medulla/pons 
had significantly higher levels of chlordecone than the cortex, midbrain, or cerebellum (Fujimori et al. 
1982a).  Mice similarly treated with mirex did not exhibit marked differences in distribution among these 
brain areas.  Chlordecone levels were 3–40 times higher than mirex levels in plasma and brain.  
Following repeated oral doses of chlordecone (10 mg/kg/day) for 12 days, the compound was rapidly 
absorbed and distributed to the brain (Wang et al. 1981).  Plasma levels of chlordecone increased during 
the 12-day treatment period.  Brain levels of chlordecone increased linearly for the first 8 days and 
reached a plateau of 90 μg/g on the 10th day (Wang et al. 1981). 
 
Chlordecone is well distributed throughout the reproductive tract of male rats and appears in the ejaculate.  
In rats given a single oral dose of 40 mg/kg chlordecone, the descending order of concentration was vas 
deferens (81.6) > seminal vesicular fluid (19.7) > unwashed sperm (14.6) > prostate (11.3) > seminal 
vesicle (6.2) > washed sperm (1.97).  This relationship persisted as levels declined over the 21-day 
observation period (Simon et al. 1986). 
 
Chlordecone accumulates in maternal tissues, readily crosses the placenta of rats, and accumulates in fetal 
tissues (Chernoff et al. 1979a; Kavlock et al. 1980).  Four hours following a single oral dose of 5 mg/kg, 
maximal concentrations of chlordecone in the placenta ranged from 3.5 to 4 ppm (Kavlock et al. 1980).  
Concentrations of chlordecone in the placenta remained steady for up to 48 hours postdosing.  
Chlordecone levels in the fetus were generally highest in the liver, followed by the brain, heart, and 
kidney.  Concentrations increased during the first 24 hours after dosing and declined in the second 
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24-hour period, regardless of gestation age at the time of dosing (Kavlock et al. 1980).  Chlordecone 
levels found in maternal and fetal tissues were slightly higher than the levels of mirex following 
administration of equal doses (Kavlock et al. 1980).  The livers of weanling rats fed diets of 0.05 mg/kg 
chlordecone or mirex for 28 days accumulated higher levels of chlordecone (6.1 ppm) than mirex 
(0.89 ppm) (Chu et al. 1980a).  Possible explanations for this are that mirex is more poorly absorbed from 
the feed than is chlordecone or that the absorbed dose of mirex accumulates in the liver to a lesser extent 
than absorbed chlordecone (Chu et al. 1980a). 
 
In a study in which lactating rat dams were dosed with 1 or 10 mg/kg chlordecone on days 2–
5 postpartum, chlordecone was found in the stomach milk of pups (Kavlock et al. 1980).  Chlordecone 
appeared in the milk in direct proportion to the dose.  Chlordecone was distributed to the liver, brain, and 
eyes of the pups in the approximate ratio of 16:4:1 (Kavlock et al. 1980). 
 
3.1.3   Metabolism  
 
Mirex.  Radiolabeling experiments showed that mirex is not metabolized in humans, rodents, cows, or 
minipigs; the parent compound was the only radiolabeled compound present in the plasma, fat, and feces 
(Dorough and Ivie 1974; Gibson et al. 1972; Kutz et al. 1974; Mehendale et al. 1972; Morgan et al. 
1979).  However, a monohydro derivative of mirex was identified in the feces, but not the fat or plasma, 
of rhesus monkeys given an oral or intravenous dose of mirex (Pittman et al. 1976; Stein et al. 1976; 
Wiener et al. 1976).  It is believed that the suspected metabolite may have arisen as a result of bacterial 
action in the lower gut or feces (Stein et al. 1976). 
 
The potential for in vivo conversion of mirex to chlordecone was also examined (Morgan et al. 1979).  
Mirex was found in a variety of tissues from minipigs administered mirex in the feed for 7 days; however, 
chlordecone was not detected in any tissues (Morgan et al. 1979).  This result indicates that significant in 
vivo conversion of absorbed mirex to chlordecone is not likely. 
 
Chlordecone.  The fate of chlordecone in humans involves uptake by the liver, enzymatic reduction to 
chlordecone alcohol, conjugation with glucuronic acid, partial conversion to unidentified polar forms, and 
excretion of these metabolites mainly as glucuronide conjugates into bile (Fariss et al. 1980; Guzelian et 
al. 1981) (see Figure 3-1).  Of the total chlordecone measured in bile of occupationally exposed workers, 
the predominant portion (72%) was unconjugated, with only a small portion conjugated with glucuronic 
acid or sulfate (9%) (Fariss et al. 1980).  The remaining fraction (19%) of total chlordecone measured in 
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the bile was stable polar metabolites, which were resistant to β-glucuronidase.  Following treatment of 
bile with β-glucuronidase plus sulfatase, the ratio of total chlordecone to total chlordecone alcohol was 
1:3 in human bile (Fariss et al. 1980).  Bioreduction of chlordecone to chlordecone alcohol is species-
specific since rats treated orally or intraperitoneally with chlordecone produced no chlordecone alcohol in 
the feces, bile, or liver (Fariss et al. 1980; Guzelian et al. 1981; Houston et al. 1981).  Following treatment 
of bile with β-glucuronidase plus sulfatase, the ratio of total chlordecone to total chlordecone alcohol in 
rat bile was in excess of 150:1 for orally exposed rats (Fariss et al. 1980; Guzelian et al. 1981).  Guinea 
pigs and hamsters given an intraperitoneal dose of 20 mg/kg chlordecone also did not convert 
chlordecone to chlordecone alcohol, as indicated by the fact that no chlordecone alcohol was detected in 
the feces, bile, or liver (Houston et al. 1981).  Therefore, rats, guinea pigs, and hamsters are not good 
animal models for predicting chlordecone metabolism in humans because they do not convert 
chlordecone to chlordecone alcohol.  Gerbils were found to be the most suitable animal model of 
chlordecone metabolism in humans because only gerbils converted chlordecone to its alcohol (Houston et 
al. 1981).  Reduction of chlordecone is catalyzed in gerbil liver by a species-specific reductase, 
chlordecone reductase.  This chlordecone reductase was characterized in gerbil liver cytosol in vitro and 
determined to be of the “aldo-keto reductase” family (Molowa et al. 1986b).  It is specific to gerbils and 
humans (Molowa et al. 1986b).  Like humans, chlordecone-treated gerbils excreted chlordecone alcohol 
exclusively in the stool and not in the urine (Houston et al. 1981).  Following intraperitoneal dosing of 
20 mg/kg 14C-chlordecone, the ratio of chlordecone to chlordecone alcohol in the bile of gerbils was 
approximately 2.5:1.  No quantitative estimate of the extent to which chlordecone was metabolized was 
given.  Following treatment of bile with β-glucuronidase plus acid hydrolysis, the ratio of chlordecone to 
chlordecone alcohol in the bile was 1:2, indicating that chlordecone is present in the bile largely in the 
form of its glucuronide conjugate (Houston et al. 1981).  Incubation of chlordecone with the cytosolic 
fraction of gerbil liver homogenate in the presence of NADPH produced chlordecone alcohol (Houston et 
al. 1981).  Intraperitoneally-injected chlordecone was biotransformed in pigs to conjugated chlordecone, 
chlordecone alcohol, and conjugated chlordecone alcohol, which were excreted in the bile and eliminated 
in the feces (Soine et al. 1983).  Relatively high levels of chlordecone alcohol and conjugated chlordecone 
alcohol in the bile and the absence of these metabolites in the plasma and liver suggest that chlordecone 
alcohol is formed and conjugated in the liver and excreted into the bile (Soine et al. 1983). 
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Figure 3-1.  Proposed Metabolic Pathways for Chlordecone 
 
 
 
Source:  Fariss et al. 1980 
 
3.1.4   Excretion  
 
Mirex.  Available information regarding mirex-related excretion in humans is limited.  Mirex was 
detected in milk samples from lactating women (Fitzgerald et al. 2001; Greizerstein et al. 1999; Mes et al. 
1978; Newsome and Ryan 1999; Newsome et al. 1995). 
 
In animals, mirex is excreted unchanged mainly in the feces; urinary excretion is negligible (Byrd et al. 
1982; Chambers et al. 1982; Gibson et al. 1972; Ivie et al. 1974b).  Female rats receiving a single oral 
dose of 14C-mirex (0.2 mg/kg) excreted 18% of the total administered dose in the feces during a 7-day 
posttreatment period; very little was excreted in the urine (0.3% of the total dose) (Gibson et al. 1972).  
Of the total quantity eliminated, 85% was excreted in the feces within the first 48 hours.  This percentage 
represents unabsorbed material.  The virtual lack of urinary excretion and the fact that fecal excretion was 
only about 3% of the administered dose after the initial 48 hours suggest that mirex is not metabolized in 
rats and that the absorbed portion is only slowly excreted.  In female rats administered a single oral dose 
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of 10 mg/kg mirex, cumulative fecal excretion of mirex during 21 days posttreatment was 18–45% (Byrd 
et al. 1982).  Most of the fecal mirex was excreted within 48 hours and represented unabsorbed mirex.  A 
biological half-life of mirex was estimated to be 460 days by a model developed to simulate mirex 
pharmacokinetics after oral administration (Byrd et al. 1982).  Male rats receiving a single oral dose of 
mirex at 6 mg/kg excreted 58.5% of the administered dose in the feces during 7 days posttreatment 
(Mehendale et al. 1972).  Fifty-five percent of the administered dose was excreted in the feces within the 
first 48 hours post-dosing and probably represented unabsorbed dose from the gut.  Only 0.69% of the 
administered dose was excreted in the urine.  Mirex was the only treatment-related compound identified 
in the urine or feces.  A half-life of 38 hours was estimated based on the first rapid elimination.  A second 
half-life was projected to be >l00 days, indicating a very slow rate of elimination from the body. 
 
Following oral administration of 1 mg/kg 14C-mirex to a female rhesus monkey, 25% of the radioactivity 
was recovered in the feces within 48 hours, with a cumulative excretion of 26.5% over 23 days.  Less than 
1% was recovered in the urine over 23 days (Wiener et al. 1976).  A monohydro derivative of mirex was 
identified in the feces of rhesus monkeys given daily doses of 1 mg/kg mirex; the exact duration of dosing 
was not specified (Stein and Pittman 1977). 
 
The secretion of mirex in milk was a major route of elimination for nursing rat dams given either 1 or 
10 mg/kg/day of mirex via gavage on postpartum days 2–5 (Kavlock et al. 1980).  Mirex entered the milk 
supply more quickly than chlordecone.  Greater amounts of mirex were excreted via the milk as compared 
with chlordecone because of the octanol-water partition coefficient.  Mirex was also excreted in the milk 
of lactating goats given daily doses of 1 mg/kg for 18 or 61 weeks followed by daily doses of 10 mg/kg 
for 4 weeks (Smrek et al. 1977).  The concentration of mirex in colostrum fat ranged from 16 to 20 ppm.  
Colostrum, which is fluid secreted for the first few days after parturition, is characterized by high protein 
and antibody content.  Over 8 weeks, the levels of mirex in milk fat decreased to less than half the amount 
excreted in colostrum immediately after birth of the kids.  The goats eliminated more mirex in colostrum 
than in regular milk.  A lactating Jersey cow given a daily dose equivalent to 0.005 mg/kg/day in the diet 
for 28 days, excreted 50% of the administered dose in the feces during the 28-day exposure period 
(Dorough and Ivie 1974).  Only approximately 3% of the administered dose of mirex was excreted in the 
feces in the 28 days after treatment ended.  These results show that the radioactivity in the feces 
represents unabsorbed mirex, and that the turnover rate of mirex stored in the tissues is very low.  In this 
study, mirex was also found in cow’s milk.  About 10% of the administered dose was excreted in the milk 
10 days after treatment began.  Cumulative excretion in the milk was 13% after 28 days of exposure.  
Only 2% of the administered dose was excreted in the milk during the entire 28-day post-treatment 
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period.  The levels of mirex in milk equilibrated after 1 week of treatment, with the concentration in 
whole milk being 0.058 ppm.  One week after treatment ended, the residues in the milk dropped to 
0.006 ppm and then declined to 0.002 ppm after 28 days (Dorough and Ivie 1974).  Mirex was the only 
treatment-related compound identified in the feces and cow’s milk. 
 
Mirex has a long retention time in the body and is excreted slowly.  Cumulative fecal excretion was 7% of 
the administered dose 21 days following intravenous dosing of 10 mg/kg in rats (Byrd et al. 1982).  
Cumulative urinary excretion was <1% of the administered dose (Byrd et al. 1982).  The biological half-
life of mirex was estimated to be 435 days (Byrd et al. 1982).  Cumulative fecal excretion was 4.69 and 
6.91% of the dose after 106 and 388 days, respectively, following a single intravenous dose of 1 mg/kg to 
female monkeys (Wiener et al. 1976).  Cumulative urinary excretion accounted for 0.18–0.37% of the 
administered dose by the end of 1 week.  Mirex was the only labeled compound identified in the feces.  
An unidentified substance found in the feces was thought to be a decomposition product of mirex, not a 
metabolite (Wiener et al. 1976).  Mirex and an unidentified metabolite, a nonpolar derivative, were found 
in the feces of rhesus monkeys given an intravenous dose of 1 mg/kg of mirex (Stein et al. 1976).  It is 
believed that the suspected metabolite may have arisen as a result of bacterial action in the lower gut or 
feces (Stein et al. 1976). 
 
Chlordecone.  Chlordecone, chlordecone alcohol, and their glucuronide conjugates were excreted in the 
bile and eliminated via the feces of humans occupationally exposed to chlordecone (Blanke et al. 1978; 
Boylan et al. 1979; Cohn et al. 1978; Guzelian et al. 1981).  In the study of Guzelian et al. (1981), most of 
the total chlordecone measured in bile was unconjugated (72%), a small amount (9%) was conjugated 
with glucuronic acid, and the final portion (19%) was present as an uncharacterized “acid releasable” 
form.  Only a minor amount of chlordecone alcohol (<10%) was present in bile as the free metabolite; the 
remainder was conjugated with glucuronide.  A substantial enterohepatic recirculation of chlordecone 
exists that curtails its excretion (Boylan et al. 1979; Cohn et al. 1978; Guzelian et al. 1981).  Only 5–10% 
of the biliary chlordecone entering the lumen of the duodenum appeared in the feces (Cohn et al. 1978; 
Guzelian et al. 1981).  Similarly, the rate of chlordecone excretion in the bile was, on average, 19 times 
greater than the rate of elimination of chlordecone in the stool (Cohn et al. 1978).  Chlordecone was not 
detected in the sweat and was detected in only minor quantities in urine, saliva, and gastric juice (Cohn et 
al. 1978).  Similarly, stool contained 11–34% of the quantities excreted in bile for workers exposed for 
6 months (Boylan et al. 1979).  When biliary contents were diverted, fecal excretion of chlordecone 
alcohol fell to low or undetectable levels; however, chlordecone excretion in feces persisted, suggesting a 
nonbiliary mechanism for the excretion of chlordecone into the intestine and feces (Boylan et al. 1979).  
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Analogous experiments with rats gave similar results (Boylan et al. 1979).  With no bile in the gut, the 
average amount of chlordecone in the human stool in two 72-hour collections was eight times as great as 
with the biliary circuit intact (Boylan et al. 1979).  This suggests that bile may suppress nonbiliary 
excretion of chlordecone.  When bile was completely diverted from the intestines of rats, however, fecal 
excretion of radiolabel was unchanged (Boylan et al. 1979). 
 
In rats, chlordecone is slowly eliminated in the feces (Egle et al. 1978).  Rats given a single oral dose of 
40 mg/kg 14C-chlordecone excreted 65.5% of the administered dose in the feces and 1.6% of the dose in 
the urine by 84 days (Egle et al. 1978).  Less than 1% of the administered dose was expired as 
radiolabeled carbon dioxide (14C-CO2) (Egle et al. 1978).  Rats fed 14C-chlordecone (0.2 mg/kg/day for 
3 days) excreted 52.16% of the radioactivity in the feces and 0.52% in the urine 25 days postdosing 
(Richter et al. 1979). 
 
Chlordecone was excreted in the saliva of rats following administration of 50 mg/kg (Borzelleca and 
Skalsky 1980; Skalsky et al 1980).  Peak levels of chlordecone in saliva were reached 6–24 hours 
postdosing (Borzelleca and Skalsky 1980; Skalsky et al. 1980).  The saliva-to-plasma ratios were 
<1 throughout the study period, indicating that chlordecone is not actively concentrated by the salivary 
glands (Borzelleca and Skalsky 1980).  Thus, chlordecone enters the salivary tissue (submaxillary, 
parotid, and sublingual tissues) and saliva by passive diffusion (Borzelleca and Skalsky 1980; Skalsky et 
al. 1980). 
 
Chlordecone is also excreted in the milk of nursing rats (Kavlock et al. 1980).  When compared with 
mirex-treated rats, chlordecone entered the milk supply more slowly than mirex.  More mirex was 
excreted via the milk than chlordecone because of a higher octanol-water partition coefficient. 
 
Chlordecone was detected in the bile and feces of rats, guinea pigs, hamsters, gerbils, and pigs given 
intraperitoneal doses of 20 mg/kg chlordecone (Houston et al. 1981; Soine et al. 1983).  Rats given 
intraperitoneal injections of chlordecone had a fecal excretion half-life of 40 days (Pore 1984).  
Chlordecone alcohol was detected in the bile and feces of gerbils and pigs only (Houston et al. 1981; 
Soine et al. 1983). 
 
Chlordecone appeared in the bile within 1–3 hours after intravenous dosing of rats (0.1, 1, or 10 mg/kg) 
(Bungay et al. 1981).  The average concentration of chlordecone in the bile varied linearly with dose: 
0.051, 0.50, and 5 μg/g in the low-, middle-, and high-dose groups, respectively (Bungay et al. 1981).  
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Rats given a single intravenous dose of 1 mg/kg had a chlordecone excretion rate in the bile of 0.22% of 
the dose per hour (Bungay et al. 1981). 
 
3.1.5   Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
 
PBPK models use mathematical descriptions of the uptake and disposition of chemical substances to 
quantitatively describe the relationships among critical biological processes (Krishnan et al. 1994).  PBPK 
models are also called biologically based tissue dosimetry models.  PBPK models are increasingly used in 
risk assessments, primarily to predict the concentration of potentially toxic moieties of a chemical that 
will be delivered to any given target tissue following various combinations of route, dose level, and test 
species (Clewell and Andersen 1985).  Physiologically based pharmacodynamic (PBPD) models use 
mathematical descriptions of the dose-response function to quantitatively describe the relationship 
between target tissue dose and toxic endpoints.   
 
PBPK models for mirex have not been developed.  Several models were developed for chlordecone.  
Bungay et al. (1979) developed a model to predict the kinetics of chlordecone in the gastrointestinal tract 
by comparing excretion following oral administration to intact rats and intravenous administration to bile-
cannulated rats.  Heatherington et al. (1998) used experimental data from chlordecone-treated young and 
adult rats to predict percutaneous absorption and disposition.  El-Masri et al. (1995) evaluated interactions 
between chlordecone and carbon tetrachloride in the rat liver using pharmacokinetic and 
pharmacodynamic modeling.  Belfiore et al. (2007) developed a model to describe sequestration of 
chlordecone in the rat liver.  None of the models are useful for predicting the toxicokinetic behavior or 
target concentrations of chlordecone in humans. 
 
3.1.6   Animal-to-Human Extrapolations  
 
The toxicokinetics of mirex has been widely studied in experimental animals (Atallah and Dorough 1975; 
Brown and Yarbrough 1988; Byrd et al. 1982; Chambers et al. 1982; Dorough and Atallah 1975; Gibson 
et al. 1972; Ivie et al. 1974b; Kavlock et al. 1980; Mehendale et al. 1972; Morgan et al. 1979; Plaa et al. 
1987; Smrek et al. 1977; Wiener et al. 1976).  Available data demonstrate that mirex accumulates in 
tissues (particularly fat), is not metabolized, and is slowly excreted in feces.  Most animal studies were 
conducted using rats.  A few studies using monkeys, goats, or cows yielded results generally similar to 
those reported for rats.  Limited human data have not identified or quantified the toxicokinetics of mirex 
(Burse et al. 1989; Kutz et al. 1974; Mes et al. 1978).  No information was located to indicate that the 
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toxicokinetics of mirex in humans would be significantly different from that observed in experimental 
animals. 
 
Toxicokinetic studies have been performed using multiple animal species; the data indicate that rats, 
guinea pigs, and hamsters may not represent appropriate models for extrapolation to humans because 
these animal species do not convert chlordecone to chlordecone alcohol (Fariss et al. 1980; Guzelian et al. 
1981; Houston et al. 1981).  Gerbils and pigs may be more appropriate species to study animal-to-human 
extrapolation because these species convert chlordecone to chlordecone alcohol (Houston et al. 1981; 
Soine et al. 1983).  Limited human toxicokinetic data are available for chlordecone (Adir et al. 1978; 
Blanke et al. 1978; Boylan et al. 1978; Cannon et al. 1978; Cohn et al. 1978; Guzelian et al. 1981; Taylor 
1982, 1985).  It does not appear that sufficient data exist to provide meaningful extrapolation from 
animals to humans with respect to chlordecone toxicokinetics. 
 
3.2   CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
 
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans.  Potential effects on offspring resulting from exposures of parental 
germ cells are considered, as well as any indirect effects on the fetus and neonate resulting from maternal 
exposure during gestation and lactation.  Children may be more or less susceptible than adults to health 
effects from exposure to hazardous substances and the relationship may change with developmental age.   
 
This section also discusses unusually susceptible populations.  A susceptible population may exhibit 
different or enhanced responses to certain chemicals than most persons exposed to the same level of these 
chemicals in the environment.  Factors involved with increased susceptibility may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  
These parameters can reduce detoxification or excretion or compromise organ function.   
 
Populations at greater exposure risk to unusually high exposure levels to mirex or chlordecone are 
discussed in Section 5.7, Populations with Potentially High Exposures. 
 
Review of the literature regarding toxic effects of mirex and chlordecone did not reveal any human 
populations that are known to be unusually sensitive to mirex or chlordecone.  However, based on 
knowledge of the toxicities of mirex and chlordecone, some populations can be identified that may 
demonstrate unusual sensitivity to these chemicals.  Those with potentially high sensitivity to mirex 
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include the very young.  Those with potentially high sensitivity to chlordecone include juvenile and 
elderly persons as well as persons being treated with some antidepressants or the anticonvulsant, 
diphenylhydantoin. 
 
In experimental animals, mirex administered within the week after birth causes a high incidence of 
cataracts and other lesions of the lens (Chernoff et al. 1979b; Gaines and Kimbrough 1970; Rogers and 
Grabowski 1984; Scotti et al. 1981).  These effects were observed whether the neonatal animals received 
mirex through the milk of lactating dams or directly by gavage.  Although it is unclear whether the lens of 
humans also undergoes a similar period of susceptibility, the possibility exists that newborn children may 
also develop cataracts if exposed to mirex shortly after birth. 
 
Studies in rats have demonstrated that certain treatments exacerbate the tremors associated with 
chlordecone exposure.  These include pretreatment with the anticonvulsant, diphenylhydantoin (Hong et 
al. 1986; Tilson et al. 1985, 1986b), and treatment with the non-selective serotonergic receptor agonist, 
quipazine (Gerhart et al. 1983).  Therefore, persons being treated with diphenylhydantoin for epilepsy or 
quipazine for depression may be likely to experience more severe tremors upon exposure to high levels of 
chlordecone.  Extrapolating from the effects seen in animals with quipazine, it might be likely that 
persons taking the prescription drug Prozac®, a selective serotonin reuptake inhibitor (SSRI) used to treat 
depression, may also experience more severe tremors.  Furthermore, the elderly may be a susceptible 
population because serotonin metabolism is increased during aging (Walker and Fishman 1991). 
 
Studies in animals have also shown that juvenile animals experience a higher death rate than adults 
following exposure to chlordecone at equivalent mg/kg doses (Huber 1965).  No explanation was given 
for these findings, but similar sensitivities may exist in children.  Furthermore, although inhibition of 
Na+K+ATPase, Mg2+ATPase, and Ca2+ATPase activities have not been definitively shown to be the 
mechanism underlying chlordecone toxicity, sufficient evidence exists to suggest that their inhibition may 
be involved in a number of adverse effects.  Neonatal rats have shown a greater inhibition of these 
enzymes than adult rats (Jinna et al. 1989).  This provides additional support for the suggestion that 
infants and young children may represent a susceptible population to the toxic effects of chlordecone. 
 
In contrast, a recent study of developing postnatal rats has shown that the young may be less susceptible 
to at least one of the toxic effects of chlordecone.  Young and adolescent rats show less potentiation of 
carbon tetrachloride toxicity than adult rats (Cai and Mehendale 1993).  This may be due to a combination 
of incomplete development of the microsomal enzyme systems and a higher level of hepatic regenerating 
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activity in the very young rats.  In adolescent rats (35 and 45 days old), the microsomal enzyme activity is 
comparable to adult levels, but the level of damage is still less than in adult rats (60 days old).  This may 
be due to that fact that hepatic regenerating activity remained higher in the adolescents than in the adults. 
 
Several studies (Dalu and Mehendale 1996; Dalu et al. 1995, 1998; Murali et al. 2004) provide additional 
insight to earlier findings of age-related differences in the lethality and hepatotoxicity induced by 
exposure of rats to nontoxic levels of chlordecone and subsequent exposure to otherwise nonlethal levels 
of carbon tetrachloride.  Results of Blain et al. (1999) indicate both sex- and age-dependent influences on 
chlordecone-carbon-tetrachloride-induced hepatotoxicity in rats. 
 
In studies performed by Sobel and coworkers (Sobel et al. 2005, 2006; Wang et al. 2008), chronic 
exposure of systemic lupus erythematosus-prone female (NZB x NZW) F1 mice to chlordecone via 
subcutaneously-implanted pellets significantly shortened the time to onset of elevated autoantibody titers 
and renal disease in a dose-related manner.  These effects were not seen in nonlupus-prone BALB/c mice.  
These results indicate that humans with lupus may be particularly sensitive to chlordecone toxicity. 
 
3.3   BIOMARKERS OF EXPOSURE AND EFFECT  
 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as biomarkers of exposure, biomarkers of effect, and biomarkers of susceptibility 
(NAS/NRC 1989). 
 
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction 
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment 
of an organism (NAS/NRC 1989).  The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta.  Biomarkers of 
exposure to mirex or chlordecone are discussed in Section 3.3.1.  The National Report on Human 
Exposure to Environmental Chemicals provides an ongoing assessment of the exposure of a generalizable 
sample of the U.S. population to environmental chemicals using biomonitoring (see 
http://www.cdc.gov/exposurereport/).  If available, biomonitoring data for mirex or chlordecone from this 
report are discussed in Section 5.6, General Population Exposure.   
 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that (depending on magnitude) can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
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tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effect caused 
by mirex or chlordecone are discussed in Section 3.3.2. 
 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.2, Children and Other Populations that are Unusually Susceptible. 
 
3.3.1   Biomarkers of Exposure 
 
The primary biomarkers of exposure to mirex include mirex concentrations in blood (Butler Walker et al. 
2003; Byrd et al. 1982; Fenster et al. 2006; Greizerstein et al. 1999; Kavlock et al. 1980; Schell et al. 
2003; Smrek et al. 1977; van Oostdam et al. 2004; Wiener et al. 1976), fat (Burse et al. 1989; Kutz et al. 
1974), feces (Byrd et al. 1982; Chambers et al. 1982; Gibson et al. 1972; Ivie et al. 1974b), or breast milk 
(Dorough and Ivie 1974; Fitzgerald et al. 2001; Greizerstein et al. 1999; Kavlock et al. 1980; Mes et al. 
1978; Newsome and Ryan 1999; Newsome et al. 1995; Smrek et al. 1977).  Since mirex is not 
metabolized, it is the only biomarker to be measured in these biological media.  Since mirex is retained in 
the body for long periods of time and only slowly excreted, its measurement is useful as a biomarker of 
acute-, intermediate-, or chronic-duration exposures to both low and high levels. 
 
The biomarkers of exposure to chlordecone include blood or saliva concentrations of chlordecone, and 
fecal or bile concentrations of chlordecone, chlordecone alcohol, and/or their glucuronide conjugates.  
Blood samples are the most useful tool for epidemiological studies of exposure to chlordecone (Guzelian 
et al. 1981).  The unusually high concentration of chlordecone in blood compared with its concentration 
in fat (1:7 in humans), which is due to chlordecone’s association with plasma proteins, and its long half-
life, make chlordecone in blood (a readily sampled tissue) a good biomarker of exposure.  The blood 
concentration of chlordecone serves as an accurate reflection of total body content of chlordecone.  Blood 
is the best biological material to monitor and to use for determining acute, intermediate, and chronic 
exposures to both low and high levels of chlordecone. 
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Blood is a better indicator of exposure to chlordecone than saliva (Borzelleca and Skalsky 1980; Skalsky 
et al. 1980).  Chlordecone has been detected in saliva of humans only in trace amounts and in rats at 
concentrations 3–4 times lower than in blood (Guzelian et al. 1981; Skalsky et al. 1980).  Peak 
chlordecone concentrations occurred within the first 24 hours of exposure; therefore, the period of utility 
of saliva as a biomarker is limited.  The movement of chlordecone from blood into saliva is one of passive 
diffusion and is not concentration dependent (Borzelleca and Skalsky 1980; Skalsky et al. 1980).  Thus, 
blood is a better biological material than saliva for monitoring chlordecone exposure. 
 
Other biomarkers of exposure include tissue concentrations of chlordecone (Bungay et al. 1981; Cannon 
et al. 1978; Cohn et al. 1978; Egle et al. 1978; Hewitt et al. 1986b; Plaa et al. 1987; Taylor 1982, 1985) 
and fecal or bile concentrations of chlordecone, chlordecone alcohol, and their glucuronide conjugates 
(Blanke et al. 1978; Boylan et al. 1979; Cohn et al. 1978; Guzelian et al. 1981).  These can be measured 
and are reliable indicators of exposure to chlordecone. 
 
3.3.2   Biomarkers of Effect 
 
Microsomal enzyme induction has been shown to be increased by both mirex and chlordecone in humans 
and/or experimental animals.  Serum levels of chlordecone associated with enzyme induction in exposed 
workers were estimated to range from 100 to 500 μg/L (Guzelian 1985).  Urinary D-glucaric acid levels 
have been shown to be a sensitive indicator of microsomal enzyme induction in workers exposed to 
chlordecone (Guzelian 1985).  However, other substances such as barbiturates, phenytoin, chlorbutanol, 
aminopyrine, phenylbutazone, and contraceptive steroids as well as other organochlorinated pesticides 
also cause microsomal enzyme induction and cause changes in urinary D-glucaric acid (Morgan and Roan 
1974). 
 
Studies in experimental animals suggest that biliary excretion of chemicals from the liver may be 
impaired by mirex or chlordecone (Berman et al. 1986; Curtis and Hoyt 1984; Curtis and Mehendale 
1979; Curtis et al. 1979b, 1981; Davison et al. 1976; Mehendale 1976, 1977b, 1977c, 1981b; Teo and 
Vore 1991).  Measurement of serum bile acid levels may provide information regarding biliary excretory 
function. 
 
Studies in experimental animals have also shown increased urinary protein accompanied or 
unaccompanied by histopathological changes of the kidneys following exposure to mirex (NTP 1990) or 
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chlordecone (Larson et al. 1979b).  Although these changes are not specific for mirex or chlordecone, 
measurement of these parameters may provide information about renal damage in exposed populations. 
 
Chlordecone causes a number of neurotoxic responses in humans and animals exposed to sufficiently high 
levels.  Tremor accentuated by intentional acts, sustained postural movement, anxiety, and/or fatigue have 
been observed in workers exposed to high levels of chlordecone.  Tremorograms have been used to 
objectively assess tremors associated with chlordecone exposure in humans (Taylor et al. 1978).  An 
infrared reflection technique and oculography have been used to assess oculomotor disturbances caused 
by chlordecone (Taylor et al. 1978).  Standard tests for memory and intelligence can be used to determine 
the presence of encephalopathy, but in the absence of baseline preexposure levels for individuals, subtle 
changes may be difficult to detect. 
 
Decreased sperm count has been observed following exposure to mirex or chlordecone in humans and/or 
experimental animals.  Clinically, the most straightforward biomarker would be examination of sperm in 
the ejaculate.  However, testicular biopsies may also be helpful.  Both procedures have been used to 
assess the male reproductive toxicity of chlordecone in exposed persons (Taylor et al. 1978). 
 
3.4   INTERACTIONS WITH OTHER CHEMICALS  
 
Limited data are available regarding interactions with other chemicals that affect the toxicity of mirex or 
chlordecone.  Selected agents have been shown to exacerbate or suppress chlordecone-induced tremors in 
laboratory animals.  Pretreatment of rats with diphenylhydantoin resulted in exacerbation of chlordecone-
induced tremors (Hong et al. 1986; Tilson et al. 1985, 1986b).  The mechanism for the exacerbation of the 
tremors is unknown.  Therefore, if persons receiving diphenylhydantoin treatment for epilepsy were 
exposed to sufficiently high concentrations of chlordecone, increased tremor severity may be likely to 
occur.  Treatment with quipazine (a nonselective serotonergic receptor agonist) was shown to potentiate 
chlordecone-induced tremors in rats (Gerhart et al. 1983).  Therefore, it is possible that persons being 
treated for depression with quipazine or with SSRIs such as Prozac® may experience enhanced tremors. 
 
A number of pharmacological agents have been shown to decrease the tremors produced by chlordecone 
in rats (Gerhart et al. 1983, 1985; Herr et al. 1987).  Agents shown to be effective in at least one study 
include yohimbe or phenoxybenzamine (α-noradrenergic antagonists), mecamylamine (a nicotinic 
antagonist), chlordiazepoxide (α benzodiazepine), muscimol (a GABA agonist), and mephenesin (a 
MIREX AND CHLORDECONE  148 
 
3.  TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
centrally acting muscle relaxant).  Persons being treated therapeutically with any of these drugs are likely 
to experience diminished tremors following exposure to chlordecone. 
 
Pretreatment of rats with difluoromethylomithine (DFMO), an inhibitor of ornithine decarboxylase, prior 
to exposure to a tremorgenic dose of chlordecone, also resulted in inhibition of the tremor (Tilson et al. 
1986b).  DFMO was more effective if given 5 hours prior to the chlordecone than if given 24 hours prior 
to exposure.  The DFMO was ineffective if given 19 hours after chlordecone exposure.  These results 
suggest an interaction of the polyamine synthetic pathway with tremors produced by chlordecone.  The 
mechanism of the interaction is unclear, but may involve effects of polyamines on intracellular calcium 
homeostasis.  Persons being treated with DFMO for cancer or protozoal infections would be likely to 
have reduced tremor severity after exposure to chlordecone. 
 
Cholestyramine, a chelating agent, binds chlordecone present in the gastrointestinal tract and limits its 
enterohepatic recirculation (Boylan et al. 1978; Cohn et al. 1978).  This interaction leads to increased 
excretion of chlordecone and decreased toxicity.  Thus, persons being treated with cholestyramine to 
lower plasma cholesterol may experience increased excretion of chlordecone and decreased toxicity. 
 
A number of animal studies have focused on effects of chlordecone on toxicity produced by other agents.  
Although these studies do not address the issue of interactions that affect chlordecone toxicity, results are 
summarized below. 
 
By far, the most extensively studied interaction of mirex or chlordecone is the ability of chlordecone to 
markedly potentiate the hepatotoxicity of halomethanes such as carbon tetrachloride (Agarwal and 
Mehendale 1983c; Bell and Mehendale 1985; Chaudhury and Mehendale 1991; Curtis et al. 1979b, 1981; 
Davis and Mehendale 1980; Klingensmith and Mehendale 1981, 1982b, 1983a, 1983b; Klingensmith et 
al. 1983; Kodavanti et al. 1989a, 1990a, 1991; Lockard et al. 1983a, 1983b; Mehendale and Klingensmith 
1988; Soni and Mehendale 1993; Tabet et al. 2016), bromotrichloromethane (Agarwal and Mehendale 
1982; Faroon and Mehendale 1990; Faroon et al. 1991; Klingensmith and Mehendale 1981), and 
chloroform (Cianflone et al. 1980; Hewitt et al. 1979, 1983, 1986a, 1986b, 1990; Iijima et al. 1983; 
Mehendale et al. 1989; Purushotham et al. 1988).  For example, pretreatment of rats with 5 mg/kg 
chlordecone resulted in a 67-fold increase in carbon tetrachloride-induced lethality due to liver failure 
(Klingensmith and Mehendale 1982b).  The increase in hepatotoxicity is characterized by increased serum 
enzymes, extensive necrosis, increased destruction of CYP450 isozymes, and decreased biliary function.  
The potentiation of hepatotoxicity does not appear to be due solely to increased metabolism of the 
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haloalkanes to toxic intermediates (CCl3, free radical and phosgene) and, as such, is distinct from the 
potentiation of halomethane toxicity by phenobarbital (Agarwal and Mehendale 1984a, 1984d; Bell and 
Mehendale 1987; Klingensmith and Mehendale 1983a, 1983b; Mehendale and Klingensmith 1988; 
Mehendale et al. 1990) or mirex (Bell and Mehendale 1985; Cianflone et al. 1980; Hewitt et al. 1979, 
1986a; Mehendale and Klingensmith 1988; Mehendale et al. 1989; Purushotham et al. 1988). 
 
Several studies (Dalu and Mehendale 1996; Dalu et al. 1995, 1998; Murali et al. 2004) provide additional 
insight to findings of age-related differences in the lethality and hepatotoxicity induced by exposure of 
rats to nontoxic levels of chlordecone and subsequent exposure to otherwise nonlethal levels of carbon 
tetrachloride (Cai and Mehendale 1993).  Results of Blain et al. (1999) indicate both sex- and age-
dependent influences on chlordecone-carbon tetrachloride induced hepatotoxicity in rats. 
 
The primary mechanism for potentiation of hepatotoxicity may be the suppression of the early tissue 
regenerative response normally seen in livers of rats and mice exposed to low doses of halomethanes 
(Mehendale 1992, 1994).  The dramatic increase in mitotic activity that normally occurs soon after 
halomethane exposure does not occur in chlordecone-pretreated animals (Faroon and Mehendale 1990; 
Lockard et al. 1983b).  Gerbils, which do not exhibit early hepatocellular regeneration following 
halomethane exposure (and thus are more susceptible to the toxic and lethal effects of halomethanes), do 
not exhibit potentiation following chlordecone pretreatment (Cai and Mehendale 1990, 1991b).  
Experiments performed with partially hepatectomized animals provide further evidence for the role of 
suppressed regeneration following carbon tetrachloride exposure (Cai and Mehendale 1991a).  Partial 
hepatectomy, which stimulates tissue regeneration, afforded partial protection from the potentiating 
effects of chlordecone in rats (Bell et al. 1988; Rao et al. 1989; Young and Mehendale 1989).  Similarly, 
Cai and Mehendale (1993) have shown that young rats with greater hepatocellular regenerative activity 
than adult rats also experience less hepatocellular damage following exposure to both chlordecone and 
carbon tetrachloride.  Cellular changes that may facilitate the chlordecone-induced suppression of 
regeneration include marked depletion of hepatocellular glycogen (Bell and Mehendale 1987; Faroon et 
al. 1991; Lockard et al. 1983a, 1983b), depletion of ATP (Faroon et al. 1991; Kodavanti et al. 1990a), and 
disruptions in the regulation of intracellular calcium (Agarwal and Mehendale 1984a, 1984c, 1984d, 
1986; Hegarty et al. 1986; Kodavanti et al. 1991).  It has been demonstrated that suppression of cell 
division due to glycogen depletion results in decreased ATP availability and, consequently, suppressed 
cellular regeneration (Soni and Mehendale 1993, 1994). 
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Both mirex and chlordecone are microsomal enzyme inducers, and as such, enhance the metabolism of 
compounds oxidized or reduced by the mixed function oxygenase system.  For example, the metabolism 
of lindane was enhanced in rats previously exposed to chlordecone (Chadwick et al. 1979).  For chemicals 
that undergo a loss of activity with metabolism, a decrease in effectiveness would be likely in mirex- or 
chlordecone-exposed persons.  For example, pretreatment of rats with chlordecone reduced the 
cholinesterase inhibition produced by a subsequent dose of methyl parathion (Tvede et al. 1989).  In this 
study, methyl parathion was apparently metabolized to its active metabolite, methyl paraoxon, and the 
methyl paraoxon was further metabolized to an inactive metabolite.  For chemicals that undergo a 
transformation to an active or toxic metabolite, enhanced activity/toxicity would be likely in mirex- or 
chlordecone-exposed persons.  An example of this type of interaction was shown in the enhancement of 
acetaminophen toxicity by 30 mg/kg of mirex or chlordecone (Fouse and Hodgson 1987).  
Acetaminophen causes hepatic necrosis as the result of the binding of the reactive intermediate, 
postulated to be N-acetylquinoneimine, formed by the microsomal CYP450 dependent monooxygenase 
system.  Mirex and chlordecone increased the activity of this system, and as a result, the toxicity of the 
acetaminophen was increased. 
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CHAPTER 4.  CHEMICAL AND PHYSICAL INFORMATION 
 
4.1   CHEMICAL IDENTITY 
 
Information regarding the chemical identity of mirex and chlordecone is located in Table 4-1. 
 
Table 4-1.  Chemical Identity of Mirex and Chlordeconea 
 
Characteristic 
Information 
Mirex Chlordecone 
Chemical name 1,1a,2,2,3,3a,4,5,5,5a,5b,6-Dodeca-
chlorooctahydro-1,3,4-metheno-
1H-cyclobuta[cd]- pentalene 
1,1a,3,3a,4,5,5,5a,5b,6-Deca-
chlorooctahydro-1,3,4- metheno-
2H-cyclobuta[cd] pentalen-2-one 
Synonym(s) and registered 
trade name(s) 
1,2,3,4,5,5-Hexachloro-
1,3-cyclopentadiene dimerb; 
dodecachlorooctahydro-
1,3,4-metheno-1H-cyclobuta[cd] 
pentaleneb 
 
CG-1283; Dechlorane; HRS1276bd; 
ENT 25719e 
Decachloroketonec; decachloro-
octahydro-1,3,4-metheno-
2H-cyclobuta[cd]pentalen-2-onec 
 
GC 1189; ENT16391d; Kepone; 
Merexc 
Chemical formula C10Cl12 C10Cl10O 
Chemical structure 
  
CAS Registry Number  2385-85-5 143-50-0 
 
aAll information obtained from Merck 1989, except where noted. 
bIARC 1979c 
cIARC 1979a 
dSittig 1985 
eHSDB 1994b 
 
CAS = Chemical Abstracts Service  
 
4.2   PHYSICAL AND CHEMICAL PROPERTIES  
 
Information regarding the physical and chemical properties of mirex and chlordecone is located in 
Table 4-2. 
  
CCl
CCl CCl
CCl
CCl
CCl
CCl
CCl2
CCl2
CCl
CCl
CCl CCl
CCl
CCl
CCl
CCl
C
CCl2
CCl
O
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Table 4-2.  Physical and Chemical Properties of Mirex and Chlordecone 
 
Property 
Information 
Mirex Chlordecone 
Molecular weight 545.59 490.68 
Color Snow-white Tan-whiteb 
Physical state Crystalline solid Crystalline solid 
Melting point 485°C (decomposes) 350°C (decomposes)b 
Boiling point No data No data 
Density at 25°C No data No data 
Odor Odorlessc Odorlesse 
Odor threshold 5.0667 mg/m3 d  
Solubility:   
 Water Practically insoluble 
0.60 mg/Lf 
insolubleg 
0.2 mg/L at 24°C (practical grade)g 
Slightly soluble 
3.0 mg/Lf  
practically insolubleb 
 Organic solvents Dioxane (15.3%); xylene (14.3%); 
benzene (12.2%); CCl4 (7.2%); 
methyl ethyl ketone (5.6%) 
Soluble in hydrocarbon solvents, 
alcohols, ketones 
Partition coefficients:   
 Log Kow 5.28h 4.50i 
 Log Koc 3.763f 3.38–3.415i 
Vapor pressure at 25°C 3x10-7 mm Hgg <3x10-7 mm Hgb 
Henry's law constant:   
 at 20°C 839.37 Pa m3/molej 2.50x10-8 atm 
 At 22°C 5.16x10-4 atm m3/molek m3/molei 
Autoignition temperature Nonflammableb Nonflammable 
Flashpoint No data No data 
Flammability limits Nonflammabled 
Supports combustion 
Nonflammable 
Conversion factors 1 ppm=0.041 mg/m3 1 ppm=0.046 mg/m3 
Explosive limits No data No data 
 
aAll information obtained from Merck 1989, except where noted. 
bIARC 1979a 
cSittig 1985 
dHSDB 1994b 
eVerschueren 1983 
fKenaga 1980 
gIARC 1979c 
hNiimi 1991 
iHoward 1991 
jDomine et al. 1992 
kYin and Hassett 1986 
 
CCl4 = carbon tetrachloride 
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CHAPTER 5.  POTENTIAL FOR HUMAN EXPOSURE 
 
5.1   OVERVIEW  
 
Mirex has been identified in at least 9 of the 1,854 hazardous waste sites that have been proposed for 
inclusion on the EPA National Priorities List (NPL) (ATSDR 2017).  However, the number of sites in 
which mirex has been evaluated is not known.  The number of sites in each state is shown in Figure 5-1.  
Of these sites, 40 are located within the United States. 
 
Figure 5-1.  Number of NPL Sites with Mirex Contamination 
 
 
Chlordecone has been identified in at least 4 of the 1,854 hazardous waste sites that have been proposed 
for inclusion on the EPA National Priorities List (NPL) (ATSDR 2017).  However, the number of sites in 
which mirex has been evaluated is not known.  The number of sites in each state is shown in Figure 5-2.  
Of these sites, 4 are located within the United States. 
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Figure 5-2.  Number of NPL Sites with Chlordecone Contamination 
 
 
• The most likely source of potential exposure of the general population to mirex or chlordecone is 
from consumption of contaminated food sources, particularly in the eastern portion of the United 
States where mirex and chlordecone were most frequently used. 
• People who live or work near hazardous waste sites where mirex and/or chlordecone may be 
stored could most likely be exposed from contaminated sediment or soil. 
• Both mirex and chlordecone bind strongly to organic matter in water, sediment, and soil where 
they may persist for long periods of time. 
• Both mirex and chlordecone are lipophilic and bioaccumulate and biomagnify in aquatic and 
terrestrial food chains. 
 
As a result of human health concerns, production of mirex ceased in 1976, at which time industrial 
releases of this chemical to surface waters were also curtailed.  However, releases from waste disposal 
sites continue to add mirex to the environment.  Virtually all industrial releases of mirex were to surface 
waters, principally Lake Ontario via contamination of the Niagara and Oswego Rivers.  About 75% of the 
mirex produced was used as a fire retardant additive, while 25% was used as a pesticide.  As a pesticide, 
mirex was widely dispersed throughout the southern United States where it was used in the fire ant 
eradication program for over 10 years. 
 
Adsorption and volatilization are the more important environmental fate processes for mirex, which 
strongly binds to organic matter in water, sediment, and soil.  When bound to organic-rich soil, mirex is 
highly immobile; however, when adsorbed to particulate matter in water, it can be transported great 
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distances before partitioning out to sediment.  Atmospheric transport of mirex has been reported based on 
its detection in remote areas without anthropogenic sources, although this is not a major source of mirex 
in the environment.  Given the lipophilic nature of this compound (high octanol-water partition 
coefficient), mirex is both bioaccumulated and biomagnified in aquatic and terrestrial food chains. 
 
Mirex is a very persistent compound in the environment and is highly resistant to both chemical and 
biological degradation.  The primary process for the degradation of mirex is photolysis in water or on soil 
surfaces; photomirex is the major transformation product of photolysis.  In soil or sediments, anaerobic 
biodegradation is also a major removal mechanism whereby mirex is slowly dechlorinated to the 
10-monohydro derivative.  Aerobic biodegradation in soil is a very slow and minor degradation process.  
Twelve years after the application of mirex to soil, 50% of the mirex and mirex-related compounds 
remained on the soil.  Between 65 and 73% of the residues recovered were mirex and 3–6% were 
chlordecone, a transformation product (Carlson et al. 1976). 
 
Mirex has been detected at low concentrations in ambient air (mean 0.35 pg/m3) and rainfall samples 
(<0.5 ng/L) from polluted areas of the Great Lakes region.  In addition, the compound has been detected 
in drinking water samples from the Great Lakes area of Ontario, Canada.  Mirex has also been detected in 
groundwater samples from agricultural areas of New Jersey and South Carolina. 
 
Mirex has been monitored in surface waters, particularly during the period that it was still being 
produced.  Concentrations of mirex in Lake Ontario, the Niagara River, and the St. Lawrence River were 
in the ng/L (ppt) range.  The highest concentrations of mirex, 1,700 μg/kg (ppb), were found in sediments 
in Lake Ontario where they accumulated after the deposition of particulate matter to which the mirex was 
bound.  A dynamic mass balance for mirex in Lake Ontario and the Gulf of St. Lawrence estimated that 
approximately 2,700 kg (6,000 pounds) of mirex have entered Lake Ontario over the past 40 years, of 
which 550 kg (1,200 pounds) have been removed (exclusive of sedimentation and burial) mainly by 
transport on sediment particles via outflowing water and migrating biota contaminated with mirex. 
 
The high bioconcentration factor (BCF) values (up to 15,000 for rainbow trout) observed for mirex 
indicate that this compound will be found in high concentrations in aquatic organisms that inhabit areas 
where the water and sediments are contaminated with mirex.  Fish taken from Lake Ontario, the St. 
Lawrence River, and the southeastern United States (areas where mirex was manufactured or used as a 
pesticide) had the highest mirex levels.  There were fish consumption advisories in effect in three states 
(New York, Pennsylvania, and Ohio) that were triggered by mirex contamination in fish.  Waterfowl and 
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game animals have also been found to accumulate mirex in their tissues.  Data on mirex residues in foods 
do not show a consistent trend with regard to contaminant levels or frequency of detection.  Mirex has 
been irregularly detected in Food and Drug Administration (FDA) Pesticide Residue Monitoring Studies 
since 1978.  Little information on the specific foods in which residues were found or levels detected was 
located. 
 
General population exposure to mirex has been determined as a result of several monitoring studies (EPA 
1986b; Kutz et al. 1979; Stehr-Green 1989).  Levels of mirex in most tissues are very low (at or near the 
detection limit).  Examination of the 1982 National Adipose Tissue Survey failed to detect mirex in the 
adipose tissues of children <14 years old, although mirex residues were detected in adults.  People who 
live in areas where mirex was manufactured or used have higher levels in their tissues.  Women who live 
in these areas were found to have detectable levels of mirex in their milk that could be passed on to their 
infants.  Since mirex is no longer manufactured, occupational exposure currently is limited to workers at 
waste disposal sites or those involved in remediation activities involving the clean-up and removal of 
contaminated soils or sediments. 
 
Production of chlordecone ceased in 1975 as a result of human health concerns; at that time industrial 
releases of this chemical to surface waters via a municipal sewage system were curtailed.  However, 
releases from waste disposal sites may continue to add chlordecone to the environment.  Major releases of 
chlordecone occurred to the air, surface waters, and soil surrounding a major manufacturing site in 
Hopewell, Virginia.  Releases from this plant ultimately contaminated the water, sediment, and biota of 
the James River, a tributary to the Chesapeake Bay. 
 
Atmospheric transport of chlordecone particles was reported during production years based on results 
from high volume air samplers installed at the site and up to 15.6 miles away.  Chlordecone is not 
expected to be subject to direct photodegradation in the atmosphere.  Chlordecone is very persistent in the 
environment.  Chlordecone, like mirex, will strongly bind to organic matter in water, sediment, and soil.  
When bound to organic-rich soil, chlordecone is highly immobile; however, when adsorbed to particulate 
matter in surface water, chlordecone can be transported great distances before partitioning out to 
sediment.  Sediment in extensive areas of the James River served as a sink or reservoir for this compound.  
The primary process for the degradation of chlordecone in soil or sediments is anaerobic biodegradation.  
Based on the lipophilic nature of this compound (high octanol-water partition coefficient), chlordecone 
has a tendency to both bioaccumulate and biomagnify in aquatic food chains.  BCF values >60,000 have 
been measured in Atlantic silversides, an estuarine fish species. 
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No information was found on atmospheric concentrations of chlordecone other than historic monitoring 
data from samples collected in the vicinity of the manufacturing site.  Chlordecone has been monitored in 
surface waters, particularly during the period shortly before and after production was terminated.  In 
1977, chlordecone was detected in surface water samples from the James River at low concentrations 
(<10 ng/L [ppt]), although it was not detected in more recent monitoring studies.  The highest 
concentrations of this compound are found in sediments, principally in the James River where it had 
accumulated after the deposition of particulate matter to which the chlordecone was bound.  In 1978, 
chlordecone was detected in sediments from the James River below its production site at concentrations 
in the mg/kg (ppm) range. 
 
The high BCF values observed for chlordecone (>60,000) indicate that the compound will be found in 
high concentrations in aquatic organisms that dwell in waters or sediments contaminated with 
chlordecone.  Chlordecone has been detected in fish and shellfish from the James River, which empties 
into the Chesapeake Bay, at levels in the μg/g (ppm) range.  There was a fish consumption advisory in 
effect for the lower 113 miles of the James River.  Chlordecone residues were detected in foods analyzed 
in 1978–1982 and 1982–1986 as part of the FDA Pesticide Residue Monitoring Studies.  Chlordecone 
was detected in one of 27,065 food samples analyzed by 10 state laboratories, but was not detected in the 
FDA Pesticide Residue Monitoring Studies in 1986–1991.  No information on the specific foods in which 
residues were found or levels detected was located. 
 
General population exposure to chlordecone has not been determined because this compound has not been 
monitored in any national program (EPA 1986b; Kutz et al. 1979; Phillips and Birchard 1991a; Stehr-
Green 1989).  Levels of chlordecone were detected in 9 of 298 samples of human milk collected from 
women in the southern United States.  Residues were detected only in residents of areas that had been 
extensively treated with the pesticide mirex for fire ant control.  People who lived in the area where 
chlordecone was manufactured had higher levels in their blood during production years.  Women who 
lived in these areas could pass chlordecone in their milk on to their infants.  Workers who manufactured 
chlordecone developed an occupationally-related illness.  However, chlordecone is no longer 
manufactured, so occupational exposure is limited to workers at waste disposal sites or those involved in 
remediation activities involving the clean-up and removal of contaminated soils or sediments. 
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5.2   PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
 
5.2.1   Production 
 
No information is available in the TRI database on facilities that manufacture or process mirex and 
chlordecone because these chemicals are not required to be reported under Section 313 of the Emergency 
Planning and Community Right-to-Know Act (Title III of the Superfund Amendments and 
Reauthorization Act of 1986) (EPA 2005). 
 
Mirex is not known to occur in the environment as a natural product (IARC 1979c; Waters et al. 1977b).  
Although it was originally synthesized in 1946, mirex was not commercially introduced in the United 
States until 1959, when it was produced by the Allied Chemical Company under the name GC-1283 for 
use in pesticide formulations and as an industrial fire retardant under the trade name Dechlorane® (EPA 
1978b; IARC 1979c; Waters et al. 1977b).  Mirex was produced as a result of the dimerization of 
hexachlorocyclopentadiene in the presence of an aluminum chloride catalyst (IARC 1979c; Sittig 1980). 
 
The technical grade of mirex consisted of a white crystalline solid in two particle size ranges, 5–10 and 
40–70 microns (IARC 1979c).  Technical-grade preparations of mirex contained 95.18% mirex, with 
2.58 mg/kg chlordecone as a contaminant (EPA 1978b; WHO 1984a).  Several formulations of mirex 
have been prepared in the past for various pesticide uses.  Some of the more commonly used formulations 
of mirex used as baits were made from corn cob grit impregnated with vegetable oil and various 
concentrations of mirex.  Insect bait formulations for aerial or ground applications contained 0.3–0.5% 
mirex, and fire ant formulations contained 0.075–0.3% mirex (IARC 1979c). 
 
Mirex is no longer produced commercially in the United States.  Hooker Chemical Company (Niagara 
Falls, New York) manufactured and processed mirex from 1957 to 1976 (Lewis and Makarewicz 1988).  
An estimated 3.3 million pounds (1.5x106 kg) of mirex were produced by Hooker Chemical Company 
between 1959 and 1975, with peak production occurring between 1963 and 1968 (EPA 1978b).  About 
25% of the mirex produced was used as a pesticide and the remaining 75% was used as an industrial fire 
retardant additive (EPA 1978b).  Hooker Chemical Company reported purchasing 1.5 million pounds of 
mirex (680,400 kg) from Nease Chemical Company during this period.  The Nease Chemical Company of 
State College, Pennsylvania, manufactured mirex from 1966 to 1974 (EPA 1978b).  Allied Chemical 
Company also manufactured technical-grade mirex and mirex bait in Aberdeen, Mississippi (EPA 1978b), 
but Allied Chemical formally transferred all registrations on mirex, along with the right to manufacture 
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and sell mirex bait, to the Mississippi Department of Agriculture on May 7, 1976 (IARC 1979c; Waters et 
al. 1977a, 1977b). 
 
Chlordecone is not known to occur in the environment as a natural product (IARC 1979a).  Chlordecone 
has been produced by reacting hexachlorocyclopentadiene and sulfur trioxide under heat and pressure in 
the presence of antimony pentachloride as a catalyst.  The reaction product is hydrolyzed with aqueous 
alkali, neutralized with acid; chlordecone is recovered via centrifugation or filtration and hot air drying 
(Epstein 1978).  Chlordecone was produced in 1951, patented in 1952, and introduced commercially in 
the United States by Allied Chemical in 1958 under the trade names Kepone® and GC-1189 (Epstein 
1978; Huff and Gerstner 1978).  The technical grade of chlordecone, which typically contained 94.5% 
chlordecone, was available in the United States until 1976 (IARC 1979a).  Chlordecone was also found to 
be present in technical-grade mirex at concentrations of up to 2.58 mg/kg and in mirex bait formulations 
at concentrations of up to 0.25 mg/kg (EPA 1978b; IARC 1979a).  Approximately 55 different 
commercial formulations of chlordecone have been prepared since its introduction in 1958 (Epstein 
1978).  The major form of chlordecone, which was used as a pesticide on food products, was a wettable 
powder (50% chlordecone) (Epstein 1978).  Formulations of chlordecone commonly used for nonfood 
products were in the form of granules and dusts containing 5 or 10% active ingredient (Epstein 1978).  
Other formulations of chlordecone contained the following percentages of active ingredient: 0.125% 
(used in the United States in ant and roach traps), 5% (exported for banana and potato dusting), 25% 
(used in the United States in ant and roach bait), 50% (used to control mole crickets in Florida), and 90% 
(exported to Europe for conversion to kelevan for use on Colorado potato beetles in eastern European 
countries) (Epstein 1978). 
 
Chlordecone is no longer produced commercially in the United States.  Between 1951 and 1975, 
approximately 3.6 million pounds (1.6 million kg) of chlordecone were produced in the United States 
(Epstein 1978).  During this period, Allied Chemical Company produced approximately 1.8 million 
pounds (816,500 kg) of chlordecone at plants in Claymont, Delaware; Marcus Hook, Pennsylvania; and 
Hopewell, Virginia.  In 1974, because of increasing demand for chlordecone and a need to use their 
facility in Hopewell, Virginia, for other purposes, Allied Chemical transferred its chlordecone 
manufacturing to Life Sciences Products Company (EPA 1978b).  Life Sciences Products produced an 
estimated 1.7 million pounds (771,000 kg) of chlordecone from November 1974 through July 1975 in 
Hopewell, Virginia (Epstein 1978).  Hooker Chemical Company also produced approximately 
49,680 (22,500 kg) pounds of chlordecone in the period from 1965 to 1967 at a plant at Niagara Falls, 
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New York.  Nease Chemical Company produced approximately 65,780 pounds (30,000 kg) of 
chlordecone between 1959 and 1966 at a plant in State College, Pennsylvania (Epstein 1978). 
 
5.2.2   Import/Export 
 
No current data are available regarding import volumes of mirex.  Mirex has reportedly been imported to 
the United States from Brazil, but data on the amounts of mirex imported are not available (DHHS 1985; 
IARC 1979c). 
 
No current data are available regarding import volumes of chlordecone. 
 
Technical mirex and technical chlordecone are not exported since these substances are no longer 
produced in the United States. 
 
Over 90% of the mirex produced from the 1950s until 1975 was exported to Latin America, Europe, and 
Africa (Sterret and Boss 1977).  No other historic data regarding the export of mirex were located. 
 
Diluted technical-grade chlordecone (80% active ingredient) was exported to Europe, particularly 
Germany, in great quantities from 1951 to 1975 by the Allied Chemical Company (Epstein 1978) where 
the diluted technical product was converted to an adduct, kelevan.  Approximately 90–99% of the total 
volume of chlordecone produced during this time was exported to Europe, Asia, Latin America, and 
Africa (DHHS 1985; EPA 1978b). 
 
5.2.3   Use 
 
Because it is nonflammable, mirex was marketed primarily as a flame retardant additive in the United 
States from 1959 to 1972 under the trade name Dechlorane® for use in various coatings, plastics, rubber, 
paint, paper, and electrical goods (EPA 1978b; IARC 1979c; Kutz et al. 1985; Merck 1989; Verschueren 
1983).  Mirex was most commonly used in the 1960s as an insecticide to control the imported fire ants 
(Solenopsis invicta and S. richteri) in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North 
Carolina, South Carolina, and Texas (Carlson et al. 1976; EPA 1978b; IARC 1979c; Waters et al. 1977a, 
1977b).  From 1962 to 1976, approximately 132 million acres (53.4 million hectares) in nine states were 
treated with approximately 485,000 pounds (226,000 kg) of mirex at a rate of 4.2 g/hectare (later reduced 
to 1.16 g/hectare) (IARC 1979c).  Mirex was chosen for fire ant eradication programs because of its 
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effectiveness and selectiveness for ants (Carlson et al. 1976; Waters et al. 1977a, 1977b).  It was 
originally applied aerially at concentrations of 0.3–0.5%. 
 
However, aerial application of mirex was replaced by mound application because of suspected toxicity to 
estuarine species and because the goal of the fire ant program was changed from eradication to selective 
control.  Mirex was also used successfully in controlling populations of leaf cutter ants in South America, 
harvester termites in South Africa, Western harvester ants in the United States, mealybugs in pineapples 
in Hawaii, and yellowjacket wasps in the United States (EPA 1978b; IARC 1979c; Waters et al. 1977b).  
All registered products containing mirex were effectively canceled on December 1, 1977 (Sittig 1980).  
However, selected ground application was allowed until June 30 1978, at which time the product was 
banned in the United States with the exception of continued use in Hawaii on pineapples until stocks on 
hand were exhausted (EPA 1976; Holden 1976; Sittig 1980; Waters et al. 1977a). 
 
Until August 1, 1976, chlordecone was registered in the United States for use on banana root borer (in the 
U.S. territory of Puerto Rico); this was its only registered food use.  Additional registered formulations 
included nonfood use on nonfruit-bearing citrus trees to control rust mites; on tobacco to control tobacco 
and potato wireworms; and for control of the grass mole cricket, and various slugs, snails, and fire ants in 
buildings, lawns, and on ornamental shrubs (EPA 1978b; Epstein 1978; IARC 1979a).  The highest 
reported concentration of chlordecone in a commercial product was 50%, which was used to control the 
grass mole cricket in Florida (Epstein 1978).  Chlordecone has also been used in household products such 
as ant and roach traps at concentrations of approximately 0.125% (IARC 1979a).  The concentration used 
in ant and roach bait was approximately 25% (Epstein 1978).  All registered products containing 
chlordecone were effectively canceled as of May 1, 1978 (Sittig 1980). 
 
5.2.4   Disposal 
 
Since mirex and chlordecone are not flammable and are very stable in the environment, many disposal 
methods investigated for these chemicals have proven unsuccessful (Sullivan and Krieger 1992; Tabaeiet 
al. 1991; Waters et al. 1977b). 
 
Mirex is unaffected by hydrochloric, sulfuric, and nitric acids, and would be expected to be extremely 
resistant to oxidation except at the high temperatures of an efficient incinerator (EPA 1978b; Sittig 1980; 
WHO 1984a).  Mirex is not identified as an EPA hazardous substance under the Superfund Amendments 
and Reauthorization Act (SARA) Title III (EPA 1993).  A recommended method of disposal for mirex is 
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incineration or long-term storage (Holloman et al. 1975; IARC 1979c).  Polyethylene glycol or 
tetraethylene glycol and potassium hydroxide when used in combination with sodium borohydride or 
alkoxyborohydrides, produce a powerful reducing media which quantitatively destroys mirex at 70°C.  
The reduction rate is further increased by using tetrahydrofuran and catalytic quantities of Bu3SnH/AiBN, 
which produce 100% destruction of mirex to hexahydromirex within 1 hour at 58°C (Tabaei et al. 1991). 
 
Chlordecone is considered an EPA hazardous waste and must be disposed of according to EPA 
regulations (EPA 1980c).  Degradation of chlordecone has been evaluated in the presence of molten 
sodium (Greer and Griwatz 1980).  Addition of chlordecone to molten sodium at a temperature of 250°C 
resulted in significant degradation of chlordecone with small quantities of <12 ppm observed in the 
reaction products.  Microwave plasma has also been investigated as a potential disposal mechanism for 
chlordecone (DeZearn and Oberacker 1980).  An estimated 99% decomposition was observed in a 5-kw 
microwave plasma system for 80% chlordecone solution, slurry, or solid.  Another recommended disposal 
method for chlordecone is destruction in an incinerator at approximately 850°C followed by off-gas 
scrubbing to absorb hydrogen chloride (IRPTC 1985). 
 
Activated carbon adsorption has been investigated for the treatment of waste waters contaminated with 
chlordecone (EPA 1982b).  The discharge of chlordecone in sewage disposal systems is not 
recommended, as it may destroy the bacteriological system (IRPTC 1985).  Chlordecone as a waste 
product in water may be dehalogenated by a process involving ultraviolet light and hydrogen as a 
reductant.  The reaction is pH dependent, and degradation is best when the system contains 5% sodium 
hydroxide.  Using this method, 95–99% of chlordecone is removed within 90 minutes.  The degradation 
products are the mono-, di-, tri-, tetra-, and pentahydro derivatives of chlordecone.  This degradation 
method is applicable to chlordecone in hazardous wastes at concentrations in the ppm (mg/L) range and 
lower (Reimers et al. 1989; Sittig 1980). 
 
5.3   RELEASES TO THE ENVIRONMENT  
 
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing 
facilities are required to report information to the TRI only if they employ ≥10 full-time employees; if 
their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 1081, and 
1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the purpose of 
generating electricity for distribution in commerce), 4931 (limited to facilities that combust coal and/or 
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oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to facilities that 
combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4953 
(limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 5169, 5171, and 
7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities primarily engaged in 
solvents recovery services on a contract or fee basis); and if their facility produces, imports, or processes 
≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI chemical in a calendar 
year (EPA 2005). 
 
Mirex has been detected in air, surface water, soil and sediment, aquatic organisms, and foodstuffs.  
Historically, mirex was released to the environment primarily during its production or formulation for use 
as a fire retardant and as a pesticide.  There are no known natural sources of mirex and production of the 
compound was terminated in 1976.  Hazardous waste disposal sites and contaminated sediment sinks in 
Lake Ontario were the major sources for mirex releases to the environment (Brower and Ramkrishnadas 
1982; Comba et al. 1993). 
 
Chlordecone has been detected in the air, surface water, soil and sediment, aquatic organisms and 
foodstuffs.  Historically chlordecone was released to the environment primarily during its production at a 
manufacturing facility in Hopewell, Virginia.  There are no known natural sources of chlordecone and 
production of the compound was terminated in 1975.  Hazardous waste disposal sites and contaminated 
sediment sinks in the James River were the major sources for chlordecone release to the environment 
(EPA 1978c; Huggett and Bender 1980; Lunsford et al. 1987). 
 
5.3.1   Air  
 
There is no information on releases of mirex and chlordecone to the atmosphere from manufacturing and 
processing facilities because these releases are not required to be reported (EPA 2005). 
 
Little information on historic releases of mirex to the air was located.  Some atmospheric contamination 
may have occurred due to releases from manufacturing facilities, which were primarily located near 
Niagara Falls, New York, and State College, Pennsylvania; however, no quantitative sampling data were 
located (EPA 1978c).  Atmospheric releases of mirex could result from airborne dust from the production 
and processing of mirex or Dechlorane®, combustion of products containing Dechlorane®, or 
volatilization of mirex applied as a pesticide (WHO 1984a).  Because mirex was principally dispersed as 
a pesticide in a bait form associated with corn cob grit particles that settle rapidly, the amount of mirex 
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remaining airborne should have been insignificant.  Furthermore, volatilization of mirex after application 
should also have been insignificant because of the high melting point and low vapor pressure of the bait 
(EPA 1978c). 
 
Although release of mirex to the atmosphere was probably small in comparison to amounts released to 
surface water, soil, and sediment, infrequent detections of minute concentrations of mirex in air (mean 
concentration 0.35 pg/m3) and rainfall (<0.5 ng/L [ppt]) samples have been reported many years after 
production ceased (Hoff et al. 1992; Strachan 1990; Wania and MacKay 1993).  Arimoto (1989) 
estimated that 5% of the total input of mirex to Lake Ontario was attributed to atmospheric deposition. 
 
Large amounts of chlordecone were released into the air from a chemical manufacturing plant in 
Hopewell, Virginia, from April 1974 through June 1975.  Throughout the manufacturing period, 
extensive areas of the environment were contaminated with the chlordecone because of improper 
manufacturing and disposal processes (Lewis and Lee 1976).  Concentrations of chlordecone in the air 
surrounding the plant ranged from 0.18 ng/m3 to a maximum of 54.8 μg/m3 which was found in a sample 
collected 200 m from the plant (Epstein 1978).  High-volume air samplers in operation 200 m from the 
plant were found to contain this chlordecone level, which constituted over 50% of the total particulate 
loading.  Chlordecone concentrations at more distant sites (up to 15.6 miles away) ranged from 1.4 to 
20.7 ng/m3 (Epstein 1978).  The long-range transport properties of chlordecone indicate that at least a 
small portion of the chlordecone emissions were of a fine particle size having a relatively long residence 
time in the atmosphere (Lewis and Lee 1976). 
 
5.3.2   Water  
 
There is no information on releases of mirex and chlordecone to water from manufacturing and 
processing facilities because these releases are not required to be reported (EPA 2005). 
 
Mirex has been released to surface waters via waste waters discharged from manufacturing and 
formulation plants, in activities associated with the disposition of residual pesticides, and as a result of its 
direct use as a pesticide, particularly in the fire ant eradication program conducted in several southern 
states. 
 
Releases of mirex in industrial wastes were greatest during the manufacture of this chemical between 
1957 and 1976 by the Hooker Chemical and Plastics Corporation in Niagara Falls, New York.  Releases 
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to the Niagara River peaked between 1960 and 1962 at 200 kg/year (440 pounds/year), but subsequently 
declined to 13.3 kg/year (29 pounds/year) in 1979, and 8 kg/year (18 pounds/year) in 1981 (Durham and 
Oliver 1983; Lewis and Makarewicz 1988).  Releases to the Oswego River occurred as a result of 
discharges from Armstrong World Industries Inc. in Volney, New York (Lum et al. 1987; Mudambi et al. 
1992).  Since production of mirex was discontinued in 1976 (Kaiser 1978), releases after 1976 were the 
result of leaching from dump sites adjacent to the Niagara and Oswego Rivers, both of which feed into 
Lake Ontario (Kaminsky et al. 1983) and releases of mirex from sediment sinks in Lake Ontario.  Total 
loading of mirex to Lake Ontario has been estimated to be 688 kg (1,517 pounds), with half of this 
incorporated into the sediments (Holdrinet et al. 1978; Lewis and Makarewicz 1988).  A study by Comba 
et al. (1993), however, estimated total loading of mirex to Lake Ontario to be 2,700 kg (6,000 pounds) 
over 40 years, of which 550 kg (1,200 pounds) has been removed mainly by transport via outflowing 
water into the St. Lawrence River. 
 
In addition to direct releases of mirex to surface waters that occurred at the manufacturing plant in 
Niagara Falls, New York, an estimated 226,000 kg (498,000 pounds) of mirex were used as a pesticide to 
treat 132 million acres (53.4 million hectares) in nine southern states from 1962 to 1976 as part of the fire 
ant eradication program conducted by the Department of Agriculture (IARC 1979c).  Mirex insecticide 
baits were dispersed by aerial applications, and mirex could be released into surface water directly or 
could reach surface waters via runoff.  Because mirex binds tightly to organic-rich soils, leaching is not 
generally expected to occur.  However, mirex residues have been detected (concentration unspecified) in 
groundwater well samples collected in proximity to agricultural land in New Jersey (Greenburg et al. 
1982).  In a South Carolina study, mirex was also detected in potable water supplies in two rural counties.  
Mirex was detected in 12.5% of water samples at a mean concentration of 2 ng/L (ppt) (range from not 
detectable to 30 ng/L) in Chesterfield County and was detected in 72.7% of the water samples at a mean 
concentration of 83 ng/L (range of not detectable to 437 ng/L) in rural Hampton County.  The authors 
attributed the higher mirex residues in the potable water of Hampton County to the extensive use of mirex 
in this county for fire ant control (Sandhu et al. 1978). 
 
Chlordecone has been primarily released to surface waters in waste waters from a manufacturing plant in 
Hopewell, Virginia, and may be released in activities associated with the disposal of residual pesticide 
stocks, and as a result of the direct use of mirex.  Chlordecone has been released directly as a contaminant 
of mirex and indirectly from the degradation of mirex. 
 
MIREX AND CHLORDECONE  166 
 
5.  POTENTIAL FOR HUMAN EXPOSURE 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
Production of chlordecone at a manufacturing plant in Hopewell, Virginia, from 1966 to 1975, resulted in 
the release of the compound, primarily through industrial discharge of waste water into the Hopewell 
municipal sewage system, which discharged into Baileys Creek, and ultimately flowed into the James 
River.  Leaching and erosion of contaminated soils from the plant site and direct discharge of solid wastes 
also contributed to the chlordecone content in the James River estuary (Colwell et al. 1981; Nichols 
1990).  Effluent from the manufacturing plant contained 0.1–1.0 mg/L (ppm) chlordecone, and water 
from the plant’s holding ponds contained 2 to 3 mg/L (ppm) chlordecone (Epstein 1978).  It has been 
estimated that 7,500–45,000 kg (16,500–100,000 pounds) of the 1,500,000 kg (3.3 million pounds) of 
chlordecone produced at the plant entered the estuary in industrial effluent or runoff (Colwell et al. 1981; 
Nichols 1990). 
 
Another source of chlordecone release to water may result from the application of mirex containing 
chlordecone as a contaminant and by the degradation of mirex, which was used extensively in several 
southern states.  Carlson et al. (1976) reported that dechlorinated products including chlordecone were 
formed when mirex bait, or mirex deposited on soil after leaching from the bait, was exposed to sunlight, 
other forms of weathering, and microbial degradation over a period of 12 years.  Chlordecone residues in 
the soil could find their way to surface waters via runoff. 
 
5.3.3   Soil  
 
There is no information on releases of mirex and chlordecone to soil from manufacturing and processing 
facilities because these releases are not required to be reported (EPA 2005). 
 
Mirex is not currently registered for use in the United States, so release of mirex to soil from pesticide 
applications is no longer of concern.  However, use of mirex as a pesticide for fire ant control required the 
spraying of this chemical on soils of an estimated 132 million acres in the southern United States (IARC 
1979c).  An estimated 226,000 kg (498,000 pounds) of mirex were used in nine states from 1962 to 1976 
as part of the fire ant eradication program conducted by the Department of Agriculture (IARC 1979c). 
 
Releases of mirex to sediment as a result of industrial waste water discharges were noted in Lake Ontario 
near the mouth of the Niagara River.  Lake Ontario sediment concentrations were correlated with the 
years of peak production and use, and were found to decrease in the upper sediments as use was restricted 
in the late 1970s (Durham and Oliver 1983).  Total loading of mirex to Lake Ontario has been estimated 
to be 688 kg (1,517 pounds), with half of this amount incorporated into the sediments (Holdrinet et al. 
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1978; Lewis and Makarewicz 1988).  However, a study by Comba et al. (1993) involving development of 
a mass balance for mirex in Lake Ontario and the Gulf of St. Lawrence estimated that over 40 years, 
approximately 2,700 kg (6,000 pounds) of mirex entered Lake Ontario, of which 550 kg (1,200 pounds) 
has been removed via transport to the St. Lawrence estuary.  Removal of mirex from Lake Ontario has 
resulted primarily by outflowing water containing suspended sediment. 
 
Chlordecone is not currently registered for use in the United States.  However, use of chlordecone as a 
pesticide to control banana borers on bananas, tobacco wireworms on tobacco, mole crickets on turf, and 
various slugs, snails, and ants in buildings, lawns, and ornamental shrubs, required the application of this 
chemical to soils (Epstein 1978; IARC 1979a).  No estimate of the amount of chlordecone released from 
these uses was found.  Chlordecone releases to soils may also occur as a result of the application of mirex 
containing chlordecone as a contaminant and by the degradation of mirex which was used extensively in a 
regional fire ant eradication program.  As stated in Section 5.2.2, Carlson et al. (1976) reported that 
dechlorinated products, including chlordecone, were formed when mirex bait, or mirex deposited on soil 
after leaching from the bait, was exposed to sunlight, other forms of weathering, and microbial 
degradation over a period of 12 years.  No estimates of the amount of chlordecone released from the 
application and degradation of mirex are available. 
 
Chlordecone releases to soil occurred at a production facility in Hopewell, Virginia.  Soil samples 
adjacent to the site contained 1–2% chlordecone (l0,000–20,000 mg/kg [ppm]), and surface soils up to 
3,000 feet from the site contained concentrations of 2–6 mg/kg (ppm) (Epstein 1978). 
 
The major release of chlordecone to sediments, however, occurred indirectly as a result of waste water 
discharges, runoff of contaminated soil, and direct disposal of solid wastes at a production facility in 
Hopewell, Virginia.  An estimated l0,000–30,000 kg (22,000–66,100 pounds) of chlordecone are 
associated with bottom sediment in the James River estuary (Huggett and Bender 1980; Nichols 1990).  
This sediment serves as a reservoir for future release of chlordecone via resuspension of sediments 
resulting from storms or dredging activities (Lunsford et al. 1987). 
 
5.4   ENVIRONMENTAL FATE  
 
5.4.1   Transport and Partitioning  
 
Mirex.  Because mirex is a very hydrophobic compound with a low vapor pressure, atmospheric transport 
is unlikely (Hoff et al. 1992).  These authors reported detecting mirex in only 5 of 143 samples at a 
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maximum and mean concentration of 22 pg/m3 and 0.35 pg/m3, respectively.  Based on a vapor pressure 
of <3x10-7 mm Hg at 25°C, mirex is expected to exist mainly in the particulate phase with a small 
proportion existing in the vapor phase in the ambient atmosphere (IARC 1979c).  A mass balance 
approach to the movement of mirex within Lake Ontario indicates that 5% of the total input of mirex to 
the lake can be attributed to atmospheric deposition compared with 72% of benzo(a)pyrene (Arimoto 
1989). 
 
Based on a calculated soil sorption coefficient (Koc) of 1,200 (5,800 experimental) for mirex, this 
compound will tightly bind to organic matter in soil and, therefore, will be highly immobile.  Thus, mirex 
is most likely to enter surface waters as a result of soil runoff (Kenaga 1980).  In addition, most land 
applications of mirex to soils containing high organic content would result in very little leaching through 
soil to groundwater.  However, leaching of mirex from some agricultural soils can occur as mirex has 
been detected in groundwater wells near agricultural areas (Greenburg et al. 1982; Sandhu et al. 1978). 
 
When released to surface waters, mirex will bind primarily (80–90%) to the dissolved organic matter in 
the water with a small amount (10–20%) remaining in the dissolved fraction, because mirex is a highly 
hydrophobic compound (Yin and Hassett 1989).  Mean mirex concentrations in sediments, collected at 
four basins in Lake Ontario between 1982 and 1986, ranged from 30 to 38 μg/kg in three of the basins 
within the water circulation pattern of the lake.  A fourth basin outside the pattern showed much lower 
concentrations (6.4 μg/kg), indicating that mirex was being transported with the lake water (Oliver et al. 
1989).  The residence time for mirex in Lake Ontario water was estimated to be 0.3 years.  This indicated 
that mirex was either scavenged by particles or was chemically reactive and, therefore, was rapidly 
removed from the water column (Arimoto 1989). 
 
Since the only sources of mirex in Lake Ontario are contaminated sediments, mirex in the water column is 
assumed to have come from resuspended sediments (Oliver et al. 1989).  The source of the mirex in Lake 
Ontario surficial sediments was determined to be suspended sediments from the Niagara River, which 
were found to contain 8–15 and 55 μg/g (ppm) mirex in the upper and lower river sections, respectively.  
The surficial sediments contained 3 μg/g in the upper river (above the manufacturing and dump sites), 
86 μg/g in the lower river (below the sites), and 10 μg/g in the western basin of Lake Ontario, indicating 
that mirex-containing sediments were being carried down the river with the current and deposited in Lake 
Ontario (Mudroch and Williams 1989).  Kaminsky et al. (1983), reported a range of 8.2–62 ppb (μg/kg) 
in sediment from the eastern and central basins of Lake Ontario.  Over 94% of the suspended particulate 
matter entering the lake is eventually deposited in lake sediments (Lum et al. 1987).  Mirex 
MIREX AND CHLORDECONE  169 
 
5.  POTENTIAL FOR HUMAN EXPOSURE 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
concentrations in sediments of Lake Ontario show a strong correlation with peak production years 
(Durham and Oliver 1983; Eisenreich et al. 1989).  Although there was evidence of sediment bioturbation 
by deposit-feeding worms and burrowing organisms, the sediment profiles for mirex and other chlorinated 
hydrocarbons were not destroyed (Eisenreich et al. 1989).  Between the 1960s when mirex production 
began, and the early 1980s after production ceased, levels of mirex in bottom sediments increased in Lake 
Ontario, with the Niagara River being the major source of this compound (Allan and Ball 1990). 
 
Mirex may be removed from Lake Ontario by several mechanisms, including the transport of 
contaminated suspended particulate material via water outflow into the St. Lawrence River), biomass 
removal through fishing and migration (e.g., migrating eels contaminated with mirex), volatilization, and 
photolysis (Comba et al. 1993; Lum et al. 1987).  Transport of mirex accumulated in body tissues by eels 
has been estimated to be 2,270 grams annually or twice the amount of mirex removed by transport of 
suspended particulates (1,370 grams annually) (Lum et al. 1987). 
 
The transport of mirex out of Lake Ontario, (a known reservoir), to its tributaries is also possible as a 
result of migrating fish, which move from the lake into the tributary streams to spawn.  Fish, such as 
Pacific salmon, become contaminated with mirex while in the lake.  These fish then swim upstream in the 
tributaries to their spawning grounds, spawn, and die.  A direct transfer of mirex may then occur when 
resident stream fish feed on the decomposing carcasses and/or eggs, both of which contain mirex 
residues.  Indirect transfer can occur as a result of the release of mirex from the salmon into the water or 
sediments and subsequent movement up the food chain.  Movement of mirex back into Lake Ontario is 
also possible when the contaminated eggs hatch and surviving juvenile salmon return to the lake (Lewis 
and Makarewicz 1988). 
 
Algae are known to bioaccumulate mirex, with BCFs in the range of 3,200–7,300, while bacteria have a 
BCF of 40,000 with an octanol-water partition coefficient of 7.8 million (Baughman and Paris 1981).  
Based on a water solubility of 0.6 mg/L, a BCF of 820 was calculated for mirex (Kenaga 1980).  
Bioaccumulation of mirex also occurred in invertebrates exposed to 0.001–2.0 μg/g mirex in water; tissue 
residues ranged from 1.06 to 92.2 μg/g (de la Cruz and Naqui 1973).  After 28 days of exposure, the BCF 
values for the amphipod (Hyallelu azteca) and crayfish (Orconectes mississippiensis) were 2,530 and 
1,060 respectively.  Fathead minnows exposed to 33 μg/L (ppb) mirex for 56 days accumulated 122 μg/g 
(ppm) mirex tissue residues (BCF of 3,700), with no other evident metabolic products.  Residues 
decreased to 88.6 μg/g 28 days after mirex was removed from the water (Huckins et al. 1982).  The half-
life of mirex in rainbow trout was >1,000 days in fish exposed for 96 days to a mean concentration of 
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4.1 ng/L, although equilibrium was not reached during the test period.  A subsequent analysis comparing 
a laboratory BCF for mirex in rainbow trout (1,200) with an actual BCF found in rainbow trout in Lake 
Ontario (15,000), indicated that ingestion of contaminated food (as would occur in the lake), rather than 
absorption across the gills, is the primary exposure route for trout (Oliver and Niimi 1985). 
 
Biomagnification of mirex is supported by a study of various aquatic organisms that comprise an aquatic 
food chain in Lake Ontario (Oliver and Niimi 1988) (see Table 5-1). 
 
Table 5-1.  Concentrations of Mirex in Aquatic Organisms 
 
Sample  Mirex concentration (μg/kg wet weight unless otherwise noted) 
Water 31+12 pg/L wet weight 
Bottom sediment 3.9+1.9 μg/kg dry weight 
Suspended sediment 15+4.4 μg/kg dry weight 
Plankton 1.3+0.1 
Mysids 8+2.8 
Amphipods 12+6.7 
Oligochaetes 6.9+2.9 
Sculpins 57 
Alewives 45 
Small smelts 26+3.6 
Large smelts 53 
Average fish 180+150 
 
Source: Oliver and Niimi 1988 
 
In these food chains, alewives feed primarily on mysids and to a lesser extent on amphipods; sculpins 
feed on amphipods, then mysids; smelt feed on mysids.  Mysids feed on zooplankton, with amphipods 
and oligochaetes consuming detrital matter.  The alewives and smelt are preyed upon by salmonids, such 
as trout (Oliver and Niimi 1988).  A comparison of concentrations of mirex in lake trout, a predator 
species, with those in smelt, a prey species, gives a ratio of 1.26, indicating that biomagnification occurs 
up the food chain (Thomann 1989). 
 
Mirex can also bioaccumulate in terrestrial plants.  Azalea leaves, exposed to 0.023 μg/kg of mirex in 
greenhouse air, had significant uptake of the pesticide resulting in a BCF of 1.18x107 (log BCF=7.07) 
(Bacci et al. 1990b).  Mirex residues ranging from 10–1,710 μg/kg (ppb) were detected in soybeans, 
garden beans, sorghum, and wheat seedlings grown on substrates containing 0.3–3.5 mg/kg (ppm) mirex 
(de la Cruz and Rajanna 1975).  Based on these data and known soil concentrations, it has been estimated 
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that plants grown on contaminated soil could contain 0.0002–2 μg/kg (ppb) mirex (EPA 1978c).  No 
information on the uptake of mirex by plants under field conditions was located. 
 
In a 1972 residue study conducted in Mississippi during the time when mirex was being used extensively 
in fire ant control programs, Naqui and de la Cruz (1973) reported mirex accumulation in grassland 
invertebrates (e.g., spiders and grasshoppers) ranging from 100 to 700 μg/kg (ppb) (mean 280 μg/kg).  
Hebert et al. (1994) studied organochlorine pesticides in a terrestrial food web on the Niagara Peninsula 
in Ontario, Canada, from 1987 to 1989.  These authors reported mirex concentrations in the various food 
web compartments as follows: soil (not detectable), plants (not detectable), earthworms (not detectable to 
0.4 μg/kg), mammals (not detectable to 0.5 μg/kg), starlings (0.9–1.6 μg/kg), robins (4.7–18.9 μg/kg), and 
kestrels (4.7–22.2 μg/kg), which suggests that biomagnification of mirex is occurring.  The earthworm 
appeared to be a particularly important species for organochlorine transfer from the soil to organisms 
occupying higher trophic levels.  Connell and Markwell (1990) reported transfer of lipophilic compounds 
(such as mirex) through a three-phase system involving soil to soil water to earthworm partitioning.  The 
transfer is a passive process and is principally dependent on the lipid content of the worms and the 
organic content of the soil. 
 
Chlordecone.  The fate and transport of chlordecone is very similar to mirex.  Based on its low vapor 
pressure and high Koc, chlordecone in the air may be expected to be associated primarily with particulate 
matter (Kenaga 1980).  However, only small amounts of chlordecone may volatilize into the air.  
Chlordecone volatilizes more slowly from water (0.024% applied amount/mL of evaporated water) than 
from sand, loam, or humus soil (0.036, 0.035, and 0.032%, respectively) (Kilzer et al. 1979). 
 
Atmospheric transport of chlordecone particles was reported as a result of emissions from a production 
facility in Virginia.  Chlordecone concentrations at up to 15.6 miles away ranged from 1.4 to 20.7 ng/m3 
(Epstein 1978).  The long-range transport properties of chlordecone indicate that at least a portion of the 
emissions were of a fine particle size having a relatively long residence time in the atmosphere (Lewis 
and Lee 1976). 
 
The major industrial release of chlordecone occurred to surface waters of the James River.  Chlordecone, 
because of its relatively low solubility in water and lipophilic nature, is readily absorbed to particulate 
matter in water and is ultimately deposited in sediments (EPA 1978; Lunsford et al. 1987).  Once 
adsorbed to sediments, chlordecone remains relatively immobile in the normal range of pH (7–8) and 
salinity (0.06–19.5 %) encountered in an estuary.  While chlordecone is associated mainly with the 
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organic portion of bottom sediments, sediment areas with high percentages of inorganic mineral grains 
are relatively clean of contamination.  The greatest mass of chlordecone (an estimated 6,260 pounds 
[2,840 kg]) was found in a sink where the sedimentation was relatively rapid.  Transport is primarily 
through adsorption of chlordecone to fine organic particles in the water column.  Its movement and 
deposition follow estuarine circulation, which is seaward from the freshwater reaches and upper estuarine 
water layer, and reflux downward for suspended materials (Nichols 1990). 
 
While much of the chlordecone that was present in contaminated sediments in 1976 is still in the 
sediment, it is continuously being buried under several centimeters of new sediment each year (Huggett 
and Bender 1980).  Storm activities and dredging are of concern because they would result in 
reenrichment of the surface sediments in areas with chlordecone contaminated sediment previously buried 
by natural ongoing sedimentation processes in the estuary (Huggett and Bender 1980; Lunsford et al. 
1987). 
 
Chlordecone has been found to have a very high bioaccumulation potential in fish and other aquatic 
organisms.  Atlantic menhaden (Brevoortia lyrunnus) and Atlantic silver-sides (Menidia menidiu) had 
28-day BCFs of 2,300–9,750 and 21,700–60,200, respectively (Roberts and Fisher 1985).  Based on a 
water solubility of 3 mg/L, a BCF of 333 was estimated for chlordecone.  However, the measured value 
was 8,400 (Kenaga 1980).  Using a log octanol-water partition coefficient for chlordecone of 6.08, a BCF 
of 6,918 was estimated for the oyster (Hawker and Connell 1986).  However, an oyster BCF of 
10,000 has been reported with tissue concentrations at equilibrium within 8–17 days (Bahner et al. 1977).  
For estuarine organisms such as mysids, grass shrimp, sheepshead minnows, and spot, BCFs were 
measured to be 13,000, 11,000, 7,000, and 3,000, respectively (Bahner et al. 1977).  Shad roe taken from 
the James River contained chlordecone levels that were 140% higher than muscle tissue residues, 
indicating a partitioning of the chemical into the lipid-rich eggs (Bender and Huggett 1984). 
 
The accumulation of chlordecone was studied in a terrestrial/aquatic laboratory model ecosystem by 
Metcalf et al. (1984).  Radiolabeled chlordecone was applied to sorghum seedlings grown on the 
terrestrial portion of the aquarium.  The treated seedlings were eaten by salt marsh caterpillars.  In the 
aquatic portion, chlordecone was transferred through several species-an algae, snail, water flea mosquito 
larvae, and mosquito fish.  After 33 days, the BCFs were 0.35 for the algae, 637.4 for the snails, 506.9 for 
the mosquito larvae, and 117.9 for the mosquito fish.  A BCF for chlordecone of approximately 2.1 was 
determined for a water-algae-oyster food chain; however, a biomagnification factor >10.5 was measured 
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for a water-brine shrimp-mysid-spot food chain with a water concentration of 0.1 mg/L (ppm) 
chlordecone (Bahner et al. 1977). 
 
Plant uptake of chlordecone from the soil via the roots, and volatilization of chlordecone from soil with 
plant uptake via the leaves were found to be negligible in a closed laboratory system using barley 
seedlings.  This indicates that bioaccumulation of chlordecone by plants (lowest on the terrestrial food 
chain) is very unlikely based on its log soil adsorption coefficient of almost 4.0 (Topp et al. 1986).  No 
information on the uptake of chlordecone by plants under field conditions was located. 
 
5.4.2   Transformation and Degradation  
 
Air 
 
Mirex.  Little information was found on the degradation of mirex in the atmosphere.  Mirex is expected to 
be stable against photogenerated hydroxyl radicals in the atmosphere (Eisenreich et al. 1981). 
 
Chlordecone.  Photolysis of chlordecone in the atmosphere does not appear to be an important 
degradation pathway for this compound.  While nonvolatile products of photolysis were not monitored, 
only 1.8% of the chlordecone adsorbed on silica gel and exposed to ultraviolet light (wavelength 
>290 nm) was photolyzed to carbon dioxide or other volatile compounds (Freitag et al. 1985). 
 
Water 
 
Mirex.  The degradation of mirex in water occurs primarily by photolysis.  During the photo-
decomposition of mirex, the chlorine atoms are replaced by hydrogen atoms.  The primary photoreduction 
product of mirex in water is photomirex (Andrade et al. 1975); the rate of this reaction can be increased 
by the presence of dissolved organic matter (such as humic acids) and was greatest at 265 nm in Lake 
Ontario water (Mudami and Hassett 1988).  In Lake Ontario, Mudambi et al. (1992) reported that the ratio 
of photomirex to mirex (P/M) increased in the stratified surface layer of the lake from spring until autumn 
and in water from Oswego Harbor.  P/M ratios in the mirex source sediments (the Niagara and Oswego 
Rivers) were very low (<0.07), whereas higher P/M ratios were seen in the lake bottom sediments (>0.10) 
and surface waters (>0.30).  These findings suggest that photomirex in Lake Ontario is produced by 
photolysis of mirex present in the surface waters and it is then partitioned between water, sediment, and 
biota. 
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Chlordecone.  Degradation of chlordecone to an unidentified compound was studied in water in a 
terrestrial/aquatic laboratory model ecosystem.  Degradation occurred to some extent during the 33-day 
exposure period, and unidentified metabolites were detected in all organisms in the system-algae, snail, 
mosquito, and mosquito fish (Francis and Metcalf 1984).  An earlier laboratory study in which fathead 
minnows were exposed to chlordecone in a flow-through diluter system for 56 days found that 
chlordecone was bioconcentrated 16,600 times by the minnows; however, only 1–5% of these residues 
were chlordecone (Huckins et al. 1982).  Several observations suggested that some of the chlordecone 
residues present in the minnows were chemically bound to biogenic compounds. 
 
Pseudomonas aeruginosa strain K03 and a mixed aerobic enrichment culture isolated from sewage sludge 
lagoon water were found to aerobically transform chlordecone to monohydrochlordecone in 8 weeks.  
Monohydrochlordecone constituted 14.2 and 14.5% of the chlordecone transformation products for the 
P. aeruginosa and mixed aerobic enrichment culture, respectively.  The P. aeruginosa K03 strain and the 
mixed culture also produced 15.6 and 4.2% dihydrochlordecone, respectively (Orndorff and Colwell 
1980).  None of the bacterial strains were able to use chlordecone as a sole carbon source; therefore, co-
metabolism appeared to be the only degradation process.  Complete mineralization of chlordecone by 
bacteria is unlikely (Orndorff and Colwell 1980).  Degradation of chlordecone can occur via microbial 
action, but the rate and extent of transformation are such that microbial action will not cause rapid 
removal of chlordecone from the environment except under highly enriched and selected conditions.  
Aerobic degradation of chlordecone by activated sludge from a municipal sewage plant showed that 
<0.1% of the applied chlordecone was degraded in 5 days, and the sludge showed a bioaccumulation 
factor of 9,900 compared with the concentration in the water (Freitag et al. 1985). 
 
Sediment and Soil 
 
Mirex.  Degradation of mirex in soil may occur by photolysis or anaerobic biodegradation, both of which 
are very slow removal processes.  Mirex is highly resistant to aerobic biodegradation and, as such, is 
extremely persistent in soils (estimated half-life of 10 years) (Carlson et al. 1976; Lal and Saxena 1982).  
Mirex appears to have no adverse effect on resident microbial communities (Jones and Hodges 1974).  
Upon exposure to ultraviolet light, mirex is known to degrade to chlordecone, photomirex, and/or 
dihydromirex (Francis and Metcalf 1984).  Detectable levels of mirex photodegradation products 
(monohydro derivative and chlordecone hydrate) occur within 3 days after exposure of mirex to sunlight, 
although after 28 days of exposure, approximately 90% of the mirex was unchanged (Ivie et al. 1974a).  
MIREX AND CHLORDECONE  175 
 
5.  POTENTIAL FOR HUMAN EXPOSURE 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
Anaerobic degradation relies on iron(II) porphyrin as the reductant for the dehalogenation reaction (Kuhn 
and Suflita 1989). 
 
Under anaerobic conditions, mirex was slowly dechlorinated to the 10-monohydro derivative by 
incubation with sewage sludge bacteria for 2 months (Andrade and Wheeler 1974; Andrade et al. 197.5; 
Williams 1977).  The primary removal mechanism for mirex was anaerobic degradation as demonstrated 
by the 6-month stability of the compound in nine aerobic soils and lake sediments (Jones and Hodges 
1974). 
 
Aerobic degradation of mirex is a very slow and minor degradation process.  Twelve years after the 
application of mirex to soil at 1 pound/acre, 50% of the mirex and mirex-related organochlorine 
compounds remained in the soil; 65–73% of the residues consisted of mirex and 3–6% consisted of 
chlordecone.  Although concentrations were slightly higher, similar ratios of mirex (76–81%) and 
chlordecone (1–6%) residues were seen 5 years after an accidental spill of mirex bait on soil.  Mirex 
underwent photolysis to form four dechlorination products: two monohydro and two dihydro compounds 
(Carlson et al. 1976).  Two soil microbes, Bacillus sphaericus and Streptomyces albus, isolated from a 
field previously treated with mirex, were able to utilize 1% mirex as a sole carbon source.  However, the 
rate of degradation, as demonstrated by carbon dioxide evolution, was slow and only about 10–20% 
greater than the controls after 20 hours (Aslanzadeh and Hedrick 1985). 
 
No evidence of microbial degradation was detected for mirex exposed to hydrosoils from a reservoir (not 
previously contaminated with chlordecone) and from chlordecone-contaminated hydrosoils from the 
James River area of Virginia under either anaerobic or aerobic conditions for 56 days (Huckins et al. 
1982).  The concentrations of chlordecone in the anaerobic and aerobic hydrosoils averaged 0.38 and 
0.54 µg/g, respectively.  Some photodegradation of mirex to photomirex was seen in an artificial salt 
marsh ecosystem; the photomirex was subsequently photodegraded to the 2,8- or 3,8-dihydro derivative.  
Most mirex loss occurred during the first 7 days after application (from 2.65 to 2.13 mg/g) with a steady 
accumulation of photomirex (610 ppb/day [μg/kg/day]) through day 21, accumulation of 17 μg/kg/day of 
2,8- or 3,8-dihydro derivative through day 35, and an accumulation rate of 206 μg/kg/day for the 
10-monohydro photoproduct that is formed in the presence of amines.  The 8-monohydro derivative 
(photomirex) was found to accumulate in the salt marsh organisms and sediment (Cripe and Livingston 
1977). 
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Application of radiolabeled mirex to plants grown in a terrestrial/aquatic laboratory model ecosystem 
indicated that when the plant leaves were eaten by caterpillars, the aquatic system became contaminated.  
Mirex was detected in all segments of two aquatic food chains (alga > snail and plankton > daphnia > 
mosquito > fish) within 33 days.  Undegraded mirex contributed to over 98.6, 99.4, 99.6, and 97.9% of 
the radiolabel in fish, snails, mosquitoes, and algae, respectively.  No metabolites of mirex were found in 
any of the organisms (Francis and Metcalf 1984; Metcalf et al. 1973). 
 
Chlordecone.  Chlordecone is similar to mirex in structure and is also highly persistent in soils and 
sediments (half-life expected to be analogous to 10 years duration for mirex) because of its resistance to 
biodegradation, although some microbial metabolism of chlordecone has been reported (Lal and Saxena 
1982; Orndorff and Colwell 1980).  No evidence of microbial degradation was detected for chlordecone 
exposed to hydrosoils from a reservoir (not previously contaminated with chlordecone) and from Bailey 
Creek (contaminated with chlordecone) under either anaerobic or aerobic conditions for 56 days (Huckins 
et al. 1982). 
 
Three Pseudomonas species extracted from soil samples to which chlordecone was added (1 mg/mL) 
were found to utilize chlordecone, as a sole carbon source, with quantifiable degradation (67–84%) in 
14 days.  Among the degradation products of chlordecone, only hydrochlordecone and 
dihydrochlordecone were identified (George and Claxton 1988; George et al. 1986).  Sewage sludge 
bacteria and sediment bacteria, primarily P. aeruginosa strain KO3, were able to aerobically degrade 
chlordecone by 10–14% to monohydrochlordecone and, to a lesser extent, dihydrochlordecone in 8 
weeks.  None of the bacterial strains was able to use chlordecone as a sole carbon source; therefore, co-
metabolism appeared to be the only degradation process.  Complete mineralization of chlordecone by 
bacteria is unlikely (Orndorff and Colwell 1980).  Concentrations of chlordecone >0.2 mg/L are likely to 
inhibit microbial activity, whereas concentrations <0.01 mg/L had no effects on cell count or uptake of 
amino acids.  Bacteria in James River sediment did not produce significant concentrations of chlordecone 
metabolites (Colwell et al. 1981). 
 
Degradation of chlordecone in a terrestrial ecosystem was studied by applying the compound to soil, 
growing plants on the soil; and then determining the amount of chlordecone in each compartment after 
1 week.  During this time, only 0.1% of the applied chlordecone (2 mg/kg) was decomposed to carbon 
dioxide from the soil, and 0.3 mg/kg (approximately 15% of the applied concentration) was accumulated 
by the barley plants.  Less than 10% of the applied chlordecone was degraded in the soil or converted by 
the barley plants, and there was no volatilization of the compound from the soil to the air (Kloskowski et 
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al. 1981).  A laboratory soil-plant system showed that degradation of chlordecone, as determined by soil 
residues remaining after volatilization and mineralization, was 1–3% after 1 week; this compared 
favorably with the residues remaining in soil in the field after one growing season (Scheunert et al. 1983).  
Analysis of soil contaminated with chlordecone collected in the vicinity of the chlordecone production 
facility showed some photolytic degradation of the compound with the production of small amounts of 
monohydro isomers of chlordecone (Borsetti and Roach 1978). 
 
5.5   LEVELS IN THE ENVIRONMENT  
 
Reliable evaluation of the potential for human exposure to mirex and chlordecone depends, in part, on the 
reliability of supporting analytical data from environmental samples and biological specimens.  
Concentrations of mirex and chlordecone in unpolluted atmospheres and in pristine surface waters are 
often so low as to be near the limits of current analytical methods.  In reviewing data on mirex and 
chlordecone levels monitored or estimated in the environment, it should also be noted that the amount of 
chemical identified analytically is not necessarily equivalent to the amount that is bioavailable. 
 
The lowest limit of detections that are achieved by analytical analysis in environmental media are 
summarized in Table 5-2 for mirex and Table 5-3 for chlordecone. 
 
Table 5-2.  Lowest Limit of Detection for Mirex Based on Standardsa 
 
Media Detection limit Reference 
Air 0.1 ng/m3 Lewis et al. 1977 
Drinking water 10 ng/L Sandhu et al. 1978 
Surface water and 
groundwater 
10 ng/L Sandhu et al. 1978 
Soil 1 ppb Seidel and Lindner 1993 
Sediment 0.002 ppb Sergeant et al. 1993 
Whole blood 0.04 ng/g Mes 1992 
 
aDetection limits based on using appropriate preparation and analytics.  These limits may not be possible in all 
situations. 
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Table 5-3.  Lowest Limit of Detection for Chlordecone Based on Standardsa
Media Detection limit Reference 
Air 10 ng/sample NIOSH 1984 
Water 20 ng/L Saleh and Lee 1978 
Soil 10–20 ppb Saleh and Lee 197 
Sediment 10–20 ppb Saleh and Lee 197 
Whole blood 10 µg/L Caplan et al. 1979 
aDetection limits based on using appropriate preparation and analytics.  These limits may not be possible in all 
situations. 
No data are available on levels of mirex or chlordecone in air, water, and soil at NPL sites (ATSDR 
2017).   
5.5.1   Air 
Mirex.  Mirex has been detected in wet precipitation over rural areas at concentrations <1 ng/L (ppt) 
(EPA 1981b).  Rain fall samples collected at several sites in 1985–1986 as part of the Great Lakes 
Organics Rain Sampling Network contained from >0.2 to <0.5 ng/L (ppt) of mirex.  Mirex was not 
detected consistently at many stations throughout the sampling period; therefore, quantitative results for 
mirex were not presented (Strachan 1990).  Air samples taken over southern Ontario in 1988 showed 
mirex in 5 of 143 samples, at an annual mean concentration of 0.35 pg/m3 (range, 0.1–22 pg/m3), with all 
of the positive samples detected in polluted environments (Hoff et al. 1992). 
Chlordecone.  Information on atmospheric concentrations of chlordecone is limited to air sampling 
results obtained at the Life Sciences Products Company production site in Hopewell, Virginia.  High 
volume air filter samples collected 200 m from the plant in March 1974 prior to initiation of production at 
the site contained only 0.18 to 0.35 ng/m3 of chlordecone.  Subsequent air sampling after production was 
initiated ranged from 3 to 55 μg/m3.  During production years 1974 and 1975, air concentrations at more 
distant sites up to 15.6 miles from Hopewell, Virginia, ranged from 1.4 to 20.7 ng/m3 (Epstein 1978). 
5.5.2   Water 
Mirex.  Mirex was detected in rural drinking water samples at concentrations ranging from not detectable 
to 437  ng/L (ppt) (Sandhu et al. 1978).  Finished drinking water samples from Niagara Falls, New York, 
taken in 1978–1979, had a maximum mirex concentration of 0.03 μg/L (ppt) (Kim and Stone 1982); 
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however, in a survey in 1987, mirex was detected in only 5 of 1,147 drinking water samples from Ontario, 
Canada (maximum concentration of 5 ng/L [ppt]) (Environment Canada 1992). 
 
The pollution of the Niagara River from chemical manufacturing effluents and leachates from chemical 
manufacturing waste dumps has been well documented.  Between 1975 and 1982, mirex was detected in 
the aqueous phase of 6 of 22 samples in the Niagara River at levels between 0.0005 and 0.0075 ng/L (ppt) 
(Allan and Ball 1990).  Twelve percent of 104 whole water samples, collected from the Niagara River 
between 1981 and 1983, had mirex concentrations that ranged from below the detection limit 
(0.06 ng/L[ppt]) to 2.6 ng/L, with a median concentration of 0.06 ng/L (Oliver and Nicol 1984).  Mirex 
was detected in the suspended particulate phase of 42 Niagara River water samples taken at the mouth of 
the river in 1986–1987; 17% of the samples had a mean mirex concentration of 0.022 ng/L (ppt) (Allan 
and Ball 1990). 
 
In 1982, Mudambi et al. (1992) reported the mean mirex concentrations in the Lake Ontario system 
ranging from 1.85 to 30 pg/L.  An intralake comparison of chemicals found in the Great Lakes during the 
1986 spring turnover did not detect mirex in any of the lakes (Stevens and Neilson 1989), nor in the 
dissolved or particulate fractions of water from the St. Lawrence River between 1981 and 1987 (Germain 
and Langlois 1988).  In 1986, low levels of mirex were found in 8 of 14 water samples taken at various 
locations along the St. Lawrence River (Kaiser et al. 1990a).  The highest concentration observed was 
0.013 ng/L (ppt).  Sergeant et al. (1993) reported mirex concentrations in Lake Ontario water samples 
declined from 0.0015 μg/L (1.5 ng/L) in 1986 to <0.0004 μg/L (0.4 ng/L) in 1988. 
 
Mirex was detected in water samples taken in 1972 from areas in Mississippi that had been aerially 
treated with mirex to control the imported red fire ant (Spence and Markin 1974).  Water samples taken 
from the bottom of a pond showed residue values that remained higher and more constant than those 
taken from the surface of the pond.  Water showed the highest residues immediately after treatment 
(bottom, 0.53 μg/L [ppb]; surface, 0.02 μg/L [ppb]), and detectable levels were still present as long as 
3 months after treatment (bottom, 0.005 μg/L [ppb]; surface, 0.003 μg/L [ppb]) (Spence and Markin 
1974). 
 
Chlordecone.  The solubility of chlordecone in water is low (1–3 mg/L) and as with mirex, contamination 
is more likely to be associated with the particulate matter in the water rather than the water itself.  
Chlordecone was detected primarily in water samples collected in and around the production facility site 
in Hopewell, Virginia, and in adjacent waters of the James River estuary.  Effluent from the Life Sciences 
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Products Company facility contained 0.1–1.0 mg/L (ppm) chlordecone, while water in holding ponds at 
the site contained 2–3 mg/L (ppm) chlordecone (Epstein 1978).  Levels of chlordecone in river water in 
August 1975 ranged from not detectable (<50 ng/L [ppt]) in the York River and Swift Creek areas, to 
levels of 1–4 μg/L (ppb) in Baileys Creek which received direct effluent discharges from the Hopewell 
Sewage Treatment Plant.  Water concentrations of up to 0.3 μg/L (ppb) were detected in the James River 
at the mouth of Bailey Creek and in the Appomattox River (upstream from Hopewell) at 0.1 μg/L (ppb) 
(Epstein 1978).  Hopewell drinking water drawn from the James River contained no detectable 
chlordecone levels (EPA 1978c; Epstein 1978).  In 1977, 12 years after production of chlordecone began 
and 2 years after production ceased, average concentrations of chlordecone in estuarine water (dissolved) 
were <10 ng/L (ppt) (Nichols 1990).  In October 1981, 6 years after production at the plant ceased, 
chlordecone water concentrations ranged from not detectable to 0.02 μg/L (ppb) (Lunsford et al. 1987). 
 
5.5.3   Sediment and Soil  
 
Mirex.  Mirex was identified in sediment samples collected in 1979 from Bloody Run Creek, which is a 
drainage ditch for the Hyde Park landfill in Niagara Falls, New York.  Mirex levels in the sediment 
ranged from 0.5 to 2 mg/kg (ppm) (detection limit, 0.5 mg/kg [ppm]) (Elder et al. 1981). 
 
Between 1979 and 1981, mean mirex concentrations in suspended sediments of the Niagara River 
declined from 12 to 1 ng/L (ppt); concentrations in bottom sediments were generally low, ranging from 
<1 μg/kg (ppb) to a maximum value of 890 μg/kg (ppb), at a site believed to be the source of mirex to the 
river (Allan and Ball 1990).  In 1981, mirex was detected in sediments of Lake Ontario near the mouth of 
the Niagara River at increasing concentrations to a maximum of 1,700 μg/kg (ppb) at a sediment depth of 
9 cm.  Concentrations decreased between 9 and 13 cm and were not detected in sediments below a depth 
of 13 cm.  Concentrations were chronologically correlated with mirex production and peak sales periods 
and were reduced when its use was restricted (Durham and Oliver 1983).  In 1982, mirex was detected in 
settling particulates from sediment traps in the Niagara River (average, 7 μg/kg [ppb]; range, 3.9–
18 μg/kg [ppb]), resuspended bottom sediments from the Niagara Basin of Lake Ontario (average, 
9.45 μg/kg [ppb], range 5.2−16 μg/kg [ppb]), and bottom sediments from Lake Ontario (average, 
48 μg/kg [ppb]) (Oliver and Charlton 1984). 
 
An analysis of urban runoff and sediment runoff collected between 1979 and 1983 from 12 urban areas in 
the Canadian Great Lakes Basin showed that mirex was not detected in any runoff waters, although it was 
found in 10% of 129 runoff sediment samples at a mean concentration of 1.3 μg/kg (ppb) (Marsalek and 
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Schroeter 1988).  Sediment samples collected from the St. Lawrence River between 1979 and 1981 
contained low concentrations of mirex (median, <0.1 μg/kg; range, <0.1–3.3 μg/kg), indicating that Lake 
Ontario is the source of the contamination to the river (Sloterdijk 1991).  Low levels of mirex were found 
in bottom sediment core samples taken from the riverine lakes in the St. Lawrence River in October 1985; 
the average concentration of mirex was 0.43 μg/kg (range, <0.01–0.95 μg/kg) (Kaiser et al. 1990a).  In 
1987, mirex was detected in suspended sediments throughout the St. Lawrence River.  At the St. 
Lawrence River stations near Kingston, the mirex concentration was approximately 5 μg/kg (ppb), but 
declined to about 1 μg/kg (ppb) near Quebec City (Kaiser et al. 1990a). 
 
In 1971 and 1972, mirex was detected in soil and sediment samples taken from areas in Louisiana and 
Mississippi that had been aerially treated with mirex to control the imported red fire ant (Spence and 
Markin 1974).  In Louisiana, samples were collected throughout the first year after spraying.  Soil and 
sediment residues in the Louisiana study peaked after 1 month (soil, 2.5 μg/kg [ppb]; sediment, 0.7 μg/kg 
[ppb]) and gradually declined over the remainder of the year.  In Mississippi, samples were collected for 
4 months following spraying.  Sediment residues in Mississippi also peaked about 1 month after spraying 
(1.1 μg/kg [ppb]) and gradually declined over the next couple of months.  The residue levels found in soil 
in Mississippi were much more variable and showed no distinctive pattern (Spence and Markin 1974). 
 
Less than 10% of the sediment samples taken from the San Joaquin River and its tributaries in California 
(an area of heavy organochloride pesticide use) in 1985 contained mirex residues; all samples contained 
<0.1 μg/kg (ppb) (Gilliom and Clifton 1990). 
 
Studies of sediment from seven sampling stations in the Upper Rockaway River, New Jersey, showed that 
sediment quality corresponded to the land-use data for the area (Smith et al. 1987).  The two upstream 
stations, which drain primarily forested areas of the Upper Rockaway Basin, had low mirex 
concentrations in the sediments (<0.1 μg/kg).  The remaining stations, which drained an area consisting of 
residential, commercial, and industrial land including six EPA Superfund sites, had mirex concentrations 
ranging from 8.2 to 80 μg/kg (ppb) (Smith et al. 1987). 
 
Sediment samples taken from 51 sampling locations in the Gulf of Mexico for the National Oceanic and 
Atmospheric Administration (NOAA) Status and Trends Mussel Watch Program were analyzed for mirex 
contamination (Sericano et al. 1990; Wade et al. 1988).  Average mirex concentrations of 0.07 μg/kg 
(ppb) (range, <0.01–0.67) and 0.18 μg/kg (ppb) (range, <0.02–3.58) were found in sediments in 1986 and 
MIREX AND CHLORDECONE  182 
 
5.  POTENTIAL FOR HUMAN EXPOSURE 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
1987, respectively.  The sampling sites represent the contaminant loading for the Gulf of Mexico estuaries 
removed from known point-sources of contamination (Sericano et al. 1990; Wade et al. 1988). 
 
Chlordecone.  With the exception of the James River area of Virginia, very little information is available 
on chlordecone residues in soil and sediment.  Chlordecone was detected in soil immediately surrounding 
the Life Sciences Products Company in Hopewell, Virginia, at levels of 1–2% (10,000–20,000 mg/kg) 
and contamination extended to 1,000 m at concentrations of 2–6 mg/kg (ppm) (Huggett and Bender 
1980). 
 
Assessment of sediment cores taken from the James River below Hopewell, Virginia, indicated that 
chlordecone concentrations were greatest nearest the release site.  Sediment concentrations of 
chlordecone in Baileys Creek, the waterbody into which effluent from the Hopewell municipal sewage 
treatment facility was discharged, were 2.2 mg/kg (ppm) (Orndorff and Colwell 1980).  Chlordecone 
concentrations of 0.44–0.74 mg/kg were found at sediment depths of 55–58 cm in the main channel of the 
James River.  This area had the highest sedimentation rate (>19 cm/year).  Further downriver, (80 km 
from Hopewell) in the James River estuary, chlordecone concentrations decreased and maximum 
concentrations were found closer to the sediment surface.  The highest chlordecone concentration of 
0.18 mg/kg (ppm) was from a sediment depth of 46–48 cm in an area with a sedimentation rate of 
10 cm/year (Cutshall et al. 1981). 
 
5.5.4   Other Media  
 
Mirex.  In general, because releases of mirex from its production and use as a pesticide were terminated 
in the late 1970s, mirex residues in various biological organisms are much lower than those reported 
during or shortly after its peak years of production and use.  This trend is supported by both regional and 
national studies. 
 
In areas where mirex was historically used for fire ant control, it has been detected in fish and other 
aquatic biota from contaminated rivers.  An analysis of mirex residues in primary, secondary, and tertiary 
consumers in oxbow lakes in Louisiana in 1980 indicated that although mirex was not detected in any 
water or sediment samples, or in the tissues of primary consumers (some fish), it was detected in the 
tissues of secondary consumers (fish and birds that consume invertebrates and insects), and in all tertiary 
consumers (fish-eating fish, birds, and snakes).  The highest mean mirex concentrations were found in 
cottonmouth snakes (0.11 mg/kg [ppm]) (Niethammer et al. 1984).  Fish taken from the lower Savannah 
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River during 1985 had mirex residues in their tissues that ranged from nondetectable to 1 mg/kg (ppm) 
wet weight, although most residues were near 0.02 mg/kg (Winger et al. 1990). 
 
Of all the Coho salmon collected from all of the Great Lakes in 1980, only fish taken from Lake Ontario 
contained detectable mirex residues at an average concentration of 0.14 μg/g (ppm) (Clark et al. 1984).  
The mean concentration of mirex residues in rainbow trout taken from Lake Ontario was 0.11 μg/g (ppm), 
while the mean water concentration in the lake was 0.008 ng/L (ppt) (Oliver and Niimi 1985).  Borgmann 
and Whittle (1991) studied the contaminant concentration trends in Lake Ontario lake trout from 1977 to 
1988.  Mirex concentrations generally declined from 0.38 μg/g (ppm) in 1977 to 0.17 μg/g (ppm) in 1988, 
although there was considerable variability in the mirex residue data.  The concentrations of mirex also 
showed a distinct east-west gradient across the lake.  The highest mirex residues were detected in fish 
collected at the western side of the basin and were 70% above those detected in fish collected at the 
eastern portion of the basin.  Suns et al. (1993) conducted a similar study of spatial and temporal trends of 
organochlorine contaminants in spottail shiners from selected sites in the Great Lakes.  These authors 
reported that mirex was only detected in fish from the Niagara River, the Credit River in western Lake 
Ontario, and in the St. Lawrence River at Cornwall.  Mirex concentrations in spottail shiners collected 
during the late 1980s were generally lower than mirex residues found in spottail shiner samples collected 
during the 1970s.  Considerable fluctuation in mirex residues in spottail shiners was observed, which 
precluded proper trend assessment.  Based on the fish data, mirex inputs to Lake Ontario appeared to be 
continuing on an intermittent basis.  Newsome and Andrews (1993) analyzed mirex in fillet samples of 
11 commercial fish species from the Great Lakes.  The highest mirex concentrations were found in carp 
from a closed fishery area (120 μg/kg [ppb]), eel (56.8 μg/kg), carp from an open fishery area 
(5.24 μg/kg), bullhead (3.63 μg/kg), and trout (2.38 μg/kg). 
 
Burbot, a bottom-feeding fish, taken from remote lakes in Canada in 1985–1986, contained liver 
concentrations of mirex ranging between 3.7 and 17.4 μg/kg (ppb) lipid weight (detection limit, 
0.5 μg/kg), while photomirex was not detected.  The lowest mirex values were seen in fish from the most 
remote locations, suggesting that atmospheric transport of this compound was occurring (Muir et al. 
1990). 
 
Ninety percent of the mussels collected in 1985 at various points along the St. Lawrence River contained 
mirex at levels up to 1.6 μg/kg (ppb).  The only source of mirex was contaminated particles entering the 
river from Lake Ontario; mussels collected from the Ottawa River, which does not receive its water from 
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Lake Ontario, did not contain any mirex.  The mirex concentrations in the mussels decreased with 
distance from the lake (Metcalf and Charlton 1990). 
Mirex concentrations were measured in 78 snapping turtles collected from 16 sites in southern Ontario, 
Canada, during 1988–1989 to evaluate the risk to human health (Herbert et al. 1993).  Mean 
concentrations of mirex in the muscle tissue were below fish consumption guidelines for mirex 
(100 μg/kg [ppb]) and ranged from not detectable to 3.95 μg/kg (ppb).  However, mirex concentrations in 
older turtles from some sites were as high as 9.3 μg/kg (ppb). 
Freshwater fish sampled (as part of the U.S. Fish and Wildlife Service National Contaminant 
Biomonitoring Program) between 1980 and 1984 contained detectable concentrations of mirex.  Mirex 
was detected in 18% of the 1980 samples (maximum concentration, 210 μg/kg [ppb]; mean concentration, 
0.01 μg/g) and in 13% of the 1984 samples (maximum concentration, 440 μg/kg [ppb]; mean 
concentration, 10 μg/kg).  The highest mirex concentrations were detected in whole fish taken from Lake 
Ontario, the St. Lawrence River, and the southeastern United States, all areas where mirex had been 
manufactured or used (Schmitt et al. 1990).  In the EPA National Study of Chemical Contaminants in 
Fish, mirex was detected at 38% of 362 sites sampled.  The mean mirex concentration was 3.86 μg/kg 
(ppb) and the maximum concentration was 225 μg/kg (ppb).  The highest concentrations of mirex were 
detected in fish collected in the Lake Ontario area of New York State (EPA 1992a). 
Of oysters (Crassostrea virginica) sampled throughout the United States between 1965 and 1972 for the 
National Pesticide Monitoring Program, only those from South Carolina locations had detectable mirex 
residues (maximum concentration, 540 μg/kg [ppb]) with most residues being <38 μg/kg (ppb) (Butler 
1973).  Oysters taken from 49 sampling locations in the Gulf of Mexico for the NOAA Status and Trends 
Mussel Watch Program 1986–1987 were analyzed for mirex contamination (Sericano et al. 1990; Wade et 
al. 1988).  Average mirex concentrations of 1.40 μg/kg (ppb) (range, <0.25–15.8 μg/kg) and 1.38 μg/kg 
(ppb) (range, <0.25–16.1) were found in oysters in 1986 and 1987, respectively (Sericano et al. 1990).  
The sampling sites represent the contaminant loading for the Gulf of Mexico estuaries removed from 
known point-sources of contamination (Wade et al. 1988). 
Mirex was also detected in the muscle and liver tissues of seven species of aquatic and terrestrial 
mammals collected in areas of Alabama and Georgia that had been repeatedly treated with mirex to 
suppress fire ant populations from March 1973 through July 1976.  At 6 months post-treatment, skunk 
and opossum muscle tissue contained the highest mean mirex concentrations of 3.50 and 1.5 1 μg/g 
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(ppm), respectively (Hill and Dent 1985).  Two years post-treatment, muscle residues declined in all 
species except the mink, which increased from 0.14 μg/g at 6 months post-treatment to a mean muscle 
residue of 0.28 μg/g at 1 year post-treatment and 0.53 μg/g at 2 years post-treatment. 
 
Mirex was detected in the subcutaneous fat and breast muscle of 55 waterfowl collected in New York 
State during 1981 and 1982.  Average mirex levels were 280 μg/kg (ppb) in fat and 2.0 μg/kg in breast 
muscle (Kim et al. 1985).  Mirex was detected at a concentration of >500 μg/kg (ppb) in 24 of 
164 samples of subcutaneous fat of six species of waterfowl (mallard, black duck, scaup, wood duck, 
bufflehead, and Canada goose) harvested by hunters in 1983–1984 (Foley 1992).  Mirex was detected in 
fat samples from 5 of 26 goldeneyes shot by hunters in December 1988 in New York State; however, no 
quantitative information on mirex residues was provided (Swift et al. 1993).  Gebauer and Weseloh 
(1993) used farm-raised mallards as sentinels for accumulation of pollutants at three sites in southern 
Ontario, Canada.  The sites included the Hamilton Harbor Confined Disposal Facility designated as an 
“Area of Concern” because of high pollutant concentrations of sediment; the Winona Sewage Lagoons, 
which contained high concentrations of metals; and Big Creek Marsh, which served as a reference area.  
The geometric mean concentrations of mirex detected in muscle tissue at each site were 7.1 μg/kg (ppb) at 
the Hamilton Harbor site after 115 days; 0.07 μg/kg at the sewage lagoon site after 112 days; and 
0.14 μg/kg at the reference site after 30 days. 
 
Mirex residues were detected in food samples analyzed as part of the FDA Pesticide Residue Monitoring 
Studies conducted from 1978 to 1982 of 49,877 food samples and from 1982 to 1986 of 49,055 food 
samples; however, the frequency of detection was unspecified but was <1 and 2% respectively (Yess et 
al. 1991a, 1991b).  A similar 1985 analysis of foods grown in Ontario, Canada, failed to detect any mirex 
or photomirex in any of the vegetable, fruit, milk, egg, or meat products tested (Davies 1988).  Mirex was 
also detected in the FDA Pesticide Residue Monitoring Study from 1986 to 1987; however, the frequency 
of detection was unspecified but <1% (FDA 1988).  Mirex was not detected in 27,065 samples of food 
collected in 10 state food laboratories from 1988 and 1989 (Minyard and Roberts 1991).  Mirex was also 
not detected in domestically produced or imported foods sampled as part of the FDA Pesticide Residue 
Monitoring Study during 1989 (FDA 1990), was detected (at <1% occurrence) in foods sampled in 1990 
(FDA 1991), and was not detected in foods sampled in 1991 (FDA 1992) and 1992 (FDA 1993).  Mirex 
residues were detected in one sample of 806 cornposited milk samples collected through the Pasteurized 
Milk Program by the EPA in 1990–1991 (Trotter and Dickerson 1993).  The milk was sampled at 
63 stations that provide an estimated 80% of the milk delivered to U.S. population centers.  At each 
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station, milk from selected sources was cornposited to represent milk routinely consumed in the station’s 
metropolitan area.  The detection of mirex occurred in milk samples from Cristobal, Panama. 
 
Chlordecone.  Because releases of chlordecone from its production and use ceased in the late 1970s, 
current chlordecone residues in various biological organisms are generally lower than those reported 
during its peak production years (1974–1975).  Releases of chlordecone from the manufacturing plant in 
Hopewell, Virginia, severely contaminated the James River estuary in Virginia from 1966 through 1975.  
In 1977, 12 years after production of chlordecone began and 2 years after it ceased, average chlordecone 
concentrations in various biological organisms in the estuary were as follows (Nichols 1990): 
phytoplankton, 1.30 μg/g; zooplankton, 4.80 μg/g; freshwater fish, 2.50 μg/g; migratory fish, 0.40 μg/g; 
and benthic fauna (molluscs), 1.50 μg/g.  Considerable variations in chlordecone concentrations detected 
in fish species in the James River were in part associated with different life histories and residence times 
of each species in the estuary (Huggett and Bender 1980).  Freshwater species that were permanent 
residents in the upper estuary exhibited the highest range in tissue residues varying from <0.1 μg/g (ppm) 
for channel catfish to >2 μg/g for largemouth bass.  Residues in marine fish increased with length of 
exposure time in the James River.  American shad that inhabited the estuary only briefly showed average 
chlordecone residues of <0.1 μg/g.  Longer-term residents that spent 6–9 months in the estuary, such as 
spot and croaker, contained 1 μg/g.  Concentrations in resident estuarine species ranged from 0.7 μg/g for 
the bay anchovy to 2.7 μg/g for white perch. 
 
Dredging of the James River in Virginia increased the chlordecone levels in resident clams (Rangia 
cuneata).  The river has contaminated sediments containing up to 3.5 μg/g (ppm) chlordecone.  Prior to 
the 2-week dredging period, chlordecone concentrations in the water column ranged from nondetectable 
to 0.02 μg/L (ppb); background concentrations in the clams ranged from 0.06 to 0.14 μg/g.  During the 
dredging, body burdens of chlordecone in clams increased by 0.01–0.04 μg/g (ppm).  Two weeks after the 
dredging was completed, residues in the clams had not returned to predredging levels (Lunsford et al. 
1987). 
 
In addition to the James River area, chlordecone residues of 0.025 and 0.23 mg/kg (ppm) were detected in 
trout and suckers, respectively, collected from Spring Creek 18 miles downstream of the Nease Chemical 
Plant in Pennsylvania (EPA 1978c).  This plant produced small quantities of chlordecone from 1966 to 
1974 (Epstein 1978). 
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Because chlordecone contamination of the James River in Virginia and Spring Creek in Pennsylvania 
represented relatively isolated incidents resulting from industrial negligence and because the compound 
was not used extensively on agricultural crops in the United States, monitoring for this compound has not 
been included as part of the U.S. Fish and Wildlife Service National Contaminant Biomonitoring Program 
(Schmitt et al. 1990) or the EPA National Study of Chemical Residues in Fish (EPA 1992a). 
 
Chlordecone residues were detected in the FDA Pesticide Residue Monitoring Studies of 49,877 food 
samples from 1978 to 1982 and of 49,055 food samples from 1982 to 1986; however, the frequency of 
detection was unspecified but was less than 1 and 2%, respectively (Yess et al. 1991a, 1991b).  
Chlordecone was also detected in 1 of 27,065 samples of food collected from 10 state laboratories during 
1988 and 1989 (Minyard and Roberts 1991).  Chlordecone was not detected in any domestically produced 
or imported foods analyzed as part of the FDA Pesticide Residue Monitoring Studies during 1986–1987, 
1988–1989, 1989–1990, 1990–1991, and 1991–1992 (FDA 1988, 1990, 1991, 1992, 1993). 
 
5.6   GENERAL POPULATION EXPOSURE  
 
Mirex.  Mirex has not been produced since 1976 and has not been used in the United States since 1977, 
when all registered uses of the product were canceled.  The potential for exposure of the general 
population, therefore, is relatively small and should continue to diminish over time.  Members of the 
general population may be exposed to low concentrations of mirex primarily through consumption of 
contaminated food stuffs, in particular contaminated fish and shellfish from Lake Ontario, the St. 
Lawrence River, and Spring Creek in Pennsylvania, which were all contaminated by industrial discharges, 
and areas of the southern United States that were extensively treated with mirex for fire ant control.  No 
dietary intake estimates are available (FDA 1990, 1991, 1992) since mirex has been so infrequently found 
in foodstuffs in recent years.  Mirex exposure from drinking water has not been found to constitute 
significant human exposure since mirex is relatively insoluble in water and rapidly adsorbs to sediment 
(EPA 1978c). 
 
Mirex has been detected in the general U.S. population.  The National Human Monitoring Program for 
Pesticides detected mirex at low frequencies in human adipose tissue collected nationwide.  In 1972, 
mirex was detected in 0.05% of all samples and in 1973, mirex was detected in 0.09% of all samples; 
however, by 1974, the percentage of positive samples had increased to 0.11% (Kutz et al. 1979).  Mirex 
was detected in 13% of samples collected as part of the 1982 National Adipose Tissue Survey (EPA 
1986b).  Concentrations of mirex ranged from 0.008 to 0.39 μg/g (ppm) (mean concentration 0.025 μg/g).  
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Further analysis of adipose tissue samples collected as part of the 1982 National Adipose Tissue Survey 
failed to detect mirex in any tissues from children (newborn infants to 14-year-olds); however, tissue 
samples from adults 15–44 and ≥45 years old were found to contain mirex residues.  The greatest 
concentrations (values not provided) for 15–44-year-old adults were found in the Northeast and South 
Atlantic States, while the greatest concentrations for >45-year-old adults were found in the West South 
Central States and Northeast States (Phillips and Birchard 1991a). 
 
In a survey of human adipose tissue from residents of southwestern Ontario between 1976 and 1979, 
mirex was detected in 32.8% of the samples at mean concentrations of <0.01 mg/kg (ppm).  In 1980–
1981, it was detected in more samples (64.8%) at greater concentrations (mean concentration, 
0.04 mg/kg); however, in 1983–1984, it was detected in only 6.2% of the samples at an average 
concentration of 0.06 mg/kg.  Adipose tissue collected from 13 infants during this time contained 
<0.01 mg/kg mirex, except for one sample that contained 0.02 mg/kg.  Mirex was not detected in any 
blood or human milk samples collected for this survey (Frank et al. 1988).  A 1985 nationwide study of 
chlorinated hydrocarbons in the adipose tissue of Canadians found mirex to be present in all 108 samples 
collected nationwide at a mean concentration of 7 ng/g (ppb) (maximum concentration, 72 ng/g).  The 
high rate of detection was a result of improved analytical procedures and lower limits of detection than 
those used in earlier studies.  Residues were evenly distributed throughout the country and did not differ 
significantly between the sexes or by age (Mes et al. 1990).  In a 1990–1991 survey of human adipose 
tissue from residents of British Columbia, Canada, mirex was detected at a minimum, mean, and 
maximum concentration of 1.15, 6.10, and 33.3 ng/g (ppb) lipid, respectively (Teschke et al. 1993). 
 
Mirex residues in human blood serum were measured as part of the Second National Health and Nutrition 
Examination Survey (NHANES II), conducted between 1976 and 1980.  Of the 4,038 samples analyzed, 
mirex concentrations ranged from not detectable to detected but below quantifiable levels (10 μg/L [ppb]) 
(Stehr-Green 1989). 
 
Mirex was detected (mean detection limit 3 pg/g [ppt]) in 62% of 412 breast milk samples collected from 
women in all Canadian provinces (Mes et al. 1993).  The mean, median, and maximum mirex 
concentrations were 0.14, 0.08, and 6.56 ng/g (ppb), respectively, in whole milk and 4.2, 2.3, and 
124.5 ng/g, respectively, in milk fat.  In previous studies, mirex residues were not detected.  None of the 
1,436 human milk samples collected in the United States in the late 1970s as part of the National Human 
Milk Study contained identifiable levels of mirex (Savage et al. 1981).  A similar national study of 
nursing mothers in Canada (Mes et al. 1986) also failed to detect mirex in any human milk samples.  The 
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high rate of detection in the Mes et al. (1993) study was a result of improved analytical procedures and 
lower limits of detection. 
 
An analysis of potential human exposure to contaminants in drinking water and foods was conducted in 
Ontario, Canada, in 1980.  Mirex was detected only in edible fish taken from Toronto Harbor on Lake 
Ontario.  The average mirex concentrations were 0.001 mg/kg (ppm) wet weight for white sucker, 
0.01 mg/kg wet weight for rainbow trout, and 0.033 mg/kg wet weight for northern pike.  Estimated 
human exposure levels, based on an average fish consumption of 0.53 kg/year for each fish species, were 
0.0005 for white sucker, 0.005 for rainbow trout, and 0.017 mg/year for northern pike, respectively 
(Davies 1990). 
 
Mirex is no longer manufactured, formulated, or used in the United States.  Therefore, there is currently 
no occupational exposure to this chemical associated with its production or application as a pesticide.  
Current occupational exposure is most likely to occur for workers employed at waste disposal sites or 
those engaged in remediation activities including removal of soils and sediments contaminated with 
mirex.  There is a slight possibility of exposure for workers involved in dredging activities (e.g., sediment 
remediation work performed by the Corps of Engineers). 
 
Chlordecone.  Chlordecone has not been produced since 1975 or used in the United States since 1978 
when all registered uses of the product were canceled.  The potential for exposure of the general 
population, therefore, is relatively small and should continue to diminish over time.  Members of the 
general population may be exposed to low concentrations of chlordecone primarily through consumption 
of contaminated foodstuffs, in particular contaminated fish and shellfish from the James River in Virginia.  
No dietary intake estimates are available (FDA 1990, 1991, 1992) since chlordecone has been so 
infrequently found in foodstuffs in recent years.  Chlordecone exposure from drinking water has not been 
found to constitute significant human exposure since chlordecone is relatively insoluble in water and 
rapidly adsorbs to sediment (EPA 1978c). 
 
No information was located for the general population on chlordecone concentrations in human adipose 
tissue or blood as this compound was not included in any major national study (e.g., National Human 
Adipose Study).  Chlordecone was detected in 9 of 298 samples of human milk collected in the southern 
United States; however, the detection limit was relatively high (1 μg/kg) (EPA 1978c). 
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With regard to occupational exposures, chlordecone was detected in blood samples from workers at the 
Life Sciences Products Company in Hopewell, Virginia.  Chlordecone levels in the blood of 32 workers 
at the manufacturing plant ranged from 0.165 to 26.0 μg/mL (ppm) (Epstein 1978).  The mean blood level 
of workers exhibiting symptoms of nervousness and tremors was 8.48 μg/mL, compared to a mean of 
1.57  μg/mL in workers exhibiting no symptoms (Epstein 1978).  In another occupational study, Cannon 
et al. (1978) reported maximum chlordecone blood levels in workers at the Hopewell facility of 
11.8 μg/mL.  Chlordecone blood levels of workers who reported illness averaged 2.53 μg/mL, while 
blood levels for workers reporting no illness averaged 0.6 μg/mL. 
 
In 1975, when chlordecone was still being produced, over half of the workers at a manufacturing plant 
developed clinical illness characterized by nervousness, tremor, weight loss, opsoclonus, pleuritic and 
joint pain, and oligospermia (Cannon et al. 1978).  During the years of production, chlordecone was also 
detected in family members of the plant workers at the Life Sciences Products Company in Hopewell, 
Virginia.  Although half of the workers at the plant had clinical signs of chlordecone poisoning, such 
signs were detected in only two family members who washed contaminated clothes (Cannon et al. 1978).  
Another study also found higher chlordecone levels in members of chlordecone workers’ families 
compared with families of workers at other local industries or other community residents (Taylor et al. 
1978).  Such illness could have been mitigated by appropriate occupational health measures that would 
prevent the transport of contaminated materials from the workplace, such as not bringing work clothes 
home (Knishkowy and Baker 1986). 
 
Current occupational exposure is most likely to occur for workers employed at waste disposal sites or 
those engaged in remediation activities associated with the clean-up or removal of soils or sediments that 
are contaminated with chlordecone. 
 
In the Fourth National Report on Human Exposures to Environmental Chemicals (CDC 2018a, 2018b), 
mirex levels in serum (lipid adjusted) were reported according to various age groups, gender, and 
race/ethnicity.  The results are presented in Tables 5-4, 5-5, 5-6, and 5-7. 
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Table 5-4.  Geometric Mean and Selected Percentiles of Mirex (Lipid Adjusted) Serum Concentrations (in ng/g of 
Lipid or Parts per Billion on a Lipid-Weight Basis) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES) 1999–2004 
 
 
Survey yearsa 
Geometric mean 
(95% CI) 
Selected percentiles (95% CI) Sample 
size 50th  75th  90th  95th 
Total 1999–2000 
2001–2002 
2003–2004 
*b 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
15.8 (<LOD–73.7) 
8.40 (<LOD–13.0) 
<LOD 
57.1 (13.2–230) 
13.2 (7.90–29.6) 
1,853 
2,257 
1,951 
Age group        
 12–19 years 1999–2000 
2001–2002 
2003–2004 
* 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
659 
728 
592 
 ≥20 years 1999–2000 
2001–2002 
2003–2004 
* 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
19.6 (<LOD–108) 
9.10 (<LOD–15.6) 
<LOD 
71.0 (14.6–305) 
15.4 (8.10–37.1) 
1,194 
1,529 
1,359 
Gender        
 Males 1999–2000 
2001–2002 
2003–2004 
* 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
16.1 (<LOD–65.6) 
9.70 (<LOD–15.4) 
<LOD 
50.8 (12.3–225) 
15.5 (9.70–24.4) 
887 
1,052 
949 
 Females 1999–2000 
2001–2002 
2003–2004 
* 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
15.0 (<LOD–108) 
<LOD 
<LOD 
63.0 (12.0–374) 
11.6 (<LOD–31.3) 
966 
1,205 
1,002 
Race/ethnicity 
 Mexican 
Americans 
1999–2000 
2001–2002 
2003–2004 
* 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
617 
548 
459 
 Non-
Hispanic 
blacks 
1999–2000 
2001–2002 
2003–2004 
* 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
13.7 (<LOD–47.3) 
<LOD 
15.5 (<LOD-42.2) 
51.3 (15.4–230) 
18.1 (8.70–40.8) 
39.5 (<LOD–115) 
153 (30.5–425) 
40.3 (15.5–82.7) 
398 
500 
484 
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Table 5-4.  Geometric Mean and Selected Percentiles of Mirex (Lipid Adjusted) Serum Concentrations (in ng/g of 
Lipid or Parts per Billion on a Lipid-Weight Basis) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES) 1999–2004 
 
 
Survey yearsa 
Geometric mean 
(95% CI) 
Selected percentiles (95% CI) Sample 
size 50th  75th  90th  95th 
 Non-
Hispanic 
whites 
1999–2000 
2001–2002 
2003–2004 
* 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
15.1 (<LOD–104) 
<LOD 
<LOD 
66.7 (12.5–291) 
11.6 (<LOD–23.4) 
688 
1,049 
884 
 
aThe limit of detection for survey years 1999–2000, 2001–2002, and 2003–2004 were 14.6, 10.5, and 7.8 ng/g, respectively. 
bNot calculated: proportion of results below limit of detection was too high to provide a valid result. 
 
CI = confidence interval; LOD = limit of detection 
 
Source:  CDC 2018a, 2018b  
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Table 5-5.  Weighted Arithmetic Mean and Unadjusted Standard Error of Mirex 
(Lipid Adjusted) Pooled Serum Concentrations (in ng/g of Lipid or Parts per 
Billion on a Lipid-Weight Basis) for the U.S. Population from the National 
Health and Nutrition Examination Survey (NHANES) 2005–2010 
 
Category 
Age 
(years) 
Survey 
yearsa 
Weighted arithmetic 
meanb 
Unadjusted standard 
errorc Number of poolsd 
Non-
Hispanic 
white male 
12–19 
 
 
20–39 
 
 
40–59 
 
 
≥60 
 
 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
*e 
* 
* 
3.88f 
* 
* 
6.39f 
4.25 
5.25 
5.32 
6.36 
4.89 
* 
* 
* 
2.18 
* 
* 
2.15 
0.31 
1.32 
0.61 
1.34 
0.44 
9 
6 
10 
12 
15 
17 
12 
16 
17 
15 
23 
21 
Non-
Hispanic 
white 
female 
12–19 
 
 
20–39 
 
 
40–59 
 
 
≥60 
 
 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
* 
* 
* 
* 
* 
* 
2.42 
2.05 
3.32 
3.51 
3.90 
4.42 
* 
* 
* 
* 
* 
* 
0.14 
0.28 
0.33 
0.24 
0.39 
0.4 
10 
7 
8 
16 
13 
19 
13 
17 
17 
17 
21 
22 
Non-
Hispanic 
black 
male 
12–19 
 
 
20–39 
 
 
40–59 
 
 
≥60 
 
 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
* 
* 
* 
2.68 
* 
* 
5.90 
16.8f 
6.44 
27.2f 
13.9 
14.2 
* 
* 
* 
0.59 
* 
* 
0.49 
6.1 
1.04 
10.1 
2.1 
4.1 
13 
6 
6 
6 
6 
7 
5 
6 
7 
5 
8 
9 
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Table 5-5.  Weighted Arithmetic Mean and Unadjusted Standard Error of Mirex 
(Lipid Adjusted) Pooled Serum Concentrations (in ng/g of Lipid or Parts per 
Billion on a Lipid-Weight Basis) for the U.S. Population from the National 
Health and Nutrition Examination Survey (NHANES) 2005–2010 
 
Category 
Age 
(years) 
Survey 
yearsa 
Weighted arithmetic 
meanb 
Unadjusted standard 
errorc Number of poolsd 
Non-
Hispanic 
black 
female 
12–19 
 
 
20–39 
 
 
40–59 
 
 
≥60 
 
 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
* 
* 
* 
1.62 
* 
* 
5.92 
5.42 
5.03 
10.3 
24.0f 
7.49 
* 
* 
* 
0.32 
* 
* 
0.65 
1.21 
0.84 
2.7 
9.3 
1.68 
14 
5 
6 
7 
8 
7 
7 
8 
7 
5 
7 
7 
Mexican 
American 
male 
12–19 
 
 
20–39 
 
 
40–59 
 
 
≥60 
 
 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
* 
* 
* 
* 
* 
* 
2.66 
4.37f 
3.08 
2.89 
11.0f 
5.1 
* 
* 
* 
* 
* 
* 
0.74 
1.38 
0.83 
0.78 
8.0 
1.27 
11 
6 
8 
9 
9 
8 
4 
6 
8 
4 
5 
5 
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Table 5-5.  Weighted Arithmetic Mean and Unadjusted Standard Error of Mirex 
(Lipid Adjusted) Pooled Serum Concentrations (in ng/g of Lipid or Parts per 
Billion on a Lipid-Weight Basis) for the U.S. Population from the National 
Health and Nutrition Examination Survey (NHANES) 2005–2010 
 
Category 
Age 
(years) 
Survey 
yearsa 
Weighted arithmetic 
meanb 
Unadjusted standard 
errorc Number of poolsd 
Mexican 
American 
female 
12–19 
 
 
20–39 
 
 
40–59 
 
 
≥60 
 
 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
* 
* 
* 
* 
* 
* 
1.84 
3.76f 
* 
2.84 
2.59 
4.04 
* 
* 
* 
* 
* 
* 
0.34 
1.3 
* 
0.37 
0.49 
0.97 
16 
5 
7 
9 
8 
10 
6 
6 
9 
3 
5 
6 
All 
Hispanic 
male 
12–19 
20–39 
40–59 
≥60 
2009–2010 
2009–2010 
2009–2010 
2009–2010 
* 
* 
4.58 
5.18 
* 
* 
1.27 
0.82 
11 
13 
13 
8 
All 
Hispanic 
female 
12–19 
20–39 
40–59 
≥60 
2009–2010 
2009–2010 
2009–2010 
2009–2010 
* 
* 
* 
4.13 
* 
* 
* 
0.55 
10 
14 
14 
11 
 
aThe limits of detection for survey years 2005–2006, 2007–2008, and 2009–2010 were 1.46, 1.4, and 2.19 ng/g, 
respectively. 
bWeighted arithmetic means are not comparable to weighted geometric means. 
cUnadjusted standard errors do not incorporate survey design effects. 
dEach pool was composed of serum from eight persons. 
eNot calculated: proportion of results below limit of detection was too high to provide a valid result. 
fStandard error of the mean estimate is >30%. 
 
CI = confidence interval; LOD = limit of detection 
 
Source:  CDC 2018a, 2018b  
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Table 5-6.  Geometric Mean and Selected Percentiles of Mirex (Whole Weight) Serum Concentrations (in ng/g of 
Serum or Parts per Billion) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES) 1999–2004 
 
 
Survey yearsa 
Geometric mean 
(95% CI) 
Selected percentiles (95% CI) Sample 
size 50th  75th  90th  95th 
Total 1999–2000 
2001–2002 
2003–2004 
*b 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
0.100 (<LOD–0.470) 
0.54 (<LOD–0.084) 
<LOD 
0.410 (0.080–1.73) 
0.093 (0.052–0.170) 
1,853 
2,257 
1,951 
Age group        
 12–19 years 1999–2000 
2001–2002 
2003–2004 
* 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
659 
728 
592 
 ≥20 years 1999–2000 
2001–2002 
2003–2004 
* 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
0.140 (<LOD–0.690) 
0.059 (<LOD–0.102) 
<LOD 
0.470 (0.090–1.92) 
0.106 (0.053–0.215) 
1,194 
1,529 
1,359 
Gender        
 Males 1999–2000 
2001–2002 
2003–2004 
* 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
0.110 (<LOD–0.470) 
0.064 (<LOD–0.106) 
<LOD 
0.370 (0.090–1.37) 
0.108 (0.062–0.170) 
887 
1,052 
949 
 Females 1999–2000 
2001–2002 
2003–2004 
* 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
0.090 (<LOD–0.510) 
<LOD 
<LOD 
0.430 (0.070–1.79) 
0.077 (<LOD–0.170) 
966 
1,205 
1,002 
Race/ethnicity 
 Mexican 
Americans 
1999–2000 
2001–2002 
2003–2004 
* 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
617 
548 
459 
 Non-
Hispanic 
blacks 
1999–2000 
2001–2002 
2003–2004 
* 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
0.090 (<LOD–0.240) 
<LOD 
0.090 (<LOD–0.220) 
0.310 (0.090–1.41) 
0.112 (0.055–0.268) 
0.220 (<LOD–0.450) 
1.08 (0.170–3.02) 
0.256 (0.089–0.635) 
398 
500 
484 
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Table 5-6.  Geometric Mean and Selected Percentiles of Mirex (Whole Weight) Serum Concentrations (in ng/g of 
Serum or Parts per Billion) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES) 1999–2004 
 
 
Survey yearsa 
Geometric mean 
(95% CI) 
Selected percentiles (95% CI) Sample 
size 50th  75th  90th  95th 
 Non-
Hispanic 
whites 
1999–2000 
2001–2002 
2003–2004 
* 
* 
* 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
<LOD 
0.100 (<LOD–0.610) 
<LOD 
<LOD 
0.450 (0.080–1.79) 
0.079 (<LOD–0.174) 
688 
1,049 
884 
 
aThe limit of detection for survey years 1999–2000, 2001–2002, and 2003–2004 were 14.6, 10.5, and 7.8 ng/g, respectively. 
bNot calculated: proportion of results below limit of detection was too high to provide a valid result. 
 
CI = confidence interval; LOD = limit of detection 
 
Source:  CDC 2018a, 2018b  
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Table 5-7.  Weighted Arithmetic Mean and Unadjusted Standard Error of Mirex 
(Whole Weight) Pooled Serum Concentrations (in ng/g of Serum or Parts per 
Billion) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES) 2005–2010 
 
Category 
Age 
(years) 
Survey 
yearsa 
Weighted arithmetic 
meanb 
Unadjusted standard 
errorc Number of poolsd 
Non-
Hispanic 
white male 
12–19 
 
 
20–39 
 
 
40–59 
 
 
≥60 
 
 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
*e 
* 
* 
0.027f 
* 
* 
0.048f 
0.031 
0.034 
0.036 
0.040 
0.030 
* 
* 
* 
0.014 
* 
* 
0.016 
0.003 
0.008 
0.004 
0.008 
0.003 
9 
6 
10 
12 
15 
17 
12 
16 
17 
15 
23 
21 
Non-
Hispanic 
white 
female 
12–19 
 
 
20–39 
 
 
40–59 
 
 
≥60 
 
 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
* 
* 
* 
* 
* 
* 
0.018 
0.014 
0.021 
0.026 
0.026 
0.027 
* 
* 
* 
* 
* 
* 
0.002 
0.002 
0.002 
0.002 
0.003 
0.002 
10 
7 
8 
16 
13 
19 
13 
17 
17 
17 
21 
22 
Non-
Hispanic 
black 
male 
12–19 
 
 
20–39 
 
 
40–59 
 
 
≥60 
 
 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
* 
* 
* 
0.016 
* 
* 
0.038 
0.109f 
0.041 
0.168f 
0.084 
0.076 
* 
* 
* 
0.004 
* 
* 
0.003 
0.04 
0.008 
0.062 
0.012 
0.023 
13 
6 
6 
6 
6 
7 
5 
6 
7 
5 
8 
9 
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Table 5-7.  Weighted Arithmetic Mean and Unadjusted Standard Error of Mirex 
(Whole Weight) Pooled Serum Concentrations (in ng/g of Serum or Parts per 
Billion) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES) 2005–2010 
 
Category 
Age 
(years) 
Survey 
yearsa 
Weighted arithmetic 
meanb 
Unadjusted standard 
errorc Number of poolsd 
Non-
Hispanic 
black 
female 
12–19 
 
 
20–39 
 
 
40–59 
 
 
≥60 
 
 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
* 
* 
* 
0.009 
* 
* 
0.038 
0.032 
0.028 
0.067 
0.146f 
0.043 
* 
* 
* 
0.002 
* 
* 
0.004 
0.008 
0.005 
0.016 
0.057 
0.01 
14 
5 
6 
7 
8 
7 
7 
8 
7 
5 
7 
7 
Mexican 
American 
male 
12–19 
 
 
20–39 
 
 
40–59 
 
 
≥60 
 
 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
* 
* 
* 
* 
* 
* 
0.022f 
0.031f 
0.020 
0.022f 
0.074f 
0.031 
* 
* 
* 
* 
* 
* 
0.007 
0.01 
0.005 
0.008 
0.052 
0.008 
11 
6 
8 
9 
9 
8 
4 
6 
8 
4 
5 
5 
Mexican 
American 
female 
12–19 
 
 
20–39 
 
 
40–59 
 
 
≥60 
 
 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
2005–2006 
2007–2008 
2009–2010 
* 
* 
* 
* 
* 
* 
0.014 
0.024f 
* 
0.022 
0.018 
0.023 
* 
* 
* 
* 
* 
* 
0.003 
0.008 
* 
0.005 
0.003 
0.005 
16 
5 
7 
9 
8 
10 
6 
6 
9 
3 
5 
6 
All 
Hispanic 
male 
12–19 
20–39 
40–59 
≥60 
2009–2010 
2009–2010 
2009–2010 
2009–2010 
* 
* 
0.031 
0.032 
* 
* 
0.008 
0.005 
11 
13 
13 
8 
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Table 5-7.  Weighted Arithmetic Mean and Unadjusted Standard Error of Mirex 
(Whole Weight) Pooled Serum Concentrations (in ng/g of Serum or Parts per 
Billion) for the U.S. Population from the National Health and Nutrition 
Examination Survey (NHANES) 2005–2010 
 
Category 
Age 
(years) 
Survey 
yearsa 
Weighted arithmetic 
meanb 
Unadjusted standard 
errorc Number of poolsd 
All 
Hispanic 
female 
12–19 
20–39 
40–59 
≥60 
2009–2010 
2009–2010 
2009–2010 
2009–2010 
* 
* 
* 
0.027 
* 
* 
* 
0.003 
10 
14 
14 
11 
 
aThe limits of detection for survey years 2005–2006 and 2007–2008 were 1.46 and 1.4 ng/g, respectively. 
bWeighted arithmetic means are not comparable to weighted geometric means. 
cUnadjusted standard errors do not incorporate survey design effects. 
dEach pool was composed of serum from eight persons. 
eNot calculated: proportion of results below limit of detection was too high to provide a valid result. 
fStandard error of the mean estimate is >30%. 
 
CI = confidence interval; LOD = limit of detection 
 
Source:  CDC 2018a, 2018b 
 
5.7   POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
 
A susceptible population will exhibit a different or enhanced response to mirex and chlordecone than will 
most persons exposed to the same level of mirex or chlordecone in the environment.  Reasons include 
genetic make-up, developmental stage, age, health and nutritional status (including dietary habits that may 
increase susceptibility, such as inconsistent diets or nutritional deficiencies), and substance exposure 
history (including smoking).  These parameters result in decreased function of the detoxification and 
excretory processes (mainly hepatic, renal, and respiratory) or the pre-existing compromised function of 
target organs (including effects or clearance rates and any resulting endproduct metabolites).  For these 
reasons, the elderly with declining organ function and the youngest of the population with immature and 
developing organs are generally expected be more vulnerable to toxic substances than healthy adults. 
 
Review of the literature regarding toxic effects of mirex and chlordecone did not reveal any human 
populations that are known to be unusually sensitive to mirex or chlordecone.  However, based on 
knowledge of the toxicities of mirex and chlordecone, some populations can be identified that may 
demonstrate unusual sensitivity to these chemicals.  Those with potentially high sensitivity to mirex 
include the very young.  Those with potentially high sensitivity to chlordecone include juvenile and 
elderly person and persons being treated with some classes of antidepressants that affect serotonin or the 
anticonvulsant, diphenylhydantoin. 
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In experimental animals, mirex administered within the week after birth causes a high incidence of 
cataracts and other lesions of the lens (Chernoff et al. 1979b; Gaines and Kimbrough 1970; Rogers and 
Grabowski 1984; Scotti et al. 1981).  These effects were observed whether the neonatal animals received 
mirex through the milk of lactating dams or directly by gavage.  Although it is unclear whether the lens of 
humans also undergoes a similar period of susceptibility, the possibility exists that newborn children may 
also develop cataracts if exposed to mirex shortly after birth. 
 
Studies in rats have demonstrated that certain treatments exacerbate the tremors associated with 
chlordecone exposure.  These include pretreatment with the anticonvulsant, diphenylhydantoin (Hong et 
al. 1986; Tilson et al. 1985, 1986b), and treatment with the nonselective serotonergic receptor agonist, 
quipazine (Gerhart et al. 1983).  Therefore, persons being treated with diphenylhydantoin for epilepsy or 
quipazine for depression may be likely to experience more severe tremors upon exposure to high levels of 
chlordecone.  Extrapolating from the effects seen in animals with quipazine, it might be likely that 
persons taking the prescription drug Prozac®, a SSRI used to treat depression, will also experience more 
severe tremors.  Furthermore, the elderly may be a susceptible population because serotonin metabolism 
is increased during aging (Walker and Fishman 1991). 
 
Studies in animals have also shown that juvenile animals experience a higher death rate than adults 
following exposure to chlordecone at equivalent mg/kg doses (Huber 1965).  No explanation was given 
for these findings, but similar sensitivities may exist in children.  Furthermore, although inhibition of 
Na+-K+ATPase, Mg2+ATPase, and Ca2+ATPase activities have not been definitively shown to be the 
mechanism underlying chlordecone toxicity, sufficient evidence exists to suggest that their inhibition may 
be involved in a number of adverse effects.  Neonatal rats have shown a greater inhibition of these 
enzymes than adult rats (Jinna et al. 1989).  This provides additional support for the suggestion that 
infants and young children may represent a susceptible population to the toxic effects of chlordecone. 
 
In contrast, a study of developing postnatal rats has shown that the young may be less susceptible to at 
least one of the toxic effects of chlordecone.  Young and adolescent rats show less potentiation of carbon 
tetrachloride toxicity than adult rats (Cai and Mehendale 1993).  This may be due to a combination of 
incomplete development of the microsomal enzyme systems and a higher level of hepatic regenerating 
activity in the very young rats.  In adolescent rats (35 and 45 days old), the microsomal enzyme activity is 
comparable to adult levels, but the level of damage is still less than in adult rats (60 days old).  This may 
be due to that fact that hepatic regenerating activity remained higher in the adolescents than in the adults. 
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In studies performed by Sobel and coworkers (Sobel et al. 2005, 2006; Wang et al. 2008), chronic 
exposure of systemic lupus erythematosus-prone female (NZB x NZW) F1 mice to chlordecone via 
subcutaneously-implanted pellets significantly shortened the time to onset of elevated autoantibody titers 
and renal disease in a dose-related manner.  These effects were not seen in nonlupus-prone BALB/c mice.  
These results indicate that humans with lupus may be particularly sensitive to chlordecone toxicity. 
 
Members of the general population who currently have potentially high exposures to mirex include 
recreational and subsistence fishers who may consume large quantities of fish and shellfish from 
waterbodies with mirex contamination, hunters who consume game species that may be contaminated 
with mirex, populations living near sites where mirex was manufactured or waste disposal sites 
contaminated with mirex, or populations living in areas where mirex was used extensively for fire ant 
control. 
 
Mirex contamination has triggered the issuance of several human health advisories nationwide.  As of 
September 1993, mirex was identified as the causative pollutant in eight fish consumption advisories in 
three different states (RTI 1993) (Table 5-8). 
 
Table 5-8.  1993 Fish Consumption Advisories for Mirex 
 
State Waterbody Extent 
Ohio Middle Fork/Little Beaver Creek SR Alternate 14 and Allen Road to SR 11, South of 
Lisbon 
Pennsylvania Spring Creek SR 3010 bridge at Oak Hall to mouth 
New York Irondequoit Bay 
Lake Ontario 
Lake Ontario 
Lake Ontario 
Niagara River 
St. Lawrence River 
Monroe County 
Below the Falls 
Below the Falls, west of Point Breeze 
Below the Falls, east of Point Breeze 
Below the Falls 
Entire River 
 
Source: RTI 1993 
 
EPA Office of Water identified mirex as a target analyte and recommended that this chemical be 
monitored in fish and shellfish tissue samples collected as part of state toxics monitoring programs.  EPA 
recommended that residue data obtained from these monitoring programs should then be used by states to 
conduct risk assessments to determine the need for issuing fish and shellfish consumption advisories for 
the protection of the general public as well as recreational and subsistence fishermen (EPA 1993a).  
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Recreational and subsistence fishers that consume appreciably larger amounts of locally caught fish from 
contaminated waterbodies may be exposed to higher levels of mirex associated with dietary intake (EPA 
1993a). 
 
Persons living in areas where mirex has been used for fire ant control or near where it was manufactured 
may be at increased risk of exposure.  Human tissue samples (unspecified) taken from 186 people at sites 
treated with mirex over the previous 10 years had mirex residues in the range of <1–1.32 μg/g (ppm) 
(mean concentration, 0.38 μg/g) (Holleman and Hammons 1980).  A 1975–1976 survey of 624 human 
adipose tissue samples from subjects living in eight southern states where mirex had been used for fire ant 
control indicated that 10.2% of the population in the area had detectable levels of mirex at a geometric 
mean concentration of 0.286 μg/g (ppm).  Populations living in two states, Texas and North Carolina, had 
no detectable mirex residues in their tissues, whereas 51.1% of the samples from populations in 
Mississippi had detectable levels (mean concentration, 0.290 μg/g) (Kutz et al. 1985).  Mirex was 
detected in human adipose tissue samples from residents of northeast Louisiana during the late 1970s 
(Greer et al. 1980).  Concentrations of mirex in adipose tissue collected during surgery and during 
postmortem examinations ranged from 0.01 to 0.60 μg/g (ppm) with a mean mirex concentration of 
0.14 μg/g.  Human adipose tissue samples from northeastern Louisiana, an agricultural area, contained 
detectable amounts of mirex in 20 of 22 samples in 1977 at a mean concentration of approximately 
0.15 μg/g (ppm), 10 of 10 samples in 1980 at a mean concentration of 0.25 μg/g, and only 2 of 10 samples 
in 1984 at a mean concentration of 0.15 μg/g (Holt et al. 1986). 
 
A comparison of mirex residues in adipose tissue samples collected between 1979 and 1981 from 
residents of Kingston, Ontario (a city located on Lake Ontario), and residents of Ottawa, Ontario, 
indicated that persons living in Kingston had significantly higher mirex and photomirex residues than 
those in Ottawa (27 and 9 ng/g [ppb], respectively, in Kingston versus 11 and 6 ng/g, respectively, in 
Ottawa).  Males from Kingston had significantly higher levels of mirex (38 ng/g) than females from the 
area (12 ng/g); this gender difference was not explained or seen in the Ottawa samples (Williams et al. 
1984).  A subsequent 1984 study examined mirex levels in six additional cities on the Canadian portion of 
Lake Ontario.  The overall mean mirex residue in human adipose tissue was 11±13 ng/g (ppb) (males, 
12±15 ng/g; females, 9.6±10 ng/g) (Williams et al. 1988). 
 
Mirex levels in the blood of pregnant women in Jackson, Mississippi, and the Mississippi Delta area 
where mirex was extensively used were correlated with the health of the infants they bore.  The mean 
mirex level in maternal blood was 0.54 μg/L (ppb) for 106 samples; however, mirex levels in the blood of 
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the infants were not correlated with differences in gestation times, Apgar score, or other problems at birth.  
Only three children with neurological problems had mothers with pesticide levels, including mirex, above 
the mean levels (Lloyd et al. 1974). 
 
In 1977, mirex was detected in human milk and colostrum samples of women living in upstate New York.  
Milk from women in Oswego and Rochester, areas adjacent to Lake Ontario (known to be contaminated 
with mirex), was compared with milk from women in Albany (considered to be free from mirex 
contamination).  Mean mirex concentrations from women in each area were as follows: 0.057 ng/g in 
colostrum (n=24) and 0.07 ng/g in milk (n=6), Albany; 0.51 ng/g in colostrum (n=18) and 0.120 ng/g in 
milk (n=16), Oswego; and 0.035 ng/g in colostrum (n=4) and 0.162 ng/g in milk (n=6), Rochester.  Only 
2 of the 28 milk samples (both from Oswego) were below the detection limit of 0.01 ng/g (ppb), while 
16 of 24 colostrum samples in Albany, 10 of 18 colostrum samples from Oswego, and 2 of 4 colostrum 
samples from Rochester were below the detection limit.  None of the women reported eating freshwater 
fish, a possible source of the mirex contamination (Bush et al. 1983a). 
 
Members of the general population currently having potentially higher exposure to chlordecone include 
recreational and subsistence fishers who may consume large quantities of fish and shellfish from 
waterbodies with chlordecone contamination, populations living near sites where chlordecone was 
manufactured, or waste disposal sites contaminated with chlordecone. 
 
Chlordecone contamination has triggered the issuance of one human health advisory.  As of September 
1993, chlordecone was identified as the causative pollutant in an advisory issued by the State of Virginia 
for the 113 miles of the James River Estuary.  The advisory extends from Richmond, Virginia, 
downstream to the Hampton-Norfolk Bridge Tunnel including all tributaries to the James River (RTI 
1993). 
 
The only data on chlordecone residues in populations living near a production site are historic and were 
collected several decades ago.  The EPA initiated a community survey in August 1975 shortly after 
production of chlordecone was halted to determine chlordecone levels in blood of persons living in the 
vicinity of the Hopewell manufacturing plant.  Two hundred nine community residents, none of whom 
had ever been employed at the Allied Chemical plant or Life Sciences Products Company (LSPC) were 
surveyed.  Chlordecone blood levels were <5 ppb in 39% of residents living 0.25 miles south of the LSPC 
plant, in 7.7% of residents living 0.25 miles north of the LSPC plant, in 5.9% of residents living 0.5 miles 
from the site, in 2.6% of residents living 0.75 miles from the site, and in 3.3% of residents living 1 mile 
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from the site.  Chlordecone blood levels were approximately linear as a function of proximity to the LSPC 
site (Epstein 1978).  No additional information was located on current chlordecone levels in residents of 
the Hopewell, Virginia, area. 
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CHAPTER 6.  ADEQUACY OF THE DATABASE 
 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of mirex and chlordecone is available.  Where adequate 
information is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a 
program of research designed to determine the adverse health effects (and techniques for developing 
methods to determine such health effects) of mirex and chlordecone. 
 
Data needs are defined as substance-specific informational needs that, if met, would reduce the 
uncertainties of human health risk assessment.  This definition should not be interpreted to mean that all 
data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.   
 
6.1   Information on Health Effects 
 
Studies evaluating the health effects of inhalation, oral, and dermal exposure of humans and animals to 
mirex and chlordecone that are discussed in Chapter 2 are summarized in Figures 6-1 and 6-2, 
respectively.  The purpose of these figures is to illustrate the information concerning the health effects of 
mirex and chlordecone.  The number of human and animal studies examining each endpoint is indicated 
regardless of whether an effect was found and the quality of the study or studies.   
 
Epidemiological data regarding potential health effects in humans exposed to mirex are essentially limited 
to investigations using mirex levels in blood samples (one study included placental mirex) as the basis for 
exposure data.  Human data for chlordecone come from reports of an occupational cohort of workers 
exposed during the manufacture of chlordecone and from investigations using chlordecone levels in blood 
samples or cord blood as the basis for exposure data.  In the occupational cohort, exposure was classified 
as intermediate-to-chronic; no precise duration or level of exposure to chlordecone could be quantified 
from these reports.  A single route of exposure could not be established for this worker population; poor 
hygiene in the plant made inhalation, oral, and dermal exposure routes likely to occur.  The information 
on human exposure in this study is extremely limited because of the possible contamination with the 
precursor used to manufacture chlordecone, hexachloropentadiene. 
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Figure 6-1.  Summary of Existing Health Effects Studies on Mirex By Route and 
Endpoint* 
   
Potential body weight, liver, and developmental effects were the most studied endpoints  
The majority of the studies examined oral exposure in animals (versus humans)  
 
 
 
 
 
 
  
*Includes studies discussed in Chapter 2; the number of studies include those 
finding no effect and those examining multiple endpoints.  No inhalation studies 
were located. 
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Figure 6-2.  Summary of Existing Health Effects Studies on Chlordecone By Route 
and Endpoint* 
   
Potential body weight, liver, and neurological effects were the most studied endpoints  
The majority of the studies examined oral exposure in animals (versus humans)  
 
 
 
 
 
*Includes studies discussed in Chapter 2; the number of studies include those 
finding no effect and those examining multiple endpoints.  No inhalation or 
dermal studies in humans or animals were located. 
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The database for the health effects of mirex and chlordecone following oral administration in 
experimental animals is more substantial.  However, no information is available on the health effects of 
inhalation exposure to mirex or chlordecone in animals. 
 
People living near hazardous waste sites may be exposed to mirex or chlordecone primarily via dermal 
contact with or ingestion of contaminated soils since mirex and chlordecone are bound to soil particles.  
Another possible mechanism for oral exposure to mirex and chlordecone is the ingestion of pesticide-
laden dust carried by the wind from a waste site or treated field and deposited on garden crops.  Ingestion 
of contaminated water is not likely to be a significant route of exposure since mirex and chlordecone have 
very limited water solubility and are generally not found in groundwater.  Likewise, inhalation exposure 
to mirex and chlordecone via volatilization from contaminated media is not a likely major route of 
exposure since mirex and chlordecone are essentially nonvolatile.  For the general population, the primary 
route of exposure to mirex and chlordecone is via ingestion of residues on contaminated foods.  
Therefore, information on the toxicity following ingestion and dermal exposure is most relevant for 
individuals living in the vicinity of hazardous waste sites. 
 
6.2   Identification of Data Needs  
 
Missing information in Figures 6-1 and 6-2 should not be interpreted as a “data need”.  A data need, as 
defined in ATSDR’s Decision Guide for Identifying Substance-Specific Data Needs Related to 
Toxicological Profiles (ATSDR 1989), is substance-specific information necessary to conduct 
comprehensive public health assessments.  Generally, ATSDR defines a data gap more broadly as any 
substance-specific information missing from the scientific literature. 
 
Acute-Duration MRLs.  No acute-duration inhalation MRLs were derived for mirex or chlordecone 
because no exposure-response inhalation data were located.  No acute-duration oral MRL was derived for 
mirex because the lowest LOAEL from available acute-duration oral studies was for serious effects (heart 
block and arrhythmias in fetuses from dams exposed during gestation) and the effects were observed at 
the lowest dose tested (Grabowski 1983a).  An acute-duration oral MRL was derived for chlordecone 
based on neurological effects in an animal study.  Human data for mirex are essentially limited to 
evaluations of health outcomes associated with mirex blood levels for which exposure-response data and 
information regarding duration of exposure are not available.  Human data for chlordecone are limited as 
well.  Data are available from one cohort of workers involved in the production of chlordecone (Cannon 
et al. 1978; Guzelian et al. 1980; Martinez et al. 1978; Sanborn et al. 1979; Taylor 1982, 1985; Taylor et 
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al 1978).  No particular exposure route or exposure duration could be established and the workers were 
likely exposed to other toxic substances as well.  Other available human studies consist of evaluations of 
health outcomes associated with chlordecone blood levels for which exposure-response data are not 
available.  Oral exposure to mirex or chlordecone from food sources grown in mirex- or chlordecone-
contaminated soil is the most likely source of mirex or chlordecone blood levels at present because mirex 
and chlordecone have not been used as pesticides for decades, although they persist in soil.  Additional 
animal studies could be designed to determine appropriate bases for deriving acute-duration inhalation 
MRLs for mirex and chlordecone and an acute-duration oral MRL for mirex.  Inhalation data do not 
appear to be particularly necessary because significant inhalation exposure is not likely since neither 
mirex nor chlordecone readily enter the air from other media where they may be present. 
 
Intermediate-Duration MRLs.  Limited human data are not suitable for MRL derivation.  No 
intermediate-duration inhalation MRLs were derived for mirex or chlordecone because no exposure-
response inhalation data were located.  No intermediate-duration oral MRL was derived for mirex 
because the most suitable point of departure based on available data is a LOAEL for endocrine effects in 
weanling rats in the absence of a NOAEL.  Application of a total uncertainty factor of 1,000 (10 for 
extrapolation from a LOAEL to a NOAEL, 10 for extrapolation from animals to humans, and 10 for 
human variability) would result in an intermediate-duration oral MRL that is lower than the provisional 
chronic-duration oral MRL derived for mirex.  A provisional intermediate-duration oral MRL was derived 
for chlordecone based on neurological effects reported in a rat study (Linder et al. 1983).  Additional 
animal studies could be designed to determine an appropriate basis for deriving intermediate-duration 
inhalation MRLs for mirex and chlordecone and an intermediate-duration oral MRL for mirex.  Inhalation 
data do not appear to be particularly necessary because significant inhalation exposure is not likely since 
neither mirex nor chlordecone readily enter the air from other media where they may be present. 
 
Chronic-Duration MRLs.  Limited human data are not suitable for MRL derivation.  No chronic-
duration inhalation MRLs were derived for mirex or chlordecone because no exposure-response 
inhalation data were located.  A provisional chronic-duration oral MRL was derived for mirex based on 
histopathologic liver effects in a 2-year rat study (NTP 1990).  A chronic-duration oral MRL was derived 
for chlordecone based on renal effects in a 2-year rat study (Larson et al. 1979b).  Additional animal 
studies could be designed to determine an appropriate basis for deriving chronic-duration inhalation 
MRLs for mirex and chlordecone.  However, inhalation data do not appear to be particularly necessary 
because significant inhalation exposure is not likely since neither mirex nor chlordecone readily enter the 
air from other media where they may be present. 
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Health Effects.   
Hepatic Effects.  There is some evidence of hepatic effects associated with occupational 
exposure to chlordecone when it was being produced (Guzelian 1982a, 1982b; Taylor 1982, 
1985; Taylor et al. 1978).  There is limited evidence of mirex-related effects on CYP-induced 
metabolism (Lambert et al. 1992).  A variety of oral studies in animals identify the liver as a 
target of mirex and chlordecone toxicity.  Additional animal data do not appear necessary.  
However, human populations with potential for exposure to mirex or chlordecone should be 
monitored for possible exposure-related hepatic effects. 
 
Neurological Effects.  Examinations of workers occupationally exposed to chlordecone during 
its production revealed some signs of neurotoxicity (e.g., tremors, anxiety, visual difficulties, 
irritability, poor recent memory, blurred vision, headaches) (Cannon et al. 1978; Taylor 1982, 
1985; Taylor et al. 1978).  Sural nerve biopsies from workers with the most notable signs of 
neurotoxicity revealed decreased numbers of small myelinated and unmyelinated axons (Martinez 
et al. 1978).  Neurological effects have been widely reported in animal studies that employed oral 
exposure to mirex or chlordecone.  Additional animal studies to not appear necessary.  However, 
human populations with potential for exposure to mirex or chlordecone should be monitored for 
possible exposure-related neurological effects. 
 
Renal Effects.  No information was located regarding mirex- or chlordecone-induced renal 
effects in humans.  However, the kidney was identified as a target of mirex and chlordecone 
toxicity in 2-year rat studies (Larson et al. 1979b; NTP 1990).  Additional animal studies do not 
appear necessary.  However, human populations with potential for exposure to mirex or 
chlordecone should be monitored for possible exposure-related renal effects. 
 
Reproductive Effects.  There is some evidence of adverse effects on the male reproductive 
system associated with occupational exposure to chlordecone when it was being produced 
(Guzelian 1982a, 1982b; Taylor 1982, 1985; Taylor et al. 1978).  Results from two human studies 
provide evidence that mirex in the blood may be associated with female reproductive effects 
(Grindler et al. 2015; Upson et al. 2013).  A variety of oral studies in animals identify the 
reproductive system as a target of mirex and chlordecone toxicity.  Additional animal data do not 
appear necessary.  However, human populations with potential for exposure to mirex or 
chlordecone should be monitored for possible exposure-related reproductive effects. 
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Developmental Effects.  Limited results from human studies provide suggestive evidence that 
blood levels of mirex (Araki et al. 2018; Puertas et al. 2010) or chlordecone (Boucher et al. 2013; 
Cordier et al. 2015; Dallaire et al. 2012; Kadhel et al. 2014) may be associated with 
developmental effects.  A variety of oral studies in animals identify developmental endpoints as 
targets of mirex and chlordecone toxicity.  Additional animal data do not appear necessary.  
However, human populations with potential for exposure to mirex or chlordecone should be 
monitored for possible exposure-related developmental effects. 
 
Cancer.  Limited human data provide little evidence for mirex- or chlordecone-induced 
carcinogenicity.  In population-based, case-control studies, lipid-adjusted serum mirex was 
associated with risk of non-Hodgkin’s lymphoma (Spinelli et al. 2007) and plasma chlordecone 
was associated with risk of prostate cancer (Multigner et al. 2010).  Other human studies that 
evaluated potential associations between blood mirex and selected cancer endpoints found no 
evidence for an association (Itoh et al. 2009; Koutros et al. 2015a, 2015b; Moysich et al. 1998; 
Sawada et al. 2010).  The carcinogenicity of mirex and chlordecone has been demonstrated in rats 
and mice (NCI 1976; NTP 1990).  Additional animal carcinogenicity studies do not appear 
necessary.  However, human populations with potential for exposure to mirex or chlordecone 
should be monitored for possible exposure-related carcinogenic effects. 
 
Epidemiology and Human Dosimetry Studies.  A single epidemiological cohort was located for 
occupational exposure to chlordecone (Cannon et al. 1978; Guzelian et al. 1980; Sanborn et al. 1979; 
Taylor 1982, 1985).  The routes of exposure in this study were probably mixed because of the poor 
hygiene in the chlordecone manufacturing plant (Taylor 1982, 1985).  The most likely identifiable 
subpopulations exposed to mirex or chlordecone would be individuals who live in areas where these 
pesticides may persist in environmental media or have become bioconcentrated in food sources.  Well-
designed epidemiological studies of these subpopulations specifically examining a wide range of health 
endpoints would be useful to evaluate possible human health outcomes similar to those observed in 
animal studies. 
 
Biomarkers of Exposure and Effect.  The biomarkers of exposure to mirex and chlordecone are 
well established and specific to each compound.  The known biomarkers of exposure to mirex are its 
concentrations in blood, fat, feces, and milk.  The known biomarkers of exposure for chlordecone include 
its concentrations in blood, saliva, and tissues, and concentrations of chlordecone or its metabolite in 
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feces or bile.  Of the biomarkers of exposure listed for chlordecone, the blood is the most useful 
biological material to monitor in order to determine exposure to chlordecone. 
 
Several potential biomarkers for the effects of mirex and chlordecone have been identified.  These include 
levels of urinary D-glucaric acid to measure hepatic enzyme induction, elevated urinary protein and renal 
histopathology to assess renal damage, electromyography and tremorograms to assess tremor, 
oculography to measure visual disturbances, and sperm counts and tests of motility to assess toxic effects 
on sperm (Guzelian 1985; Larson et al. 1979b; Taylor et al. 1978).  However, these biomarkers are not 
specific for either mirex or chlordecone.  Measurement of serum bile acids may be helpful in assessing 
hepatobiliary function after exposure to chlordecone.  Examination of this possibility and further 
investigation of other serum biomarkers of effect in populations exposed to mirex or chlordecone would 
be helpful. 
 
Absorption, Distribution, Metabolism, and Excretion.  No data were located regarding 
absorption of mirex in humans following inhalation, oral, or dermal exposure.  Limited epidemiological 
data were located regarding the distribution and excretion of mirex following inhalation, oral, and dermal 
exposure.  Mirex is not metabolized by humans or animals.  There are a number of animal studies 
describing absorption, distribution, metabolism, and excretion of mirex following oral exposure.  
Information is available to assess the relative rates and extent of these toxicokinetic parameters by the oral 
route.  Most of the toxicokinetic data, however, involve acute exposures to mirex; only very limited data 
deal with intermediate or chronic exposures.  Additional intermediate and chronic data would be useful to 
adequately assess the rates and extent of the toxicokinetic parameters for these durations.  Limited animal 
data were located regarding the absorption, distribution, and excretion of mirex following inhalation 
exposure.  Additional acute-, intermediate-, and chronic-duration data would be useful to adequately 
assess the relative rates and extent of the toxicokinetic parameters by this route.  No animal data were 
located for the toxicokinetic parameters by the dermal exposure route. 
 
Limited occupational data exist regarding absorption, distribution, metabolism, and/or excretion of 
chlordecone by humans.  There are a number of animal studies describing the absorption, distribution, 
metabolism, and excretion of chlordecone following oral exposure.  Most of these data concern acute 
exposures.  However, the available data are sufficient to assess the relative rates and extent of the 
pharmacokinetics following oral exposure.  Dermal absorption occurs only to a limited extent.  No studies 
were located regarding distribution, metabolism, or excretion following dermal exposure.  No animal data 
were located regarding absorption, distribution, metabolism, or excretion of chlordecone following 
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inhalation exposure.  Additional acute-, intermediate-, and chronic-duration data would be useful to 
adequately compare the toxicokinetic parameters across all routes of exposure. 
 
Comparative Toxicokinetics.  The absorption, distribution, metabolism, and excretion of mirex and 
chlordecone have been studied in animals.  However, information on the toxicokinetics of mirex and 
chlordecone in humans is very limited.  Furthermore, little information is available regarding interspecies 
differences in the kinetics of mirex.  Toxicokinetic studies have been performed for chlordecone using 
multiple animal species.  Based on the available data, rats, guinea pigs, and hamsters are not good animal 
models for studying chlordecone metabolism in humans because they do not convert chlordecone to 
chlordecone alcohol (Fariss et al. 1980; Guzelian et al. 1981; Houston et al. 1981).  Gerbils and pigs were 
found to be the most practical animal models of chlordecone metabolism in humans because they 
converted chlordecone to chlordecone alcohol (Houston et al. 1981; Soine et al. 1983).  Additional studies 
of various animal species would be useful to determine the most appropriate animal model(s) to predict 
the toxicokinetics of mirex and chlordecone in humans. 
 
Children’s Susceptibility.  Results from animal studies suggest that the fetus and newborn may be 
more sensitive than adults to mirex or chlordecone toxicity.  Mirex administered within 1 week after birth 
caused a high incidence of cataracts and other lesions of the lens in experimental animals.  Infants and 
young children should be monitored for potential mirex- or chlordecone-related effects, particularly in 
areas with potential for significant exposure to these persistent pesticides. 
 
Physical and Chemical Properties.  The physical and chemical properties of mirex and chlordecone 
are sufficiently documented to permit estimation of their environmental fate.  No further information is 
necessary. 
 
Production, Import/Export, Use, Release, and Disposal.  Mirex and chlordecone are no longer 
being produced or used in the United States.  Mirex was most commonly used from 1962 to 1976 as an 
insecticide to control fire ants.  Mirex was also used as a flame retardant from 1959 to 1972 in various 
coatings, plastics, rubber, paint, paper, and electrical goods.  Until 1976, chlordecone was used as an 
insecticide on bananas, non-bearing citrus trees, tobacco, and ornamental shrubs.  It was also used in 
household products such as ant and roach traps.  However, all registered products containing mirex and 
chlordecone were canceled in 1977 and 1978, respectively.  Since mirex and chlordecone are not 
flammable and are very stable in the environment, many disposal methods have proven unsuccessful.  
Since mirex is not identified by EPA as a hazardous waste under SARA Title III, no regulatory 
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information is available for the disposal of mirex.  However, the recommended method of disposal for 
mirex is incineration.  Efficient disposal methods exist for chlordecone.  Chlordecone is considered an 
EPA hazardous waste and must be disposed of according to EPA regulations. 
 
Environmental Fate.  Mirex and chlordecone released to the environment partition to soil and 
sediment.  Small amounts may remain dissolved in water.  Mirex and chlordecone released to the 
atmosphere are eventually deposited on soil or surface waters.  On the surface of soil or water, mirex 
undergoes photolysis with the subsequent loss of a chlorine atom.  Both compounds are resistant to 
aerobic degradation, although some anaerobic biodegradation does occur.  When not exposed to sunlight 
or anaerobic conditions, mirex and chlordecone persist in soil, particularly sediments, for many years.  
Additional information on the persistence of mirex and chlordecone in water and soil would be useful. 
 
Bioavailability from Environmental Media.  Both mirex and chlordecone can be absorbed 
following oral exposure, although chlordecone is more readily absorbed than mirex.  No data were 
located regarding absorption of mirex following dermal exposure.  Limited animal data indicate that 
dermal absorption of chlordecone is low.  Information regarding the bioavailability of mirex and 
chlordecone from oral exposure via contaminated food sources and dermal contact with contaminated 
soils would be helpful, particularly for populations living near areas where mirex and/or chlordecone 
were used in the past. 
 
Food Chain Bioaccumulation.  Both mirex and chlordecone are highly lipophilic and, therefore, 
have high bioconcentration potentials.  They are bioaccumulated in aquatic food chains with virtually no 
degradation of the compounds by exposed organisms.  Uptake and bioaccumulation of mirex in terrestrial 
food chains have also been shown to occur.  No further information is necessary.  Only limited 
information is available on uptake and bioaccumulation of chlordecone in terrestrial food chains, and little 
uptake of chlordecone by plants was observed.  Additional information on uptake of chlordecone in plants 
under field conditions would be helpful. 
 
Exposure Levels in Environmental Media.  Environmental monitoring data are available for mirex 
levels in air, water, soil, and sediment.  Limited information on mirex concentrations in groundwater is 
available; however, because mirex binds tightly to organic matter in soil, additional leaching data are not 
necessary.  Data on atmospheric releases and levels of chlordecone are available only for 2 years (1974–
1975) of its production at the Hopewell, Virginia facility; however, since chlordecone production in the 
United States ceased in 1975 and because most of the chlordecone produced was exported or was used in 
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insect bait traps so that it was not widely dispersed in the environment, no additional current information 
on chlordecone in the atmosphere is required.  Historic chlordecone levels in surface waters, soils, and 
sediments in the vicinity of the Hopewell, Virginia facility have been well characterized.  Because 
chlordecone binds tightly to organic matter in soil, leaching into groundwater is not anticipated to occur 
extensively.  Minimal information was found on the uptake of mirex and chlordecone by plants grown 
under field conditions.  Adequate information on mirex and chlordecone levels in fish and shellfish are 
available.  Further information on foods other than fish and shellfish, particularly in foods grown in areas 
where mirex was used as a pesticide, would be helpful in estimating current human and animal intake. 
 
Exposure Levels in Humans.  Mirex has been detected in human adipose tissue, blood, and milk.  
Because of the lipophilic nature of mirex, most determinations of exposure are based on residues found in 
adipose tissue.  Higher levels in tissue have been correlated with areas of mirex usage, manufacture, or 
disposal at waste sites.  Chlordecone has not been detected in human adipose tissue or in blood samples 
from the general population, although it has been detected in human milk samples.  Adequate information 
is available regarding chlordecone levels in blood of occupationally exposed workers and their families 
during 1974–1975 employed at the Hopewell, Virginia site.  Additional information for mirex and 
chlordecone would be helpful in determining areas with greatest potential for human exposure. 
 
Exposures of Children.  Fetuses and nursing infants may be exposed to mirex or chlordecone via their 
mothers.  Available animal data indicate that early stages of life may be relatively sensitive timepoints for 
mirex or chlordecone toxicity.  Areas where mirex or chlordecone may persist in soil or food sources 
should be monitored for potential pre- and postnatal exposure. 
 
Analytical Methods.  Improvements in detection sensitivity for mirex and chlordecone in 
environmental media would be useful for monitoring these pesticides in areas with potential for 
significant exposure. 
 
6.3   Ongoing Studies  
 
No ongoing studies were identified for mirex or chlordecone. 
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CHAPTER 7.  REGULATIONS AND GUIDELINES 
 
Pertinent international and national regulations, advisories, and guidelines regarding mirex and 
chlordecone in air, water, and other media are summarized in Table 7-1.  This table is not an exhaustive 
list, and current regulations should be verified by the appropriate regulatory agency. 
 
ATSDR develops MRLs, which are substance-specific guidelines intended to serve as screening levels by 
ATSDR health assessors and other responders to identify contaminants and potential health effects that 
may be of concern at hazardous waste sites.  See Section 1.3 and Appendix A for detailed information on 
the MRLs for mirex and chlordecone. 
 
Table 7-1.  Regulations and Guidelines Applicable to Mirex and Chlordecone 
 
Agency Description Information Reference 
Air 
EPA RfC No data IRIS 1992, 2009 
WHO Air quality guidelines No data WHO 2010 
Water & Food 
EPA Drinking water standards and health advisories  No data EPA 2012 
National primary drinking water regulations No data EPA 2009 
RfD  
  
Mirex 0.0002 mg/kg/day IRIS 1992 
Chlordecone 0.0003 mg/kg/day IRIS 2009 
WHO Drinking water quality guidelines Mirex excluded from 
guideline value 
derivation because 
unlikely to occur in 
drinking water 
WHO 2017 
FDA EAFUS No dataa FDA 2013 
Cancer 
ACGIH Carcinogenicity classification No data ACGIH 2016 
HHS Carcinogenicity classification 
  
Mirex Reasonably 
anticipated to be a 
human carcinogenb 
NTP 2016b 
Chlordecone Reasonably 
anticipated to be a 
human carcinogenb 
NTP 2016a 
EPA Carcinogenicity classification 
  
 Chlordecone Likely to be 
carcinogenic to 
humans 
IRIS 2009 
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Table 7-1.  Regulations and Guidelines Applicable to Mirex and Chlordecone 
 
Agency Description Information Reference 
IARC Carcinogenicity classification 
  
Mirex Group 2Bc IARC 1987b 
Chlordecone Group 2Bc IARC 1987a 
Occupational 
ACGIH TLV No data ACGIH 2016 
OSHA PEL (8-hour TWA) for general industry, 
construction, and shipyards 
No data OSHA 2016a, 2016b, 
2017 
NIOSH REL (up to 10-hour TWA) 
  
Chlordecone 0.001 mg/m3d NIOSH 2016 
Emergency Criteria 
EPA AEGLs-air No data EPA 2016 
DOE PACs-air   DOE 2016a 
 Mirex   
 PAC-1e 6.3 mg/m3  
 PAC-2e 69 mg/m3  
 PAC-3e 410 mg/m3  
 Chlordecone   
 PAC-1e 1.6 mg/m3  
 PAC-2e 17 mg/m3  
 PAC-3e 100 mg/m3  
 
aThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 
additives or listed or affirmed as GRAS. 
bBased on sufficient evidence of carcinogenicity from studies in experimental animals. 
cGroup 2B: Possibly carcinogenic to humans. 
dPotential occupational carcinogen. 
eDefinitions of PAC terminology are available from U.S. Department of Energy (DOE 2016a). 
 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels; 
DOE = Department of Energy; EAFUS = Everything Added to Food in the United States; EPA = Environmental 
Protection Agency; FDA = Food and Drug Administration; GRAS = generally recognized as safe; HHS = Department 
of Health and Human Services; IARC = International Agency for Research on Cancer; IRIS = Integrated Risk 
Information System; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology 
Program; OSHA = Occupational Safety and Health Administration; PAC = Protective Action Criteria; 
PEL = permissible exposure limit; REL = recommended exposure limit; RfC = inhalation reference concentration; 
RfD = oral reference dose; TLV = threshold limit values; TWA = time-weighted average; WHO = World Health 
Organization 
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APPENDIX A.  ATSDR MINIMAL RISK LEVEL WORKSHEETS 
 
MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the 
most sensitive health effect(s) for a specific duration for a given route of exposure.  An MRL is an 
estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk 
of adverse noncancer health effects over a specified route and duration of exposure.  MRLs are based on 
noncancer health effects only; cancer effects are not considered.  These substance-specific estimates, 
which are intended to serve as screening levels, are used by ATSDR health assessors to identify 
contaminants and potential health effects that may be of concern at hazardous waste sites.  It is important 
to note that MRLs are not intended to define clean-up or action levels. 
 
MRLs are derived for hazardous substances using the NOAEL/uncertainty factor approach.  They are 
below levels that might cause adverse health effects in the people most sensitive to such chemical-
induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and chronic 
(≥365 days) durations and for the oral and inhalation routes of exposure.  Currently, MRLs for the dermal 
route of exposure are not derived because ATSDR has not yet identified a method suitable for this route 
of exposure.  MRLs are generally based on the most sensitive substance-induced endpoint considered to 
be of relevance to humans.  Serious health effects (such as irreparable damage to the liver or kidneys, or 
birth defects) are not used as a basis for establishing MRLs.  Exposure to a level above the MRL does not 
mean that adverse health effects will occur. 
 
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
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Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Human Health Sciences, expert panel peer reviews, and agency-wide MRL 
Workgroup reviews, with participation from other federal agencies and comments from the public.  They 
are subject to change as new information becomes available concomitant with updating the toxicological 
profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously published MRLs.  
For additional information regarding MRLs, please contact the Division of Toxicology and Human 
Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop 
S102-1, Atlanta, Georgia 30329-4027. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Mirex 
CAS Numbers: 2385-85-5 
Date: August 1995 
 April 2017—Updated literature search 
Profile Status: Final, Draft for Public Comment 
Route: Inhalation 
Duration: Acute 
 
MRL Summary:  There are insufficient data for derivation of an acute-duration inhalation MRL. 
 
Rationale for Not Deriving an MRL:  No acute-duration inhalation studies were identified for mirex. 
 
Agency Contact (Chemical Manager):  Obaid Faroon, D.V.M., Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Mirex 
CAS Numbers: 2385-85-5 
Date: August 1995 
 April 2017—Updated literature search 
Profile Status: Final, Draft for Public Comment 
Route: Inhalation 
Duration: Intermediate 
 
MRL Summary:  There are insufficient data for derivation of an intermediate-duration inhalation MRL. 
 
Rationale for Not Deriving an MRL:  No intermediate-duration inhalation studies were identified for 
mirex. 
 
Agency Contact (Chemical Manager):  Obaid Faroon, D.V.M., Ph.D. 
  
MIREX AND CHLORDECONE  A-5 
 
APPENDIX A 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Mirex 
CAS Numbers: 2385-85-5 
Date: August 1995 
 April 2017—Updated literature search 
Profile Status: Final, Draft for Public Comment 
Route: Inhalation 
Duration: Chronic 
 
MRL Summary:  There are insufficient data for derivation of a chronic-duration inhalation MRL. 
 
Rationale for Not Deriving an MRL:  No chronic-duration inhalation studies were identified for mirex. 
 
Agency Contact (Chemical Manager):  Obaid Faroon, D.V.M., Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Mirex 
CAS Numbers: 2385-85-5 
Date: August 1995 
 April 2017—Updated literature search 
Profile Status: Final, Draft for Public Comment 
Route: Oral 
Duration: Acute 
 
MRL Summary:  There are insufficient data for derivation of an acute-duration oral MRL. 
 
Rationale for Not Deriving an MRL:  No acute-duration oral MRL was derived for mirex because 
serious effects (arrhythmias in neonatal pups from maternal exposure during gestation) were observed at 
the lowest dose tested (0.1 mg/kg/day) (Grabowski 1983a).  ATSDR does not derive MRLs based on 
serious effects in the absence of identified NOAEL values. 
 
Agency Contact (Chemical Manager):  Obaid Faroon, D.V.M., Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Mirex 
CAS Numbers: 2385-85-5 
Date: August 1995 
 April 2017—Updated literature search 
Profile Status: Final, Draft for Public Comment 
Route: Oral 
Duration: Intermediate 
 
MRL Summary:  There are insufficient data for derivation of an intermediate-duration oral MRL. 
 
Rationale for Not Deriving an MRL:  Intermediate-duration oral studies in humans are lacking for mirex.  
The most suitable animal study provides a LOAEL of 0.25 mg/kg/day for endocrine effects (dilation of 
rough endoplasmic reticulum cisternae of the thyroid) in weanling Sprague-Dawley rats (Singh et al. 
1985).  Application of a total uncertainty factor of 1,000 (10 for extrapolation from a NOAEL to a 
LOAEL, 10 for animal to human extrapolation, and 10 for human variability)and a modifying factor of 
3 to be protective of mirex-induced developmental toxicity, including arrhythmias in neonatal pups 
following maternal exposure during gestation at a dose level as low as 0.1 mg/kg/day in the absence of an 
identified NOAEL (Grabowski 1983a) would yield an intermediate-duration oral MRL of 0.0001 
mg/kg/day.  This potential MRL is lower than the chronic-duration oral MRL of 0.0003 mg/kg/day 
derived from an NTP (1990) study in rats (see chronic-duration oral MRL).  Another candidate study for 
derivation of an intermediate-duration oral MRL for mirex identifies a LOAEL of 0.25 mg/kg/day for 
cataracts in female rat pups (4/10 versus 0/14 controls) (Chu et al. 1981b).  The parental rats had been 
administered mirex in the diet for 91 days prior to mating and during mating (males and females) and 
throughout gestation and lactation (females).  This LOAEL of 0.25 mg/kg/day is considered a serious 
LOAEL and the study did not identify a NOAEL.  Therefore, no intermediate-duration oral MRL was 
developed for mirex. 
 
Agency Contact (Chemical Manager):  Obaid Faroon, D.V.M., Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 
CAS Numbers: 
Date: 
Profile Status: 
Route: 
Duration: 
MRL 
Critical Effect: 
Reference: 
Point of Departure: 
Uncertainty Factor: 
Modifying Factor: 
LSE Graph Key: 
Species: 
Mirex 
2385-85-5 
May 2019 
Final, Draft for Public Comment 
Oral 
Chronic 
0.0003 mg/kg/day (provisional) 
Histopathologic liver lesions 
NTP 1990 
NOAEL of 0.075 mg/kg/day 
100 
3 
79 
Rat 
MRL Summary:  An MRL of 0.0003 mg/kg/day has been derived for chronic-duration oral exposure to 
mirex based on dose-related hepatic changes from a 2-year oral study of male and female F344/N rats 
(NTP 1990).  The NOAEL of 0.075 mg/kg/day was divided by a total uncertainty factor of 100 (10 for 
animal to human extrapolation and 10 for human variability) and a modifying factor of 3 (to protect for 
developmental toxicity). 
Selection of the Critical Effect:  Available animal data identify the liver and kidney as critical targets of 
mirex toxicity following chronic-duration oral exposure.  Potential candidate studies for deriving a 
chronic-duration oral MRL for mirex are summarized in Table A-1; the lowest LOAEL is 0.75 mg/kg/day 
for hepatic effects and the corresponding NOAEL is 0.075 mg/kg/day. 
Table A-1.  NOAELs and LOAELs Identified in Chronic-Duration Oral Studies of 
Mirex 
Endpoint Effect 
NOAEL 
(mg/kg/day) 
LOAEL 
(mg/kg/day) Reference 
Body weight 11% lower mean body weight in female 
rats treated for 2 years 
1.95 3.9 NTP 1990 
Body weight No effect in rats treated for 21 months 0.32 Chu et al. 1981c 
Hepatic No effect in rats treated for 21 months 0.32 Chu et al. 1981c 
Hepatic Focal and centrilobular necrosis; fatty 
metamorphosis; dilation of sinusoids in 
rats treated for 2 years 
0.075 0.75 NTP 1990 
Hepatic Megalocytosis in rats treated for 
18 months followed by 6 months of 
recovery 
2.4 Ulland et al. 1977 
Renal Increased severity of nephrotoxicity in rats 
treated for 2 years 
0.75 1.95 NTP 1990 
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Table A-1.  NOAELs and LOAELs Identified in Chronic-Duration Oral Studies of 
Mirex 
 
Endpoint Effect 
NOAEL 
(mg/kg/day) 
LOAEL 
(mg/kg/day) Reference 
Renal Increased incidence of epithelial 
hyperplasia of the renal pelvis in rats 
treated for 2 years 
0.075 0.75 NTP 1990 
 
LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level 
 
Selection of the Principal Study:  NTP (1990) was selected as the principal study for deriving a 
provisional chronic-duration oral MRL for mirex because it identified the lowest reliable LOAEL for liver 
effects, a clearly sensitive effect of mirex toxicity. 
 
Summary of the Principal Study: 
 
NTP.  1990.  Toxicology and carcinogenesis studies of mirex (CAS No. 2385-85-5) in F344/N rats (feed 
studies).  Research Triangle Park, NC:  U.S. Department of Health and Human Services, Public Health 
Service, National Institutes of Health, National Toxicology Program.  NTP TR 313. 
 
Groups of male and female F344/N rats (52/sex/group; approximately 7–8 weeks of age) were 
administered mirex (95% purity) in the diet at 0, 0.1, 1.0, 10, 25, or 50 ppm for 104 weeks (first study).  
During the first 6 months of the study, additional groups of groups of female rats were started on 0, 50, or 
100 ppm mirex in the diet (second study), based on the lack of observable toxic effects in the initial 
groups of female rats.  Based on body weight and food consumption data, the study authors estimated 
average mirex doses to 0.1, 1, 10, 25, and 50 ppm groups from the first study at 0.007, 0.07, 0.7, 1.8, and 
3.8 mg/kg/day, respectively, for the males and 0.007, 0.08, 0.7, 2.0, and 3.9 mg/kg/day, respectively, for 
the females (for the combined sexes, the author estimated doses at 0.007, 0.075, 0.75, 1.95, and 
3.85 mg/kg/day, respectively).  Estimated doses to the 50 and 100 ppm groups of females from the second 
study were 3.9 and 7.7 mg/kg/day, respectively.  Animals were monitored for survival, clinical signs, 
body weight, and food intake.  All rats were subjected to gross pathologic examination and all major 
organs and tissues were processed for histopathologic examination. 
 
Survival of 1.95 and 3.85 mg/kg/day male rats was significantly less than that of controls (19/52 and 
15/52, respectively, compared to 44/52 controls), most deaths occurred after treatment weeks 86–87.  
Survival was not affected in mirex-dosed females.  By week 100, mean body weights of 1.95 and 
3.85 mg/kg/day surviving males were 11–18% less than that of controls and mean body weights of 
3.9 and 7.7 mg/kg/day females were 12–18% less than that of controls.  The most notable compound-
related histopathologic lesions were observed in the liver of male and female rats and included dose-
related increased incidence of fatty metamorphosis, cytomegaly, angiectasis (males only), and necrosis.  
The NOAEL for liver effects was 0.075 mg/kg/day and the LOAEL was 0.75 mg/kg/day for focal and 
centrilobular necrosis, fatty metamorphosis, and dilation of sinusoids.  Incidences of nephropathy 
occurred at similar frequency in controls and mirex-dosed groups; however, the severity was judged to be 
greater in the 1.95, 3.9, and 7.7 mg/kg/day groups.  Hyperplasia of the renal pelvis epithelium occurred at 
significantly increased incidence in male rats of the 10, 25, and 50 ppm groups (5/52, 14/51, and 9/52, 
respectively, versus 0/51 among controls).  Incidences of neoplastic nodules in the liver were significantly 
greater in 0.75, 1.95, and 3.85 mg/kg/day groups of males than controls (14/52, 15/52, and 26/52, 
respectively, versus 3/52 in control males).  Incidences of neoplastic liver nodules in the female rats of the 
first study were not significantly different from that of controls.  However, the incidence among control 
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females (10/52 or 19%) was significantly greater than the historical control incidence (2.8%).  In the 
second study that included 0, 3.9, and 7.7 mg/kg/day groups of female rats, incidences of neoplastic liver 
nodules (usually consisting of enlarged hepatocytes with eosinophilic or clear cytoplasm arranged in 
irregular distorted cords one or two cell layers thick, but some consisting of cells with basophilic 
cytoplasm) were 23/52 (44%), and 30/52 (58%), respectively, versus 2/52 (4%) within a concurrent 
control group.  Incidences of transitional cell papillomas of the renal pelvis of male rats occurred with a 
positive trend (p<0.02).  The incidence in the 3.85 mg/kg/day males was 3/52 (6%) compared to 
0/51  (0%) among controls and was noted to be higher than the highest incidence previously observed in 
controls (1/48 or 2%).  Incidences of pheochromocytomas of the adrenal gland occurred with a positive 
trend and the incidences in 1.95 and 3.85 mg/kg/day male rats were significantly greater than that of 
controls.  Incidences of mononuclear cell leukemia in analysis of all female rats in the first and second 
studies (combined) were significantly increased in the 0.75, 1.95, 3.9, and 7.7 mg/kg/day groups (14/52 or 
27%, 18/52 or 35%, 27/104 or 26%, and 14/52 or 27%) versus 14/104 (13%) among controls. 
 
Selection of the Point of Departure:  The treatment-related increased incidence of renal pelvis 
hyperplasia identified in the 2-year dietary study of rats (NTP 1990) was not considered an appropriate 
basis for deriving a chronic-duration oral MRL for mirex because the hyperplasia was observed in areas 
of the kidney that also exhibited tumors.  Therefore, the hyperplasia may represent a preneoplastic lesion.  
However, the liver lesions (focal and centrilobular necrosis, fatty metamorphosis, dilation of sinusoids) 
identified in the same study (NTP 1990) are nonneoplastic effects that were selected as the critical effects 
for deriving a chronic-duration oral MRL.  The NOAEL of 0.075 mg/kg/day for liver effects was selected 
as the point of departure for deriving a provisional chronic-duration oral MRL for mirex. 
 
Uncertainty Factor:  The NOAEL of 0.075 mg/kg/day was divided by a total uncertainty factor of 100: 
• 10 for animal to human extrapolation 
• 10 for human variability 
 
Modifying Factor:  A modifying factor of 3 was applied to be protective of mirex-induced developmental 
toxicity (see Section 2.17), including arrhythmias in neonatal pups following maternal exposure during 
gestation at a dose level as low as 0.1 mg/kg/day in the absence of an identified NOAEL (Grabowski 
1983a). 
 
Other Additional Studies or Pertinent Information that Lend Support:  Adverse hepatic effects were 
reported in a number of intermediate- or chronic-duration animal studies that employed oral exposure to 
mirex (Bell and Mehendale 1985; Chu et al. 1980c, 1981a, 1981b; Curtis and Hoyt 1984; Dai et al. 2001; 
Davison et al. 1976; Gaines and Kimbrough 1970; Larson et al. 1979a; Mehendale 1981b; Ulland et al. 
1977a). 
 
Agency Contacts (Chemical Managers):  Obaid Faroon, D.V.M., Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Chlordecone 
CAS Numbers: 143-50-0 
Date: August 1995 
 April 2017—Updated literature search 
Profile Status: Final, Draft for Public Comment 
Route: Inhalation 
Duration: Acute 
 
MRL Summary:  There are insufficient data for derivation of an acute-duration inhalation MRL. 
 
Rationale for Not Deriving an MRL:  No acute-duration inhalation studies were identified for 
chlordecone. 
 
Agency Contact (Chemical Manager):  Obaid Faroon, D.V.M., Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Chlordecone 
CAS Numbers: 143-50-0 
Date: August 1995 
 April 2017—Updated literature search 
Profile Status: Final, Draft for Public Comment 
Route: Inhalation 
Duration: Intermediate 
 
MRL Summary:  There are insufficient data for derivation of an intermediate-duration inhalation MRL. 
 
Rationale for Not Deriving an MRL:  No intermediate-duration inhalation studies were identified for 
chlordecone. 
 
Agency Contact (Chemical Manager):  Obaid Faroon, D.V.M., Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Chlordecone 
CAS Numbers: 143-50-0 
Date: August 1995 
 April 2017—Updated literature search 
Profile Status: Final, Draft for Public Comment 
Route: Inhalation 
Duration: Chronic 
 
MRL Summary:  There are insufficient data for derivation of a chronic-duration inhalation MRL. 
 
Rationale for Not Deriving an MRL:  No chronic-duration inhalation studies were identified for 
chlordecone. 
 
Agency Contact (Chemical Manager):  Obaid Faroon, D.V.M., Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Chlordecone 
CAS Numbers: 143-50-0 
Date: August 1995 
 April 2017—Updated literature search 
Profile Status: Final, Draft for Public Comment 
Route: Oral 
Duration: Acute 
MRL 0.01 mg/kg/day 
Critical Effect: Neurological effects 
Reference: EPA 1986c 
Point of Departure: NOAEL of 1.25 mg/kg/day 
Uncertainty Factor: 100 
LSE Graph Key: 12 
Species: Rat 
 
MRL Summary:  An acute-duration oral MRL of 0.01 mg/kg/day was derived for chlordecone based on 
neurological effects (increased startle response) observed in young adult male Fischer 344 rats in a 10-day 
gavage study conducted by EPA (1986c).  The MRL is based on a NOAEL of 1.25 mg/kg/day and a total 
uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human variability). 
 
Selection of the Critical Effect:  Numerous studies have evaluated the toxicity of chlordecone following 
acute-duration oral exposure.  Many studies reported treatment-related neurological effects or 
developmental effects.  Other studies collectively identified the following targets: body weight, 
cardiovascular system, hematological system, musculoskeletal system, liver, renal system, endocrine 
system, immunological system, and female reproductive system.  A summary of the lowest LOAELs for 
each endpoint is presented in Table A-2.  A comparison of the LOAEL values across endpoints supports 
the identification of the nervous system as the most sensitive target of toxicity. 
 
Table A-2.  Lowest LOAELs Identified in Acute-Duration Oral Studies of 
Chlordecone 
 
Endpoint Effect 
NOAEL 
(mg/kg/day) 
LOAEL 
(mg/kg/day) Reference 
Body weight 
 
15% depressed maternal body 
weight gain in rats gavaged daily 
on gestation days 7–16 
 2 Chernoff and 
Rogers 1976 
Hematological Decreased neutrophils in rats 
exposed for 10 days 
5 10 Smialowicz et al. 
1985 
Hepatic Increased serum alkaline 
phosphatase, ALT, gamma-
glutamyl transferase in rats 
gavaged daily for 10 days 
5 10 EPA 1986c 
Renal Increased blood urea nitrogen in 
rats gavaged daily for 10 days 
5 10 EPA 1986c 
Endocrine Depletion of epinephrine in adrenal 
medulla of rats treated for 8 days in 
diet 
 17 Baggett et al. 1980 
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Table A-2.  Lowest LOAELs Identified in Acute-Duration Oral Studies of 
Chlordecone 
 
Endpoint Effect 
NOAEL 
(mg/kg/day) 
LOAEL 
(mg/kg/day) Reference 
Immunological Decreases in spleen and thymus 
weights, leukocyte counts, natural 
killer cell activity, Concanavalin A 
responsiveness in rats gavaged 
daily for 10 days 
5 10 EPA 1986c 
Neurological Increased startle response in young 
adult male rats gavaged daily for 
10 days 
1.25 2.5 EPA 1986c 
Reproductive Persistent estrus in rats gavaged 
once 
 35 Swanson and 
Woolley 1982 
Developmental 86% decreased postnatal day 3 
pup survival following daily gavage 
treatment of maternal rats during 
gestation days 7–16 
 10 EPA 1986c 
 
ALT = alanine transaminase; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect 
level 
 
Selection of the Principal Study:  The lowest LOAEL values were identified for body weight and 
neurological effects.  Chernoff and Rogers (1976) reported decreases in maternal body weight gain in rat 
dams administered 2 mg/kg/day chlordecone on gestation days 7–16 and EPA (1986c) reported increased 
startle response in young adult male rats administered 2.5 mg/kg/day chlordecone for 10 days.  These 
comparable LOAELs are at least 4 times lower than the LOAELs for hematological, hepatic, renal, 
immunological, reproductive, and developmental effects.  The EPA (1986c) study was selected as the 
principal study for deriving an acute-duration oral MRL for chlordecone because it identified a NOAEL 
(1.25 mg/kg/day). 
 
Summary of the Principal Study: 
 
EPA.  1986c.  Final report on the evaluation of four toxic chemicals in an ‘in vivo/in vitro’ toxicological 
screen:  Acrylamide, chlordecone, cyclophosphamide, and diethylstilbestrol.  Research Triangle Park, 
NC:  U.S. Environmental Protection Agency, Health Effects Research Laboratory.  EPA600186002. 
 
Groups of young adult male Fischer 344 rats (10/group) were administered chlordecone (in corn oil 
vehicle) by gavage for 10 days at 0, 0.625, 1.25, 2.5, 5.0, or 10.0 mg/kg/day.  Animals were monitored for 
survival and body weight.  Motor activity (performance in a figure 8 maze) and acoustic startle response 
were evaluated at 1 day following the final dose treatment.  Urine was collected for urinalysis and blood 
was drawn for serum chemistry.  At sacrifice, selected organ weights were determined.  At 
≥2.5 mg/kg/day, the amplitude of the acoustic startle response was significantly increased.  At the other 
two doses, the amplitude was increased with all decibel stimuli.  Motor activity in a figure-8 maze was 
decreased at the highest dose tested.  Terminal body weight was depressed by 12% at 10 mg/kg/day.  
Relative liver weight was significantly increased at 5 and 10 mg/kg/day (15–16% higher than controls).  
Selected serum chemistry parameters were statistically significantly different from controls only in the 
high-dose group. 
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Selection of the Point of Departure:  The NOAEL of 1.25 mg/kg/day was selected as the point of 
departure for deriving an acute-duration oral MRL for chlordecone. 
 
Uncertainty Factor:  The NOAEL of 1.25 mg/kg/day was divided by a total uncertainty factor of 100: 
• 10 for animal to human extrapolation 
• 10 for human variability 
 
Other Additional Studies or Pertinent Information that Lend Support:  As stated above, numerous 
animal studies reported neurological effects associated with acute-duration oral exposure to chlordecone 
(Albertson et al. 1985; Aldous et al. 1984; Baggett et al. 1980; Chang-Tsui and Ho 1979; Desaiah et al. 
1980b; Egle et al. 1979; End et al. 1981; Fujimori et al. 1982b; Hoskins and Ho 1982; Huang et al. 1980; 
Jordan et al. 1981; Klingensmith and Mehendale 1982a; Mactutus et al. 1984; Mishra et al. 1980; 
Smialowicz et al. 1985; Swanson and Wooley 1982; Tilson et al. 1985). 
 
Agency Contacts (Chemical Managers):  Obaid Faroon, D.V.M., Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: 
CAS Numbers: 
Date: 
Profile Status: 
Route: 
Duration: 
MRL 
Critical Effect: 
Reference: 
Point of Departure: 
Uncertainty Factor: 
LSE Graph Key: 
Species: 
Chlordecone 
143-50-0 
May 2019 
Final, Draft for Public Comment 
Oral 
Intermediate 
0.003 mg/kg/day (provisional) 
Neurological and male reproductive effects 
Linder et al. 1983 
NOAEL of 0.26 mg/kg/day 
100 
57 
Rat 
MRL Summary:  A provisional MRL of 0.003 mg/kg/day has been derived for intermediate-duration oral 
exposure to chlordecone based on neurological and male reproductive effects from a 90-day oral study of 
male Sprague-Dawley rats (Linder et al. 1983).  The NOAEL of 0.26 mg/kg/day was divided by a total 
uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human variability). 
Selection of the Critical Effect:  Studies that evaluated chlordecone toxicity in humans did not include 
dose-response data; therefore, human data were not considered for MRL derivation.  Treatment-related 
effects on the liver, nervous system, body weight, cardiovascular system, endocrine system, reproductive 
system, and development have been consistently associated with intermediate-duration oral exposure of 
laboratory animals to chlordecone.  A summary of the lowest LOAELs for each endpoint is presented in 
Table A-3. 
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Table A-3.  Lowest LOAELs Identified in Intermediate-Duration Oral Studies of 
Chlordecone 
 
Endpoint Effect 
NOAEL 
(mg/kg/day) 
LOAEL 
(mg/kg/day) Reference 
Body weight 13% decreased body weight gain in 
rats treated for 3 months in diet 
 1.17 Cannon and 
Kimbrough 1979 
Hepatic Focal necrosis in rats treated for 
3 months in diet 
 1.17 Cannon and 
Kimbrough 1979 
Endocrine Reversible hyperplasia of adrenal 
cortex in rats treated for 3 months in 
diet 
 1.17 Cannon and 
Kimbrough 1979 
Neurological Hyperexcitability, mild tremors in rats 
treated for 90 days in diet 
0.26 0.83 Linder et al. 1983 
Reproductive 46–48% decreased sperm motility and 
viability; 19% decreased epididymal 
sperm concentration in rats treated for 
90 days in diet 
0.26 0.83 Linder et al. 1983 
Developmental Decreased postnatal survival in pups 
from parental rats treated for up to 
130 days in diet 
1.87 7.01 Huber 1965 
 
LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level 
 
A comparison of the LOAEL values across endpoints supports the identification of the nervous system 
and male reproductive system as the most sensitive targets of toxicity.  The identification of the 
neurotoxicity and reproductive toxicity as sensitive endpoints for chlordecone is supported by several 
other intermediate-duration studies, which are summarized in Tables A-4 and A-5, respectively.   
 
MIREX AND CHLORDECONE  A-19 
 
APPENDIX A 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
Table A-4.  Selected LOAELs for Neurological Effects Identified in Intermediate-
Duration Oral Studies of Chlordecone 
 
Species 
(strain) Effect 
NOAEL 
(mg/kg/day) 
LOAEL 
(mg/kg/day) Reference 
Rat (Sprague-
Dawley) 
Tremors in rats treated for 15 days in 
diet 
 4.31 Agarwal and 
Mehendale 1984c 
Rat (Sherman) Tremors, hyperexcitability, 
exaggerated startle response in rats 
treated for 3 months in diet 
 1.17 M 
1.62 F 
Cannon and 
Kimbrough 1979 
Rat (Zivac-
Miller) 
Tremors, decreased operant behavior 
in rats repeatedly gavaged for 90 days 
 1 Dietz and McMillan 
1979 
Rat (Wistar) Tremors (dose-related earlier onset 
and increased severity) in rats treated 
for up to 6 months in diet 
 2.30 M 
2.56 F 
Larson et all 1979b 
Rat (Sprague-
Dawley) 
Hyperexcitability, mild tremors in rats 
treated for 90 days in diet 
0.26 0.83 Linder et al. 1983 
Rat (Sprague-
Dawley) 
Tremors, hypersensitivity to noise and 
stress in rats treated for 16 days in diet 
 3.95 Mehendale et al. 
1978b 
Rat (Fischer 
344) 
Increased startle response in rats 
repeatedly gavaged for 15 weeks 
2.8 4.1 Pryor et al. 1983 
Rat (Fischer 
344) 
Exaggerated startle response in rats 
treated for 90 days in diet 
 0.86 Squibb and Tilson 
1982b 
Mouse 
(BALB/c) 
Tremor in mice treated for 2–
12 months in diet 
1.87 5.6 Huber 1965 
 
LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level 
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Table A-5.  Lowest LOAELs for Reproductive Effects Identified in Intermediate-
Duration Oral Studies of Chlordecone 
 
Species 
(strain) Effect 
NOAEL 
(mg/kg/day) 
LOAEL 
(mg/kg/day) Reference 
Rat (Sherman) Decreased number of litters born to 
control males mated to females treated 
for 3 months in diet 
 1.62 Cannon and 
Kimbrough 1979 
Rat (Wistar) Testicular atrophy in 4/5 males treated 
for 3 months in diet 
 2.3 Larson et al. 1979b 
Rat (Sprague-
Dawley) 
46–48% decreased sperm motility and 
viability; 19% decreased epididymal 
sperm concentration in rats treated for 
90 days in diet 
0.26 0.83 Linder et al. 1983 
Mouse 
(BALB/c) 
36% decrease in second litters in mice 
treated for 5 months (including 1 month 
premating) in diet 
 0.93 Good et al. 1965 
Mouse 
(BALB/c) 
8% decrease in litter size and 19% 
increase in pair-days to litter among 
mice treated for 130 days (1 month 
premating) in diet 
 1.87 Huber 1965 
Mouse (CD-1) Increased ovulation, persistent vaginal 
estrus in mice gavaged for 4 or 
6 weeks (5 days/week) 
 2 Swartz et al. 1988 
 
LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level 
 
Selection of the Principal Study:  The study of Linder et al. (1983) identified the lowest LOAEL 
(0.83 mg/kg/day) for both tremors and impaired sperm parameters; the NOAEL was 0.26 mg/kg/day.  
This multiple dose study was selected as the principal study for derivation of an intermediate-duration 
oral MRL for chlordecone. 
 
Summary of the Principal Study: 
 
Linder RE, Scotti TM, McElroy WK, et al.  1983.  Spermotoxicity and tissue accumulation of 
chlordecone (Kepone) in male rats.  J Toxicol Environ Health 12:183-192. 
 
Groups of 20 adult male Sprague-Dawley rats were administered technical grade chlordecone (purity not 
specified) in the diet at 0, 5, 15, or 30 ppm for 90 days.  Rats were monitored for clinical signs, body 
weight, and food intake.  The study authors estimated chlordecone doses to the 5, 15, and 30 ppm groups 
to have been 0.26, 0.83, and 1.67 mg/kg/day, respectively.  After the 90-day treatment period, 
10 rats/group were sacrificed; testes, epididymides, prostate, and seminal vesicles were weighed; 
epididymal fluid was extracted for evaluation of spermatozoal motility and viability.  Reproductive 
tissues were then processed for histologic examination.  The other 10 rats/group were returned to normal 
diet and each bred to two untreated virgin females during a 14-day posttreatment period.  Mated females 
were sacrificed on gestation day 20 and fetal weights, fetal viability, and total implants were determined.  
Male rats used for breeding were sacrificed at 4.5 months after cessation of treatment for evaluation of 
recovery from chlordecone treatment. 
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One 0.83 mg/kg/day rat died on treatment day 84; one rat each in the 0.26 and 1.67 mg/kg/day groups 
died during the recovery period (recovery days 64 and 30, respectively).  Clinical signs of neurotoxicity, 
including hyperexcitability and mild tremors, were observed in rats of the 0.83 and 1.67 mg/kg/day 
groups (incidences not included in the study report).  The 1.67 mg/kg/day group sacrificed at 90 days 
exhibited approximately 7% lower mean final body weight than controls (not considered an adverse effect 
because the decrease was <10%).  The 1.67 mg/kg/day group of rats exhibited significantly lower 
absolute weights of seminal vesicles and prostate (12 and 24%, respectively, less than controls).  Sperm 
concentration (sperm count) and incidences and type of morphologically abnormal spermatozoa were 
similar between controls and all chlordecone-treated groups.  However, within the 0.83 and 
1.67 mg/kg/day groups, decreases in sperm motility (48 and 39%, respectively, less than controls), sperm 
viability (46 and 33%, respectively, less than controls), and epididymal concentration (19% less than 
controls for both 0.83 and 1.67 mg/kg/day groups) were observed.  There were no chlordecone treatment-
related effects on reproductive performance (number of males siring litters, live litters, average litter size, 
average number of implants, percent resorptions, or fetal weight).  At the end of the recovery period, 
sperm parameters and reproductive organ weights were similar to those of controls.  The study identified 
a NOAEL of 0.26 mg/kg/day and a LOAEL of 0.83 mg/kg/day for clinical signs of neurotoxicity 
(tremors) and effects on sperm parameters.  The LOAEL for effects on sperm parameters is not 
considered a serious LOAEL due to the lack of effects on reproductive performance. 
 
Selection of the Point of Departure:  The NOAEL of 0.26 mg/kg/day was selected as the point of 
departure for deriving a provisional intermediate-duration oral MRL for chlordecone. 
 
Benchmark dose analysis of the neurological effects in the principal study (Linder et al. 1983) was 
precluded by lack of incidence data for the treatment-related tremors.  Benchmark dose analysis was 
conducted on the datasets for sperm motility and sperm viability (Table A-6) to identify potential points 
of departure for deriving a provisional intermediate-duration oral MRL for chlordecone. 
 
Table A-6.  Sperm Motility and Viability Data for Sprague-Dawley rats 
Administered Chlordecone in the Diet for 90 Days 
 
Dose (mg/kg/day) 0 0.26 0.83 1.67 
Number of rats 10 10 10 10 
Percent motile sperma 37.0±3.9 33.2±3.8 19.2±4.4b 22.6±5.5b 
Percent live sperma 46.0±4.7 36.2±3.3 25.0±3.3b 30.9±4.8b 
 
aMean ± standard error of the mean (SEM). 
bSignificantly different from control (p<0.05). 
 
Source:  Linder et al. 1983 
 
The data for sperm motility and for sperm viability were fit to all available continuous models in EPA’s 
Benchmark Dose Software (BMDS, version 2.6.0).  The following procedure for fitting continuous data 
was used:  the simplest model (linear) was first applied to the data while assuming constant variance; if 
the data were consistent with the assumption of constant variance (p≥0.1), then the fit of the linear model 
to the means was evaluated and the polynomial, power, and Hill models were fit to the data while 
assuming constant variance.  Adequate model fit was judged by three criteria:  goodness-of-fit p-value 
(p>0.1), visual inspection of the dose-response curve, and scaled residual at the data point (except the 
control) closest to the predefined benchmark dose response (BMR).  Among all models providing 
adequate fit to the data, the lowest BMDL (the lower limit of a one-sided 95% confidence interval [CI] on 
the BMD) was selected as a reasonably conservative point of departure when differences between the 
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BMDLs estimated from these models are >2–3-fold; otherwise, the BMDL from the model with the 
lowest Akaike's information criterion (AIC) was chosen.  If the test for constant variance was negative, 
the linear model was run again while applying the power model integrated into the BMDS to account for 
nonhomogenous variance.  If the nonhomogenous variance model provided an adequate fit (p≥0.1) to the 
variance data, then the fit of the linear model to the means was evaluated and the polynomial, power, and 
Hill models were fit to the data and evaluated while the variance model was applied.  Model fit and point 
of departure selection proceeded as described earlier.  For both datasets, a BMR of 1 standard deviation 
(SD) change from the control was used. 
 
None of the available continuous models provided adequate fit to the data for sperm motility (as 
summarized in Table A-7).   
 
Table A-7.  Results of BMD Analysis of Sperm Motility Data in the Study of 
Linder et al. (1983) 
 
Model 
Test for 
significant 
difference 
p-valuea 
Variance 
p-valueb 
Means 
p-valueb 
Scaled residualsc 
AIC 
BMD1SD 
(mg/kg/d) 
BMDL1SD 
(mg/kg/d) 
Dose 
below 
BMD 
Dose 
above 
BMD 
Overall 
largest 
Constant variance 
Exponential 
(model 2)d 
0.054 0.61 0.19 -1.47 0.94 -1.47 256.63 ND ND 
Exponential 
(model 3)d 
0.054 0.61 0.19 -1.47 0.94 -1.47 256.63 ND ND 
Exponential 
(model 4)d 
0.054 0.61 0.21 0.68 -0.89 -0.89 256.85 ND ND 
Exponential 
(model 5)d 
0.054 0.61 ND 9.91x10-7 -0.40 -0.40 257.60 ND ND 
Hilld 0.054 0.61 0.57 2.4x10-7 -0.40 -0.40 255.60 ND ND 
Lineare 0.054 0.61 0.12 -1.69 0.80 -1.69 257.44 ND ND 
Polynomial 
(2-degree)e 
0.054 0.61 0.12 -1.69 0.80 -1.69 257.44 ND ND 
Polynomial 
(3-degree)e 
0.054 0.61 0.12 -1.69 0.80 -1.69 257.44 ND ND 
Powerd 0.054 0.61 0.12 -1.69 0.80 -1.69 257.44 ND ND 
 
aValues >0.05 fail to meet conventional goodness-of-fit criteria. 
bValues <0.10 fail to meet conventional goodness-of-fit criteria. 
cScaled residuals at doses immediately below and above the benchmark dose; also the largest residual at any dose. 
dPower restricted to ≥1. 
eCoefficients restricted to be negative. 
 
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); d = day; ND = not 
determined, model did not provide adequate fit 
 
The results of BMD analysis of sperm viability are presented in Table A-8.  For the sperm viability data, 
the Exponential Model 4 was the only model to provide adequate statistical fit to the mean data.  
However, visual inspection of the plotted data from Exponential Model 4 (Figure A-1) indicated a poor fit 
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of the estimated mean values to the measured mean values for sperm viability.  Therefore, the BMDL 
estimated from this model was not considered suitable as the basis of the MRL.  It is also noted that the 
estimated BMDL1sd of 0.0014 mg/kg/day is approximately 200 times lower than the NOAEL of 
0.26 mg/kg/day identified by Linder et al. (1983).   
 
Table A-8.  Results of BMD Analysis of Sperm Viability Data in the Study of 
Linder et al. (1983) 
 
Model 
Test for 
significant 
difference 
p-valuea 
Variance 
p-valueb 
Means 
p-
valueb 
Scaled residualsc 
AIC 
BMD1SD 
(mg/kg/d) 
BMDL1SD 
(mg/kg/d) 
Dose 
below 
BMD 
Dose 
above 
BMD 
Overall 
largest 
Constant variance 
Exponential 
(model 2)d 
0.014 0.44 0.033 -1.79 1.25 -1.79 253.40 ND ND 
Exponential 
(model 3)d 
0.014 0.44 0.033 -1.79 1.25 -1.79 253.40 ND ND 
Exponential 
(model 4)d 
0.014 0.44 0.21 0.33 -0.97 -0.97 250.18 0.30 0.0014 
Exponential 
(model 5)d 
0.014 0.44 ND -3.19x10-7 0.75 0.75 251.73 ND ND 
Hilld 0.014 0.44 ND -1.39-9 -0.75 -0.75 251.73 ND ND 
Lineare 0.014 0.44 0.022 -1.96 1.04 -1.96 254.22 ND ND 
Polynomial 
(2-degree)e 
0.014 0.44 0.022 -1.96 1.04 -1.96 254.22 ND ND 
Polynomial 
(3-degree)e 
0.014 0.44 0.022 -1.96 1.04 -1.96 254.22 ND ND 
Powerd 0.014 0.44 0.022 -1.96 1.04 -1.96 254.22 ND ND 
 
aValues >0.05 fail to meet conventional goodness-of-fit criteria. 
bValues <0.10 fail to meet conventional goodness-of-fit criteria. 
cScaled residuals at doses immediately below and above the benchmark dose; also the largest residual at any dose. 
dPower restricted to ≥1. 
eCoefficients restricted to be negative. 
 
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); d = day; ND = not 
determined, model did not provide adequate fit 
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Figure A-1.  Predicted (Exponential Model 4 with Constant Variance, 1 Standard 
Deviation Benchmark Response) and Observed Sperm Viability in Sprague-
Dawley rats Administered Chlordecone in the Diet for 90 Days 
 
 
 
A NOAEL/LOAEL approach to deriving a provisional intermediate-duration oral MRL for chlordecone 
was applied because a BMD approach was precluded by lack of adequate modeling results.   
 
Uncertainty Factor:  The NOAEL of 0.26 mg/kg/day was divided by a total uncertainty factor of 100: 
• 10 for animal to human extrapolation 
• 10 for human variability 
 
Other Additional Studies or Pertinent Information that Lend Support:  Squibb and Tilson (1982b) 
reported chlordecone-induced exaggerated startle response in male rats administered chlordecone in the 
diet for 90 days at 10 ppm (estimated chlordecone dose of 0.86 mg/kg/day).  Cannon and Kimbrough 
(1979) reported tremors, hyperactivity, and exaggerated startle response among male and female rats 
receiving chlordecone from the diet for 3 months at 1.17 and 1.62 mg/kg/day, respectively (lowest 
exposure level tested).  Good et al. (1965) reported decreased numbers of second litters produced by mice 
at a chlordecone dose level as low as 0.93 mg/kg/day.  Cannon and Kimbrough (1979) reported 
1.62 decreased number of litters born to control males mated to chlordecone-treated females dosed at 
1.62 mg/kg/day.  Larson et al. (1979b) reported testicular atrophy in male rats administered chlordecone 
for 3 months at 2.3 mg/kg/day. 
 
Agency Contacts (Chemical Managers):  Obaid Faroon, D.V.M., Ph.D. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
 
Chemical Name: Chlordecone 
CAS Numbers: 143-50-0 
Date: August 1995 
 April 2017—Updated literature search 
Profile Status: Final, Draft for Public Comment 
Route: Oral 
Duration: Chronic 
MRL 0.0005 mg/kg/day 
Critical Effect: Renal effects 
Reference: Larson et al. 1979b 
Point of Departure: NOAEL of 0.05 mg/kg/day 
Uncertainty Factor: 100 
LSE Graph Key: 75 
Species: Rat 
 
MRL Summary:  An MRL of 0.0005 mg/kg/day was derived for chronic-duration oral exposure to 
chlordecone based on renal effects in rats administered chlordecone in the diet for up to 2 years (Larson et 
al. 1979b).  The NOAEL of 0.05 mg/kg/day was divided by a total uncertainty factor of 100 (10 for 
animal to human extrapolation and 10 for human variability). 
 
Selection of the Critical Effect:  Treatment-related effects on body weight, hematological system, liver, 
renal system, and nervous system, and dermal irritation have been associated with chronic-duration oral 
exposure of laboratory animals to chlordecone.  A summary of the lowest LOAELs for each endpoint is 
presented in Table A-9.  A comparison of the LOAEL values across endpoints supports the identification 
of the renal system as the most sensitive target of toxicity. 
 
Table A-9.  Lowest LOAELs Identified in Chronic-Duration Oral Studies of 
Chlordecone 
 
Endpoint Effect 
NOAEL 
(mg/kg/day) 
LOAEL 
(mg/kg/day) Reference 
Body weight >10% depressed body weight in rats 
treated for 1 or 2 years in diet 
0.5 1.25 Larson et al. 1979b 
Hematological Anemia in male rats treated for 
80 weeks in diet 
 0.4 NCI 1976 
Hepatic Fatty infiltration and degeneration in 
male rats treated for 80 weeks in diet 
 0.4 NCI 1976 
Renal Proteinuria and increased severity of 
glomerulosclerosis in rats treated for 
up to 2 years in diet 
0.05 0.25 Larson et al. 1979b 
Dermal Dermatitis in rats treated for 80 weeks 
in diet 
 0.4 NCI 1976 
Neurological Tremors in rats treated for 80 weeks in 
diet 
 0.4 NCI 1976 
 
LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level 
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Results from several studies were considered in the selection of the critical effect for derivation of a 
chronic-duration oral MRL for chlordecone.  Larson et al. (1979b) administered chlordecone in the diet to 
rats for up to 2 years and reported depressed body weight gain, decreased hematocrit levels, and tremors 
at 1.25 mg/kg/day; fatty changes in the liver at 0.5 mg/kg/day; and proteinuria and increased severity of 
glomerulosclerosis in the kidney at 0.25 mg/kg/day.  In an 80-week study of rats administered 
chlordecone in the diet (NCI 1976), adverse dermal, hepatic, hematological, and neurological effects were 
observed at the lowest dose tested (0.4 and 0.9 mg/kg/day for males and females, respectively).  
Similarly-treated mice exhibited adverse hepatic and neurological effects at the lowest dose tested 
(2.6 mg/kg/day for both males and females).  Larson et al. (1979b) also treated dogs for up to 128 weeks 
at doses up to 0.625 mg/kg/day and observed no neurological effects.  Chu et al. (1981c) reported 
histopathological thyroid lesions in male Sprague-Dawley rats treated with chlordecone in the diet for 
21 months at 0.07 mg/kg/day.  However, the study report indicated that 4/10 control rats exhibited thyroid 
lesions (mild degenerative and proliferative changes in follicular epithelium without alteration in colloid 
density) and that 4/6 chlordecone-treated rats exhibited mild histological changes that may have included 
decreased colloid density.  Thus, it is not clear whether a significant difference existed between controls 
and chlordecone-treated rats regarding thyroid lesions.  Therefore, the thyroid lesion data were not 
considered for MRL derivation. 
 
Selection of the Principal Study:  Larson et al. (1979b) was selected as the principal study for deriving a 
chronic-duration oral MRL for chlordecone because it identified a NOAEL (0.05 mg/kg/day) associated 
with the lowest LOAEL (0.25 mg/kg/day for renal effects).  The kidney effect observed in rats treated for 
up to 2 years represents the lowest reliable LOAEL (0.25 mg/kg/day) among the candidate treatment-
related adverse effects from chronic-duration oral exposure to chlordecone, and was therefore selected as 
the critical effect for deriving a chronic-duration oral MRL for chlordecone.   
 
Summary of the Principal Study: 
 
Larson PS, Egle JL Jr, Hennigar CR, et al.  1979b.  Acute, subchronic, and chronic toxicity of 
chlordecone.  Toxicol Appl Pharmacol 48:29-41. 
 
Groups of Wistar rats (40/sex/group) were administered chlordecone in the diet for up to 2 years at 0, 5, 
10, 25, 50, or 80 ppm (estimated chlordecone doses of 0, 0.25, 0.5, 1.25, 2.5, and 4.0 mg/kg/day, 
respectively).  After 1 year, five rats/sex/dose group were sacrificed.  Other groups of male and female 
Wistar rats (40/sex/group) were administered chlordecone in the diet for up to 2 years at 0 or 1 ppm 
(estimated chlordecone doses of 0 and 0.05 mg/kg/day, respectively) and similarly evaluated.  All rats in 
the 50 and 80 ppm groups died by week 25.  Proteinuria was noted in all 5, 10, and 25 ppm groups (0.25, 
0.5, and 1.25 mg/kg/day, respectively) at all intervals after 3 months except in males at 21 and 24 months 
when control levels were elevated, and in females at 24 months when the levels in only the 10 and 
25 ppm groups (0.5 and 1.25 mg/kg/day, respectively) were elevated.  There was no indication of 
proteinuria in the 1 ppm group (0.05 mg/kg/day) of male or female rats.  The severity of observed 
glomerulosclerosis was increased in both males and females at ≥5 ppm (0.25 mg/kg/day).  Non-
statistically significantly increased kidney weight relative to body weight was reported.  The NOAEL for 
kidney effects was 0.05 mg/kg/day.  At 1- and 2-year sacrifice, NOAELs of 0.25 and 0.5 mg/kg/day and 
their respective LOAELs (0.5 mg/kg/day for fatty changes in the liver and 1.25 mg/kg/day for depressed 
hematocrit levels) were identified. 
 
Selection of the Point of Departure for the MRL:  The NOAEL of 0.05 mg/kg/day was selected as the 
point of departure for deriving a chronic-duration oral MRL for chlordecone. 
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Uncertainty Factor:  The NOAEL of 0.05 mg/kg/day was divided by a total uncertainty factor of 100: 
• 10 for animal to human extrapolation 
• 10 for human variability 
 
Other Additional Studies or Pertinent Information that Lend Support to this MRL:  Although other 
available chronic-duration oral studies did not identify renal effects in chlordecone-treated animals, 
adverse dermal, hepatic, hematological, and/or neurological effects were observed at doses in the range of 
0.4–2.6 mg/kg/day. 
 
Agency Contacts (Chemical Managers):  Obaid Faroon, D.V.M., Ph.D. 
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APPENDIX B.  LITERATURE SEARCH FRAMEWORK FOR MIREX AND 
CHLORDECONE 
 
The objective of the toxicological profile is to evaluate the potential for human exposure and the potential 
health hazards associated with inhalation, oral, or dermal/ocular exposure to mirex and chlordecone. 
 
B.1  LITERATURE SEARCH AND SCREEN  
 
A literature search and screen was conducted to identify studies examining health effects, toxicokinetics, 
mechanisms of action, susceptible populations, biomarkers, and chemical interactions data for mirex and 
chlordecone.  ATSDR primarily focused on peer-reviewed articles without publication date or language 
restrictions.  Non-peer-reviewed studies that were considered relevant to the assessment of the health 
effects of mirex and chlordecone have undergone peer review by at least three ATSDR-selected experts 
who have been screened for conflict of interest.  The inclusion criteria used to identify relevant studies 
examining the health effects of mirex and chlordecone are presented in Table B-1. 
 
Table B-1.  Inclusion Criteria for the Literature Search and Screen 
 
Health Effects 
 Species 
  Human 
  Laboratory mammals 
 Route of exposure 
  Inhalation 
  Oral 
  Dermal (or ocular) 
  Parenteral (these studies will be considered supporting data) 
 Health outcome 
  Death 
  Systemic effects 
  Body weight effects  
  Respiratory effects 
  Cardiovascular effects 
  Gastrointestinal effects 
  Hematological effects 
  Musculoskeletal effects 
  Hepatic effects 
  Renal effects 
  Dermal effects 
  Ocular effects 
  Endocrine effects 
  Immunological effects 
  Neurological effects 
  Reproductive effects 
  Developmental effects 
  Other noncancer effects 
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Table B-1.  Inclusion Criteria for the Literature Search and Screen 
 
  Cancer 
Toxicokinetics 
 Absorption 
 Distribution 
 Metabolism 
 Excretion 
 PBPK models 
Biomarkers 
 Biomarkers of exposure 
 Biomarkers of effect 
Interactions with other chemicals 
 
B.1.1  Literature Search 
 
The current literature search was intended to update the health effects sections of the existing 
toxicological profile for mirex and chlordecone (ATSDR 1995), thus, the literature search was restricted 
to studies published between January 1993 to April 2017.  The following main databases were searched in 
April 2017: 
 
• PubMed  
• National Library of Medicine’s TOXLINE 
• Scientific and Technical Information Network’s TOXCENTER 
 
The search strategy used the chemical names, Chemical Abstracts Service (CAS) numbers, 
synonyms, and Medical Subject Headings (MeSH) terms for mirex and chlordecone.  The query 
strings used for the literature search are presented in Table B-2.  
 
The search was augmented by searching the Toxic Substances Control Act Test Submissions (TSCATS), 
NTP website, and National Institute of Health Research Portfolio Online Reporting Tools Expenditures 
and Results (NIH RePORTER) databases using the queries presented in Table B-3.  Additional databases 
were searched in the creation of various tables and figures, such as the TRI Explorer, the Substance 
priority list (SPL) resource page, and other items as needed.  Regulations applicable to mirex and 
chlordecone were identified by searching international and U.S. agency websites and documents. 
 
Review articles were identified and used for the purpose of providing background information and 
identifying additional references.  ATSDR also identified reports from the grey literature, which included 
unpublished research reports, technical reports from government agencies, conference proceedings and 
abstracts, and theses and dissertations.   
 
Table B-2.  Database Query Strings  
 
Database 
search date Query string 
PubMed  
04/2017 ((("mirex"[mh]) OR ("chlordecone"[mh])) AND (1993 : 3000[dp] OR 1993 : 3000[mhda])) 
OR ((("1,1a, 2,2,3,3a, 4,5,5,5a, 5b, 6-Dodecachlorooctahydro-1,3,4-metheno-1H-
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Table B-2.  Database Query Strings  
 
Database 
search date Query string 
cyclobuta(cd)pentalene"[tw] OR "1,2,3,4,5,5-Hexachloro-1,3-cyclopentadiene dimer"[tw] 
OR "1,3,4-Metheno-1H-cyclobuta(cd)pentalene, 1,1a, 2,2,3,3a, 4,5,5,5a, 5b, 6-
dodecachlorooctahydro-"[tw] OR "1,3,4-Metheno-1H-cyclobuta(cd)pentalene, 
dodecachlorooctahydro-"[tw] OR "1,3-Cyclopentadiene, 1,2,3,4,5,5-hexachloro-, dimer"[tw] 
OR "Bichlorendo"[tw] OR "CG-1283"[tw] OR "Cyclopentadiene, hexachloro-, dimer"[tw] OR 
"Dechlorane"[tw] OR "Dodecachlorooctahydro-1,3,4-metheno-1H-
cyclobuta(cd)pentalene"[tw] "Dodecachloropentacyclodecane"[tw] OR "Dodecaclor"[tw] OR 
"Ferriamicide"[tw] OR "Fire Ant Bait"[tw] OR "GC 1283"[tw] OR 
"Hexachlorocyclopentadiene dimer"[tw] OR "HRS 1276"[tw] OR "HRS l276"[tw] OR 
"Mirex"[tw] OR "Paramex"[tw] OR "Pentacyclodecane, dodecachloro-"[tw] OR 
"Perchlordecone"[tw] OR "Perchlorodihomocubane"[tw] OR 
"Perchloropentacyclodecane"[tw]) OR ("Dodecachloropentacyclo(3.2.2.0(sup 2,6),0(sup 
3,9),0(sup 5,10))decane"[tw] OR 
"Dodecachloropentacyclo(5.2.1.0(2,6).0(3,9).0(5,8))decane"[tw] OR 
"Dodecachloropentacyclo(5.2.1.02,6.03,9.05,8)decane"[tw] OR 
"Perchloropentacyclo(5.2.1.0(2,6).0(3,9).0(5,8))decane"[tw] OR 
"Perchloropentacyclo(5.2.1.0(sup 2,6).0(sup 3,9).0(sup 5,8))decane"[tw] OR 
"Perchloropentacyclo(5.3.0.0(2,6).0(3,9).0(4,8))decane"[tw]) OR ("1,1a, 3,3a, 4,5,5,5a, 5b, 
6-Decachlorooctahydro-1,3,4-metheno-2H-cyclobuta(cd)pentalen-2-one"[tw] OR 
"1,2,3,4,5,5,6,7,8,9,10,10-Dodecachlorooctahydro-1,3,4-metheno-2-cyclobuta(c, 
d)pentalone"[tw] OR "1,3,4-Metheno-2H-cyclobuta(cd)pentalen-2-one, 1,1a, 3,3a, 4,5,5,5a, 
5b, 6-decachlorooctahydro-"[tw] OR "2,3,3a, 4,5,6,7,7a, 8,8a-Decachloro-3a, 4,7,7a-
tetrahydro-4,7-methanoinden-1-one"[tw] OR "Chlordecone"[tw] OR "Ciba 8514"[tw] OR 
"Clordecone"[tw] OR "Compound 1189"[tw] OR "Decachloro-1,3,4-metheno-2H-
cyclobuta(cd)pentalen-2-one"[tw] OR "Decachloroketone"[tw] OR "Decachlorooctahydro-
1,3,4-methano-2H-cyclobuta(cd)pentalen-2-one"[tw] "Decachlorooctahydro-1,3,4-metheno-
2H-cyclobuta(cd)pentalen-2-one"[tw] "Decachlorotetracyclodecanone"[tw] OR 
"Decachlorotetrahydro-4,7-methanoindeneone"[tw] OR "GC 1189"[tw] OR "General 
chemicals 1189"[tw] OR "Kepone"[tw] OR "Kepone-2-one, decachlorooctahydro-"[tw] OR 
"Merex"[tw]) OR ("1,2,3,5,6,7,8,9,10,10-Decachloro(5.2.1.0(sup 2,6).0(sup 3,9).0(sup 
5,8))decano-4-one"[tw] OR "Decachloropentacyclo(5.2.1.0(2,6).0(3,9).0(5),(8))decan-4-
one"[tw] OR "Decachloropentacyclo(5.2.1.0(sup 2,6).0(sup 3,9).0(sup 5,8))decan-4-
one"[tw] OR "Decachloropentacyclo(5.3.0.0(sup 2,6).0(sup 4,10).0(sup 5,9))decan-3-
one"[tw] OR "Perchloropentacyclo(5.3.0.0(2,6).0(3,9).0(4,8))decan-5-one"[tw])) AND (1993 
: 3000[dp] OR 1993 : 3000[mhda] OR 1993 : 3000[edat] OR 1993 : 3000[crdat])) 
Toxline  
04/2017 ( "1 2 3 5 6 7 8 9 10 10 decachloro ( 5 2 1 0 ( sup 2 6 ) 0 ( sup 3 9 ) 0 ( sup 5 8 ) ) decano 
4 one" OR "decachloropentacyclo ( 5 2 1 0 ( 2 6 ) 0 ( 3 9 ) 0 ( 5 ) ( 8 ) ) decan 4 one" OR 
"decachloropentacyclo ( 5 2 1 0 ( sup 2 6 ) 0 ( sup 3 9 ) 0 ( sup 5 8 ) ) decan 4 one" OR 
"decachloropentacyclo ( 5 3 0 0 ( sup 2 6 ) 0 ( sup 4 10 ) 0 ( sup 5 9 ) ) decan 3 one" OR 
"perchloropentacyclo ( 5 3 0 0 ( 2 6 ) 0 ( 3 9 ) 0 ( 4 8 ) ) decan 5 one" ) AND 1993:2017 [yr] 
AND ( ANEUPL [org] OR BIOSIS [org] OR CIS [org] OR DART [org] OR EMIC [org] OR 
EPIDEM [org] OR FEDRIP [org] OR HEEP [org] OR HMTC [org] OR IPA [org] OR 
RISKLINE [org] OR MTGABS [org] OR NIOSH [org] OR NTIS [org] OR PESTAB [org] OR 
PPBIB [org] ) AND NOT PubMed [org] AND NOT pubdart [org]  
( "decachlorotetracyclodecanone" OR "decachlorotetrahydro 4 7 methanoindeneone" OR 
"gc 1189" OR "general chemicals 1189" OR "kepone" OR "kepone 2 one 
decachlorooctahydro " OR "merex" ) AND 1993:2017 [yr] AND ( ANEUPL [org] OR BIOSIS 
[org] OR CIS [org] OR DART [org] OR EMIC [org] OR EPIDEM [org] OR FEDRIP [org] OR 
HEEP [org] OR HMTC [org] OR IPA [org] OR RISKLINE [org] OR MTGABS [org] OR 
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Table B-2.  Database Query Strings  
 
Database 
search date Query string 
NIOSH [org] OR NTIS [org] OR PESTAB [org] OR PPBIB [org] ) AND NOT PubMed [org] 
AND NOT pubdart [org]  
( "chlordecone" OR "ciba 8514" OR "clordecone" OR "compound 1189" OR "decachloro 1 
3 4 metheno 2h cyclobuta ( cd ) pentalen 2 one" OR "decachloroketone" OR 
"decachlorooctahydro 1 3 4 methano 2h cyclobuta ( cd ) pentalen 2 one" OR 
"decachlorooctahydro 1 3 4 metheno 2h cyclobuta ( cd ) pentalen 2 one" ) AND 1993:2017 
[yr] AND ( ANEUPL [org] OR BIOSIS [org] OR CIS [org] OR DART [org] OR EMIC [org] 
OR EPIDEM [org] OR FEDRIP [org] OR HEEP [org] OR HMTC [org] OR IPA [org] OR 
RISKLINE [org] OR MTGABS [org] OR NIOSH [org] OR NTIS [org] OR PESTAB [org] OR 
PPBIB [org] ) AND NOT PubMed [org] AND NOT pubdart [org]  
( "1 1a 3 3a 4 5 5 5a 5b 6 decachlorooctahydro 1 3 4 metheno 2h cyclobuta ( cd ) pentalen 
2 one" OR "1 2 3 4 5 5 6 7 8 9 10 10 dodecachlorooctahydro 1 3 4 metheno 2 cyclobuta ( c 
d ) pentalone" OR "1 3 4 metheno 2h cyclobuta ( cd ) pentalen 2 one 1 1a 3 3a 4 5 5 5a 5b 
6 decachlorooctahydro " OR "2 3 3a 4 5 6 7 7a 8 8a decachloro 3a 4 7 7a tetrahydro 4 7 
methanoinden 1 one" ) AND 1993:2017 [yr] AND ( ANEUPL [org] OR BIOSIS [org] OR CIS 
[org] OR DART [org] OR EMIC [org] OR EPIDEM [org] OR FEDRIP [org] OR HEEP [org] 
OR HMTC [org] OR IPA [org] OR RISKLINE [org] OR MTGABS [org] OR NIOSH [org] OR 
NTIS [org] OR PESTAB [org] OR PPBIB [org] ) AND NOT PubMed [org] AND NOT pubdart 
[org]  
( 143-50-0 [rn] ) AND 1993:2017 [yr] AND ( ANEUPL [org] OR BIOSIS [org] OR CIS [org] 
OR DART [org] OR EMIC [org] OR EPIDEM [org] OR FEDRIP [org] OR HEEP [org] OR 
HMTC [org] OR IPA [org] OR RISKLINE [org] OR MTGABS [org] OR NIOSH [org] OR 
NTIS [org] OR PESTAB [org] OR PPBIB [org] ) [not] PubMed [org] [not] pubdart [org]  
( "perchloropentacyclo ( 5 2 1 0 ( 2 6 ) 0 ( 3 9 ) 0 ( 5 8 ) ) decane" OR "perchloropentacyclo 
( 5 2 1 0 ( sup 2 6 ) 0 ( sup 3 9 ) 0 ( sup 5 8 ) ) decane" OR "perchloropentacyclo ( 5 3 0 0 ( 
2 6 ) 0 ( 3 9 ) 0 ( 4 8 ) ) decane" ) AND 1993:2017 [yr] AND ( ANEUPL [org] OR BIOSIS 
[org] OR CIS [org] OR DART [org] OR EMIC [org] OR EPIDEM [org] OR FEDRIP [org] OR 
HEEP [org] OR HMTC [org] OR IPA [org] OR RISKLINE [org] OR MTGABS [org] OR 
NIOSH [org] OR NTIS [org] OR PESTAB [org] OR PPBIB [org] ) AND NOT PubMed [org] 
AND NOT pubdart [org]  
( "dodecachloropentacyclo ( 3 2 2 0 ( sup 2 6 ) 0 ( sup 3 9 ) 0 ( sup 5 10 ) ) decane" OR 
"dodecachloropentacyclo ( 5 2 1 0 ( 2 6 ) 0 ( 3 9 ) 0 ( 5 8 ) ) decane" OR 
"dodecachloropentacyclo ( 5 2 1 02 6 03 9 05 8 ) decane" ) AND 1993:2017 [yr] AND ( 
ANEUPL [org] OR BIOSIS [org] OR CIS [org] OR DART [org] OR EMIC [org] OR EPIDEM 
[org] OR FEDRIP [org] OR HEEP [org] OR HMTC [org] OR IPA [org] OR RISKLINE [org] 
OR MTGABS [org] OR NIOSH [org] OR NTIS [org] OR PESTAB [org] OR PPBIB [org] ) 
AND NOT PubMed [org] AND NOT pubdart [org]  
( "fire ant bait" OR "gc 1283" OR "hexachlorocyclopentadiene dimer" OR "hrs 1276" OR 
"hrs l276" OR "mirex" OR "paramex" OR "pentacyclodecane dodecachloro " OR 
"perchlordecone" OR "perchlorodihomocubane" OR "perchloropentacyclodecane" ) AND 
1993:2017 [yr] AND ( ANEUPL [org] OR BIOSIS [org] OR CIS [org] OR DART [org] OR 
EMIC [org] OR EPIDEM [org] OR FEDRIP [org] OR HEEP [org] OR HMTC [org] OR IPA 
[org] OR RISKLINE [org] OR MTGABS [org] OR NIOSH [org] OR NTIS [org] OR PESTAB 
[org] OR PPBIB [org] ) AND NOT PubMed [org] AND NOT pubdart [org]  
( "1 3 cyclopentadiene 1 2 3 4 5 5 hexachloro dimer" OR "bichlorendo" OR "cg 1283" OR 
"cyclopentadiene hexachloro dimer" OR "dechlorane" OR "dodecachlorooctahydro 1 3 4 
metheno 1h cyclobuta ( cd ) pentalene" OR "dodecachloropentacyclodecane" OR 
"dodecaclor" OR "ferriamicide" ) AND 1993:2017 [yr] AND ( ANEUPL [org] OR BIOSIS 
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Table B-2.  Database Query Strings  
 
Database 
search date Query string 
[org] OR CIS [org] OR DART [org] OR EMIC [org] OR EPIDEM [org] OR FEDRIP [org] OR 
HEEP [org] OR HMTC [org] OR IPA [org] OR RISKLINE [org] OR MTGABS [org] OR 
NIOSH [org] OR NTIS [org] OR PESTAB [org] OR PPBIB [org] ) AND NOT PubMed [org] 
AND NOT pubdart [org]  
( "1 1a 2 2 3 3a 4 5 5 5a 5b 6 dodecachlorooctahydro 1 3 4 metheno 1h cyclobuta ( cd ) 
pentalene" OR "1 2 3 4 5 5 hexachloro 1 3 cyclopentadiene dimer" OR "1 3 4 metheno 1h 
cyclobuta ( cd ) pentalene 1 1a 2 2 3 3a 4 5 5 5a 5b 6 dodecachlorooctahydro " OR "1 3 4 
metheno 1h cyclobuta ( cd ) pentalene dodecachlorooctahydro " ) AND 1993:2017 [yr] 
AND ( ANEUPL [org] OR BIOSIS [org] OR CIS [org] OR DART [org] OR EMIC [org] OR 
EPIDEM [org] OR FEDRIP [org] OR HEEP [org] OR HMTC [org] OR IPA [org] OR 
RISKLINE [org] OR MTGABS [org] OR NIOSH [org] OR NTIS [org] OR PESTAB [org] OR 
PPBIB [org] ) AND NOT PubMed [org] AND NOT pubdart [org]  
( 2385-85-5 [rn] ) AND 1993:2017 [yr] AND ( ANEUPL [org] OR BIOSIS [org] OR CIS [org] 
OR DART [org] OR EMIC [org] OR EPIDEM [org] OR FEDRIP [org] OR HEEP [org] OR 
HMTC [org] OR IPA [org] OR RISKLINE [org] OR MTGABS [org] OR NIOSH [org] OR 
NTIS [org] OR PESTAB [org] OR PPBIB [org] ) [not] PubMed [org] [not] pubdart [org]  
Toxcenter  
04/2017      FILE 'TOXCENTER' ENTERED AT 13:20:16 ON 05 APR 2017 
CHARGED TO COST=EH011.13.01.01 
L1         4295 SEA FILE=TOXCENTER 2385-85-5  
L2         2774 SEA FILE=TOXCENTER 143-50-0  
L3         6422 SEA FILE=TOXCENTER L1 OR L2  
L4         2663 SEA FILE=TOXCENTER L3 AND PY>1992  
L5         2663 SEA FILE=TOXCENTER L4 NOT TSCAT/FS  
L6         2663 SEA FILE=TOXCENTER L4 NOT TSCATS/FS  
L7         2565 SEA FILE=TOXCENTER L4 NOT PATENT/DT  
                ACTIVATE TOXQUERY/Q 
               --------- 
L19             QUE (CHRONIC OR IMMUNOTOX? OR NEUROTOX? OR TOXICOKIN? OR  
                BIOMARKER? OR NEUROLOG?)  
L20             QUE (PHARMACOKIN? OR SUBCHRONIC OR PBPK OR  
EPIDEMIOLOGY/ST,CT, 
                IT)  
L21             QUE (ACUTE OR SUBACUTE OR LD50# OR LD(W)50 OR LC50# OR  
                LC(W)50)  
L22             QUE (TOXICITY OR ADVERSE OR POISONING)/ST,CT,IT  
L23             QUE (INHAL? OR PULMON? OR NASAL? OR LUNG?  OR RESPIR?)  
L24             QUE ((OCCUPATION? OR WORKPLACE? OR WORKER?) AND EXPOS?)  
L25             QUE (ORAL OR ORALLY OR INGEST? OR GAVAGE? OR DIET OR DIETS 
OR  
                DIETARY OR DRINKING(W)WATER?)  
L26             QUE (MAXIMUM AND CONCENTRATION? AND (ALLOWABLE OR 
PERMISSIBLE)) 
 
L27             QUE (ABORT? OR ABNORMALIT? OR EMBRYO? OR CLEFT? OR FETUS?)  
L28             QUE (FOETUS? OR FETAL? OR FOETAL? OR FERTIL? OR MALFORM? 
OR  
                OVUM?)  
L29             QUE (OVA OR OVARY OR PLACENTA? OR PREGNAN? OR PRENATAL?)  
MIREX AND CHLORDECONE  B-6 
 
APPENDIX B 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
Table B-2.  Database Query Strings  
 
Database 
search date Query string 
L30             QUE (PERINATAL? OR POSTNATAL? OR REPRODUC? OR STERIL? OR  
                TERATOGEN?)  
L31             QUE (SPERM OR SPERMAC? OR SPERMAG? OR SPERMATI? OR 
SPERMAS? OR  
                SPERMATOB? OR SPERMATOC? OR SPERMATOG?)  
L32             QUE (SPERMATOI? OR SPERMATOL? OR SPERMATOR? OR 
SPERMATOX? OR  
                SPERMATOZ? OR SPERMATU? OR SPERMI? OR SPERMO?)  
L33             QUE (NEONAT? OR NEWBORN? OR DEVELOPMENT OR 
DEVELOPMENTAL?)  
L34             QUE (ENDOCRIN? AND DISRUPT?)  
L35             QUE (ZYGOTE? OR CHILD OR CHILDREN OR ADOLESCEN? OR 
INFANT?)  
L36             QUE (WEAN? OR OFFSPRING OR AGE(W)FACTOR?)  
L37             QUE (DERMAL? OR DERMIS OR SKIN OR EPIDERM? OR CUTANEOUS?)  
L38             QUE (CARCINOG? OR COCARCINOG? OR CANCER? OR PRECANCER? 
OR  
                NEOPLAS?)  
L39             QUE (TUMOR? OR TUMOUR? OR ONCOGEN? OR LYMPHOMA? OR 
CARCINOM?)  
L40             QUE (GENETOX? OR GENOTOX? OR MUTAGEN? OR 
GENETIC(W)TOXIC?)  
L41             QUE (NEPHROTOX? OR HEPATOTOX?)  
L42             QUE (ENDOCRIN? OR ESTROGEN? OR ANDROGEN? OR HORMON?)  
L43             QUE (OCCUPATION? OR WORKER? OR WORKPLACE? OR EPIDEM?)  
L44             QUE L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR  
                L27 OR L28 OR L29 OR L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR  
                L36 OR L37 OR L38 OR L39 OR L40 OR L41 OR L42 OR L43  
L45             QUE (RAT OR RATS OR MOUSE OR MICE OR GUINEA(W)PIG? OR 
MURIDAE  
                OR DOG OR DOGS OR RABBIT? OR HAMSTER? OR PIG OR PIGS OR 
SWINE  
                OR PORCINE OR MONKEY? OR MACAQUE?)  
L46             QUE (MARMOSET? OR FERRET? OR GERBIL? OR RODENT? OR 
LAGOMORPHA  
                OR BABOON? OR CANINE OR CAT OR CATS OR FELINE OR MURINE)  
L47             QUE L44 OR L45 OR L46  
L48             QUE (HUMAN OR HUMANS OR HOMINIDAE OR MAMMALS OR MAMMAL? 
OR  
                PRIMATES OR PRIMATE?)  
L49             QUE L47 OR L48  
               --------- 
L50        1690 SEA FILE=TOXCENTER L7 AND L49  
L51         151 SEA FILE=TOXCENTER L50 AND MEDLINE/FS  
L52         325 SEA FILE=TOXCENTER L50 AND BIOSIS/FS  
L53        1177 SEA FILE=TOXCENTER L50 AND CAPLUS/FS  
L54          37 SEA FILE=TOXCENTER L50 NOT (L51 OR L52 OR L53)  
L55        1390 DUP REM L51 L52 L54 L53 (300 DUPLICATES REMOVED) 
                     ANSWERS '1-1390' FROM FILE TOXCENTER 
L*** DEL    151 S L50 AND MEDLINE/FS 
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Table B-2.  Database Query Strings  
 
Database 
search date Query string 
L*** DEL    151 S L50 AND MEDLINE/FS 
L56         151 SEA FILE=TOXCENTER L55  
L*** DEL    325 S L50 AND BIOSIS/FS 
L*** DEL    325 S L50 AND BIOSIS/FS 
L57         244 SEA FILE=TOXCENTER L55  
L*** DEL   1177 S L50 AND CAPLUS/FS 
L*** DEL   1177 S L50 AND CAPLUS/FS 
L58         961 SEA FILE=TOXCENTER L55  
L*** DEL     37 S L50 NOT (L51 OR L52 OR L53) 
L*** DEL     37 S L50 NOT (L51 OR L52 OR L53) 
L59          34 SEA FILE=TOXCENTER L55  
L60        1239 SEA FILE=TOXCENTER (L56 OR L57 OR L58 OR L59) NOT MEDLINE/FS  
                D SCAN L60 
 
Table B-3.  Strategies to Augment the Literature Search 
 
Source Query and number screened when available 
TSCATSa  
04/2017 Compounds searched: 2385-85-5, 143-50-0 
NTP  
04/2017 Searched for items 1990-present or not dated: 
143-50-0 OR Chlordecone OR Clordecone OR Decachloroketone OR 
Decachlorotetracyclodecanone OR Kepone OR Merex 
2385-85-5 OR Bichlorendo OR Dechlorane OR Dodecachloropentacyclodecane OR 
Dodecaclor OR Ferriamicide OR Mirex OR Paramex OR Perchlordecone OR 
Perchlorodihomocubane OR Perchloropentacyclodecane 
"Ciba 8514" 
"Compound 1189" 
"Decachloro-1 3 4-metheno-2H-cyclobuta(cd)pentalen-2-one" 
"Decachlorooctahydro-1 3 4-methano-2H-cyclobuta(cd)pentalen-2-one" 
"Decachlorooctahydro-1 3 4-metheno-2H-cyclobuta(cd)pentalen-2-one" 
"Decachlorotetrahydro-4 7-methanoindeneone" 
"GC 1189" 
"General chemicals 1189" 
"Kepone-2-one decachlorooctahydro-" 
"CG-1283" 
"Cyclopentadiene hexachloro-dimer" 
"1 3-Cyclopentadiene 1 2 3 4 5 5-hexachloro-dimer" 
"Dodecachlorooctahydro-1 3 4-metheno-1H-cyclobuta(cd)pentalene" 
"GC 1283" 
"Fire Ant Bait" 
"HRS 1276" 
"HRS l276" 
"Pentacyclodecane dodecachloro-" 
"Hexachlorocyclopentadiene dimer" 
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Table B-3.  Strategies to Augment the Literature Search 
 
Source Query and number screened when available 
NIH RePORTER 
10/2017 Text Search: "1;1a;2;2;3;3a;4;5;5;5a;5b;6-Dodecachlorooctahydro-1;3;4-metheno-1H-
cyclobuta(cd)pentalene" OR "1;2;3;4;5;5-Hexachloro-1;3-cyclopentadiene dimer" OR 
"1;3;4-Metheno-1H-cyclobuta(cd)pentalene; 1;1a;2;2;3;3a;4;5;5;5a;5b;6-
dodecachlorooctahydro-" OR "1;3;4-Metheno-1H-cyclobuta(cd)pentalene; 
dodecachlorooctahydro-" OR "1;3-Cyclopentadiene; 1;2;3;4;5;5-hexachloro-; dimer" OR 
"Bichlorendo" OR "CG-1283" OR "Cyclopentadiene; hexachloro-; dimer" OR 
"Dechlorane" OR "Dodecachlorooctahydro-1;3;4-metheno-1H-cyclobuta(cd)pentalene" 
OR "Dodecachloropentacyclodecane" OR "Dodecaclor" OR "Ferriamicide" OR "Fire Ant 
Bait" OR "GC 1283" OR "Hexachlorocyclopentadiene dimer" OR "HRS 1276" OR "HRS 
l276" OR "Mirex" OR "Paramex" OR "Pentacyclodecane; dodecachloro-" OR 
"Perchlordecone" OR "Perchlorodihomocubane" OR "Perchloropentacyclodecane" OR 
"Dodecachloropentacyclo(3.2.2.0(sup 2;6);0(sup 3;9);0(sup 5;10))decane" OR 
"Dodecachloropentacyclo(5.2.1.0(2;6).0(3;9).0(5;8))decane" OR 
"Dodecachloropentacyclo(5.2.1.02;6.03;9.05;8)decane" OR 
"Perchloropentacyclo(5.2.1.0(2;6).0(3;9).0(5;8))decane" OR 
"Perchloropentacyclo(5.2.1.0(sup 2;6).0(sup 3;9).0(sup 5;8))decane" OR 
"Perchloropentacyclo(5.3.0.0(2;6).0(3;9).0(4;8))decane" OR "1;1a;3;3a;4;5;5;5a;5b;6-
Decachlorooctahydro-1;3;4-metheno-2H-cyclobuta(cd)pentalen-2-one" OR 
"1;2;3;4;5;5;6;7;8;9;10;10-Dodecachlorooctahydro-1;3;4-metheno-2-
cyclobuta(c;d)pentalone" OR "1;3;4-Metheno-2H-cyclobuta(cd)pentalen-2-one; 
1;1a;3;3a;4;5;5;5a;5b;6-decachlorooctahydro-" OR "2;3;3a;4;5;6;7;7a;8;8a-Decachloro-
3a;4;7;7a-tetrahydro-4;7-methanoinden-1-one" OR "Chlordecone" OR "Ciba 8514" OR 
"Clordecone" OR "Compound 1189" OR "Decachloro-1;3;4-metheno-2H-
cyclobuta(cd)pentalen-2-one" OR "Decachloroketone" OR "Decachlorooctahydro-1;3;4-
methano-2H-cyclobuta(cd)pentalen-2-one" OR "Decachlorooctahydro-1;3;4-metheno-
2H-cyclobuta(cd)pentalen-2-one" OR "Decachlorotetracyclodecanone" OR 
"Decachlorotetrahydro-4;7-methanoindeneone" OR "GC 1189" OR "General chemicals 
1189" OR "Kepone" OR "Kepone-2-one; decachlorooctahydro-" OR "Merex" OR 
"1;2;3;5;6;7;8;9;10;10-Decachloro(5.2.1.0(sup 2;6).0(sup 3;9).0(sup 5;8))decano-4-one" 
OR "Decachloropentacyclo(5.2.1.0(2;6).0(3;9).0(5);(8))decan-4-one" OR 
"Decachloropentacyclo(5.2.1.0(sup 2;6).0(sup 3;9).0(sup 5;8))decan-4-one" OR 
"Decachloropentacyclo(5.3.0.0(sup 2;6).0(sup 4;10).0(sup 5;9))decan-3-one" OR 
"Perchloropentacyclo(5.3.0.0(2;6).0(3;9).0(4;8))decan-5-one" (Advanced)  
Search in: Projects AdminIC: All; Fiscal Year: Active Projects " 
Other Identified throughout the assessment process 
 
aSeveral versions of the TSCATS database were searched, as needed, by CASRN including TSCATS1 via Toxline 
(no date limit), TSCATS2 via https://yosemite.epa.gov/oppts/epatscat8.nsf/ReportSearch?OpenForm (date restricted 
by EPA receipt date), and TSCATS via CDAT (date restricted by ‘Mail Received Date Range’), as well as google for 
recent TSCA submissions. 
 
The 2017 results were:  
• Number of records identified from PubMed, TOXLINE, and TOXCENTER (after duplicate 
removal):  2,288 
• Number of records identified from other strategies:  37 
• Total number of records to undergo literature screening:  2,325 
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B.1.2  Literature Screening  
 
A two-step process was used to screen the literature search to identify relevant studies on mirex and 
chlordecone:   
 
• Title and abstract screen 
• Full text screen 
 
Title and Abstract Screen.  Within the reference library, titles and abstracts were screened manually for 
relevance.  Studies that were considered relevant (see Table B-1 for inclusion criteria) were moved to the 
second step of the literature screening process.  Studies were excluded when the title and abstract clearly 
indicated that the study was not relevant to the toxicological profile.   
 
• Number of titles and abstracts screened: 2,325 
• Number of studies considered relevant and moved to the next step:  127 
 
Full Text Screen.  The second step in the literature screening process was a full text review of individual 
studies considered relevant in the title and abstract screen step.  Each study was reviewed to determine 
whether it was relevant for inclusion in the toxicological profile.   
 
• Number of studies undergoing full text review:  127 
• Number of studies cited in the health effects sections of the existing toxicological profile 
(August, 1995):  290 
• Total number of studies cited in the health effects sections of the updated profile:  361 
 
A summary of the results of the literature search and screening is presented in Figure B-1. 
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Figure B-1.  April 2017 Literature Search Results and Screen for Mirex and 
Chlordecone 
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APPENDIX C.  USER'S GUIDE 
 
Chapter 1.  Relevance to Public Health 
 
This chapter provides an overview of U.S. exposures, a summary of health effects based on evaluations of 
existing toxicologic, epidemiologic, and toxicokinetic information, and an overview of the minimal risk 
levels.  This is designed to present interpretive, weight-of-evidence discussions for human health 
endpoints by addressing the following questions: 
 
 1. What effects are known to occur in humans? 
 
 2. What effects observed in animals are likely to be of concern to humans? 
 
 3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
 
Minimal Risk Levels (MRLs) 
 
Where sufficient toxicologic information is available, ATSDR derives MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
 
MRLs should help physicians and public health officials determine the safety of a community living near 
a hazardous substance emission, given the concentration of a contaminant in air or the estimated daily 
dose in water.  MRLs are based largely on toxicological studies in animals and on reports of human 
occupational exposure. 
 
MRL users should be familiar with the toxicologic information on which the number is based.  
Section 1.2, Summary of Health Effects, contains basic information known about the substance.  Other 
sections, such as Section 3.2 Children and Other Populations that are Unusually Susceptible and 
Section 3.4 Interactions with Other Substances, provide important supplemental information. 
 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
 
To derive an MRL, ATSDR generally selects the most sensitive endpoint which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen endpoint are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human variability to 
protect sensitive subpopulations (people who are most susceptible to the health effects caused by the 
substance) and for interspecies variability (extrapolation from animals to humans).  In deriving an MRL, 
these individual uncertainty factors are multiplied together.  The product is then divided into the 
inhalation concentration or oral dosage selected from the study.  Uncertainty factors used in developing a 
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substance-specific MRL are provided in the footnotes of the levels of significant exposure (LSE) tables 
that are provided in Chapter 2.  Detailed discussions of the MRLs are presented in Appendix A. 
 
Chapter 2.  Health Effects 
 
Tables and Figures for Levels of Significant Exposure (LSE) 
 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species and MRLs to humans for noncancer 
endpoints.  The LSE tables and figures can be used for a quick review of the health effects and to locate 
data for a specific exposure scenario.  The LSE tables and figures should always be used in conjunction 
with the text.  All entries in these tables and figures represent studies that provide reliable, quantitative 
estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE tables and figures follow.  The numbers in the left column of the legends correspond to 
the numbers in the example table and figure. 
 
TABLE LEGEND 
See Sample LSE Table (page C-5) 
 
(1) Route of exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  
Typically, when sufficient data exist, three LSE tables and two LSE figures are presented in the 
document.  The three LSE tables present data on the three principal routes of exposure 
(i.e., inhalation, oral, and dermal).  LSE figures are limited to the inhalation and oral routes.  Not 
all substances will have data on each route of exposure and will not, therefore, have all five of the 
tables and figures.  Profiles with more than one chemical may have more LSE tables and figures. 
 
(2) Exposure period.  Three exposure periods—acute (<15 days), intermediate (15–364 days), and 
chronic (≥365 days)—are presented within each relevant route of exposure.  In this example, two 
oral studies of chronic-duration exposure are reported.  For quick reference to health effects 
occurring from a known length of exposure, locate the applicable exposure period within the LSE 
table and figure. 
 
(3) Figure key.  Each key number in the LSE table links study information to one or more data points 
using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 51 identified NOAELs and less serious LOAELs (also see the three 
"51R" data points in sample LSE Figure 2-X). 
 
(4) Species (strain) No./group.  The test species (and strain), whether animal or human, are identified 
in this column.  The column also contains information on the number of subjects and sex per 
group.  Chapter 1, Relevance to Public Health, covers the relevance of animal data to human 
toxicity and Section 3.1, Toxicokinetics, contains any available information on comparative 
toxicokinetics.  Although NOAELs and LOAELs are species specific, the levels are extrapolated 
to equivalent human doses to derive an MRL. 
 
(5) Exposure parameters/doses.  The duration of the study and exposure regimens are provided in 
these columns.  This permits comparison of NOAELs and LOAELs from different studies.  In 
this case (key number 51), rats were orally exposed to “Chemical X” via feed for 2 years.  For a 
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more complete review of the dosing regimen, refer to the appropriate sections of the text or the 
original reference paper (i.e., Aida et al. 1992). 
 
(6) Parameters monitored.  This column lists the parameters used to assess health effects.  Parameters 
monitored could include serum (blood) chemistry (BC), behavioral (BH), biochemical changes 
(BI), body weight (BW), clinical signs (CS), developmental toxicity (DX), enzyme activity (EA), 
food intake (FI), fetal toxicity (FX), gross necropsy (GN), hematology (HE), histopathology 
(HP), lethality (LE), maternal toxicity (MX), organ function (OF), ophthalmology (OP), organ 
weight (OW), teratogenicity (TG), urinalysis (UR), and water intake (WI). 
 
(7) Endpoint.  This column lists the endpoint examined.  The major categories of health endpoints 
included in LSE tables and figures are death, body weight, respiratory, cardiovascular, 
gastrointestinal, hematological, musculoskeletal, hepatic, renal, dermal, ocular, endocrine, 
immunological, neurological, reproductive, developmental, other noncancer, and cancer.  "Other 
noncancer" refers to any effect (e.g., alterations in blood glucose levels) not covered in these 
systems.  In the example of key number 51, three endpoints (body weight, hematological, and 
hepatic) were investigated. 
 
(8) NOAEL.  A NOAEL is the highest exposure level at which no adverse effects were seen in the 
organ system studied.  The body weight effect reported in key number 51 is a NOAEL at 
25.5 mg/kg/day.  NOAELs are not reported for cancer and death; with the exception of these two 
endpoints, this field is left blank if no NOAEL was identified in the study. 
 
(9) LOAEL.  A LOAEL is the lowest dose used in the study that caused an adverse health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific endpoint used to 
quantify the adverse effect accompanies the LOAEL.  Key number 51 reports a less serious 
LOAEL of 6.1 mg/kg/day for the hepatic system, which was used to derive a chronic exposure, 
oral MRL of 0.008 mg/kg/day (see footnote "c").  MRLs are not derived from serious LOAELs.  
A cancer effect level (CEL) is the lowest exposure level associated with the onset of 
carcinogenesis in experimental or epidemiologic studies.  CELs are always considered serious 
effects.  The LSE tables and figures do not contain NOAELs for cancer, but the text may report 
doses not causing measurable cancer increases.  If no LOAEL/CEL values were identified in the 
study, this field is left blank. 
 
(10) Reference.  The complete reference citation is provided in Chapter 8 of the profile. 
 
(11) Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  For example, footnote "c" indicates that the LOAEL of 6.1 mg/kg/day in key 
number 51 was used to derive an oral MRL of 0.008 mg/kg/day. 
 
FIGURE LEGEND 
See Sample LSE Figure (page C-6) 
 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
 
(13) Exposure period.  The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the chronic exposure period are illustrated. 
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(14) Endpoint.  These are the categories of health effects for which reliable quantitative data exist.  
The same health effect endpoints appear in the LSE table. 
 
(15) Levels of exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
 
(16) LOAEL.  In this example, the half-shaded circle that is designated 51R identifies a LOAEL 
critical endpoint in the rat upon which a chronic oral exposure MRL is based.  The key number 
51 corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 6.1 mg/kg/day (see entry 51 in the sample LSE table) to 
the MRL of 0.008 mg/kg/day (see footnote "c" in the sample LSE table). 
 
(17) CEL.  Key number 59R is one of studies for which CELs were derived.  The diamond symbol 
refers to a CEL for the test species (rat).  The number 59 corresponds to the entry in the LSE 
table. 
 
(18) Key to LSE figure.  The key provides the abbreviations and symbols used in the figure. 
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APPENDIX D.  QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
 
 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances may find the following information helpful for fast 
answers to often-asked questions. 
 
 
Primary Chapters/Sections of Interest 
 
Chapter 1:  Relevance to Public Health: The Relevance to Public Health Section provides an overview 
of exposure and health effects and evaluates, interprets, and assesses the significance of toxicity 
data to human health.  A table listing minimal risk levels (MRLs) is also included in this chapter. 
 
Chapter 2:  Health Effects: Specific health effects identified in both human and animal studies are 
reported by type of health effect (e.g., death, hepatic, renal, immune, reproductive), route of 
exposure (e.g., inhalation, oral, dermal), and length of exposure (e.g., acute, intermediate, and 
chronic).   
 NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting.   
 
Pediatrics:    
 Section 3.2 Children and Other Populations that are Unusually Susceptible 
 Section 3.3  Biomarkers of Exposure and Effect  
 
 
ATSDR Information Center  
 
 Phone:   1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)   
 Internet:  http://www.atsdr.cdc.gov 
 
The following additional materials are available online: 
 
Case Studies in Environmental Medicine are self-instructional publications designed to increase primary 
health care providers’ knowledge of a hazardous substance in the environment and to aid in the 
evaluation of potentially exposed patients (see https://www.atsdr.cdc.gov/csem/csem.html).   
 
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident (see https://www.atsdr.cdc.gov/MHMI/index.asp).  Volumes I and II are planning guides 
to assist first responders and hospital emergency department personnel in planning for incidents 
that involve hazardous materials.  Volume III—Medical Management Guidelines for Acute 
Chemical Exposures—is a guide for health care professionals treating patients exposed to 
hazardous materials. 
 
Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances (see 
https://www.atsdr.cdc.gov/toxfaqs/Index.asp). 
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Other Agencies and Organizations 
 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 
30341-3724 • Phone:  770-488-7000 • FAX:  770-488-7015 • Web Page:  
https://www.cdc.gov/nceh/. 
 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 395 E Street, S.W., Suite 9200, 
Patriots Plaza Building, Washington, DC 20201 • Phone:  202-245-0625 or 1-800-CDC-INFO 
(800-232-4636) • Web Page: https://www.cdc.gov/niosh/. 
 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W.  Alexander Drive, 
Research Triangle Park, NC 27709 • Phone:  919-541-3212 • Web Page: 
https://www.niehs.nih.gov/. 
 
 
Clinical Resources (Publicly Available Information) 
 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:  
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266 • Web Page:  
http://www.acoem.org/. 
 
The American College of Medical Toxicology (ACMT) is a nonprofit association of physicians with 
recognized expertise in medical toxicology.  Contact:  ACMT, 10645 North Tatum Boulevard, 
Suite 200-111, Phoenix AZ 85028 • Phone:  844-226-8333 • FAX:  844-226-8333 • Web Page:  
http://www.acmt.net. 
 
The Pediatric Environmental Health Specialty Units (PEHSUs) is an interconnected system of specialists 
who respond to questions from public health professionals, clinicians, policy makers, and the 
public about the impact of environmental factors on the health of children and reproductive-aged 
adults.  Contact information for regional centers can be found at http://pehsu.net/findhelp.html. 
 
The American Association of Poison Control Centers (AAPCC) provide support on the prevention and 
treatment of poison exposures.  Contact:  AAPCC, 515 King Street, Suite 510, Alexandria VA 
22314 • Phone:  701-894-1858 • Poison Help Line: 1-800-222-1222 • Web Page:  
http://www.aapcc.org/. 
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APPENDIX E.  GLOSSARY 
 
 
Absorption—The process by which a substance crosses biological membranes and enters systemic 
circulation.  Absorption can also refer to the taking up of liquids by solids, or of gases by solids or liquids. 
 
Acute Exposure—Exposure to a chemical for a duration of ≤14 days, as specified in the Toxicological 
Profiles. 
 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
 
Benchmark Dose (BMD) or Benchmark Concentration (BMC)—is the dose/concentration 
corresponding to a specific response level estimate using a statistical dose-response model applied to 
either experimental toxicology or epidemiology data.  For example, a BMD10 would be the dose 
corresponding to a 10% benchmark response (BMR).  The BMD is determined by modeling the dose-
response curve in the region of the dose-response relationship where biologically observable data are 
feasible.  The BMDL or BMCL is the 95% lower confidence limit on the BMD or BMC.   
 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
 
Biomarkers—Indicators signaling events in biologic systems or samples, typically classified as markers 
of exposure, effect, and susceptibility. 
 
Cancer Effect Level (CEL)—The lowest dose of a chemical in a study, or group of studies, that 
produces significant increases in the incidence of cancer (or tumors) between the exposed population and 
its appropriate control. 
 
Carcinogen—A chemical capable of inducing cancer. 
 
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-control study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without the outcome. 
 
Case Report—A report that describes a single individual with a particular disease or exposure.  These 
reports may suggest some potential topics for scientific research, but are not actual research studies. 
 
Case Series—Reports that describe the experience of a small number of individuals with the same 
disease or exposure.  These reports may suggest potential topics for scientific research, but are not actual 
research studies. 
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Ceiling Value—A concentration that must not be exceeded.   
 
Chronic Exposure—Exposure to a chemical for ≥365 days, as specified in the Toxicological Profiles. 
 
Clastogen—A substance that causes breaks in chromosomes resulting in addition, deletion, or 
rearrangement of parts of the chromosome. 
 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome, and who are disease-free at start of follow-up.  Often, at 
least one exposed group is compared to one unexposed group, while in other cohorts, exposure is a 
continuous variable and analyses are directed towards analyzing an exposure-response coefficient. 
 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at a specific point in time. 
 
Data Needs—Substance-specific informational needs that, if met, would reduce the uncertainties of 
human health risk assessment. 
 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the response or amount of the response. 
  
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
effect occurs.  Effects include malformations and variations, altered growth, and in utero death. 
 
Epidemiology—The investigation of factors that determine the frequency and distribution of disease or 
other health-related conditions within a defined human population during a specified period.   
 
Excretion—The process by which metabolic waste products are removed from the body.   
  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
 
Half-life—A measure of rate for the time required to eliminate one-half of a quantity of a chemical from 
the body or environmental media. 
 
Health Advisory—An estimate of acceptable drinking water levels for a chemical substance derived by 
EPA and based on health effects information.  A health advisory is not a legally enforceable federal 
standard, but serves as technical guidance to assist federal, state, and local officials. 
 
Immediately Dangerous to Life or Health (IDLH)—A condition that poses a threat of life or health, or 
conditions that pose an immediate threat of severe exposure to contaminants that are likely to have 
adverse cumulative or delayed effects on health. 
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Immunotoxicity—Adverse effect on the functioning of the immune system that may result from 
exposure to chemical substances.   
 
Incidence—The ratio of new cases of individuals in a population who develop a specified condition to 
the total number of individuals in that population who could have developed that condition in a specified 
time period.   
 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
 
In Vivo—Occurring within the living organism. 
 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals. 
 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
 
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals. 
 
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population. 
 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
  
Metabolism—Process in which chemical substances are biotransformed in the body that could result in 
less toxic and/or readily excreted compounds or produce a biologically active intermediate. 
 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors.  The default value for a MF is 1. 
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Morbidity—The state of being diseased; the morbidity rate is the incidence or prevalence of a disease in 
a specific population. 
 
Mortality—Death; the mortality rate is a measure of the number of deaths in a population during a 
specified interval of time. 
 
Mutagen—A substance that causes mutations, which are changes in the DNA sequence of a cell’s DNA.  
Mutations can lead to birth defects, miscarriages, or cancer. 
 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
hazardous substance. 
 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Although effects may be produced at this dose, they 
are not considered to be adverse. 
 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor).  An odds ratio that is greater than 1 is considered to indicate greater risk of 
disease in the exposed group compared to the unexposed group. 
 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
regulatory limit on the amount or concentration of a substance not to be exceeded in workplace air 
averaged over any 8-hour work shift of a 40-hour workweek. 
 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests (insects or other organisms harmful to cultivated plants or animals). 
 
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body. 
 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body. 
 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic 
endpoints.  These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance.   
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Physiologically Based Pharmacokinetic (PBPK) Model—A type of physiologically based dose-
response model that is comprised of a series of compartments representing organs or tissue groups with 
realistic weights and blood flows.  These models require a variety of physiological information, including 
tissue volumes, blood flow rates to tissues, cardiac output, alveolar ventilation rates, and possibly 
membrane permeabilities.  The models also utilize biochemical information, such as blood:air partition 
coefficients, and metabolic parameters.  PBPK models are also called biologically based tissue dosimetry 
models. 
 
Prevalence—The number of cases of a disease or condition in a population at one point in time.   
 
Prospective Study—A type of cohort study in which a group is followed over time and the pertinent 
observations are made on events occurring after the start of the study.   
 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek. 
 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation RfC is expressed in units of mg/m3 or ppm. 
 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily oral exposure of the human population to a potential hazard that is likely to be without risk of 
deleterious noncancer health effects during a lifetime.  The oral RfD is expressed in units of mg/kg/day.   
 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  RQs are 
(1) ≥1 pound or (2) for selected substances, an amount established by regulation either under CERCLA or 
under Section 311 of the Clean Water Act.  Quantities are measured over a 24-hour period. 
 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a hazardous substance.  The toxicity may be directed to the reproductive organs and/or 
the related endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual 
behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the 
integrity of this system. 
 
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
 
Risk—The possibility or chance that some adverse effect will result from a given exposure to a hazardous 
substance. 
 
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, existing health 
condition, or an inborn or inherited characteristic that is associated with an increased occurrence of 
disease or other health-related event or condition. 
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Risk Ratio/Relative Risk—The ratio of the risk among persons with specific risk factors compared to the 
risk among persons without risk factors.  A risk ratio that is greater than 1 indicates greater risk of disease 
in the exposed group compared to the unexposed group. 
 
Short-Term Exposure Limit (STEL)—A STEL is a 15-minute TWA exposure that should not be 
exceeded at any time during a workday.   
 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which it is believed that nearly all workers may be repeatedly 
exposed, day after day, for a working lifetime without adverse effect.  The TLV may be expressed as a 
Time-Weighted Average (TLV-TWA), as a Short-Term Exposure Limit (TLV-STEL), or as a ceiling 
limit (TLV-C). 
 
Time-Weighted Average (TWA)—An average exposure within a given time period.   
 
Toxicokinetic—The absorption, distribution, metabolism, and elimination of toxic compounds in the 
living organism. 
 
Toxics Release Inventory (TRI)—The TRI is an EPA program that tracks toxic chemical releases and 
pollution prevention activities reported by industrial and federal facilities.   
 
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL), 
Reference Dose (RfD), or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.  
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis (3 being the approximate logarithmic 
average of 10 and 1). 
 
Xenobiotic—Any substance that is foreign to the biological system. 
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AAPCC American Association of Poison Control Centers 
ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ACMT American College of Medical Toxicology 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AEGL Acute Exposure Guideline Level 
AIC Akaike’s information criterion  
AIHA American Industrial Hygiene Association  
ALT alanine aminotransferase 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
AST aspartate aminotransferase 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BCF bioconcentration factor 
BMD/C benchmark dose or benchmark concentration 
BMDX dose that produces a X% change in response rate of an adverse effect 
BMDLX 95% lower confidence limit on the BMDX 
BMDS Benchmark Dose Software   
BMR benchmark response 
BUN  blood urea nitrogen  
C centigrade 
CAA Clean Air Act 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
cm centimeter 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy 
DWEL drinking water exposure level 
EAFUS  Everything Added to Food in the United States  
ECG/EKG electrocardiogram 
EEG electroencephalogram 
EPA Environmental Protection Agency 
ERPG  emergency response planning guidelines  
F Fahrenheit 
F1 first-filial generation 
FDA Food and Drug Administration 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
MIREX AND CHLORDECONE  F-2 
 
APPENDIX F 
 
 
 
 
 
 
***DRAFT FOR PUBLIC COMMENT*** 
FR Federal Register 
FSH follicle stimulating hormone 
g gram 
GC gas chromatography 
gd gestational day 
GGT γ-glutamyl transferase  
GRAS  generally recognized as safe  
HEC  human equivalent concentration  
HED  human equivalent dose  
HHS  Department of Health and Human Services  
HPLC high-performance liquid chromatography 
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
IRIS Integrated Risk Information System   
Kd adsorption ratio 
kg kilogram 
kkg kilokilogram; 1 kilokilogram is equivalent to 1,000 kilograms and 1 metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Level of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
mCi millicurie 
MCL maximum contaminant level 
MCLG maximum contaminant level goal 
MF modifying factor 
mg milligram 
mL milliliter 
mm millimeter 
mmHg millimeters of mercury 
mmol millimole 
MRL Minimal Risk Level 
MS mass spectrometry 
MSHA Mine Safety and Health Administration 
Mt metric ton 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NCEH National Center for Environmental Health 
ND not detected 
ng nanogram 
NHANES National Health and Nutrition Examination Survey 
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NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NTP National Toxicology Program 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
PAC  Protective Action Criteria  
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic  
PEHSU Pediatric Environmental Health Specialty Unit 
PEL permissible exposure limit 
PEL-C permissible exposure limit-ceiling value 
pg picogram 
PND postnatal day 
POD point of departure 
ppb parts per billion 
ppbv parts per billion by volume 
ppm parts per million 
ppt parts per trillion 
REL recommended exposure level/limit 
REL-C recommended exposure level-ceiling value 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SD standard deviation 
SE standard error 
SGOT serum glutamic oxaloacetic transaminase (same as aspartate aminotransferase or AST) 
SGPT serum glutamic pyruvic transaminase (same as alanine aminotransferase or ALT) 
SIC standard industrial classification 
SMR standardized mortality ratio 
sRBC sheep red blood cell 
STEL short term exposure limit 
TLV threshold limit value 
TLV-C threshold limit value-ceiling value 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States 
USDA United States Department of Agriculture 
USGS United States Geological Survey 
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USNRC U.S. Nuclear Regulatory Commission 
VOC volatile organic compound 
WBC white blood cell 
WHO World Health Organization 
 
> greater than 
≥ greater than or equal to 
= equal to 
< less than 
≤ less than or equal to 
% percent 
α alpha 
β beta 
γ gamma 
δ delta 
μm micrometer 
μg microgram 
q1* cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 
(–) weakly negative result 
 
